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Colorectal cancer (CRC) was the second commonest cancer and the third leading 
cause of cancer-related deaths worldwide in 2018. In the UK, the overall 5-year 
survival rate of CRC patients is approximately 60%.  Colorectal cancer patients are 
staged based on the staging system recommended by the American Joint Committee 
on Cancer (AJCC). The 5-year survival rates vary from approximately 90% for stage 
I to 10% for stage IV CRC patients. Although the AJCC stage is the main indicator of 
patients’ prognosis, there is still substantial variation in terms of the survival outcomes 
of CRC patients within each stage. This merits further examination of other prognostic 
factors to improve prediction of CRC survival. Previous evidence revealed that 
germline genetic background plays an important role in determining survival 
outcomes of CRC patients. However, the human germline genome consists of millions 
of genetic variants and no specific genetic loci have been robustly mapped in relation 
to prognosis of CRC patients to date. Firstly, this thesis seeks to systematically review 
existing literature and explore whether germline genetic variants have been adopted 
in published multivariable models in attempts to predict CRC survival. Secondly, 
multiple CRC patient cohorts were leveraged to investigate associations between 
germline genetic variants and survival outcomes of CRC patients after diagnosis.  
Methods  
A systematic literature search was conducted in MEDLINE and Embase databases to 
retrieve published multivariable prediction models that were developed to forecast 
survival outcomes of CRC. Risk of bias for included models was assessed using 
published evaluation tools and metrics evaluating model performance were extracted 
and quantitatively assessed using meta-analysis.  
Multiple study cohorts were used in this thesis including the Study of Colorectal 
Cancer in Scotland (SOCCS), incident CRC cases from the UK Biobank cohort and 
datasets from three previously published clinical trials (QUASAR2, SCOT and 
VICTOR). Firstly, germline genetic variants associated with CRC survival that were 
reported by published genome-wide association studies (GWAS) were identified by 
searching the NHGRI-EBI GWAS catalogue.  Associations between these variants 




the SOCCS cohort. Then I explored the potential predictive value of these previously 
reported variants in the UK Biobank study by developing a genetic predictor 
combining these variants, and evaluated the predictive performance of the predictor 
along with other variables (age at diagnosis, sex, AJCC stage and tumour grade) 
using the SOCCS as an external validation cohort. The model performance was 
assessed in terms of the discriminative ability and model calibration. The next step 
was to conduct two candidate genetic association studies to test the potential effects 
of two groups of genetic variants—variants associated with CRC risk and variants 
associated with prognosis of other cancers—on survival outcomes of CRC patients 
from the SOCCS study. These two groups of variants were identified from two large 
GWAS meta-analyses and the GWAS catalogue. Stratified analyses were performed 
by sex, AJCC stage (stage II/III and IV) and tumour site (colon and rectum). Cox 
regression models were used to estimate effects—hazard ratios (HRs)--of genetic 
variants on survival outcomes with age at diagnosis, sex and AJCC stage as 
covariates. The false discovery rate (FDR) approach was used to correct for multiple 
testing. Genetic effects were tested under both the additive and recessive genetic 
models.   
Finally, I performed a GWAS on both overall and CRC-specific survival by 
investigating a total of overall eight million autosomal genetic variants throughout the 
genome using the SOCCS study. The effect estimates for each variant were obtained 
using a Martingale-residual based approach.  Discoveries of the GWAS were then 
replicated by performing meta-analysis combining effect estimates from the UK 
Biobank cohort and the three clinical trials. Stratified GWASs were also conducted in 
SOCCS for stage II/III and stage IV CRC patients separately.  Enrichment analyses 
were employed to detect potential genomic signals enriched in possible genes and 
gene-sets that are involved in relevant biological pathways.   
Results  
The systematic literature review identified 83 original prediction models and 52 
separate external validation studies. Five models (Basingstoke score, Fong score, 
Nordinger score, Peritoneal Surface Disease Severity Score and Valentini nomogram) 
were validated in at least two external datasets and showed positive discriminative 
ability in terms of model performance. No germline genetic variants had been used 
as prognostic predictors in published prediction models.  
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A total of 5,675 CRC patients from the SOCCS cohort, 2,474 incident CRC cases 
from the UK Biobank cohort and 4,771 CRC patients from the three clinical trials were 
included in the main analysis.  By searching the GWAS catalogue, I identified 43 
independent genetic variants (r2<0.2) that were previously linked with CRC survival 
outcomes. After correcting for FDR, none of these 43 variants, under the additive 
genetic model, were significantly associated with either overall or CRC-specific 
survival of CRC patients from the SOCCS cohort. Only three variants (rs17026425, 
rs17057166 and rs6854845) at nominal significance (unadjusted p<0.05) showed 
concordant direction of effects with previously published GWASs, whereas one 
variant with uncorrected p<0.05 showed opposite direction of effect (rs11138220). 
The polygenic risk score (PRS) combining the 43 variants was not associated with 
CRC survival outcomes. No significant associations after adjusting for FDR were 
found in the stratified analysis. Although four variants (rs17280262, rs16867335, 
rs6854845 and rs17057166) showed potential effects when the recessive model of 
inheritance was used in SOCCS, I failed to replicate these effects using data from the 
UK Biobank cohort.   
With respect to the predictive performance of the 43 variants in the UK Biobank cohort, 
the genetic predictor combining the 43 variants did not show statistically significant C 
statistics after internal validation, with the 95% confidence intervals (CIs) including the 
null (overall survival: C=0.510, 95%CI=0.498-0.521; CRC-specific survival: C=0.518, 
95%CI=0.498-0.530).  Similarly, non-significant C statistics were observed for the 43-
variant predictor in the external validation analysis using the SOCCS cohort.  
Moreover, the prediction model composed of the 43 variants was poorly calibrated in 
both the UK Biobank and the SOCCS cohorts.  The model performance remained 
nearly unchanged when combining the genetic predictor with other variables including 
age at diagnosis, sex, AJCC stage and tumour grade in the SOCCS cohort, 
suggesting no incremental predictive value had been introduced by the addition of 
genetic variants.   
Regarding the other two groups of candidate genetic variants, a total of 128 
independent variants (r2<0.2) associated with CRC risk and 82 independent variants 
(r2<0.2) associated with survival outcomes of other cancers were included. Overall, 
none of the variants were observed in statistically significant associations (after FDR 
correction) with CRC survival under the additive model using the SOCCS cohort. The 




survival.  Stratified analysis did not identify any significant associations after 
correcting for FDR. Three CRC-risk variants (rs10161980, rs9537521 and rs7495132) 
showed significant genetic effects (recessive model after FDR correction) on survival 
outcomes of CRC patients from the SOCCS, and a significant association between 
the TT genotype of the variant rs7495132 and CRC-specific survival was also 
observed in the UK Biobank cohort (HR=1.69, 95%CI=1.03-2.79, p=0.038).    
In relation to the results of the GWAS, I identified one variant in chromosome 6 
(rs143664541) that was significantly associated with both overall and CRC-specific 
survival (overall survival: HR=1.92, 95%CI=1.52-2.42, p=4.24x10-8; CRC-specific 
survival: HR=2.17, 95%CI=1.69-2.78, p=1.14x10-9).  Another variant in chromosome 
9 (rs75809467) was observed to be significantly associated with CRC-specific 
survival (HR=1.80, 95%CI=1.48-2.20, p=7.07x10-9) of patients from the SOCCS study.  
However, meta-analysis combining the UK Biobank and the three clinical trials failed 
to replicate significant associations between the two GWAS-identified variants and 
overall survival of CRC patients. CRC-specific survival was not investigated in the 
replication analysis due to lack of available data. In stratified GWASs by AJCC stage, 
I identified a variant on chromosome 5 (rs323694) that was significantly associated 
with CRC-specific survival of stage II/III patients from the SOCCS cohort (HR=1.33, 
95%CI=1.20-1.47, p=2.92x10-8).  Genome-wide gene based analysis revealed 
significant enrichment of genetic signals in the CCDC135 gene in relation to CRC-
specific survival (p=9.92x10-7).  For the gene-set based analysis, significant 
enrichment of signals was detected in genes involved in the biosynthetic process of 
galactolipids for overall survival (p=2.09x10-6) and genes associated with up-
regulating the differentiation of adipocytes for CRC-specific survival (p=2.52x10-7).             
Conclusions 
Although the systematic literature review identified no germline genetic variants used 
as predictors for CRC survival in published prediction models. Five prediction models 
(Basingstoke score, Fong score, Nordinger score, Peritoneal Surface Disease 
Severity Score and Valentini nomogram) that include clinic-pathological predictors 
can potentially be applied to assist clinical decision-making.  
This thesis also presents a comprehensive investigation of potential effects of 
germline genetic variants on survival outcomes of CRC patients.  For genetic variants 
previously linked with CRC survival, the results of the thesis suggest poor 
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reproducibility of these variants given that none of these associations were 
successfully replicated in the SOCCS cohort. In addition, the combined effect of the 
43 variants, represented by a PRS, on CRC survival is also negligible. There is also 
very limited predictive value of these variants as a group in predicting survival 
outcomes of CRC. Although small effects cannot be confidently excluded, major 
effects of these variants on CRC survival are unlikely.     
For genetic variants associated with CRC risk, the lack of association between the 
CRC-risk PRS and survival outcomes of CRC indicates that the overall genetic 
susceptibility to CRC has no significant subsequent influence on survival outcomes. 
For each individual CRC-risk variant, their effects on CRC survival under the additive 
genetic model are unlikely to be clinically relevant. However, potential genetic effects 
under recessive model were detected for three CRC-risk variants (rs10161980, 
rs9537521 and rs7495132) in the SOCCS cohort, especially for the variant rs7495132 
whose association with CRC-specific survival was successfully replicated in the UK 
Biobank cohort. These findings merit further investigation in future large-scaled 
studies. With respect to genetic variants associated with prognosis of other cancers, 
the results of this thesis do not support any significant effects of these variants on 
survival outcomes of CRC patients, indicating that there is a limited shared genetic 
basis across different types of cancers in terms of survival outcomes.    
Although the GWAS-identified variant rs143664541 was not successfully replicated in 
meta-analysis of results from the UK Biobank and the three clinical trials, effects with 
concordant direction were observed across all the datasets on overall survival. 
Therefore, future large-scale investigation of this variant in association with CRC 
survival outcomes, especially for CRC-specific survival, are warranted. As to the other 
GWAS-identified variant rs75809467, further investigation in terms of its effect on 
CRC-specific survival is still needed, although no significant association was found 
between this variant and overall survival in the replication analysis. A potential variant 
rs323694 was identified from the GWAS of stage II/III patients. This variant, if 
replicated in the future, could be of clinical relevance in stratifying stage II/III CRC 
patients of varied prognostic profiles so as to assist informing tailored treatment 
strategies. The results of gene and gene-set based analysis provide preliminary 
evidence favouring future exploration of the biological roles of the CCDC135 gene 
and pathways associated with the biosynthetic process of galactolipids and the 





Colorectal cancer (CRC) is a group of malignancies located along the human large 
bowel. It is the second most common cancer and the third leading cause of cancer-
related death worldwide. On average, approximately 60% of CRC patients live longer 
than five years after they are confirmed to have developed CRC. For each individual, 
however, survival time can vary substantially from less than a year to more than ten 
years. There has been a growing interest in investigating factors that may explain this 
patient-to-patient variation in terms of their survival time. Identification of such factors 
can help clinicians evaluate risk of death and predict how long a patient may survive. 
A better-informed decision can then be made by clinicians regarding how intensive 
the treatment strategy should be for the patient.    
Researchers investigated families with parents and children both diagnosed with CRC. 
They found that the children tend to live a shorter life if their parents did not live long 
after their CRC diagnosis. This indicates that factors that can influence survival time 
of CRC patients could be inherited from their parents. Genetic information passed 
from parents to children is recorded in the human DNA sequence. The human DNA 
is constituted by billions of ‘small units’, known as nucleotides [which form genes], 
that are inherited from parents, the vast majority of which are consistent across all 
human beings. However, there are still millions of such units that are different among 
individuals, and these units are known as genetic variants.  Genetic variants are 
present at varying frequencies in the population and they confer varied effects on a 
wide range of common human traits such as height, hair colour and susceptibility to 
different diseases. The thesis employs the survival outcomes of CRC patients as the 
trait of interest, and investigates associations between this trait and common genetic 
variants in the DNA sequence of CRC patients by using multiple large-scale human 
studies in the UK.   
Firstly, the thesis comprehensively searched previously published literature to identify 
studies aiming to forecast survival outcomes of CRC patients. After reviewing 139 
relevant publications in depth, no genetic variants had been used to help successfully 
predict survival outcomes of CRC. Then I searched for candidate variants that could 
potentially influence survival outcomes of CRC, including genetic variants that had 
previously been linked to CRC susceptibility or survival outcomes of other cancers. 




genetic variants, which had been linked to CRC susceptibility, also showed possible 
effects on survival outcomes of CRC.  In addition to previously known variants, I also 
scanned the entire human DNA including millions of genetic variants in order to 
identify possible novel variants associated with CRC survival. This resulted in 
identification of two new variants with possible effects. Although the thesis provides 
suggestive evidence on associations between several genetic variants and CRC 
survival, further validation of these variants in other populations of CRC patients can 
still be beneficial before they are ready to be used as valid predictors in clinical 
practice. Moreover, investigations in the biological implications of these genetic 
variants will also be helpful to illuminate their possible roles in the progression of CRC, 
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Colorectal cancer (CRC), also known as bowel cancer, includes any malignancies 
located along the large intestine (from the cecum to the anorectal ring). It arises from 
the inner wall of the intestine. According to the anatomic site, CRC can be generally 
divided into colon and rectal cancer. In this chapter, background knowledge regarding 
CRC risk, diagnosis and prognosis will be introduced, so as to lay the foundation on 
which the research aims of this thesis will be proposed. Currently, CRC is the second 
commonest cancer worldwide (Bray et al, 2018), and this chapter will start by 
presenting the disease burden of CRC using the latest population-based statistics 
regarding both the prevalence and incidence rates of CRC. The metric of prevalence 
measures the number (or the proportion) of cases in a specific population at a given 
time point, whereas the incidence—the number of newly diagnosed CRC cases per 
population at risk—conveys probability of developing CRC during a given time period. 
Common risk and protective factors which can potentially affect CRC risk will then be 
introduced. In addition to epidemiological observations, biological evidence will also 
be reviewed to introduce the genetic and molecular pathogenesis of CRC. The second 
section features the diagnosis of CRC. In lieu of discussing the routine process and 
technologies employed in making CRC diagnosis, the focus of this section will be on 
diagnostic features that can inform treatment strategies and long-term prognosis, 
including tumour stage, histological type and grade. The last section will describe 
prognosis of CRC. In particular, population-based estimates on mortality and survival 
will be presented. Mortality is defined by the number of cases (or the proportion) in 
the general population who died of CRC within a specific time span. As opposed to 
mortality which is measured in the general population, survival rates are defined by 
the probability of being alive, or free of specific events such as postoperative 
recurrence, for CRC patients within a given time after their diagnosis. Common 
prognostic factors will then be presented with the main focus on genetic factors.  
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According to the newly-released prevalence estimates from the International Agency 
for Research on Cancer (IARC) and the World Health Organisation (WHO), there are 
a total of 4.8 million people worldwide, as of 2018, living with colorectal cancer (CRC) 
within five years since the initial diagnosis (Cancer Fact Sheets 2018, IARC/WHO, 
URL1-1). Geographically, the highest prevalence is observed in Asia, accounting for 
49.2% of the total number of cases. Europe ranks 2nd, accountable for 29.3% of the 
global number of CRC cases. A pie chart of geographic distribution of global CRC 
prevalence is shown in Figure 1-1.  
 
 
Figure 1-1 Geographic distribution of 5-year global prevalence (2013-2018) of colorectal 
cancer. Reprinted from Cancer Fact Sheets, colorectum and anus (C-18-21), Copyright 
(2018) (URL1-1) with written permission from IARC/WHO.  
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In the UK, there was an estimate of 0.24 million individuals living with CRC in 2010 
ever since their initial diagnoses. This number is projected to increase to 0.34 million 
by 2020 (approximately 1,021 survivors per 100,000 population)(Maddams et al, 
2012). In Scotland, the latest estimates by Scottish Cancer Registry in 2017 reported 
an aggregated number of 24,174 survivors with their CRC diagnosed up to 20 years 
ago, resulting in a prevalence of 0.45% in the Scottish population (Scottish Cancer 
Registry, URL1-2). 
           
1.2.2 Incidence  
 
Based on the latest GLOBOCAN estimates in 2018, there was an estimate of 1.84 
million newly diagnosed CRC cases worldwide in 2018 (Cancer Fact Sheets 2018, 
IARC/WHO, URL1-1). Moreover, the crude global CRC incidence is projected to reach 
more than 2.2 million newly-diagnosed CRC cases per year by 2030 (Arnold et al, 
2017). Amongst all cancer types, CRC is the second most commonly diagnosed 
cancer, accounting for 10.2% of the 18.1 million newly-diagnosed cancer cases 
worldwide (Bray et al, 2018).  
Given that the age structure of a certain population significantly affects the CRC 
incidence rate, the incidence rate is often standardised by taking the weighted mean 
of crude rates in each age groups to derive the age-standardised rate when 
comparing incidence rates across different populations. Presented in Figure 1-2 is 
the age-standardised CRC incidence rate worldwide (Torre et al, 2015). As the figure 
indicates, higher incidence rates are widely observed in well-developed areas 
including Europe, North America and Oceania. Taking UK as an example, there were 
approximately 42,000 new CRC cases per year from 2014 to 2016, accounting for 
around 12% of all new cancer cases according to the data from Cancer Research UK 
(CRUK) (Bowel Cancer Statistics, CRUK, URL1-3). The age-standardised incidence 
rate in the UK was 69.3 per 100,000 population in 2016. In Scotland, there were 3,776 
newly diagnosed CRC cases in 2017 with an age-standardised incidence rate of 73.7 
per 100,000 population (Scottish Cancer Registry, URL1-2). In the USA, there was an 
average of 145,600 new CRC cases diagnosed per year from 2014 to 2016, with an 
age-standardised incidence rate of 38.6 per 100,000 population (Marley & Nan, 2016). 
Whilst absolute incidence rates remain highest in these well-developed countries, 
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there has been a stable or declining trend of CRC incidence (Arnold et al, 2017) 
(URL1-1). The age-standardised CRC incidence rates in Scotland from 1993 to 2017 




Figure 1-2 Worldwide colorectal cancer incidence rates (age adjusted according to the 








Figure 1-3 Colorectal cancer incidence trend in Scotland from 1993 to 2017.Created using 
data from the Scottish Cancer Registry (Scottish Cancer Registry, URL 1-2).  
 
However, there are widening disparities in CRC incidence patterns, primarily between 
well-and less-developed countries. For less-developed areas where historically there 
had been lower CRC incidence rates, the number of newly diagnosed CRC cases has 
kept rising over recent decades. For instance, in China, the age-standardised 
incidence rate of CRC has increased from 14.3 to 25.3 per 100,000 population from 
1990 to 2016 (Zhang et al, 2019). Similarly, in Thailand, this number is projected to 
increase by 42% from 2000 to 2025 (Virani et al, 2017). This increase could be 
attributed to the changing diet patterns, obesity and other lifestyle risk factors that can 
potentially increase CRC risk (Bray et al, 2018).  
Stratified by sex, CRC is the third commonest cancer in men (10.9% in all men with 
CRC) following lung and prostate cancer. For women, it ranks fourth (9.5%) among 
all cancer types (Bray et al, 2018). The 2018 GLOBOCAN estimates indicate that men 
are subject to slightly higher CRC risk than women (23.6 vs. 16.3 per 100,000 
population) (Bray et al, 2018). Although the magnitude varies, this sex difference in 
CRC incidence is consistent over the globe (Cancer Fact Sheets 2018, IARC/WHO, 
URL1-1). Colorectal cancer incidence rate increases with age. In the UK, 
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approximately 44% of new CRC cases were diagnosed at the age of 75 or older in 
2018 (Bowel Cancer Statistics, CRUK, URL1-3). Figure 1-4 presents the distribution 
of age at diagnosis separated by sex in the UK from 2014 to 2016. The CRC incidence 
rates for both men and women peak at individuals between 85 to 89 years of age. 
    
 
 
Figure 1-4  Distribution of age at colorectal cancer diagnosis in the UK from 2014 to 
2016.Reproduced with permission from the graph created by Cancer Research UK (Bowel 
Cancer Statistics, CRUK, URL1-3). 
  
 Common risk and protective factors   
 
Colorectal cancer can be categorised into familial and sporadic disease. The heritable 
components of CRC will be introduced in the next section. Sporadic CRC accounts 
for up to 60% of existing CRC cases, in which no family history has been reported at 
diagnosis. Aside from aforementioned demographic factors such as gender and age, 
epidemiological studies have identified a wide range of other factors associated with 
CRC risk. According to recommendations from the World Cancer Research Fund 
(WCRF) (Bowel Cancer, WCRF, URL1-4) and a systematic literature review by 
Johnson and colleagues (Johnson et al, 2013), commonly known risk and protective 
factors that are categorised as strong evidence are summarised as follows:  




—red and processed meat intake (Chao et al, 2005) 
—cigarette smoking (Botteri et al, 2008)  
—obesity (Edge et al, 2010)  
—alcohol consumption (Fedirko et al, 2011) 
—personal history of polyps and inflammatory bowel diseases (Munkholm, 2003)  
Protective factors:  
— physical activity (Wolin et al, 2009)  
—dietary intake of fibre (Negri et al, 1998) 
—Dairy products (Aune et al, 2012)  
—Calcium supplements (Huncharek et al, 2009) 
It is worth noting that the CRC screening strategy varies across the world and it per 
se can also influence the observed CRC incidence rate due to more cases detected. 
Colorectal cancer screening in the UK includes three tests: faecal immunochemical 
test, faecal occult blood test, and colonoscopy. Individuals over 60 years of age (50 
for Scotland) are invited to participate the screening.  
There are other factors identified by the systematic review that are associated with 
CRC risk. For example, individual studies reported that aspirin intake (Rothwell et al, 
2010) and hormone replacement therapy in women (Johnson et al, 2009) were 
associated with lower risk of CRC. However, no significant associations were 
identified in meta-analyses of all published studies (Johnson et al, 2013). Therefore, 
more evidence is needed before any recommendations can be made.  
These aforementioned modifiable risk and protective factors can have potentially far-
reaching implications for CRC prevention provided that causal effects in these 
observed associations are established by randomised clinical trials (e.g. calcium 
intake) or other approaches like Mendelian randomisation studies (e.g. obesity) if 
clinical trials are not feasible.           
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1.2.4 Genetic and molecular pathogenesis   
 
Genetic models of tumorigenesis 
Colorectal cancer occurrence follows a well-understood transformation pattern—it 
starts from normal colorectal epithelium to benign adenomas and eventually 
progresses to invasive and metastatic CRC. This process is accompanied by stepwise 
accumulation of both germline and somatic genetic alterations.   
As with other malignancies, CRC is in fact a group of heterogeneous conditions that 
encompasses a number of subtypes characterised by distinct genetic patterns. In 
particular, CRC can be classified into sporadic (50-60%), familial (30-40%) and 
hereditary (4-6%) CRC (American Society of Colon and Rectal Surgeons, ASCRS, 
URL 1-5). Sporadic cases, with no family history, are more likely to be diagnosed after 
the age of 50. Recently, an increased incidence of sporadic CRCs has been observed 
among young adults (<50 years of age) from high-income countries (Araghi et al, 
2019). The formation of sporadic CRC features sequential acquisition of somatic 
mutations. In contrast, hereditary CRCs tend to occur at an earlier age with an 
identifiable high-penetrance germline predisposition. These hereditary cases can be 
further divided into groups of syndromes: one group manifests colonic polyposis, 
including familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP) 
and other less commonly observed syndromes; the other group manifests without 
polyposis—namely hereditary nonpolyposis CRC (HNPCC, also known as Lynch 
syndrome).  
A comparison between genetic patterns of sporadic and hereditary CRC from normal 
epithelium to invasive cancer is presented in Figure 1-5. For sporadic CRCs, multiple 
somatic mutations are sequentially accumulated to trigger formation of neoplastic 
lesion as well as to expedite progression to invasive cancer. Whereas in the case of 
hereditary CRCs, germline genetic alterations play an essential role in tumorigenesis. 
The distinction between polyposis and nonpolyposis hereditary CRC lies in the 
specific phase when germline genetic alterations take effect. For individuals with 
polyposis syndromes like the FAP, germline alterations mainly accelerate the 
formation of adenomas, but for nonpolyposis CRC, such as the Lynch syndrome, 
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germline alterations primarily affect the progression rate from adenomas to invasive 
cancers (Figure 1-5).    
The third type is familial CRC. The genetic mechanisms of this type of CRC have 
been less clearly understood. These cases present inconsistent patterns compared 
with the aforementioned inherited syndromes. A family history is reported in these 
individuals who are at significantly higher risk of developing CRC. It is estimated that 
having a single first-degree relative diagnosed with CRC imposes a twice as high risk 
onto an individual compared with the general population (Tuohy et al, 2014).  
 
 
Figure 1-5 Comparison of genetic models between sporadic and hereditary colorectal 
cancer.  Recreated based on (Fearon, 2011).   
 
Genetic mutations  
Germline mutations  
These mutations occur within germ cells and can be passed on to off-spring. 
Mutations in potential pathogenic genes of the CRC tumorigenesis can exert large 
effects on increased CRC risk (also known as high penetrance), although these 
mutations are usually rare (<1%) in the general population.  
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With regard to pathogenic genes responsible for CRC development, the 
Adenomatous polyposis coli (APC) gene is a tumour suppressor gene that has been 
extensively studied and plays a critical role in formation of colorectal adenomas. The 
APC protein, encoded by the APC gene, is able to assist in maintaining cell division, 
adhesion, and chromosome stability, thus can serve as a key suppressor that 
prevents uncontrolled cell proliferation (Fodde, 2002). Germline mutations in the APC 
gene can lead to premature truncation of the APC protein, rendering it unable to 
effectively control overgrowth of cells that eventually develop into adenomas (Fodde, 
2002). An estimate of 90% individuals affected by FAP carry germline defects in the 
APC gene (Fearon, 2011). Besides FAP, inactivation of the APC gene is also involved 
in other hereditary CRC syndromes with polyposis such as Gardner syndrome and 
attenuated adenomatous polyposis coli.  
The MUTYH gene is another common gene that harbours mutations causing another 
type of hereditary polyposis CRC syndrome, namely the MAP. The MUTYH gene 
encodes the MUTYH glycosylase which is engaged in the base excision repair 
pathway. In particular, this enzyme can excise adenine bases when nucleotide bases 
are incorrectly paired mostly due to oxidative DNA damage (Sampson et al, 2005). 
Homozygous germline mutations in the MUTYH gene can cause failure of DNA 
damage repair and subsequently provoke somatic mutations in relevant oncogenes—
genes that can potentially cause cancer growth. 
Pertaining to HNPCC, the genetic basis is constituted of germline mutations in a single 
copy of allele in one of the DNA mismatch repair (MMR) genes, for example the MSH2 
or MLH1 gene, while the other allele is somatically silenced via mechanisms including 
loss of heterozygosity and promoter hypermethylation (Peltomaki, 2001). Loss of 
heterozygosity refers to a common genetic event in carcinogenesis where a 
heterozygous locus in the germline turns into homozygous in the tumour DNA. 
Promoter hypermethylation is an epigenetic change (inheritable alteration not 
involving the DNA sequence) in the promoter region featuring enrichment of CpG 
islands (A cytosine base followed immediately by a guanine base). Impaired DNA 
mismatch repair can subsequently lead to microsatellite instability (MSI)—changes in 
the number of repeats of short sequence in the tumour DNA— which is widely-
accepted as one of the key activators of CRC tumorigenesis.  
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Somatic mutations  
In addition to germline genetic defects, the role of acquisition of somatic mutations is 
also indispensable throughout CRC pathogenesis, particularly for the most common 
type of sporadic CRCs. Common somatic mutations in both oncogenes and tumour 
suppressor genes involved in the CRC tumorigenesis are listed in Table 1-1.  
Table 1-1 Reported mutation frequencies of selected common somatic mutations observed 
in colorectal cancer tumour tissues   

















 *Frequency estimates are based on references (Fearon, 2011) (Kudryavtseva et al, 2016; 
Li et al, 2015; Molinari & Frattini, 2013; Nguyen & Duong, 2018; Yeh et al, 2018). 
 
As a well-established gatekeeper of tumorigenesis, the APC gene can also mutate 
somatically to initiate the formation of colorectal adenomas. An estimate of 80% of 
colorectal adenomas (hereditary and sporadic combined) are driven by defects in the 
Chapter 1 Background 
12 
APC gene which initiate a whole chain of genetic alterations (Fearon, 2011). 
Approximately 80 somatic mutations are expected to be detected in a given CRC 
sample, among which an average of 15 are predicted to be potential driver mutations 
throughout CRC tumorigenesis (Wood et al, 2007).  
A major group of oncogenes is the RAS family which consists of KRAS, NRAS and 
HRAS genes. Proteins encoded by these genes, namely K-RAS4A, K-RAS4B, H-RAS 
and N-RAS, are guanosine triphosphate (GTP) binding proteins that participate in 
transforming extracellular signals to intracellular regulatory factors, such as cell cycle 
proteins, so as to mediate cell differentiation, proliferation and apoptosis (Jinesh et al, 
2018). The RAS family is among the most frequently observed genes with mutations 
associated with tumorigenesis of many human malignancies. With respect to CRC, 
approximately 40% of CRC cases carry KRAS mutations and less than 5% carry 
NRAS mutations (Fearon, 2011). Mutations in the KRAS gene occur in a relatively 
early stage of the CRC tumorigenesis, and can provoke the mitogen-activated protein 
kinase (MAPK) pathway, rendering uncontrolled cell growth (Jinesh et al, 2018).  
Around 10% of CRCs are identified with mutations in another important oncogene 
known as the BRAF gene (Barras, 2015). The BRAF protein is a serine/threonine 
protein kinase that plays a vital role in key regulatory pathways related to 
carcinogenesis such as the Hippo signalling pathway which regulates cell proliferation 
and apoptosis. Hence, mutations in the BRAF gene exert profound effects in the CRC 
tumorigenesis (Barras, 2015).  
In addition to these oncogenes above, there are also tumour suppressor genes 
harbouring somatic mutations engaged in CRC tumorigenesis. For instance, the p53 
gene is among the most well-known tumour suppressor genes and mutations in this 
gene are commonly observed in up to 70% of CRC cases (Fearon, 2011). The p53 
tumour suppressor protein can bind to DNA sequences and regulate the expression 
of many vital genes that can maintain cell cycle, and apoptosis, particularly under 
circumstances with stimuli like DNA damage and hypoxia (Ozaki & Nakagawara, 
2011). Mutations in the p53 gene are frequently clustered in the p53 DNA binding 
domain, and they can impair normal p53 function by hindering it binding to relevant 
DNA sequences (Li et al, 2015). This effect is thought to be active in the 
transformation from adenoma to invasive CRC (Lopez et al, 2012). 
  




Molecular pathways    
On the basis of molecular events that have been partially discussed above, CRC 
tumorigenesis is generally classified into three molecular pathways: (a) the 
chromosomal instability (CIN) pathway, (b) the microsatellite instability (MSI) pathway 
and (c) the CpG island methylator phenotype (CIMP) pathway. Of note, these three 
pathways are not mutually exclusive, thus can be observed simultaneously in the 
same CRC sample.  
The CIN pathway can be triggered both in sporadic and hereditary CRCs. Primarily, 
it is characterised by chromosomal abnormalities such as insertions, deletions or loss 
of heterozygosity. These abnormalities are frequently paired with inherited or acquired 
mutations that can potentially activate relevant pathways of CRC tumorigenesis (Pino 
& Chung, 2010). The second pathway that features MSI is typically identified in 
HNPCC. Germline mutations in MMR genes lead to dysfunction of MMR enzymes 
and, as a consequence, failures to repair mismatches are accumulated throughout 
the genome. Colorectal cancers that develop through this pathway can be typically 
identified with high level of MSI (noted as MSI-high tumours). With respect to the 
CIMP pathway, epigenetic alterations such as DNA methylations can suppress the 
level of the relevant oncogene and tumour suppressor gene expression, including but 
not limited to MMR genes. In particular, CRCs characterising the CIMP pathway are 
enriched with methylated CpG islands (Weisenberger et al, 2006). For instance, 
methylation of the CpG islands in the promoter region of the MGMT gene, which 
encodes the O6-methylguanine DNA methyltransferase (MGMT), can inhibit the 
corresponding gene expression, leading to aberrant genomic alterations (Inno et al, 
2014). Common molecular events of the three pathways are summarised in Table 1-2 
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Table 1-2 Genetic characteristics of molecular pathways of colorectal cancer tumorigenesis 
  CIN pathway MSI pathway CIMP pathway 
Prevalence 60-70% ~15% 15-20% 
Heredity  Hereditary/sporadic Hereditary Hereditary/sporadic 
Genetic markers 
MSI status MSS MSI-high MSI-high/low 
CIN + - - 
KRAS mutation + +/- - 
BRAF mutation  - - + 
MLH1 status Normal  Mutated Methylated 
MGMT 
methylation  
- - + 
CIN, chromosomal instability; MSI, microsatellite instability; MSS, microsatellite stability; 
CIMP, CpG island methylator phenotype. This table is created based on references (Al-
Sohaily et al, 2012) and (Noffsinger, 2009). 
 
Common germline genetic variations  
Unlike hereditary CRC cases where major pathogenic germline mutations can often 
be ascertained, the mass of sporadic as well as familial CRC cases remains to be 
investigated in the sense of their genetic components related to higher CRC risk. 
There has been a growing awareness that the development of these types of CRC is 
attributed to complex interactive effects of the patients’ genetic background and 
environmental risk factors.      
Human genomes differ from each other at an estimated 4 to 5 million sites, of which 
more than 99.9% are single nucleotide polymorphisms (SNP) and short indels 
(Genomes Project et al, 2015). SNPs are substitutions of single nucleotides that occur 
at specific genetic loci with a relatively common frequency (>1%) in a given population. 
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Other variations include copy number variations and chromosomal translocations. 
These common genetic variations have been widely linked with a wide spectrum of 
phenotypes and can modify the susceptibility to diseases such as CRC, although the 
penetration is comparatively lower than that of rare germline mutations. Since early 
2000s, the emergence of genome-wide association studies (GWAS) has successfully 
mapped numerous genetic risk loci to complex phenotypes including human 
malignancies. Additional details regarding study design and analysis of GWASs will 
be introduced at length in later chapters.  
As to CRC, the two most recent (to date) meta-analyses of large GWASs identified 
over 100 independent risk loci throughout the human genome (Huyghe et al, 2019; 
Law et al, 2019). Among these hits, most of them are mapped to non-coding regions 
in the genome—DNA sequences that do not encode proteins. Although this indicates 
mostly regulatory effects of these genetic variants, some of them are enriched in or 
near genes involved in several known cancer related pathways such as the 
transforming growth factor beta (TGF-β) pathway and the Wnt-pathway, as well as 
other pathways responsible for immune response, cell apoptosis and differentiation 
(Law et al, 2019). Other variants may assist in revealing novel pathways related to 
CRC tumorigenesis that are not understood extensively. A list of basic characteristics 
of common genetic variations identified by GWASs that are associated with CRC risk 
are presented in Chapter 5 (Table 5-19). Notably, these CRC-risk variants were 
identified mostly in the European population, with a small number of variants that were 
uniquely identified in the Eastern Asian population. It is estimated that the common 
variants identified to date in European populations can explain approximately 11% of 
the 2.2 fold familial relative risk for CRC (Law et al, 2019). 
Besides GWASs, a large number of hypothesis-driven studies of smaller scale have 
been conducted in order to explore associations between specific candidate genetic 
variants and CRC risk. Field synopsis is a systematic approach using meta-analysis 
and established criteria to summarise and appraise published candidate genetic 
association studies. The latest field synopsis by our group highlighted credible 
associations between 18 common genetic variants and CRC risk (Montazeri et al, 
2019). These findings are highly concordant with previous GWASs.  
It should be noted that these common genetic variants identified by association 
studies could either be or near the potential driver variant that needs to be determined 
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by functional characterisation. Although evidence for the biological function of these 
genetic variants is still sparse, observed associations between these variants and 
CRC risk can be harnessed to improve risk prediction and stratification in the general 
population.    
                  
1.3 Diagnosis of colorectal cancer—staging, typing 
and grading   
 
In clinical practice, a diagnosis of CRC is accompanied by information on the 
characteristics of the tumour, so as to assist clinicians in evaluating how serious the 
cancer is, predicting prognosis and determining potential treatment strategies. These 
characteristics mainly include the stage, type and grade of the tumour.  
Staging  
Staging is the process during which clinicians assess how much the tumour has grown 
and spread. In particular, the depth of tumour invasion into the bowel wall, the 
involvement of local lymph nodes and distant organs are evaluated. Staging assesses 
the extent of tumour progression for CRC patients and, therefore, it is currently 
considered as the principal prognostic indicator. Patients diagnosed with more 
advanced stage manifest poorer prognosis, thus are subject to more aggressive 
therapy. There have been two widely-used staging systems, namely the American 
Joint Committee on Cancer (AJCC) TNM system and the Dukes’ system. 
The Dukes’ system—a specific classification system for CRC— was first proposed in 
1932 by the British pathologist Cuthbert Dukes (1890-1977). It categorises CRC 
based on whether the tumour is local, regional (local lymph nodes involved) or 
metastatic. Although followed by several modified versions (Kyriakos, 1985), this 
system now serves mainly historical purposes and is rarely applied in today’s practice.  
The TNM staging system, however, is used more widely in recent clinical practice as 
it is also generally applicable to other cancers with the exception of leukaemia and 
tumours of the central nervous system. As suggested, this system evaluates three 
aspects of the bowel tumour: T (tumour) measures the extent of tumour growing into 
the bowel wall which is composed of an inner layer (mucosa), a middle layer 
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(submucosa and muscle), and an outer layer (subserosa and serosa); N (nodes) 
represents any involvement of nearby lymph nodes; M (metastasis) shows whether 
the tumour has spread to any distant lymph nodes or organs such as the liver and 
lung. Figure 1-6 depicts CRCs at different stages in relation to the basic anatomy.        
 
Figure 1-6 Anatomic diagram of colorectal cancer at different stages. A: stage I (Dukes’ A); 
B: stage II (Dukes’ B); C: stage III (Dukes’ C); D: stage IV (Dukes’ D). Adapted with 
permission based on graphs created by Cancer Research UK (Bowel Cancer Stages, Types 
and Grades, CRUK, URL1-6).  
 
According to combinations of different measures in these three aspects, Roman 
numbers of 0 to IV are assigned to group CRC into five stages (the AJCC stage). 
Table 1.3 presents the basic classification rules of stage 0 to IV based on the 8 h 
edition TNM staging system of CRC (Colorectal Cancer Stages, American Cancer 
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Society, URL1-7). Each stage can be further divided into sub-stages according to 
detailed TNM measures (details can be found in URL1-7).   











Tis Also known as carcinoma in situ (Tis). It has not 
grown beyond the inner layer (mucosa) of the 





T1-2 The tumour has grown through the mucosa into 
the submucosa (T1), or into the muscularis 
propria (T2), but has not spread to nearby lymph 
nodes (N0) or to distant sites (M0). 
N0 
M0 
II B T3-4 The tumour has grown into the outer layers 
(subserosa and serosa) but has not gone 
through them (T3). T4 refers to the tumour that 
has grown through the bowel wall with or without 
attachment to nearby tissues or organs. It has 
not spread to nearby lymph nodes (N0) or to 




III C T1-4 The tumour has spread to 1 to 3 (N1) or more 
than 3 nearby lymph nodes. It has not spread to 
distant sites (M0). N1-2 
M0 
  
IV D Any T The tumour has spread to distant parts of the 
peritoneum, distant set of lymph nodes or distant 




By default, the staging system above refers to the pathological stage (noted as pTNM) 
which is ascertained by examining the tumour tissue removed from surgery. There is 
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also clinical staging (noted as cTNM) which occurs prior to surgery, and is ascertained 
by evaluating results of physical examination, biopsies and imaging. Although not as 
accurate as pathological staging, clinical staging can inform necessary neoadjuvant 
therapy (chemotherapy or radiotherapy applied prior to surgery) and decision on the 
most appropriate surgical approach. Given the fact that neoadjuvant therapy can 
potentially downgrade the tumour stage, a prefix ‘y’ symbol is added to indicate 
staging after neoadjuvant treatment (noted as ypTNM).        
Typing  
The World Health Organisation first introduced a histological typing system in 1970 
(Morson & Sobin, 1976). Up to 96% of the CRCs are classified as adenocarcinomas 
(URL1-6) which stem from the gland cells in the lining of the bowel wall. In addition to 
classical colorectal adenocarcinomas, there are two less frequent subtypes: 
mucinous and signet ring carcinomas. Not only do these subtypes morphologically 
differ under the microscope, they are related to distinct tumour biology, thus indicative 
of varied prognostic outcomes. There has been evidence reporting that patients with 
mucinous and signet ring carcinomas tend to be diagnosed with more advanced stage, 
and can be predisposed to worse survival (Nitsche et al, 2013). Other types of CRC 
such as squamous cell carcinoma, stromal tumours and carcinoid tumours are too 
rare to have been extensively investigated.  
Grading  
Analogous to the staging, a grading system has been introduced to provide an overall 
description on the amount of abnormality of tumour cells under the microscope in an 
attempt to quantify how fast the tumour is likely to grow and spread (also described 
as cancer differentiation). Pathologists assign grades from G1 to G4 to the CRC by 
examining the tumour tissue. Grade 1 (well-differentiated) represents a tumour that 
looks most like normal cells; grade 2 (moderately-differentiated) denotes a tumour 
with cells that fall between normal and abnormal; grade 3 (poorly-differentiated) refers 
to a tumour with abnormal cells; grade 4 (undifferentiated) tumours, are those tumours 
that look completely different from the tissue from which they originate. At times, G3 
and G4 tumours are jointly presented as G3. Tumours of higher grades exhibit more 
invasiveness than ones of lower grades. Depicted in Figure 1.7 are microscopic views 
of CRCs from grade 1 to grade 3 (4).  




Figure 1-7 Grade 1 to 3 (4) colorectal cancer tissue under a microscope.  Reproduced from 
the Atlas of Genetics and Cytogenetics in Oncology and Haematology with permission 
(Huret et al, 2013) (URL1-8).      
 
1.4 Colorectal cancer prognosis      
 
1.4.1 Mortality      
 
In 2018, there was an aggregate number of 0.88 million deaths caused by CRC 
globally. By 2030, this number is estimated to increase to 1.1 million per year (Arnold 
et al, 2017). Similar to the global distribution of CRC prevalence, roughly 80% of CRC-
related deaths occurred in Asia or Europe (ULR1-1). Presented here in Figure 1-8 is 
the geographic distribution of CRC-related deaths in 2018. The latest statistics from 
the IARC indicate that CRC was the second leading cause of cancer-related death in 
2018, with 9.2% of all cancer deaths attributed to CRC (Bray et al, 2018). With regard 
to sex-stratified mortality, CRC was the third highest cause of cancer related deaths 
in females and fourth in males (9.5% of female cases and 9% of male cases) (Bray et 
al, 2018). As shown in Figure 1-9, high CRC mortality (age-standardised) is mainly 









Figure 1-8 Geographic distribution of colorectal cancer related deaths in 2018. Reprinted 
from Cancer Fact Sheets, Colorectum and anus (C-18-21), Copyright (2018) (URL1-1) with 
written permission from IARC/WHO. 
 
 
Figure 1-9 Worldwide colorectal cancer mortality rates (age adjusted according to the world 
standard population, per 100 000) in 2012. Adapted from (Arnold et al, 2017) with 
permission. 
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In contrast to incidence where substantial variation exists between developing and 
developed countries, the difference of CRC mortality, however, lies primarily in the 
changing pattern with time where decreasing age-standardised CRC mortality rates 
have been observed mainly in many developed countries such as the USA, UK and 
Singapore (Arnold et al, 2017; Bray et al, 2018). In the UK, there were on average 
approximately 16,000 CRC deaths every year (44 per day) from 2014 to 2016. Over 
the past decade, however, the age-standardised CRC mortality rate in the UK has 
declined by 14% (Bowel Cancer Statistics, CRUK, URL1-3). In Scotland, the CRC 
mortality rate has been reduced from 47.4 per 100,000 person-years in 1992 to 31.1 
in 2017 (detailed numbers for each year plotted in Figure 1-10) (Scottish Cancer 
Registry, URL1-2). Improved patient care along with advancing multi-disciplinary 
treatment strategies could be behind this. However, relatively stable CRC mortality 
rates have been observed in developing countries. For example, the CRC mortality 
rate in China was 11.65 per 100,000 population in 1990 and 11.34 in 2016 (Zhang et 
al, 2019). The stable trend of CRC mortality rates may point to the balance between 
improvement of treatment strategies and rapid growth of CRC incidence in these 
areas.     




Figure 1-10 Colorectal cancer mortality trend in Scotland from 1992 to 2017. Created with 
data from Scottish Cancer Registry.  
 
1.4.2 Survival  
 
Given the fact that survival estimates reflect directly the clinical outcome of CRC 
patients after diagnosis, they are widely used both in evaluating the population 
disease burden and in the context of clinical research. This metric will therefore be 
adopted as the study outcome of the thesis.  
Based on the cause of death, survival metrics can be divided into overall survival (OS) 
and CRC-specific survival (CSS)—the probability of surviving in the absence of other 
causes such as cardiovascular events or car accidents. Deaths of other causes were 
considered as censored when presenting the CSS. Both the OS and the CSS 
estimates absolute survival rates in a certain population.  
However, in order to compare survival rates of CRC patients across different 
populations, net survival rates (also known relative survival rates) are widely adopted 
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by taking the ratio of the proportion of survivors in the CRC patient cohort (absolute 
overall survival rate) to that in a reference cancer-free cohort with comparable 
common characteristics like age, sex, ethnicity and residence. Therefore, the net 
survival rate provides a useful measurement for comparison of survival estimates 
amongst different populations by peeling off the potential varying effects of death risk 
from other causes.  
The CONCORD programme, a global surveillance programme of cancer survival 
including data from population-based cancer registries from 71 countries and 
territories, published separate age-standardised 5-year net survival estimates for 
colon and rectal cancer in 2018 (Allemani et al, 2018). Based on these estimates, 
survival rates of colon and rectal cancer vary widely across the word. From 2010 to 
2014, the highest survival rates were observed in Australia (colon cancer: 70.7%, 
rectal cancer: 71.0%). However, in countries such as South Africa, these estimates 
were as low as 12.3% for colon cancer and 9.1% for rectal cancer (Allemani et al, 
2018).  
This substantial variation may reflect to a certain extent differences in CRC screening 
programmes, treatment strategies, as well as surveillance across these countries. For 
instance, loss to follow-up rates greater than 15% were more common in African 
countries than in Europe and North America, making the survival estimates less 
reliable (Allemani et al, 2018). Other than that, distinct distributions of CRC patient 
characteristics across these areas may also be an essential attribute to this variation 
of survival estimates.  
Tumour stage is currently the most commonly known determinant of patients’ survival. 
Stratified survival estimates of individuals of different stage at diagnosis are provided 
by some large cancer registries or surveillance programmes. The Surveillance, 
Epidemiology, and End Results Programme (SEER), operated by the National Cancer 
Institute of the USA, is the largest cancer surveillance programme in the world (NCI, 
2018). According to the latest SEER estimates, the 5-year (2009-2015) net survival 
rate of CRC patients in the USA is 64.4%. In lieu of AJCC stage, the latest SEER 
statistics reported the stage-specific survival estimates by grouping CRC into 
localised (stage I, IIA and IIB cancer), regional (stage IIC and stage III) and distant 
(stage IV) tumours. As shown in Figure 1-11, the 5-year relative survival drops 
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drastically as the tumour stage progresses (from 89.9% for localised to 14.2% for 
distant CRC) (NCI, 2018). 
 
Figure 1-11 5-year relative survival estimates (2009-2015) by stage from the SEER 
programme of the USA. Reproduced from the NCI public data with permission.   
  
In the UK, the 5-year net survival (2002-2006) of CRC patients (England and Wales) 
is approximately 60% based on the statistics from CRUK (URL1-6). In Scotland, the 
5-year (2007-2011) net survival rate is 59.8% based on the latest estimates provided 
by the Scottish Cancer Registry (Scottish Cancer Registry, URL1-2). CRUK provides 
stage-specific relative survival estimates separately by gender. Figure 1-12 
demonstrates a clear trend of decreased survival rates with more advanced stage. 
Females show slightly favourable survival in each stage compared with males, 
although none of these differences are statistically significant (Bowel Cancer Statistics, 
CRUK, URL1-3).                          
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Figure 1-12 5-year relative survival rates (2002 to 2006) by stage for colorectal cancer 
patients in the UK.  Reproduced with permission from the graph created by Cancer 
Research UK. 
 
As described in section 1.3, the AJCC staging system is derived primarily on anatomic 
basis rather than empirical data regarding CRC prognosis. Therefore, the wide 
variation with respect to survival probabilities cannot be fully explained by cancer 
stage. There is still large heterogeneity in terms of individualised survival even within 
each specific stage, where the AJCC staging system (sub-stages such as IIA and IIB) 
may not be able to reliably further distinguish patients of varied prognosis. To take the 
SEER data as an example, the absolute survival estimates for each AJCC stage are 
plotted in Figure 1-13 for colon and Figure 1-14 for rectal cancer cases. As shown 
by the graphs, the 5-year overall survival rates for stage II and III CRC can vary from 
28% to as high as 74%. Even within stage II, the differential of survival rates between 
IIC and IIA can be approximately 40%. Graphically, survival curves of stage II/III are 
heavily intertwined, indicating imperfect performance of the stratification by AJCC 
sub-stages.  
 




Figure 1-13 Absolute survival rates of 28,491 colon cancer patients stratified by stage from 
the SEER programme (1973-2005). The original source of this graph is the AJCC Cancer 




Chapter 1 Background 
28 
  
Figure 1-14 Absolute survival rates of 9,860 rectal cancer patients stratified by stage from 
the SEER programme (1973-2005).  The original source of this graph is the AJCC Cancer 
Staging Manual, seventh edition (2010)(Edge et al, 2010). Reproduced with written 
permission. 
   
Beyond these aforementioned metrics in which deaths are used as the primary event 
of outcome, other alternative metrics, including disease-free survival (DFS), 
recurrence (relapse)-free survival (RFS), and progression-free survival (PFS), are 
also commonly adopted especially in the context of clinical trials. Whilst the OS or 
CSS is often deemed as the ‘gold standard’ endpoint of survival outcomes given that 
they are immune from measurement bias, the median survival time for CRC patients 
(all stages combined) can be as long as roughly 40 months (Laohavinij et al, 2010), 
hence increasing potential risk for cohort attrition as well as cost for long-time follow-
up. These alternative endpoints can be accurately measured in clinical trials with more 
intense surveillance in a shorter observation time-window. Since events like CRC 
recurrence or progression usually occur prior to death, trials with such alternative 
endpoints as the primary outcome often require a smaller sample size to reach a pre-
specified statistical power. In addition, there has been evidence supporting these 
endpoints as good surrogates with satisfied approximation to the OS (Oba et al, 2013). 
Definitions and common usage of some frequently used endpoints are summarised 
in the following Table 1-4.  
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Table 1-4 Summary of common endpoints of survival outcomes in clinical research. 
Endpoint Definition  Common clinical 
settings  
Overall survival The length of time from initial 
diagnosis (or primary treatment) to 
death from any cause. 
Population statistics or 
clinical trials  
CRC-specific survival  The length of time from initial 
diagnosis (or primary treatment) to 
death from CRC related causes. 
Deaths from other causes are 
often considered as censored. 
Population statistics or 




The length of time from primary 
treatment (usually curative 
surgery) to disease recurrence. 
Trials for adjuvant 
(postoperative) therapy  
Progression-free 
survival  
The length of time from primary 
treatment (non-curative) to disease 
progression. 




Of note, all the metrics discussed above are probability estimates measuring the 
proportion of survivors (free from pre-specified events) within a given time period. The 
other approach to evaluate survival is to estimate the time length from initial diagnosis 
of CRC (or primary treatment) to the endpoint of interest. In this case, an order 
statistic—the median of all the observed survival time, is often used as an estimate. 
The median survival time provides an intuitive estimate on how long an average 
individual can potentially survive.     
   
1.4.3 Prognostic factors  
 
As discussed in the previous section 1.3, diagnostic features of CRC, such as TNM 
measures, tumour site and grade, are important indicators for CRC prognosis. 
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However, even these factors combined cannot accurately predict survival outcomes 
of CRC patients. The survival estimates from Figure 1-13 and Figure 1-14 reveal 
substantial residual variation of prognosis for CRC-affected individuals, which merits 
incorporating more prognostic factors. Moreover, such factors, if modifiable, can lead 
to novel interventions to prolong survival time. For unmodifiable predictors like genetic 
variations, accurate prediction can inform decisions about more enhanced 
surveillance and more intensive treatment.  
In concordance with the topic of this thesis, genetic factors, with a focus on germline 
genetic factors, will be introduced in this section. Thus far, most of the widely known 
clinical guidelines as well as organisation, except for the Canadian Cancer Society 
(Canadian Cancer Society, URL1-9), have not officially listed and recommended 
prognostic factors of CRC patients. Therefore, factors associated with CRC prognosis 
will be selected and introduced in this section mainly based on the recommendations 
from the Canadian Cancer Society.  
 
Germline genetic variations  
Empirical evidence has demonstrated an effect of inheritable genetic background on 
survival outcomes of CRC patients. A Swedish population-based study first revealed 
a familial concordance of cancer-specific survival by investigating over 4,800 pairs of 
parents and children diagnosed with the same type of primary cancer (Lindstrom et 
al, 2007). For CRC, in particular, children with a parent who died within 10 years of 
CRC diagnosis tended to have significantly poorer CRC-specific survival compared 
with those whose parent lived longer than 10 years since diagnosis (Lindstrom et al, 
2007). Notably, this concordance was not identified among parents and children 
diagnosed with different types of primary cancers, indicating that this effect is most 
likely attributed to shared genetic basis rather than common environmental factors or 
similar behaviours. Current evidence suggests that the impact of germline variations 
on survival outcomes of CRC patients could possibly be mediated by their effects on 
tumour progression and response to treatment. 
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Germline genetics and cancer progression—As indicated previously, cancer 
progression and metastasis are the most lethal aspects of tumour behaviour that 
largely determines the survival outcomes of CRC patients. In the late 1990s, animal 
breeding studies developed the metastatic tumour mouse model by transferring a 
specific oncogene—the polyoma middle-T antigen transgene (Lifsted et al, 1998), and 
found that mice of different genetic origins exhibit varying tendencies of the primary 
mammary tumour to disseminate to the lung (Lifsted et al, 1998). This observed 
variation in metastatic potential is most likely attributed to the germline genome, 
considering the same initial oncogene was introduced in all the mice under study. In 
the following study, Hunter and colleagues successfully mapped this varied metastatic 
potential of primary mammary tumours in the mouse model to the genetic locus of 
Mtes1 on the chromosome 19 of the mice (Hunter et al, 2001). Another source of 
evidence comes from gene expression data. Ramaswamy et al. identified a distinct 
gene expression signature of 17 genes that is significantly associated with the 
metastatic potential of multiple types of human solid tumour including CRC 
(Ramaswamy et al, 2003). The pattern of the differential expression of these genes 
between tumours of high and low metastatic tendency was subsequently replicated 
in the mouse model by Hunter et al. with a fixed driver oncogene (Hunter et al, 2003), 
which further underscored the role of germline genetics in cancer metastasis. Despite 
shared genetic basis for metastasis of different types of cancers, currently there is a 
dearth of such evidence from animal models specifically developed to study CRC 
metastasis.                 
Impact on treatment response—Drug metabolism entails complex networks inside the 
human body engaging a very large number of biological molecules including 
transporters, enzymes and receptors. Genetic variations can modulate key steps of 
drug metabolism, and as a consequence cause varied responses to drugs. In terms 
of CRC, major drugs involved in chemotherapy include cytotoxins such as 
fluoropyrimidines (5-fluorouracil, capecitabine, S1 and tegafur), irinotecan and 
oxaliplatin. Targeted agents such as cetuximab and bevacizumab are also commonly 
used. Taking 5-fluorouracil as an example, it is a fluoropyrimidine analogue that can 
inhibit thymidylate synthase (TS)—an enzyme encoded by the TYMS gene catalysing 
the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine 
monophosphate (dTMP). Inhibiting TS supresses the formation of thymidine which is 
an indispensable part of DNA replication. Therefore, 5-fluorouracil can efficiently 
restrain proliferation of cancer cells. A germline variation in the number of tandem 
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repeats (repetitions of single or multiple nucleotides adjacent to each other) in the 
promoter region of the TYMS gene has been identified to be associated with the 
TYMS gene expression, leading to varied responses to the 5-fluorouracil (Iacopetta 
et al, 2001). A patient’s response to the treatment is measured by the extent to which 
the tumour has shrunk after chemotherapy. The inhibitory effect of 5-fluorouacil also 
applies to normal cells, which incurs toxic effects, such as myelosuppression and 
hand-foot syndrome, on CRC patients. The 5-fluorouracil is catabolised by an 
enzyme—the dihydropyrimidine dehydrogenase (DPD)—encoded by the DYPD gene. 
Evidence suggests that the DPD function is regulated by germline variations within 
the DYPD gene; individuals carrying the DYPD risk variant show deficient DPD 
function, and therefore are prone to higher risk of toxic effects (Amstutz et al, 2011). 
Other genes, such as the MTHFR and ABCB1 gene, harbouring variations linked with 
treatment response of CRC patients to various drugs have been summarised by 
previous systematic reviews (Ab Mutalib et al, 2017). In addition to chemotherapy, 
emerging evidence also supports an important role of germline genetics in regulating 
the patients’ sensitivity to radiotherapy (Kerns et al, 2014). Albeit proven efficacy of 
these drugs in improving clinical outcomes, robust associations between germline 
variations affecting the treatment response and CRC survival have not been 
established. This could be due to restricted data availability regarding treatment in 
large cohorts.  
As previously mentioned, hereditary CRC cases such as HNPCC exhibit strong 
genetic predisposition driven by high-penetrance germline mutations. These cases 
only account for 4-6% of all CRC cases and the mutation profiles vary remarkably 
among patients, rendering each single pathogenic mutation too rare to be investigated 
individually in prognostic studies. Hence, previous efforts tended to aggregate these 
cases together and compared them to sporadic cases to explore overall effects of 
germline alterations as a whole on survival outcomes. For example, HNPCC patients 
had once been linked with better survival than sporadic cases (Sankila et al, 1996) 
before subsequent evidence found no significant difference in survival after adjusting 
for a variety of clinic-pathological factors that were largely discrepant between the two 
types of CRCs (Bertario et al, 1999). Results of a large cohort from our group also 
found lack of association between germline mutations in DNA mismatch repair genes 
(MLH1, MSH2 and MSH6) and survival outcomes (Barnetson et al, 2006). Current 
evidence suggests limited value of adding these rare germline mutations in predicting 
survival outcomes of CRC patients.     
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With respect to common germline genetic variants with lower penetrance, thus far 
there has been no published meta-analysis of GWASs on survival outcomes of CRC. 
According to the NHGRI-EBI GWAS Catalogue (URL1-10)—an online portal with all 
published GWASs indexed, three individual GWASs have been conducted investing 
CRC survival outcomes including the OS, CSS (Phipps et al, 2016; Xu et al, 2015) 
and time to distant metastasis (Penney et al, 2019); two of them were based on CRC 
patients from the same cohort (Penney et al, 2019; Xu et al, 2015). The largest GWAS 
by Phipps et al. identified no genetic variants significantly associated with either the 
OS or CSS among 3,494 CRC patients (Phipps et al, 2016). Although the other 
smaller cohort with 431 CRC patients reported several potential signals associated 
with time to metastasis, these findings were prone to false positivity or overestimated 
associations due to the limited sample size and lack of replication. These common 
germline variants reported by previous GWASs will be presented and discussed at 
length in Chapter 5. There have also been a number of published candidate genetic 
association studies focusing on specific sets of genetic variants. However, these 
variants were mostly investigated by single small studies. Therefore, hitherto 
accumulated evidence is insufficient to conduct a field synopsis and meta-analysis to 
summarise and further appraise potential prognostic roles of these variants.    
In summary, the overall effect of germline genetic background on survival outcomes 
of CRC patients has been well supported by previous evidence. However, this effect 
is yet to be further dissected in order to identify specific loci that can potentially be 
employed as predictors to better inform patients’ prognosis.    
            
Somatic alterations and molecular subtypes   
There has been extensive discussion of the prognostic role of somatic events 
acquired during CRC development. The Canadian Cancer Society recommends three 
somatic alterations that can potentially be used to predict survival: MSI, KRAS and 
BRAF mutations (Canadian Cancer Society, URL1-9).      
As mentioned in section 1.2.4, deficiency of mismatch repair (MMR) genes can result 
in high level of MSI (instability of more than 30% of microsatellite loci) which is one of 
the genetic signatures enriched mainly in localised CRCs instead of metastatic ones. 
There has been evidence from meta-analyses supporting an association between 
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MSI-high tumours and improved survival compared with MSI-low or MSS tumours 
(Guastadisegni et al, 2010). However, this association is less prominent in metastatic 
CRCs possibly due to the low frequency of MSI-high tumours and the presence of a 
rich set of other somatic mutations observed in metastatic CRCs (Venderbosch et al, 
2014).  
A large meta-analysis found that KRAS mutation carriers manifest worse survival 
outcomes in comparison to wild type CRC patients (Petrelli et al, 2015). Given the fact 
that KRAS mutations are actually a group of mutations that occur at different positions 
of the gene, prognostic effects vary among these mutations. For example, Andreyev 
et al. looked into the prognostic effects of a spectrum of KRAS mutations and found 
that only one mutation in codon 12 was independently associated with CRC survival 
(Andreyev et al, 2001).  
The BRAF mutations are mostly observed in codon 600 (also known as mutation 
V600E). Evidence from meta-analysis revealed a significant detrimental effect of the 
V600E mutation on overall survival of CRC patients (Ardekani et al, 2012). This effect, 
however, disappears in MSI-high CRCs, indicating possible interactions between this 
mutation and the MMR deficiency (Taieb et al, 2017).  
There has been growing interest in devising molecular classification systems to better 
inform prognosis in addition to the current TNM staging system. These systems adopt 
somatic events including mutation profiles, molecular pathways and other 
characteristics discussed in section 1.1.2. Listed in Table 1-5 is currently the most 
widely accepted classification system, known as the consensus molecular subtypes 
(CMS) (Guinney et al, 2015). The CMS harmonised six previous systems using 
clustering algorithms based on the relatedness of genetic and molecular 
characteristics.  
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Table 1-5 Summary of consensus molecular subtypes of colorectal cancer 
Classification Genetic features Median survival 
months* (95% CI) 
CMS1(Immune type) High MSI and CIMP, high 
BRAF mutations, immune 
infilatration and activation  
11.7(10.9-18.0) 
CMS2(Canonical type) High SCNA, Wnt and MYC 
activation  
42.0(39.3-54.4) 
CMS3(Metabolic type) Mixed MSI status, low 
SCNA and CMIP, high 





High SCNA, stromal 
infiltration, TGF-beta 
activation, angiogenesis  
30.8(24.4-43.5) 
*Median survival estimates were based on (Lenz et al, 2019). CMS, consensus molecular 
subtypes; SCNA, somatic copy number alterations; TGF, transforming growth factor. MSI, 
microsatellite instability; CMIP, CpG island methylator phenotype; CI, confidence interval.       
        
As shown in the table above, CMS1 tumours are characterised by high burden of MSI, 
CIMP and BRAF mutations and highly expressed genes involved in immune function 
(Guinney et al, 2015). CMS2 CRCs can be distinguished by activation of the Wnt and 
MYC pathway, whereas CMS3 CRCs mainly entail impaired metabolic pathways 
(Guinney et al, 2015). As for the CMS4 subtype, markers of lymphocytes as well as 
monocytes are expressed in these CRCs, which points to the epithelial-to-
mesenchymal transition of the tumour cells (De Sousa et al, 2013). The prognostic 
significance of the CMS was validated by an external cohort of 581 CRC patients 
(Lenz et al, 2019). The study found that the CMS as a risk factor was significantly 
associated with the OS and PFS of CRC patients. However, as indicated by the 
median survival estimates in Table 1-5, the predictive performance of the CMS is still 
suboptimal particularly for CMS3 and CMS4 patients who manifested similar survival 
outcomes (Lenz et al, 2019).      
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Other genetic factors 
With biotechnology advancing rapidly, more and more novel genetic markers have 
been detected and linked with prognosis of CRC. A review by Compton published in 
the UpToDate® systematically summarised factors associated with CRC prognosis 
(Compton, 2019) (URL1-11). According to Compton’s review, other genetic factors 
that have not been introduced in section 1.4.3 mainly include: gene expression 
profiles of oncogenes and tumour suppressor genes (Munro et al, 2005) (Ellis et al, 
2000), epigenetic changes such as methylation levels (Jiang et al, 2014), microRNA 
levels (Gao et al, 2018), and circulating tumour cells and tumour DNA (Garlan et al, 
2017) (Chou et al, 2018). A full list of these markers can be found in the review 
(Compton, 2019). Although a wide range of genetic factors have been identified, these 
markers were mostly reported by small studies with inconsistent findings or by studies 
without replication (Compton, 2019). Therefore, their exact effects on CRC prognosis 
still remain to be investigated.       
 
Non-genetic factors 
Pathological factors  
Based on the recommendations of Canadian Cancer Society (URL1-9), main 
pathological factors associated with CRC prognosis include: tumour stage, 
histological type and grade, lymphovascular invasion, and surgical margin.   
As described in section 1.3, the TNM stage that encompasses information on how far 
the tumour has advanced is instrumental in predicting survival outcomes of CRC 
patients. The numeric stage (I to IV), however, causes inevitable information loss from 
the original T, N and M measurements. In addition to accounting for the T, N and M 
stages separately, other modified measurements such as the lymph node ratio (the 
number of positive lymph nodes divided by the number of nodes examined) (Rausei 
et al, 2013), as well as other advanced data technologies such as machine learning 
(Hueman et al, 2019) have also been devised in an attempt to optimise prediction on 
CRC survival. However, the trade-off between stratification performance and 
attainability for clinicians ought to be balanced.  
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The histological type of CRC, for example the presence of signet ring cells, and 
tumour grade of differentiation harbour indications on biological behaviour related to 
tumour aggressiveness and therefore can serve as common prognostic factors of 
CRC. These effects have been well supported by large registry data (NCI, 2018).  
Lymphovascular invasion, defined by identification of tumour cells within veins or 
lymphatic vessels, can also inform poor prognosis (Yuan et al, 2017). Of note, 
lymphovascular invasion is listed in recommendations from both the American Society 
of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) 
as one of the risk factors for postoperative recurrence of stage II patients (Benson et 
al, 2004; Schmoll et al, 2012), which justifies more intensive therapy for these patients. 
Additional recommended pathological factors that increase the risk of postoperative 
recurrence include pathological T4 stage (pT4), grade 3 or 4 tumour and perineural 
invasion (Benson et al, 2004; Schmoll et al, 2012). Similar to lymphovascular invasion, 
perineural invasion has been associated with poor prognosis of CRC patients as 
identified by a previous meta-analysis (Knijn et al, 2016).  
Surgery with curative intent is instrumental in the management of CRC patients. A 
surgical margin refers to the unaffected normal tissue surrounding the removed 
tumour. Inferior survival outcomes of CRC have been associated with narrow margins, 
which indicates that the resected tumour is close to the surgical edge (Bernstein et al, 
2009).   
 
Clinical factors 
Bowel obstruction with or without perforation is generally reported to be associated 
with adverse survival outcomes of CRC (Chen & Sheen-Chen, 2000). Current 
guidelines also consider obstruction and perforation as risk factors that may warrant 
adjuvant chemotherapy for stage II CRC patients (Schmoll et al, 2012). It is worth 
noting that CRC cases with bowel obstruction and perforation tend to exhibit more 
invasive histopathological features that can potentially confound the observed 
association between these clinical manifestations and survival outcomes (Ghazi et al, 
2013).  
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The other prognostic factor listed by the Canadian Cancer Society is the circulating 
level of carcinoembryonic antigen (CEA). It is commonly used in clinical practice to 
monitor potential risk of postoperative recurrence of CRC. This association is 
independent from tumour stage (Thirunavukarasu et al, 2011). However, there is still 
a heated dispute over the best cut-off value for CEA level.  
 
Lifestyle factors 
Lifestyle after CRC diagnosis may also influence patients’ survival outcomes, 
although these factors were not officially recommended by either the Canadian 
Cancer Society (URL1-9) or the systematic review by Compton (Compton, 2019). A 
meta-analysis of prospective cohort studies found that increased physical activity after 
CRC diagnosis was associated with improved survival outcomes (Schmid & 
Leitzmann, 2014).  With respect to dietary factors after diagnosis, Meer et al. 
systematically reviewed published literature, and found no consistent findings 
regarding associations between dietary factors, such as overall dietary patterns, meat 
intake and alcohol intake, and survival outcomes of CRC patients (van Meer et al, 
2013). Future investigations are still needed to provide more solid evidence regarding 
the effects of lifestyle factors on CRC survival.    
 
Treatment 
It is well established that the treatment CRC patients receive can greatly influence 
their survival outcomes. Prognostic effects of certain treatment are estimated mostly 
via prospective studies, particularly randomised controlled trials (RCT), and thus are 
generally deemed credible evidence. In reality, however, the treatment variable itself 
is often not included in multivariable models, because of the challenges in obtaining 
detailed information in a large cohort regarding treatment regimens - such as number 
of completed cycles and presence of discontinuation of chemo- or radiotherapy. The 
flow of CRC management varies across different regions. In view of the scope of this 
thesis, only over-arching principles of patient management will be introduced here, 
according to the guidelines from the National Institute for Health and Care Excellence 
(NICE) (URL1-12).  
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In general, curative surgery is the centrepiece for all localised and regional CRCs. For 
stage I and part of stage II patients without any risk factors mentioned previously, no 
additional chemotherapy is needed following the surgery. Adjuvant chemotherapy is 
usually given to stage II (with one or more aforementioned risk factors) and stage III 
patients after surgery in order to reduce recurrence risk. Therapeutic agents for 
chemotherapy mainly include 5-fluorouracil/capecitabine alone or combined with 
oxaliplatin as the first-line regimen. Irinotecan is usually used as the second-line agent 
when the first-line does not work or incurs severe side effects.  
Regarding metastatic CRCs, a multidisciplinary team (MDT) effort is recommended. 
A curative surgery may be considered if both the primary and metastatic tumours are 
deemed potentially resectable. Chemotherapy, radiotherapy or targeted therapy 
(monoclonal antibody) may be applied to alleviate symptoms and shrink tumours. 
Notably, for rectal cancer that has grown into nearby tissues, preoperative (also 
known as neoadjuvant) short course radiotherapy or chemoradiotherapy may be 
considered to increase the chance of a tumour-free surgical margin.   
 
Other non-genetic factors 
Based on the systematic review by Compton (Compton, 2019), a wide range of factors 
have been reported to be associated with CRC prognosis, yet have not been officially 
recommended. These factors mainly include:  
●tumour budding (TB, defined as a single or cluster of tumour cells at the invasive 
margin of the cancer) (Rogers et al, 2016)  
●host immune function (e.g. density of tumour-infiltrating lymphocytes in the tumour 
tissue)(Pages et al, 2005) 
●intra-tumour microvessel density (Des Guetz et al, 2006)  
●tumour location(Petrelli et al, 2017) 
Further validation is needed before these factors can be officially recommended to 
guide CRC management.  
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1.5 Summary  
 
Colorectal cancer is the second most common and third most lethal cancer around 
the world. As of 2018, approximately 4.8 million people were living with CRC. In terms 
of incidence, an estimate of 1.84 million newly-diagnosed CRC cases was observed 
worldwide in 2018, and there will be an estimate of 2.2 million newly-diagnosed CRC 
patients per year by 2030.  Both inheritable genetic components and environmental 
factors can contribute to CRC susceptibility. Somatic genetic alterations in oncogenes 
(e.g. KRAS) and tumour suppressor genes (e.g. p53) are sequentially acquired during 
the development of CRC. Based on the incidence pattern, CRC can be categorised 
into hereditary (4-6%), familial (30-40%) and sporadic (50-60%) cases. Hereditary 
CRC s are mostly driven by rare germline mutations with high penetrance, such as 
mutations in the APC and MUTYH genes, whereas common germline variations with 
low penetrance have been found to be associated with increased risk of familial and 
sporadic CRC cases. In addition to genetic markers, environmental factors such as 
red or processed meat intake, cigarette smoking and alcohol consumption have also 
been linked to increased CRC susceptibility.  
There was a total of 0.88 million CRC-related deaths worldwide in 2018, and this 
number is projected to be 1.1 million per year by 2030.  The 5-year overall survival 
rate of CRC patients is approximately 60%. Colorectal cancer patients can be grouped 
into different stages (0 to IV) based on the extent of tumour invasion and 
dissemination at diagnosis. Patients diagnosed with more advanced stages show 
significantly worse survival outcomes.  Although tumour stage serves as a main 
indicator of CRC prognosis, a substantial amount of variation in terms of survival 
outcomes has been observed for patients diagnosed with the same stage. For 
example, the 5-year overall survival rates for stage II CRC patients can vary from 36% 
to 67%. Other known factors that may influence patients’ survival mainly include 
pathological features such as tumour grade and lymphovascular invasion, clinical 
manifestations such as bowel obstruction and treatment strategies for patients.  For 
genetic markers, somatic mutations involved in CRC carcinogenesis (e.g. KRAS and 
BRAF mutations) could have subsequent effects on survival outcomes of CRC. 
Previous evidence found familiar concordance of CRC patients in terms of their 
survival outcomes, indicating possible prognostic effects of germline genetic 
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variations. However, there is lack of solid evidence supporting associations between 
specific germline genetic loci and survival outcomes of CRC.   
 
 
Chapter 2 Study aims and objectives 
43 
 
Chapter 2 Study aims and objectives  
 
As introduced in Chapter 1, there has been both epidemiological and biological 
evidence supporting the overall effect of germline genetic background on survival 
outcomes of CRC. However, the genetic architecture of CRC survival still remains 
poorly understood, due to the paucity of hitherto identified genetic risk loci robustly 
associated with CRC survival. Although previous GWASs with small sample sizes 
reported possible associations between a few genetic variants and CRC survival, 
these associations have not been replicated and are subject to risk of false positive 
findings.  Moreover, it is also unknown whether incorporating these germline genetic 
variants into established prediction models of other prognostic factors can further 
improve predicting survival outcomes of CRC. Given this large knowledge gap, the 
overarching aim of this thesis is to examine associations between germline common 
variations and survival outcomes of CRC patients after diagnosis, to identify genetic 
variants that may be predictive, and to develop prediction models on CRC survival by 
integrating genetic predictors. The overall study design of the thesis is presented in 








Objective 2: To validate previously reported associations between germline 
genetic variants and CRC survival (presented in Chapters 4-6)  
Overall, there has been a paucity of solid evidence supporting associations between 
specific genetic risk loci and CRC survival. Currently, study designs for investigating 
population-based genetic associations include: candidate genetic association studies 
and genome-wide association studies (GWAS). Ioannidis et al. reported that ~99% of 
disease risk loci identified in candidate genetic association studies were unable to be 
validated due to flawed study design and various sources of biases (Ioannidis et al, 
2011); thus critical appraisal on the credibility of these claimed associations is crucial 
before efforts of replicating them in large cohorts. Given the lack of a field synopsis 
that could systematically summarise and appraise previous candidate genetic 
association studies, the main focus of this objective will be on validating genetic 
variants reported by GWASs that investigated survival outcomes of CRC. Findings of 
GWASs are also subject to risk of false positive findings due to millions of markers 
being tested in one study. Although procedures like multiple-testing correction can to 
some extent reduce this risk, it is still essential to validate GWAS-identified signals in 
large well-conducted cohorts. As discussed in Chapter 1, only three GWASs have 
been published and only a few variants, identified in a small cohort of 431 CRC 
patients, survived the stringent criteria of genome-wide significance (p<5x10-8). This 
further underpins the need of replication. For the second objective of the thesis, 
germline genetic variants that have been linked to CRC survival by GWASs will be 
retrieved by searching the GWAS catalogue (URL1-10). Associations between these 
variants and overall and CRC-specific survival will be validated in a Scottish cohort 
(details about the cohort will be presented in Chapter 4).  
 
Objective 3: To develop a multi-variable prediction model combining previous 
GWAS-identified genetic variants and other non-genetic prognostic factors 
(presented in Chapters 4-6)   
As opposed to the second objective where the focus is on the individual association 
between each variant and CRC survival, I aim to look into the predictive value of these 
previously identified variants as a group in predicting survival outcomes of CRC, 
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combined with common non-genetic predictors such as AJCC stage.  Efforts of 
identifying prognostic factors serve the ultimate goal of informing clinical decision-
making towards improved clinical outcomes for patients at various levels of risk. This 
relies on accurate prediction on prognosis for each patient.  Over the past decade, 
there has been an increasing interest in genomic prediction with the genetic 
underpinnings of disease outcomes progressively unravelled by large GWASs.  In the 
context of CRC, incorporation of GWAS-identified genetic variants has led to 
improved prediction on CRC risk compared with models with phenotypic variables 
only, although the incremental margin of performance is moderate (McGeoch et al, 
2019). However, similar predictions on prognostic outcomes have not been reported 
thus far. In this phase, genetic variants identified by previous GWASs on CRC survival 
will be used to develop a genetic predictor in CRC cases from the UK Biobank cohort 
(details in Chapter 4). Then the performance of this genetic predictor together with 
other non-genetic factors will be tested in the Scottish cohort.   
 
Objective 4: To investigate associations between CRC survival outcomes and 
candidate genetic variants using a hypothesis-driven approach (presented in 
Chapters 4-6)   
This objective is to explore the impact of two groups of genetic variants of interest on 
survival outcomes of CRC. Genetic variants used in this section will be identified from 
previously published GWAS meta-analyses and the GWAS catalogue (URL1-10) 
based on two prior hypotheses. Associations of these variants with overall and CRC-
specific survival will be tested in the Scottish cohort. Any statistically significant 
associations will be further validated in CRC cases from the UK Biobank cohort.   
Hypothesis 1: Genetic variants associated with CRC risk can subsequently affect 
tumour progression and metastasis, and therefore may be associated with CRC 
survival.  As introduced in the background, genetic events of CRC tumorigenesis, 
such as the KRAS and BRAF mutations, have also been shown to be associated with 
CRC prognosis, indicating possible continuing effects of these pathogenic genetic 
alterations on CRC progression and metastasis. Although survival difference between 
CRC patients carrying inherited predisposition, for example HNPCC, and sporadic 
cases is yet inconclusive, there has been interest in exploring the impact of genetically 
determined CRC susceptibility on subsequent survival outcomes. Recent large 
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GWAS meta-analysis expanded the spectrum of known common germline variants 
associated with CRC risk, allowing for further investigation in the prognostic 
significance of these CRC-risk variants.       
Hypothesis 2:  In relation to prognosis, there is possibly shared genetic basis across 
different cancer types. Hence, genetic variants associated with survival outcomes of 
other cancers may also influence CRC survival.  Early evidence of family-based large 
observational studies found that family history of a specific cancer also increased risk 
for other cancers, indicating common genetic basis of risk for multiple cancers 
(Amundadottir et al, 2004). This finding was further strengthened by later combined 
analysis of GWAS data on risk for multiple cancers.  Jiang and colleagues quantified 
genetic correlation among six cancers (head and neck, breast, lung, ovarian and 
colorectal cancer), and revealed shared genetic components contributing to risk for 
these cancers (Jiang et al, 2019). Although genetic correlations among prognostic 
outcomes of multiple cancers have not been explored due to the dearth of 
accumulated data, there has been other evidence suggesting these shared genetic 
components. For instance, several regulators in key pathways, such as the Notch 
signalling pathway, can modulate the invasion-metastasis cascade of multiple 
cancers by governing critical processes like epithelial-mesenchymal transition and 
tumour angiogenesis(Hu et al, 2012).  Beyond CRC, there have been GWASs 
investigating survival outcomes of a few types of other cancers; genetic variants 
identified in these studies will be tested as the second part of this objective.    
 
Objective 5: To discover potential novel genetic variants associated with CRC 
survival by performing a genome-wide association study (presented in 
Chapters 4-6)    
In general, the genetic architecture of CRC survival remains unclear. Under 
circumstances with limited prior knowledge, GWAS is a powerful approach for 
discoveries on disease related genetic risk loci, given large well-characterised cohorts 
of CRC patients being aggregated. In contrast to candidate gene approach, in a 
GWAS, the whole human genome is scanned, and thus novel genetic variants located 
in specific genomic regions involved in the prognosis of CRC can be found. The final 
objective of the thesis is to conduct a GWAS on CRC survival using the Scottish 
cohort. Any discoveries will be validated by a pooled analysis of CRC cases from the 
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UK Biobank cohort and three previously published CRC clinical trials (additional 
details in Chapter 4).   
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Chapter 3 Systematic literature review 
 
3.1 Introduction  
 
In Chapter 1, I presented a summary of background epidemiological evidence 
regarding both genetic and non-genetic factors that can potentially affect survival 
outcomes of CRC.  These factors are also known as ‘predictors’ when used to 
estimate the probability of a future event of interest, for example death within five 
years after diagnosis for CRC patients. This estimation process leverages information 
from a spectrum of predictors, and is widely recognised as risk prediction which can 
be realised by developing statistical prediction models. In clinical practice, prediction 
models can assist clinicians in their decision-making based on the specific risk profile 
of candidate predictors for a given patient.  Subsequent to Chapter 1 where prognostic 
factors are summarised, this chapter aims to further look at the real-world clinical utility 
of CRC prognostic factors in the setting of risk prediction by systematically reviewing 
published prediction models on CRC survival and conducting evidence synthesis to 
quantitatively evaluate the predictive performance of these models.  
This chapter presents a published paper in Surgical Oncology entitled ‘Performance 
of prediction models on survival outcomes of colorectal cancer with surgical 
resection: A systematic review and meta-analysis’ (He et al, 2019a). As 
introduced in Chapter 1, clinical and pathological factors, such as AJCC stage and 
tumour grade, are most commonly accepted as prognostic predictors for CRC, and 
these factors rely on assessment of tumour specimens retrieved from surgical 
resections. Therefore, the systematic review focuses on published studies including 
CRC patients who underwent surgical resections. Based on current clinical guidelines 
(see Chapter 1 page 38), this resulted in inclusion of all prediction models for stage I 
to III CRC patients and part of models for stage IV patients whose primary and 
metastatic tumours are considered resectable. Following the structure of the 
publication, this chapter is composed of introduction, methods, results, discussion and 
conclusion. As the main investigator of this published work, I conducted the literature 
search, study selection, data extraction and statistical analysis. A parallel review was 
conducted independently to screen for eligible studies by a medical student (Ong Y. 
from the Western General Hospital, Edinburgh). Another investigator—Wang Z. (West 
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China Hospital, Chengdu) helped check the extracted data, and Li X. (Usher Institute, 
Edinburgh) independently appraised the quality of a randomly selected subset of 
included studies. I drafted the manuscript and revised it based on the comments from 
the editor and peer reviewers of the journal.  Other authors (Theodoratou E, 
Farrington S, Campbell H, Dunlop M, Timofeeva M, Din F, and Brown E) critically 
reviewed and edited the manuscript.       
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3.2 Systematic review and meta-analysis on prediction 
models of survival outcomes of colorectal cancer  
 
Title: Performance of prediction models on survival outcomes of colorectal 
cancer with surgical resection: A systematic review and meta-analysis 
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3.2.1 Abstract  
 
Prediction models allow accurate estimate of individualized prognosis. Increasing 
numbers of models on survival of CRC patients with surgical resection are being 
published. However, their performance and potential clinical utility have been unclear. 
A systematic search in MEDLINE and Embase databases (until 9th April 2018) was 
performed. Original model development studies and external validation studies 
predicting any survival outcomes from CRC (follow-up ≥1 year after surgery) were 
included. We conducted random-effects meta-analyses in external validation studies 
to estimate the performance of each model.  A total of 83 original prediction models 
and 52 separate external validation studies were identified. We identified five models 
(Basingstoke score, Fong score, Nordinger score, Peritoneal Surface Disease 
Severity Score and Valentini nomogram) that were validated in at least two external 
datasets with a median summarized C-statistic of 0.67 (range: 0.57-0.74). These 
models can potentially assist clinical decision-making. There is a pressing need for 
more external validation studies so as to evaluate the performance of other abundant 
published prediction models that have not been adequately validated. Future research 
should also focus on investigating the real-word impact and cost-effectiveness of 
existing prediction models for CRC prognosis in clinical practice.   
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3.2.2 Introduction  
 
Colorectal cancer (CRC) is responsible for 8.5% of deaths attributed to cancer 
worldwide(Ferlay et al, 2015). The overall 5-year survival of CRC varies from 50% to 
81% even within stage II CRC patients. This within-stage variation can be explained 
to some extent by a wide range of other established prognostic factors such as 
carcinoembryonic antigen (CEA)(Spindler et al, 2017). Although surgery is the 
mainstay treatment modality, prognostic modelling integrating these factors may help 
optimize individualized clinical decision-making on targeting adjuvant treatment to 
those at most risk of relapsing and who may respond better to certain treatment 
modalities(Vickers, 2011), so as to minimize the potential harms of overtreatment. 
Over the past decades, numerous statistical prediction models have been developed, 
incorporating various variables such as demographic(Bowles et al, 2013), 
genetic(Goossens-Beumer et al, 2015a) and clinic-pathological(Bowles et al, 2013) 
factors. However, their performance, reliability and clinical validity have been unclear.  
This systematic review aims to provide a comprehensive overview of current 
prognostication models for CRC patients undergoing surgical resection, to perform 
meta-analysis for models that have been validated in multiple datasets, as well as to 





Literature search and study selection   
This study was conducted in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement(Moher et al, 2009). A 
systematic search (limited to English and human studies) was performed in MEDLINE 
and Embase from inception to April 9th 2018 to identify all relevant studies. Three sets 
of search terms, “Colorectal cancer”, “Prognosis” and “Prediction model”, were 
applied.  The search strategy was formulated based on the search filter for identifying 
clinical prediction studies(Ingui & Rogers, 2001) and previous publications(Brush et 
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al, 2011) (detailed search syntax presented in Table 3-1). The reference list of each 
eligible article was also cross-checked.  
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Table 3-1 Search strategy for the systematic review   
Database: MEDLINE (limit to English language and human studies; not 
review or editorial or letter or comment) 
exp Colorectal Neoplasms/ or ((rectal or rectum or colonic or colon or colorectal) 
adj2 (cancer* or carcinoma* or neoplas* or tumor* or tumour* or malignan* or 
adenocarcinoma* )).mp.  
AND 
exp Prognosis/ or prognos*.mp. or Survival Analysis/ or Survival/ or surviv*.mp. 
or mortality.mp. or exp Mortality/ or metastas*.mp. or Neoplasm Metastasis/ or 
recurren*.mp. or Neoplasm Recurrence, Local/ 
AND 
exp Models, Statistical/ or predict*. ab,ti. or validat* .ab,ti. or Validation Studies/ 
 
 Database: Embase (limit to English language and humans; not review or 
editorial or letter or comment, excluding MEDLINE journals) 
exp colorectal cancer/ or rectum tumor/ or colon tumor/ or ((rectal or rectum or 
colonic or colon or colorectal) adj2 (cancer* or carcinoma* or neoplas* or tumor* 
or tumour* or malignan* or adenocarcinoma* )).mp.   
AND   
prognos*.mp. or cancer prognosis/or exp survival or surviv*.mp. or metastasis/ 
or metastas* .mp. or cancer recurrence/ or recurren*.mp. or mortality/ or cancer 
mortality/ 
AND   








We applied the following inclusion criteria: 1) studies developing or validating 
statistical model(s) based on time-to-event data to predict survival outcome (≥ 1 year) 
in CRC patients with surgical resection; 2) studies with at least two predictors; 3) 
studies that reported a quantitative measure of any aspect of model performance, 
such as metrics evaluating overall performance, discriminative ability and calibration. 
Conference abstracts, editorials and commentaries were excluded. Studies were also 
excluded if the prediction rule of the model was unavailable.       
Two reviewers (YH and YO) screened the titles and abstracts independently. 
Potentially relevant articles were reviewed in full. Any disagreement was resolved by 
discussion, and a senior author (ET) was consulted if necessary.           
 
Data extraction and critical appraisal   
One reviewer (YH) extracted all relevant data following the guidelines of conducting 
systematic reviews of prediction model studies(Debray et al, 2017). A second 
reviewer (ZW) verified the accuracy of the extracted data. Model performance metrics 
that evaluated discriminative ability (Harrell’s C statistic, also known as the area under 
the receiver operating characteristic curve (AUC)), calibration (e.g. calibration plot), 
and other metrics (e.g. R2) were extracted. If a paper reported multiple models with 
different predictors or prediction rules, data were extracted separately for each model.   
We appraised each model using the CHecklist for critical Appraisal and data 
extraction or systematic Reviews of prediction Modelling Studies (CHARMS)(Moons 
et al, 2014). Based on this checklist, the risk of bias for each model was assessed 
following the criteria described in previous publications (Lamain–de Ruiter et al, 2017; 
Smit et al, 2015) which included six domains: 1) Participant selection; 2) Measurement 
and reporting of predictors; 3) Definition and measurement of the outcome; 4) Events 
per variable (EPV); 5) Attrition (loss to follow-up); 6) Data analysis. Details for the 
assessment rules are summarised in Appendix Table S1. One reviewer (YH) 
appraised all included studies. A second blinded reviewer (XL) evaluated a 25% 
random sample of all studies and cross-checked for any discrepancies.     
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Statistical analysis  
Based on data availability, we performed meta-analyses of C statistics across external 
validation studies that evaluated the same prediction model to estimate the overall 
discriminative performance for each model. The original dataset used to construct the 
model was not included in the meta-analysis to avoid inflated estimates (Debray et al, 
2017). We rescaled the C statistic by applying a logit transformation (Debray et al, 
2017). The extracted 95% CI of a C statistic was used to estimate its variance, and if 
this was not reported, the formula proposed by Debray et. al was used to approximate 
the 95% CI(Debray et al, 2017). The C statistic was considered statistically significant 
if the 95% CI excluded 0.5(Hosmer & Lemeshow, 2000).  Given the relatively small 
number of validation studies for each model and the inherent heterogeneity across 
external datasets with diverse populations and clinical settings, we adopted the 
restricted maximum likelihood (REML) estimation along with the Hartung-Knapp-
Sidik-Jonkman (HKSJ) method under a random-effects model to estimate the pooled 
C-statistic and 95% CI {IntHout, 2014 #850}. We also calculated the 95% prediction 
interval (PI) integrating the heterogeneity for the summarised C statistic to indicate a 
possible range where a C statistic of a future validation study may be located (Higgins 
et al, 2009; IntHout et al, 2016).  Due unavailable data, we were unable to perform 




Overview of eligible models     
We obtained 15,465 unique records from the initial search. An additional validation 
study was identified from cross-checking the reference of eligible studies(Takakura et 
al, 2011).  In total, 83 articles comprising 83 original model development studies and 
52 separate external validation studies (Appendix Table S2-S3) were included in this 
systematic review. The detailed study selection is summarised in Figure 3-1.    
 





Figure 3-1 Flow diagram of study selection 
 
Among the 83 model development studies, forty-five (54%) of these original models 
were based on early to locally advanced CRC (stage I-III) patients, and 24% (N=20) 
focused on metastatic CRC. As for the predictors, these models included a median of 
5 predictors (range 2 to 18).  Age was the commonest predictor (N=56, 67%). Other 
common predictors included CEA (N=26, 31%), tumour grade or differentiation (N=23, 
28%), sex (N=19, 23%), T stage (n=16, 19%) and N stage (N=16, 19%). Surgery type 
was adopted as a predictor in 13% (N=11) of all models. The majority of the models 
(N=73, 88%) were developed using Cox proportional hazards regression. Other 
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methods included Weibull regression(Peng et al, 2018) and tree-based 
models(Arostegui et al, 2018).  The main outcome to be predicted was overall survival 
(OS) (N=47, 57%), disease-free survival (DFS) (N=17, 20%) and CRC specific 
survival (N=13, 16%). The prediction time horizon varied from 1 year to 10 years, with 
80% (N=66) of the models reporting a 5-year prediction horizon.  To adjust for 
potential overfitting, 44 (53%) models were internally validated using split-sample, 
bootstrapping or cross-validation. Twenty-eight (34%) models were validated in an 
external dataset by the same group of investigators. Only 11 (13%) models were 
externally validated by independent investigators. For model presentation, 55 of the 
83 models (66%) were presented as nomograms, and the remainder as formulae, 
prediction rules, or web-based calculators.  Detailed characteristics for each model 
development study are presented in Appendix Table S2.  
Among the 52 separate external validation studies (detailed characteristics in 
Appendix Table S2), 22 (42%) of them validated original models identified in our 
systematic review. For the other 30 studies validating pre-existing models where the 
model performance was not evaluated in the initial model development reports, we 
evaluated their performance in these external validation studies. The study cohorts of 
external validation studies had significantly smaller sample size than model 
development studies (median 277 vs. 814, Mann-Whitney-Wilcoxon test: P<0.001). 
The comparison of basic characteristics between model development and external 
validation studies are summarised in Table 3-2.  
 
Table 3-2 Summarised basic characteristics of included model development studies and 
external validations 
Variables Model Development(N=83) External validation(N=52) 
   
Participants (CRC patients)   
Cohort origin    
Europe  16(19%) 23(44%) 
Asia  52(63%) 19(36%) 
America    15(18%) 5(10%) 
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Variables Model Development(N=83) External validation(N=52) 
Other 0 5(10%) 
   
CRC Stage    
I-III 45(54%) 8(15%) 
IV 20(24%) 44(85%) 
Any 18(22%) 0 
   
Tumour location    
Colon  15(18%) 3(6%) 
Rectum  16(19%) 3(6%) 
Any 52(63%) 46(88%) 
   
Sample size   
<500 28(34%) 9(17%) 
>=500 55(66%) 43(83%) 
   
No. predictors    
<5 30(36%) 16(31%) 
 5-10 50(60%) 36(69%) 
>10 3(4%) 0 
   
Outcome   
Overall survival  47(57%) 24(46%) 
Chapter 3 Systematic literature review 
61 
 
Variables Model Development(N=83) External validation(N=52) 
CRC-specific survival  13(16%) 16(31%) 
Disease-free survival  17(20%) 11(21%) 
Recurrence-free survival  7(8%) 15(29%) 
Other 10(12%) 3(6%) 
   
Model discrmination    
C statistic/AUC 76(92%) 50(96%) 
Other† 4(5%) 5(10%) 
   
Model calibration    
Calibration plot 47(57%) 7(13%) 
Hosmer-Lemeshow test 6(7%) 0 
   
Internal validation    
Split sample  14(17%) NA 
Bootstrapping  13(16%) NA 
Cross validation  18(22%) NA 
Not reported 39(47%) NA 
   
Model presentation    
Nomogram  55(66%) NA 
Formula  21(25%) NA 
Other** 7(8%) NA 
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*including D-statistic, sensitivity and specificity.    
**including score rule and decision tree.    
CRC, colorectal cancer; AUC, area under receiver’s operating characteristic curve. 
 
 Critical appraisal    
Risk of bias distribution of each domain for all included studies is summarised in 
Figure 3-2. Overall, only two models reported by one article were classified as low 
risk of bias for all domains (Rees et al, 2008a). The majority of the models were 
classified as ‘low’ risk for participant selection (N=97, 72%), predictors (N=104, 77%), 
outcome (N=122, 90%), and EPV (N=74, 89%).  However, for dataset attrition, 71 
studies (53%) were classified as ‘high’ risk, and with regard to data analysis, most 
studies (N=104, 77%) were classified as ‘moderate’ risk of bias.  The detailed scores 
of risk of bias for each domain are presented in Appendix Table S4 (model 
development studies) and Appendix Table S5 (external validation studies).    




Figure 3-2 Risk of bias assessment for six predefined domains for each included study. For 
participant selection, studies were rated as ‘moderate’ risk of bias if participants were 
possibly selected in a non-consecutive manner as this allowed for potential selection bias. 
We categorized studies to be high risk of bias if their selection criteria were inadequately 
described. With respect to the predictors, we assigned ‘moderate’ risk to studies where it 
was unclear whether the predictors were measured after the outcome was revealed, and 
‘high’ risk to studies where the measurement of predictors was not clearly described.  For 
the outcome domain, studies were assigned with ‘moderate’ risk when the measurement of 
CRC recurrence or progression was not clearly stated and ‘high’ risk if the whole follow-up 
procedure was not adequately described. For EPV, studies were scored as ‘moderate’ risk 
with an EPV between six and ten, and ‘high’ risk if their EPVs could not be calculated or 
were less than six. Studies were assigned with ‘high’ risk of attrition bias if insufficient 
information on loss to follow-up, and ‘moderate’ risk due to less than 20% of loss to follow-
up. In relation to data analysis, studies were classified as ‘moderate’ risk given that either 
internal validation or missing data handling was not performed, and as ‘high’ risk if they 
neglected to report on either. The detailed classification rules are summarized in Appendix 
Table S1. 
 
Model performance   
Of all studies, 126 (93%) reported a C statistic to assess the discriminative ability of 
the model. The reported C statistic for model development studies was significantly 
larger than external validation studies (median 0.73 vs. 0.66, Mann-Whitney-Wilcoxon 
test: P<0.001).   
We performed 15 meta-analysis for including eight models (each single model can be 
applied to predict multiple survival outcomes) that had been externally validated at 
least twice: Basingstoke preoperative score, Fong score, Iwatsuki score, Memorial 
Sloan Katherine Cancer Centre (MSKCC) nomogram, Nordinger score, Peritoneal 
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Surface Disease Severity Score (PSDSS), Kanemitsu nomogram and Valentini 
nomogram. Their basic characteristics and estimate C statistics from meta-analysis 
are presented in Figure 3-3. We found significant discriminative ability for five models 
predicting six outcomes: the Basingstoke score (preoperative) predicting recurrence-
free survival (RFS), the Fong score predicting RFS; the Nordinger score predicting 
RFS; the PSDSS score predicting OS; the Valentini nomogram predicting distant 
metastasis and OS. The pooled C-statistic of these six meta-analyses ranged from 
0.57 to 0.74 (median 0.67). We were able to calculate the 95% PI for five meta-
analyses (Figure 3-3). The 95% PI of all the five models crossed 0.5, suggesting that 
a future validation study could possibly found a negative discriminative performance 
of that model. 




Figure 3-3 Summarised C statistics of prediction models included in meta-analysis. Adapted from the original publication with permission 
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The Fong score was the most commonly validated model. It utilized seven predictors 
(positive resection margin, extrahepatic lesion, lesion of regional lymph nodes for 
primary tumour, metastases-free period, number of metastases, the largest size of 
metastasis and CEA) to predict the RFS and OS of CRC patients with liver metastasis 
after curative resection. The meta-analysis found a significant C-statistic of 0.62 (95% 
CI: 0.55-0.68) for RFS prediction, but non-significant for OS 0.60 (C-statistic=0.60 95% 
CI: 0.45-0.74). The strongest discriminative performance in relation to point estimates 
of C statistics was observed for the Basingstoke preoperative score (C statistic: 0.74, 
95% CI: 0.52-0.88) and the Valentini nomogram (C statistic: 0.74, 95% CI: 0.60-0.85). 
For model calibration, 54 (40%) of all studies presented a calibration plot. Six studies 
employed the Hosmer-Lemeshow test to explore the overall goodness of model fit, 
and none of them reported a statistically significant departure of predicted outcomes 
from observed (Table S4). We were unable to quantitatively synthesize the model 
calibration because none of the studies reported the slope of the calibration plot or 
observed-to-expected events ratio.    
 
3.2.5 Discussion  
 
Interpretation and clinical application  
To the best of our knowledge, this is the first systematic review and meta-analysis 
evaluating the performance of prediction models for survival outcomes of CRC 
patients with surgical resection. Prediction models can assist in estimating 
individualised prognosis, therefore guiding more precise treatment for CRC patients. 
In this study, we reviewed 83 original prediction models along with 52 external 
validation studies, and identified eight models that had been externally validated at 
least twice demonstrating significant discriminative performance.  
With regard to predictors, most of the included models were based on common 
demographic and clinic-pathological factors. Genetic markers such as RAS, BRAF 
mutations and microsatellite instability (MSI) have already been recommended to 
guide treatment for metastatic CRC. However, their predictive performance has barely 
been investigated in existing prediction models. Other strong prognostic factors for 
CRC such as chemo- or radiotherapy were only adopted in a small proportion of 
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included models (13/83) due to limited data accessibility. For the CRC community, 
therefore, these variables should be routinely recorded in the future to develop 
stronger prediction models. Exploring the potential incremental predictive value of 
these prognostic predictors and other novel markers such as circulating tumor cells 
(CTC) (Rahbari et al, 2010) and immune-scores(Mlecnik et al, 2018), is still of merit.    
In relation to model performance, the Fong score is the most commonly studied model 
and it has been externally validated four times. The European Society for Medical 
Oncology (ESMO) consensus guidelines has discussed possible application of this 
score to guide adjuvant treatment for CRC with liver metastasis after 
hepatectomy(Van Cutsem et al, 2016), but no formal recommendations have been 
made. Our study identified statistically significant but modest discriminative ability for 
this score (C statistic: 0.62 for RFS) as well as other models (range 0.55 to 0.74), 
which merits further improvement. Additionally, the relatively small number of external 
validations for each model and inherent heterogeneity across different clinical settings 
resulted in C statistics with wide PIs crossing the null. The estimate discriminative 
performance of these models should therefore be interpreted with caution. Whilst 
most models adopted the C statistic to evaluate the discriminative ability, its limitations 
have been widely discussed. For instance, it is hard to interpret the variation among 
C statistics to compare the performance of different models derived from the same 
sample (Diouf et al, 2014; Kawai et al, 2015). Novel metrics, such as the expected 
information for discrimination(McKeigue, 2018), may be adopted in future research. 
Our review also found that model calibration was poorly reported, which made it even 
more challenging to evaluate the model accuracy.  
 Risk of bias evaluation 
The main sources for risk of bias for the current models stemmed from potential cohort 
attrition and methodological flaws in data analysis. The vast majority of included 
studies did not specify the presence and extent of loss to follow-up in the study cohort, 
which could bias the results and affect their validity(Dettori, 2011).  With regard to 
data analysis, none of the external validation studies in our review reported how the 
missing data were dealt with, and only 22% of the model development studies 
employed missing data imputation. In addition, according to the CHARMS checklist 
and the proposed checklist of Transparent Reporting of a multivariable prediction 
model for Individual Prognosis Or Diagnosis (TRIPOD) (Moons et al, 2015), future 
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model development studies should also present more detailed prediction rules 
including the intercept or baseline survival to allow for individualized risk prediction 
rather than simply stratify CRC patients into risk groups. As for validation studies, our 
review identified a paucity of external validation studies that compared the validation 
dataset with the original model development dataset in terms of characteristics of 
participants and distribution of predictors.  Model updating, if necessary, is also 
expected to be conducted and clearly presented in future validation studies.  It should 
be noted that the CHARMS checklist is less sensitive to some sources of bias specific 
to survival analysis. For example, some predictors that can vary with time such as 
chemotherapy dosage, BMI and other biomarkers are mostly assessed as a fixed 
baseline measurement, and other predictors such as second-line therapy are 
immeasurable at the baseline, resulting in possible time-dependent bias(van 
Walraven et al, 2004).                    
 Model validation and impact studies 
Model performance can be artificially inflated if the metrics are simply estimated based 
on the original sample that was used to develop the model(Harrell et al, 1996). This 
‘over-optimism’ could be attenuated with internal validation. However, only half of the 
model development studies identified in our systematic review reported internal 
validation metrics. Fourteen (32%) of these models adopted split-sample approach 
despite this method being less favored due to its inefficiency (Steyerberg et al, 2001). 
Future studies should consider more sophisticated internal validation methods such 
cross-validation and bootstrapping(Steyerberg et al, 2001).  External validation can, 
but is not limited to, quantify the potential overfitting of the original model and explore 
the generalizability of a model in diverse clinical settings (Collins et al, 2014). It is 
ideally performed by independent investigators to avoid over-interpretation(Collins et 
al, 2014), but of note, only 13% of the new models in our review have been externally 
validated by independent investigators. Furthermore, all the external validation 
studies reported by independent investigators evaluated models constructed and 
published prior to 2011, and therefore, future work on validating newer CRC 
prognostic models is required.    
It is also noteworthy that we failed to identify any impact studies, which are critical in 
defining the models’ real-world impact by head-to-head comparisons(Moons et al, 
2009). Aside from that, cost-effectiveness should also be evaluated by health 
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economic modelling, which is scarce in current CRC prognostic models(van Giessen 
et al, 2017). Finally, few studies have explored how prediction models can be 
integrated into the clinical workflow(Vickers, 2011), which will also have ramifications 
on their clinical utility.   
Limitations 
Our study has several limitations. Firstly, the majority of the included models were 
constructed and validated in developed countries. The performance of these models 
remains unclear, and therefore, needs to be validated and updated in other 
epidemiological settings. It is also imperative to develop and validate models in those 
less-studied areas especially where increasing CRC mortality rates have been 
observed (such as Eastern Europe and South America)(Arnold et al, 2017). Secondly, 
our literature search was restricted to English-language publications, inadvertently 
omitting models developed or validated in some other populations. Thirdly, the 
relatively small number of included validation studies (<5) for each meta-analysis and 
between-study heterogeneity led to wide confidence intervals. Therefore, the results 
of each meta-analysis ought to be interpreted with caution, and need to be updated 
as more validation studies for these models become available. In addition, our meta-
analysis was based on reported face value of model performance metrics such as C 
statistics. Multiple adaptations that enable the calculation of the C statistic from time-
to-event data have been proposed (Austin et al, 2017; Blanche et al, 2013). However, 
most included models did not report this information, which made it challenging to 
harmonize the extracted statistics and could compromise the accuracy of the meta-
analysis. Fourthly, this study aimed to comprehensively review the performance of 
existing prediction models for CRC prognosis. Potentially useful models that did not 
report a quantitative measure of model performance were excluded, although this has 
been mitigated to some extent by the inclusion and evaluation of any available 
external validation studies of these models. Lastly, studies without a clear prediction 
rule, such as models derived from genomic data using neural network, were also 
excluded. It is impractical for these exploratory models to be validated by independent 
investigators, and so they are beyond the scope of this systematic review.                      
 Conclusion  
Although there exist abundant prediction models on survival outcomes of CRC 
patients with surgical resection, only five of them (Basingstoke score, Fong score, 
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Nordinger score, Peritoneal Surface Disease Severity Score and Valentini nomogram) 
have been externally validated in at least two datasets. Most of these scores 
demonstrate significant discriminative ability, which may potentially assist clinical 
decision-making. However, other aspects of these five models such as model 
calibration, their impact in real-word and cost-effectiveness should be further 
investigated before formal recommendation can be made for use in clinical practice. 
As for other models that have not been validated in independent datasets and are 
subject to risk of bias, current evidence is insufficient to evaluate their performance 
externally, which does not support for these models to be routinely applied. Future 
research should focus not only on constructing new models with novel predictors, but 
also on validating and investigating the impact of existing prediction models to 




This chapter presents a published systematic literature review regarding prediction 
models on survival outcomes of CRC patients. I reviewed 83 original model 
development studies and 52 external validation studies.  This review found that the 
majority of published prediction models had not been validated by external datasets, 
and their performance could potentially be overestimated in the original report. As for 
models that had been validated in at least two datasets, five models were identified 
by meta-analysis with significant discriminative ability to predict survival outcomes of 
CRC. No cost-effectiveness analyses or model impact studies were identified in this 
review, indicating that future efforts are still warranted before these prediction models 
can be applied in routine practice to guide more accurate patient management.  In 
this review, I also summarised the predictors employed in published prediction models.  
However, none of the included prediction models adopted germline genetic variations 
as predictors to develop their models, indicating the paucity of solid evidence on 
associations between any germline variants and survival outcomes of CRC.  The 
following chapters of the thesis will leverage multiple patient cohorts and explore 
potential effects of germline genetic variations on CRC survival.
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Chapter 4 Materials and methods 
 
4.1 Introduction  
 
This chapter mainly describes materials and methods used in this thesis. It consists 
of two sections. In the first section, datasets including the Study of Colorectal Cancer 
in Scotland (SOCCS), CRC cases from UK Biobank and three previously published 
clinical trials will be introduced. The second section describes at length the study 
design and the main steps of data analysis for genetic association studies, prediction 
modelling and the GWAS. 
 
4.2 Data sources   
 
4.2.1 The Study of Colorectal Cancer in Scotland   
 
The Study of Colorectal Cancer in Scotland (SOCCS) is a population-based case 
control study which has been actively recruiting CRC patients and matched healthy 
controls (age, sex and health board) from all areas of Scotland since February 1999. 
It should be noted that controls were only used for other research purposes such as 
investigating risk factors for CRC susceptibility. For analysis in this thesis, only CRC 
cases from the SOCCS were used as a case cohort to explore survival outcomes of 
patients. The main aim of the SOCCS study is to investigate genetic and 
environmental factors contributing to CRC risk and survival outcomes. This study was 
funded by CRUK, Medical Research Council (MRC) and Chief Scientist Office of the 
Scottish Executive (CSO).   
 
Research Ethics approval  
The SOCCS study was approved by the MultiCentre Research Ethics committee for 
Scotland (MREC; approval number MREC/ 01/0/0), 18 Local Research Ethics 
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committees, 18 Caldicott guardians and 16 NHS Trust management committees 
(Theodoratou et al, 2008). Informed consents were signed by participants regarding 
their DNA samples and other relevant clinical and lifestyle data being stored and used 
by the research team based in the University of Edinburgh as well as collaborators 
from other research groups. Each participant was assigned a unique identification 
number and all data were entered into an anonymised Access database (except the 
genotype data which are also anonymised and stored separately).    
Inclusion and exclusion criteria for CRC cases   
The SOCCS study consists of two phases.  Participants recruited from February 1999 
to 2006 formed the first phase of the study.  For this phase, all incidental CRC cases 
throughout Scotland were included in the study if they were:  
1) histologically diagnosed with CRC  
2) were 16 to 84 years of age 
3) permanently resident in Scotland   
The diagnosis of CRC was confirmed histologically by referring to patients’ 
pathological reports.   
Patients were excluded if they were:  
1) recurrent colorectal cancer cases;    
2) unable to provide informed consent, for example if they were too ill or had mental 
health disorders.  
The second phase of the SOCCS study consists of incident CRC patients recruited 
from 2007 onwards at the Western General Hospital, Edinburgh.  In this phase, UK 
residents of 16 years or older with a diagnosis of CRC at any time were included. 
Other inclusion and exclusion criteria remained the same.    
Genotype data   
Blood samples were collected at recruitment and leucocyte DNA was extracted 
following standard protocols. DNA samples were genotyped using the Illumina® 
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HumanHap300, HumanHap240S and OmniExpressExome BeadChip 8v1 arrays. 
Detailed specifications of these genotyping arrays can be found at the Illumina® 
Support Centre (URL4-1). As of December 2018, a total of 6,366 CRC cases and 
14,692 controls were genotyped in the SOCCS study.  
Quality control 
Dr Maria Timofeeva, a statistical geneticist in the Colon Cancer Genetics Group, 
performed the quality control and imputation for the genotype data of the SOCCS 
cohort. Detailed technical information can be found in previous publications (He et al, 
2018b; Law et al, 2019). In particular, the quality control was conducted in 
concordance with the protocol proposed by Anderson and colleagues (Anderson et 
al, 2010). Participants were excluded based on the following criteria, and detailed 
numbers of individuals excluded in each step are presented in Chapter 5.       
1) High missing rate of genotyping (>5%). This is an indicator of possible low quality 
of the DNA sample, which can potentially impair the genotyping accuracy.  
2) Abnormal heterozygosity (>3 standard deviations from the mean). Extreme 
heterozygosity rates indicate possible contamination of the DNA sample or inbreeding.    
3) Discordant sex classification.   
4) Individuals recruited twice or who had first-degree relatedness to other included 
participants.  
5) Evidence of non-white European ancestry. This was evaluated by principal 
component analysis (PCA) in conjunction with samples of European ancestry from 
the 1000 Genome Project (URL4-2).  PCA is a method that evaluates the 
resemblance among samples under study by clustering them based on a range of 
their features. For example, samples in the SOCCS study were clustered according 
to a few hundred thousand of genetic variants arrayed. This method incorporates 
common genetic variants (minor allele frequency>1%) throughout the germline 
genome into a restricted number of independent principal components (PCs) that are 
numbered by a descending order of importance--that is, PC1 accounts for the largest 
amount of genetic difference across all included individuals.  Principal components 1 
and 2 are plotted in Figure 4-1 and Figure 4-2 to show the clusters of individuals in 
the SOCCS and the 1000 Genome Project.   




Figure 4-1 Principal components clustering of individuals in the SOCCS study with 
European (EUR), Asian (ASN) and African (AFR) populations from the 1000 Genome 
Project.  Created by Dr. Maria Timofeeva (Institute of Genetics and Molecular Medicine, 




Figure 4-2 Principal components clustering of individuals in the SOCCS study with 
European populations of the Northern and Western European Ancestry (CEU), Toscani in 
Italia (TSI), Finnish in Finland (FIN), British in England and Scotland (GBR) and Iberian in 
Spain (IBS) from the 1000 Genome Project. Created by Dr. Maria Timofeeva (Institute of 
Genetics and Molecular Medicine, Edinburgh) and used with permission. 
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As shown in these two figures, all SOCCS samples clustered tightly with the five 
European populations sequenced as part of the 1000 Genome project (Figure 4-2)—
Northern and Western European Ancestry (CEU), Toscani in Italia (TSI), Finnish in 
Finland (FIN), British in England and Scotland (GBR), and Iberian Population in Spain 
(IBS), yet no clustering with Asian and African populations was detected (Figure 4-1). 
The closely clustered samples from the SOCCS cohort indicate that population 
structure is unified and therefore relatively unlikely to affect observed associations 
between genetic markers and phenotypes.  
Imputation 
Genotyping arrays are normally designed to detect a limited number of genetic 
variants (usually 250,000 to 500,000 variants) instead of the entire set of common 
genetic variants throughout the human genome. Especially for large-scale genetic 
association studies with thousands of samples included, it is often too costly to 
sequence the whole genome for each individual. Nonetheless, genetic variants 
genotyped by arrays, also known as tag variants, are still informative given the 
ubiquitous linkage disequilibrium (LD) throughout the genome. Linkage disequilibrium 
reflects the fact that alleles at nearby genetic loci tend to be inherited together, leading 
to non-random associations among these alleles.  In an attempt to leverage these 
associations among correlated genetic loci, a range of imputation methods have been 
proposed to infer undetected genotypes that can be used to map genetic risk loci for 
specific disease outcomes. Imputation increases the density of genetic variants and 
hence adds extra statistical power to discover potential genetic loci. The imputation 
process for the SOCCS study is briefly introduced here.    
After an extensive procedure of quality control, the genotype data of the SOCCS study 
were phased using the SHAPEIT (v2.r837) software (Delaneau et al, 2011). Phasing, 
also known as haplotype estimation, refers to the statistical method used to infer the 
haplotypes—combinations of genotypes that are inherited together— based on 
arrayed genotypes. For instance, the genotypes of two loci are detected as ‘AB’ and 
‘AB’ (A and B refer to different alleles); then the haplotypes in theory can be ‘AB/AB’ 
or ‘AA/BB’. A variety of probabilities models have been developed to estimate the 
most likely haplotypes—that is, to reconstruct the chromosome origin for each allele. 
The SHAPEIT software adopts a linear complexity method to estimate haplotypes and 
additional details regarding the estimation process are presented elsewhere 
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(Delaneau et al, 2011). There has been evidence showing that inferring haplotypes 
prior to imputing genotypes can improve accuracy and efficiency of imputation, and 
therefore has been recommended by the operating manual of the IMPUTE2 software 
(URL4-3).    
The inferred haplotypes were then passed to the IMPUTE2 software for the imputation 
of untyped genotypes (URL4-3). The IMPUTE2 module operates based on the 
imputation method proposed by Howie et al (Howie et al, 2009). Figure 4-3 depicts 
the conceptual framework of imputation. The basic idea is to compare the genotyped 
sample with a reference panel from the same ancestry that has been more densely 
genotyped or sequenced, so as to infer unknown genotypes of the sample leveraging 
the genomic LD structure.   
  
Figure 4-3 Conceptual framework for genotype imputation.  Horizontal boxes denote 
haplotypes of the reference panel. Reproduced from (Howie et al, 2009) with permission. 
The original source is covered by a Creative Commons Attribution License.   
 
 
The reference panels we used for imputation were the UK10k release (ALSPAC and 
TWINSUK studies, April 2014 release), and the 1000 Genome V3 (December 2013 
release). All variants were coded and mapped to their chromosome positions based 
on the Genome Reference Consortium Human Build 37 (GRCh37)—a digital 
database of DNA sequences which was derived from a number of volunteers recruited 
from the USA and released in February 2009 (URL4-4).  We excluded variants that 
have discrepancies in strand (5’ end to 3’ end or 3’ end to 5’ end) and chromosome 
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position information across the two reference panels (<1% of variants). The two 
reference panels were merged in IMPUTE2, and the imputation was conducted in 
5Mbp chunks. Monomorphic variants [only one allele present in the dataset, rare 
variants with minor allele counts <20 and poorly imputed variants] were excluded from 
the analysis. Poor quality of imputation for a specific variant was defined as an 
information score less than 0.80. The information score estimates the ratio between 
the effective sample size accounting for imputation uncertainty and the real sample 
size (Marchini & Howie, 2010). For example, an information score of 0.5 indicates that 
the imputed genotype data are equal to half of the sample size of accurately 
genotyped data in terms of estimating a pre-defined genetic effect. A total of 
8,328,632 autosomal genetic variants were included in the analysis.  
 
Phenotype data   
Covariates 
As introduced in Chapter 1 (page 36), prognostic factors that are officially listed by 
the Canadian Cancer Society include: AJCC stage, surgical margins, lympho-
vascular invasion, CEA levels, bowel obstruction or perforation, tumour grade, 
histological type, microsatellite instability (MSI0, KRAS gene mutation, BRAF gene 
mutation). Among these factors, the AJCC and tumour grade were available in our 
SOCCS datasets and therefore were extracted with other basic demographic 
variables. These variables were used as covariates and are summarised in the 
following Table 4-1. 
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Table 4-1 Summary of non-genetic variables extracted from the database of the SOCCS 
study 
Variables Descriptions 
Age at diagnosis Collected from clinical records  
 
Sex Biological sex ascertained from genetic data  
AJCC stage Derived from the TNM stage based on the 6th 
edition AJCC staging manual  




Overall and CRC-specific survival were both employed as outcomes for analysis. The 
death status and date for each CRC patient in the SOCCS study were retrieved by 
linking the database to the Scottish Cancer Registry on January 1st 2018. Notably, it 
takes up to six months for the Scottish Cancer Registry to enter all updates of death 
records received from the National Death Registry. Hence, deaths occurred between 
July 2017 to January 2018 could possibly be missed in our dataset. In order to 
minimise this bias, we set the endpoint of follow-up at July 1st 2017—that is, deaths 
between July 1st 2017 and January 1st 2018 were treated as censored. The survival 
time for each patient was defined as the time span from the date of definitive treatment 
(starting date of surgery or chemo/radiotherapy for patients without surgery) and the 
date of death or July 1st 2017 whichever happened first. I assigned the cause of death 
based on information provided by death certificates. Rules for assigning the cause of 
death for each case are summarised below:  
1) All deaths with the primary diagnosis of CRC reported in death certificates were 
noted as CRC-related deaths (N=1,212).    
2) If the death certificate mentioned the presence of ‘metastasis’ or ‘carcinomatosis’, 
then the cause of death was presumed to be CRC (N=92).  
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3) If the case was reported with unknown primary tumour, then the death was 
assigned as CRC unless the certificate clearly stated otherwise (N=37).   
4) If the death certificate stated that either the primary or metastatic tumour site had 
been unresectable, then the cause of death was noted as CRC (N=8).  
5) If the certificate stated that the cause of death was due to a visceral or intra-
abdominal complication which could be directly related to CRC or the treatment of the 
disease, the cause of death was attributed to CRC (N=9).   
6) If no clear diagnosis was reported by the death certificate, then the death was 
deemed as non-CRC related.  
A randomly selected sample of 200 death records were evaluated independently by 
a colorectal surgeon, Dr Peter Vaughan-Shaw, and the concordance of results were 
checked. Only two cases (1%) were identified with discordant results upon which 
agreement was reached after discussion.   
 
4.2.2 UK Biobank  
 
UK Biobank is a large, population-based prospective cohort study designed to 
investigate genetic and environmental determinants of a wide spectrum of human 
complex traits and disorders.  From 2006 to 2010, the study recruited over 500,000 
participants aged 40-69 years throughout the UK.  More details regarding participant 
recruitment for the UK Biobank can be found in the online study protocol (URL4-5).   
Research Ethics approval  
The UK Biobank study was approved by North West Multicentre Research Ethics 
Committee (Reference 11/NW/0382). Each participant signed an electronic consent 
form at one of the 22 assessment centres across the UK. The dataset of CRC cases 
used in this thesis was based on a study proposal approved by the UK Biobank 
(Project No. 7441: ‘Investigation of genetic, environmental and gene x environmental 
interaction in colorectal cancer risk and survival’, Principal investigator: Professor 
Evropi Theodoratou).  The Project 7441 adopted a case-control design including all 
the prevalent and incident CRC cases along with healthy controls (cases vs controls: 
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1:4) matched by age, gender, date of blood sampling, ethnicity and region of 
residence. Similar to the SOCCS study, only CRC cases from the Project 7441 were 
used as a case cohort to explore survival outcomes of patients.      
 
Identification of CRC cases  
UK Biobank retrieves diagnoses of medical conditions by linking participants to the 
Hospital Episode Statistics (HES) and the cancer registry.  Diagnoses are coded using 
both the 9th and 10th version of the International Classification of Diseases (ICD). 
Classification codes corresponding to CRC are summarised in the Table 4-2. The 
project (7441) includes individuals from the UK Biobank cohort with diagnoses of ICD9 
codes 153.0-154.1 and ICD10 codes C18.0-C20.  It is worth mentioning that UK 
Biobank also documented self-reported conditions at recruitment. Self-reported CRC 
cases were excluded from the analysis unless they were confirmed by ICD9 or ICD10 
codes.  
Table 4-2 ICD9 and ICD10 codes for colorectal cancer  
Sites ICD9 ICD10 
Colon   
Hepatic flexure  153.0 C18.3 
Transverse colon  153.1 C18.4 
Descending colon  153.2 C18.6 
Sigmoid colon  153.3 C18.7 
Cecum 153.4 C18.0 
Appendix 153.5 C18.1 
Ascending colon 153.6 C18.2 
Splenic flexure 153.7 C18.5 
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Sites ICD9 ICD10 
Overlapping lesion of colon*  153.8 C18.8 
Colon, unspecified sites 153.9 C18.9 
Rectum    
Rectosigmoid junction  154.0 C19 
Rectum (includes rectal ampulla) 154.1 C20 
*Subcategory 153.8 and C18.8 denotes malignancies that overlap two or more continuous 
sites or the point of origin cannot be determined.   
 
Genotype data  
Peripheral blood samples for each participant in UK Biobank were taken at 
recruitment and the DNA was extracted following a standard protocol described 
elsewhere (URL4-6). Genotyping was conducted using the Affymetrix UK BiLEVE 
Axiom array for the initial 50,000 participants; a customised array—the Affymetrix UK 
Biobank Axiom®—was used to genotype the remaining 450,000 participants. These 
two arrays tagged over 95% of overlapped genetic variants.  Additional details 
regarding the genotyping arrays can be found online (ULR 4.6).    
Quality control 
Two rounds of marker-based quality control were performed by the Affymetrix 
laboratory and the Wellcome Trust Centre for Human Genetics (WTCHG) respectively.  
In brief, the Affymetrix laboratory applied a cluster-based method which contained a 
range of metrics to identify variants that were genotyped with poor accuracy. More 
technical details can be found elsewhere (URL4-7).  Based on the filtered variants 
from the initial round, the WTCHG designed a panel of six statistical tests to further 
detect poorly genotyped variants by examining the consistency across various 
experimental factors such as array difference and batch effect.  Descriptions on the 
panel of statistical tests can be found in the previous publication (Bycroft et al, 2018).  
An aggregate of 805,426 genetic variants passed these two rounds of marker-based 
quality control.   
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The UK Biobank cohort consists of participants of diverse ancestral origins across the 
UK.  The WTCHG conducted PCA to dissect the population structure of the whole 
cohort, although self-reported ethnic background was also documented in the study.  
The first four principal components were plotted in the Figure 4-4 below with self-
reported ethnic background marked by different colours and signs.   
 
Figure 4-4 Principal components of genetic background of participants in UK Biobank. 
Reproduced with permission. The original source is covered by a Creative Commons 
Attribution License. 
  
Given the dispersed distribution of genetic background of UK Biobank participants 
(Figure 4-4), further sample-based quality control procedures were conducted within 
the cases-control study (Project 7441). In particular, firstly participants with self-
reported non-white origin were excluded; then individuals with evidence of non-
European ancestry were identified and excluded by applying the same procedure as 
in the SOCCS study (described in section 4.2.1).  Accordingly, individuals with 
discordant sex information, duplication or first-degree relatedness, high missing rate 
(>5%) and abnormal heterozygosity were also excluded.    
Imputation 
Genotype imputation for the UK Biobank cohort was conducted by the WTCHG. 
Similar to the imputation procedure of the SOCCS study, genotype data that passed 
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quality control were first phased using the SHAPEIT (v3) software. With regard to 
genotype imputation, the WTCHG employed an updated version of the IMPUTE2 
module—known as IMPUTE4 (URL4-8)—that applied the same statistical model but 
with improved computational efficiency.  In line with the SOCCS study, genetic 
markers in UK Biobank were also coded based on the Genome Reference 
Consortium Human Reference 37 (GRCh37). Based on the imputed dataset, we 
excluded genetic variants with an information score less than 0.8. Eventually, a total 
of 9,067,367 autosomal genetic variants were included in the genotype dataset of the 
UK Biobank.   
Phenotype data  
Covariates 
Extensive phenotyping of the UK Biobank cohort has been underway as of this writing.  
For instance, disease characteristics for patients diagnosed with certain disorders 
such as cancer have not been available for researchers.  With regard to our study, 
clinic-pathological data including cancer stage and grade for CRC patients have not 
yet been released in November 2019.  Other relevant variables available in UK 
Biobank are summarised in the Table 4-3. The variable ‘Age when attended 
assessment centre’ was used to differentiate incident and prevalent CRC cases. In 
particular, cases who were diagnosed with CRC within six months since attendance 
or before attendance were categorised as prevalent cases.  
 
Table 4-3 Summary of non-genetic variables extracted from the UK Biobank cohort study  
Variable  UK 
Biobank ID 
Descriptions 
Age at diagnosis  40008 Collected from the clinical records 
Sex 31 Biological sex ascertained from genetic 
data 
Age when attended 
assessment centre 
21003 Documented at recruitment  
 
 




UK Biobank retrieves death records based on the linkage to the National Death 
Registry; death records are updated quarterly. Since the records were directly 
synchronised with the National Death Registry, here we assumed no delay of data 
entry that could cause potential bias. The death status and date for our study (Project 
7441) was last updated in February 2018. Therefore, the survival time for each 
individual was defined as the time span between the date of CRC diagnosis (UK 
Biobank variable ID: 40005, acquired from the Central Registry) to the date of death 
(UK Biobank variable ID: 40000) or February 1st 2018 for cases that were alive.  As 
for the cause of death, UK Biobank assigned putative primary (UK Biobank variable 
ID:40001) and secondary causes of death (UK Biobank variable ID:40002) to each 
individual based on the death certificate. The causes of death were coded using 
ICD10 codes. In our study, death records were treated as CRC-related deaths in the 
analysis of CRC-specific survival if either primary or secondary causes of death 
contained ICD10 codes of CRC (Table 4-2) or any indications of conditions listed in 
the criteria applied to the SOCCS study.   
 
4.2.3 Clinical trials datasets  
 
I obtained summary-level data from three previously published clinical trials in order 
to validate potential discoveries from the genome-wide association study of 
associations between genetic variants and overall survival of CRC patients. The 
summary-level results were extracted and provided by Dr Claire Palles from the 
Institute of Cancer and Genomic Sciences, the University of Birmingham. More 
descriptions on the summary-level results will be presented in Chapter 5, and here 
basic characteristics of these three clinical trials will be briefly introduced.   
The QUASAR2 trial 
This trial explored potential added survival benefits of bevacizumab in addition to 
capecitabine in adjuvant chemotherapy of stage II and III CRC patients (Kerr et al, 
2016). Bevacizumab is an antiangiogenic agent commonly used in the treatment of 
metastatic CRC.  The study was approved by the West Midlands Research Ethics 
Committee (Edgbaston, Birmingham, UK; REC reference: 04/MRE/11/18).  From April 
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25, 2005 to October 12, 2010, a total of 1,952 patients were recruited from 170 
hospitals in seven countries with the central trial office based in Oxford, UK. Separate 
informed consent was obtained from all patients whose blood samples were to be 
taken for further genotyping.  
The SCOT trial 
This trial was an international collaborative effort aiming to establish the non-inferiority 
of a 3-month versus 6-month duration of adjuvant oxaliplatin plus fluoropyrimidine 
chemotherapy in stage II and III CRC patients (Iveson et al, 2018). The ethical 
approval for the trial was granted by the West Glasgow Research Ethics Committee 
and equivalent committees in participating countries (244 centres in six countries). 
Between March 27, 2008, and November 29, 2013, the SCOT trial eventually enrolled 
a total of 6,088 CRC patients, of which 5,244 patients were recruited in the UK. All 
participants provided informed consent including the use of blood samples for further 
research.   
The VICTOR trial 
This was a phase III randomised controlled trial investigating the efficacy of Rofecoxib 
in adjuvant chemotherapy of stage II and III CRC patients (Midgley et al, 2010).  
Rofecoxib is an inhibitor of Cyclooxygenase-2 (COX-2) which plays a key role in CRC 
tumourigenesis.  In 2004, however, Rofecoxib was withdrawn globally due to growing 
concerns on increased risk of cardiovascular events. Therefore, the VICTOR trial was 
terminated after 2,434 patients had been entered between April 2002 and September 
2004. This trial was approved by the Cancer Research Campaign, the Multicentre 
Research Ethics Committee, and committees at each participating centres in the UK 
(details presented in the original publication (Midgley et al, 2010)). Participants also 
provided informed consent for use of their blood samples.    
As with the SOCCS and UK Biobank, participants with European ancestry from these 
three trials were genotyped and included in the latest GWAS meta-analysis on CRC 
risk by Law and colleagues (Law et al, 2019).  Colorectal cancer cases in the SCOT 
trial were genotyped using the Illumina® Global Screening Array, whereas cases in 
the QUASAR2 and VICTOR trials were arrayed using the Illumina® Hap300 and 
Hap370. Quality control and genotype imputation for these genotyped samples were 
harmonised with the SOCCS and UK Biobank studies by Law et al. (Law et al, 2019). 
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In particular, the same reference panel as in the SOCCS study—the UK10k release 
(ALSPAC and TWINSUK studies, April 2014 release), and the 1000 Genome V3 
(December 2013 release)—was used for genotype imputation of these three datasets, 
and all genetic variants were coded based on the GRCh37. Additional details of 
genotyping, quality control and imputation can be found in the published GWAS meta-
analysis (Law et al, 2019).  
 
4.3 Study design and data analysis   
 
4.3.1 Candidate genetic association study    
 
Study design  
The two main study designs for investigating population-based genetic associations 
are candidate genetic association studies and genome-wide association studies. 
Candidate genetic association studies use a hypothesis-driven approach to test a 
prior hypothesis that a single or a group of genetic variants of interest are associated 
with certain disease outcomes.  Hypotheses are made based on previous evidence, 
for example biological plausibility that can potentially link a genetic variant in a specific 
gene with the disease outcome under study. In this thesis, I conducted three 
candidate genetic association studies investigating three groups of common genetic 
variants: a) genetic variants previously reported to be associated with survival 
outcomes of CRC, b) genetic variants associated with CRC risk, c) genetic variants 
previously linked with survival outcomes of other cancers. The flow chart of study 
design for these three studies is presented in Figure 4-5.  
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The catalogue assigns subject headings to all indexed traits, allowing search for 
genetic variants by trait of interest.  As of December 10 h 2018, there were three 
subject headings corresponding to prognosis-related traits: ‘Survival time’, ‘Mortality’ 
and ‘Disease prognosis measurement’.  The traits ‘Disease prognosis measurement’ 
and ‘Mortality’ contained no prognostic outcomes of cancer, and therefore were 
excluded from the search. The trait ‘Survival time’ encompassed six secondary traits 
that included all outcomes related to cancer prognosis: ‘disease free survival’, ‘distant 
metastasis free survival’, ‘event free survival time’, ‘metastasis free survival’, ‘overall 
survival’, and ‘progression free survival’.  I retrieved all variant-trait associations under 
the subject heading ‘Survival time’ including the secondary traits. Associations 
between genetic variants and survival outcomes of non-cancer diseases were 
excluded. Leukaemia was also excluded considering its distinct pattern of progression 
compared with solid tumours.       
CRC risk GWAS meta-analyses 
Led by the Colon Cancer Genetics Group here in Edinburgh, the latest GWAS meta-
analysis on CRC risk revealed 31 new CRC risk loci, bringing the total number of 
identified CRC risk variants  to ~130 (Law et al, 2019). In this study, Law et al. 
summarised all previously reported CRC risk loci. Therefore, we extracted CRC-risk 
variants from this study directly, before it got indexed by the GWAS catalogue. 
Variants reported by another independent newly-published large GWAS meta-
analysis (Huyghe et al, 2019) that had not been indexed in the catalogue were also 
extracted and merged with the variant list extracted from Law’s study. In addition, we 
also searched the GWAS catalogue under the subject heading of ‘Colorectal Cancer’ 
to check if any previously reported risk loci were missed.   
Accounting for linkage disequilibrium 
Linkage disequilibrium (LD) reflects the fact that alleles at different positions 
(haplotypes) of the chromosome occur in a non-random manner—that is they are 
correlated to each other. The structure of LD is mainly determined by the population 
origin and genetic distance between two alleles. On the contrary, alleles are in linkage 
equilibrium if they are inherited independently. There have been two widely used 
metrics in genetic association studies to quantify the LD between two variants: D’ and 
r2. Assuming there are two biallelic genetic loci with alleles A1A2 and B1B2; the 
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frequencies of these two loci are noted as p and q. The deviation (D) of the observed 
haplotype frequency (f) from the expected frequency can be calculated as: 
D = 𝑓(𝐴1𝐵1) − 𝑝1𝑞1  
D’ is defined as the normalised D (D’= D/Dmax), where Dmax denotes the theoretical 
maximum of D (detailed formula can be found elsewhere (Lewontin, 1964)). Whilst D’ 
is easy to be calculated, it has been shown to be sensitive to alleles of extreme 
frequencies (Ranganathan et al, 2018). Therefore, an alternative measure, r2, is more 
frequently adopted in genetic association studies where risk loci of interest are often 
of low minor allele frequencies. The r2 is expressed as:  
𝑟2 ==
𝐷2
𝑝1 × 𝑝2 × 𝑞1 × 𝑞2
 
and it ranges from 0 to 1, where 0 means completely independent alleles and 1 means 
being perfect proxy for each other. In this thesis, the r2 was used to measure the LD 
between two variants, and I calculated it in the British population by using the 1000 
Genomes phase 3 GBR data from the Ensembl portal (URL4-9).  I chose an r2 of 0.2 
as the threshold, and any pairs of variants with an r2>0.2 were considered as being in 
LD.  When LD was detected, the variant associated with the trait of interest (CRC risk 
or cancer survival) with the smaller p-value was retained.    
 
Statistical analysis  
Genetic model 
Based on the assumed pattern of inheritance, each genetic variant can be coded in 
different ways, also known as genetic models. There are three main genetic models 
that are widely used in genetic association studies: dominant model, recessive model 
and co-dominant model.  For a biallelic genetic variant with alleles A and a, the 
dominant model assumes that it takes only one risk allele (A) to exert the effect. That 
is, the model compares individuals with the genotype AA or Aa versus individuals with 
aa. The recessive model, however, assumes that an individual must have two copies 
of risk alleles (AA) to show the effect, and therefore it compares AA versus Aa + aa.  
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As for the co-dominant model, it assumes that the genetic risk conferred by Aa lies 
somewhere between AA and aa. The co-dominant model can be further divided into 
additive and multiplicative models according to the pattern of relative risk among these 
three genotypes. The conceptual framework of different genetic models is depicted in 
Figure 4-6.   
 
Figure 4-6 Conceptual framework of different genetic models       
 
Among these genetic models, the additive model has been most widely adopted as 
the assumed model in both candidate and genome-wide association analyses. This 
model assumes a linear increase in risk for each allele copy. Evidence based on 
simulation studies indicated that the additive model also has acceptable statistical 
power to detect possible dominant effects in addition to additive effects of a certain 
genetic variant (Lettre et al, 2007). Moreover, the number of risk alleles of imputed 
genetic variants are presented as expected values in a continuous order (range from 
0 to 2), and can be naturally modelled in an additive pattern. Therefore, I chose the 
additive genetic model as the primary model of analysis of genetic associations. 
However, simulation analysis suggests that the additive model has limited statistical 
power to identify a possible recessive effect (Lettre et al, 2007); thus I also rounded 
the imputed allele dosage to integers—that is, any imputed allele dosage that is 
greater than 1.5 was coded as 1, otherwise coded as 0—so as to fit a recessive model 
and investigated their associations with CRC survival. Notably, there has been no 
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previous evidence indicating the mode of inheritance being recessive for any of these 
included candidate genetic variants in this thesis. Therefore, investigation using 
recessive model should be considered as sensitivity analysis.      
 
Polygenic risk score 
The previous section introduced genetic models used to code each single variant 
before analysing the genetic association with CRC survival. In addition, I also 
investigated the combined effect of a set of genetic variants, for example CRC-risk 
variants as a group, on survival outcomes by constructing a polygenic risk score (PRS) 
for each patient.  I calculated the PRS using a naive unweighted approach due to lack 
of prior knowledge on the potential distribution of effects on survival for these 
candidate variants. This approach assumes equivalent effect sizes for all the variants 
included in the PRS. To create the PRS for each patient, I added the number of risk 
alleles of all the candidate variants in a group. To take variants associated with CRC 
risk as an example, I first harmonised their direction of effects on CRC risk, and 
identified genetic alleles responsible for increased CRC risk. Then the exact number 
or imputed dosage of risk-increasing alleles for each variant was summed up.  
Time-to-event outcome 
In contrast to common outcomes that are either categorical or continuous, survival 
outcomes have a special nature; that is, the outcome for each individual under study 
consists of two elements: event status (D) and survival time (T).  In this thesis, the 
events of interest were defined as death of any cause for overall survival and CRC-
related death for CRC-specific survival. The status of patients with event occurrence 
was coded as ‘1’ and patients who were alive until the last time of updating the death 
records (also known as right censored observations) were coded as ‘0’. As mentioned 
previously, the other element—survival time—was defined as the time span from the 
date of definitive treatment (SOCCS) or CRC diagnosis (UK Biobank) to the date of 
event or censoring; the time period was measured by years of follow-up. Finally, the 
survival outcome for each CRC patient was expressed as a combined measure: (T, 
D).      
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Kaplan-Meier estimator and log-rank test 
In order to estimate the probability of surviving a certain amount of time (denoted as 
t) after CRC diagnosis, a few statistical concepts need to be introduced. At first, I 
define two random variables Ts for the survival time, and Tc for the censoring time in 
response to the aforementioned time element for the survival outcome of each patient. 
An assumption here is that Ts and Tc are independent of each other. Then, the 
cumulative distribution function (CDF) for Ts and Tc can be expressed as:  
𝐹𝑠 = P(𝑇𝑠 ≤ t) 
and  
𝐹𝑐 = P(𝑇𝑐 ≤ t) 
In the context of survival analysis, however, the complementary function of the CDF 
of Ts is commonly used as we are often more interested in the probability of patients 
surviving at least a certain time span. Hence, the survival and censoring function are 
defined as:   
S(t) = P(𝑇𝑠 > t) = 1 − 𝐹𝑠(𝑡) 
and  
C(t) = P(𝑇𝑐 > t) = 1 − 𝐹𝑐(𝑡) 
Since we are only interested in evaluating future risk of death for each patient, the 
primary focus of this section is concerning estimating the S(t).     
Amongst many methods proposed to estimate the S(t), the Kaplan-Meier estimator 
has been the most widely-used statistic, especially in epidemiological and clinical 
research settings. The estimator was named after Kaplan and Meier who first 
proposed it in 1958 (Kaplan & Meier, 1958). The Kaplan-Meier estimator is defined 
by the following expression:     
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Here, ti refers to a certain time point when at least one death occurs; di denotes the 
number of deaths that occur at ti; and ni refers to the size of risk set which is measured 
by the number of individuals that are still alive entering the time ti. Given the fact that 
each ti is a time point actually observed from the sample dataset, the distribution of 
estimated S(t) will not be continuous. Instead, there are ‘jumps’ at time points where 
events occur.  
In this thesis, I calculated the Kaplan-Meier estimates for CRC patients and plotted 
the estimates against the follow-up time to make survival curves. Patients were 
grouped and their survival curves were stratified by prognostic factors such as AJCC 
stage for descriptive purposes and potential genetic variants as a graphic display for 
the study results. The Kaplan-Meier estimates were calculated using the packages 
‘survival’ (URL4-10) and ‘survminer’ (URL4-11) in the R software (version 3.5.1, 
URL4-12).  
In addition, a log-rank test was conducted to test the difference across multiple 
survival curves (Peto & Peto, 1972). Assuming a two-group comparison, I first used 
i=0 or 1 to denote the two groups, and j to define each time point for observed events. 
Let N be the number of individuals at risk and O be the number of observed events at 
the same time point. The null hypothesis assumes that the two groups have an 
identical hazard function h(t). Under this hypothesis, the expected number of events 
occurring at each time point can be calculated, and a test statistic Z is defined as 
follows:   
𝑍𝑖 =







It has been demonstrated that the statistic is asymptotically normal as j increases; a 
p-value can then be derived from a standard normal distribution (Peto & Peto, 1972).  
I conducted the log-rank test using the ‘survival’ (URL4-10) package.   
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Proportional hazards model 
To estimate effects of prognostic factors, such as genetic variants and other non-
genetic factors, on survival outcomes of CRC, regression techniques are needed to 
accommodate single or multiple variables simultaneously in a model. The proportional 
hazards model, also known as Cox regression model, is the most widely applied 
method to quantify the association between prognostic factors and survival outcomes. 
The basic ideas and principles of the Cox regression model will be briefly introduced 
here.   
Proposed by Cox (Cox, 1972), this method is based on the proportional hazards 
assumption—the effect of a certain factor on the survival outcome remains constant 
over time.  A few statistical concepts need to be defined to explain the method.  Firstly, 
based on the survival function described in the previous section, the hazard (h) can 
be interpreted as the derivative of the survival function, or intuitively as the 
instantaneous risk of death for those individuals who are at risk.  The hazard function 
is expressed as:      
h(t)𝑑𝑡 = P(T < t + 𝑑𝑡|T ≥ t) 
 
The left side of the of equation refers to the risk of death during a short time period dt, 
and it is related to the survival function by the right side which denotes the probability 
of death within dt given that the individual has survived up to the time point t.  The Cox 
regression model relates potential prognostic factors under study to the hazard 
function by the following equation:   
h(t) = ℎ0(t)exp(𝑏1𝑋1 + 𝑏2𝑋2 + ⋯ + 𝑏𝑛𝑋𝑛) 
It should be noted that in this expression, the hazard function h(t) is the expected (or 
predicted) hazard at the time point t instead of the observed hazard derived from the 
survival estimates. On the right side, coefficients b1 to bp are effects on the hazard at 
t per single unit change of each factor X (also known as covariates).  The h0(t) is the 
baseline hazard—the hazard function of individuals with all the factors at baseline 
level (all Xs equal to zero). In order to clearly explain the coefficients, or the prognostic 
effects estimated from the Cox model, we consider a simple univariable Cox model:  
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h(t) = ℎ0(t)exp(𝑏1𝑋1) 
Assuming the covariate X is a binary variable, such as sex, coded with values 0 or 1, 
the ratio of hazards between the two groups of patients with X=1 or X=0 is defined as 






HR = exp(𝑏1) 
Notably, the exp(b1) is a constant that does not depend on the time t, pointing to the 
proportional hazard assumption of the Cox regression model.  
In this thesis, the Cox regression model was fitted using the ‘coxph’ function from the 
R package ‘survival’. Estimation of the regression coefficients when applying the 
‘coxph’ function to fit a Cox model relies on a method called partial likelihood; a Wald 
statistic is calculated to generate a two-sided p-value for the inference of the statistical 
significance of the estimated coefficient (HR). Additional technical details about this 
method can be found in the original paper by Cox (Cox, 1972).  As presented in the 
flow chart of study design, I investigated associations between three sets of candidate 
genetic variants and overall and CRC-specific survival outcomes using the SOCCS 
study. Age at diagnosis, sex and AJCC tumour stage at presentation for each patient 
were fitted in the Cox regression as covariates in addition to the genetic variant. For 
possible validation analysis using the UK Biobank cohort, covariates only included 
sex and age at CRC diagnosis due to unavailable data of AJCC stage. I also 
conducted Cox regression analysis in different strata of CRC patients stratified by sex 
(male and female), AJCC stage (stage II-III and stage IV) and tumour site (colon and 
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Adjusting for multiple testing 
I conducted three candidate genetic association studies with each study including a 
set of variants whose associations with CRC survival were tested simultaneously. If a 
normal threshold of p<0.05 was applied for each test, it would have caused 
remarkably higher false positive rates (or type I error) when considering a set of tests 
together. There are two approaches that have been widely used to adjust for this 
problem: the Bonferroni correction and the false discovery rate (FDR), also known as 
the Benjamini-Hochberg approach. The Bonferroni correction adjusts the significance 
threshold to α /n where the n denotes the number of tests to be conducted. The α 
here refers to the familywise error rate (FWER) which measures the probability of 
making at least one type I error (false positive) in the whole family of tests. Similar to 
a single statistical test, this threshold of the FWER is often set to be α=0.05. Given 
that the Bonferroni correction directly adjusts the α level, it can be readily applied to 
estimate the statistical power using an adjusted α.  Power calculation will be described 
in the following section.  
Although effective in controlling type I error, the Bonferroni correction could lead to 
increased non-rejection of a false null hypothesis (type II error). Therefore, in addition 
to the Bonferroni correction, we also adopted a less conservative approach--the FDR 
approach (Benjamini & Hochberg, 1995)--to evaluate the significance of results and 
to screen for potential signals from the candidate genetic association studies that 
merited further validation. This approach is designed to control the expected 
proportion of false positive findings. To be specific, instead of adjusting for the α 
threshold to assess significance, the FDR approach adjusts all the p-values generated 
from the set of tests. It first sorts the n p-values in an ascending order, with p1 the 
smallest and pn the largest. With the largest pn remains the same, the adjusted ith p-
value (i<n) is expressed as:  




Then a pre-specified α threshold (<0.05 for example) is used to evaluate the adjusted 
p-values.  
 




Statistical power of a genetic association test estimates the probability of detecting 
significant association of a given variant with CRC survival when a genetic effect truly 
exists. Owzar et al. provided a widely-used approach to estimate the statistical power 
of a genetic association study on survival outcomes (Owzar et al, 2012). Some basic 
metrics used in this approach to calculate the power are introduced here. Firstly, the 
minor allele frequency (MAF) is the observed frequency of the second commonest 
allele of a given genetic variant (assuming the variant is biallelic) in a specific 
population.  Another important metric is the effect size which in survival analysis is 
presented as the hazard ratio. The event rate, namely the proportion of overall or 
CRC-specific deaths in the study sample, is also needed for the power estimation. 
Combined with the sample size and the α level, these metrics were integrated into the 
formula provided in Owzar’s paper to estimate the power (Owzar et al, 2012). Notably, 
the method developed by Owzar et al relies on a score statistic to make statistical 
inference which is different from the Wald statistic used in the ‘coxph’ function that we 
adopted to test the genetic associations. Nonetheless, these two statistics have been 
shown to be asymptotically identical as the sample size increases (Owzar et al, 2012).  
In order to adjust for multiple testing, we specified the α level as 0.05/n where n was 
the number of variants in each candidate genetic association study. We also chose 
the additive genetic model to calculate the power in response to our main association 
analyses. Power estimation was conducted using the ‘survSNP’ package (URL4-13).  
Additional technical details regarding the method can be found in the original 
publication (Owzar et al, 2012).    
 
4.3.2 Predictive modelling 
 
Study design 
Following the previous section where I validated individual association between each 
genetic variant that had been linked to CRC prognosis and survival outcomes of CRC 
patients in the SOCCS study, here in this section, I focused on exploring the predictive 
value of variants that had been previously linked with CRC survival as a group in 
forecasting survival outcomes of CRC. As discussed in Chapter 3, a multivariable 
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prediction model is an algorithm that provides an average estimate of the probability 
by combining all predictors together. In this study, I fitted Cox regression models to 
develop a genetic predictor and then evaluated its performance in predicting the 
survival rates of CRC patients.   
In order to establish and validate a genetic predictor combining these variants 
together, two datasets—UK Biobank and the SOCCS study—were leveraged. As 
introduced in Chapter 1, a substantial amount of within-stage variation has been 
observed in relation to survival outcomes of CRC patients.  From a clinical perspective, 
it has been of great interest to develop novel predictors to further improve prediction 
on the basis of tumour stage. Clinical interest also lies in predicting survival outcomes 
within specific stage, for example CRC patients at stage II-III, where the optimal 
treatment strategies for patients with varied prognostic profiles are still to be decided. 
Given that tumour stage is unavailable in UK Biobank, this dataset was used as the 
training set to develop the genetic predictor; external validation of the genetic predictor 
derived from the UK Biobank and within-stage prediction were then conducted in the 
SOCCS study. The flow chart of the study design is shown in the Figure 4-7 below:  
 




Figure 4-7 Flow chart of study design for prediction modelling 
 
Developing the genetic predictor  
Full model 
In order to apply the predictor across different datasets, I first harmonised the 
reference allele of each genetic variant across the published GWASs and our two 
study cohorts--the SOCCS and UK Biobank study. In contrast to the analysis 
approach used in the preceding section where a single variant was fitted along with 
age, sex and AJCC stage, here I added all the 43 variants that were reportedly 
associated with CRC survival into one Cox regression model in the UK Biobank cohort 
to estimate the coefficient for each variant. All variants were coded under an additive 
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genetic model. The linear predictor (LP) combining the 43 genetic variants is 
expressed as:     




Here βi denotes the coefficient of the ith variant extracted from the fitted Cox model, 
and Xi is the allele count.   
Feature selection 
As discussed in Chapter 3, it has been widely accepted that an increased number of 
predictors leads to higher events per variable (EPV) which further results in increased  
risk for over-optimism, where the developed model is over-fitted to the data under 
study and therefore incurs poor generalisability when applied to external data.  
Therefore, feature selection techniques have been developed and widely employed 
to reduce the model dimension.   
In this study, I first used a least absolute shrinkage and selection operator (LASSO) 
for feature selection.  This method reduces over-fitting by penalising the Cox 
regression coefficients towards zero. In particular, the LASSO regression seeks to 
minimise the following expression: 





+ 𝜆 ∑ |𝛽𝑗|
𝑗=1
 
The former part of the expression refers to the sum of squared errors in general linear 
models. The later part is the penalty term with the 𝜆 as the tuning factor that controls 
the strength of penalisation. The addition of the penalty term shrinks the coefficients 
and some of them can be reduced to zero, and therefore are excluded from the final 
model. In practice, a range of lambdas can be used to generate different models. 
Breiman et al. suggested an ‘one-standard-error’ approach utilising cross-validation 
to assist selection of the tuning factor (Breiman et al). Cross-validation is a resampling 
technique that randomly splits the study sample into k groups (also called k-fold cross-
validation). Each time, the model takes out one group as a test dataset and uses the 
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remaining groups as a training dataset. Then the statistical model is fitted repeatedly 
and the parameters of interest are summarised afterwards. Following this method, we 
used a 10-fold cross-validation to identify the lambda in response to the most 
parsimonious model where the cross-validation prediction error is within one standard 
error of the minimum. Technical details of the method can be found in the original 
publication (Breiman et al). The LASSO regression was conducted using the ‘glmnet’ 
R package (URL4-14). 
In addition to the LASSO approach, I also conducted backward selection to screen 
for potential useful variants in predicting CRC survival. This method starts with a full 
model with all the candidate variables included. The model then removes the least 
significant variable (evaluated by its p-value) and iterates this process until the all the 
remaining variables are below the pre-defined p-value threshold. Here in this thesis, 
I set the p-value threshold at 0.15 based on recommendations from a previous 
publication which conducted optimisation analysis to determine this threshold (Heinze 
et al, 2018). The backward variable selection was conducted using the ‘validate’ 
function in the ‘rms’ R package (URL4-15).     
 
Model performance assessment   
Evaluating the performance of a given prediction model is to quantify how concordant 
the predictions made from the model are with the observed outcomes. As opposed to 
the previous section where I focused on the relative risk effect (hazard ratio) of a 
single genetic variant, here the absolute probabilities of survival were used in the 
setting of risk prediction. To quantitatively evaluate the concordance, both the 
observed and predicted survival estimates are needed. The method used to generate 
Kaplan-Meier estimates for the observed survival rates has been introduced in the 
previous section. I obtained the predicted survival estimates by one minus predicted 
death risk which had been generated in the Cox regression. There are two major 
properties relevant to the model performance: discrimination and calibration.  In this 
thesis, I adopted multiple metrics to quantify the model performance based on these 
two aspects.  
The discriminative ability of a given prediction model reflects how good the model is 
to distinguish between individuals with and without the outcome of interest. In the case 
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of the time-to-event outcome, the Harrell’s C statistic is the mostly commonly used 
measure of the discriminative ability (Harrell et al, 1996). The C statistic calculates 
the proportion of randomly selected pairs of subjects in which an individual with longer 
observed survival time also exhibits higher predicted probability of survival. A C 
statistic of 0.5 suggests random predictions with null predictive value. Notably, pairs 
with an individual who has a shorter censoring time than the survival time of the other 
individual are not counted when calculating the C statistic. I calculated the C statistic 
using the “rcorr.cens” function in the ‘rms’ package (URL4-15).  It is worth mentioning 
that the “rccor.cens” function derives the C statistic along with its standard error from 
another measure called Somers’ D statistic. This statistic is defined as: 
𝐷𝑥𝑦 = E(sign(X1 − X2)sign(Y1 − Y2))  
Where (X1,Y1) and (X2,Y2) are two randomly selected pairs of random variables 
denoting the predicted and observed survival probability respectively. Ranging from -
1 to 1, the Somers’ D is related to the C statistic by: 
D = 2 × (C − 0.5) 
In order to identify the added predictive value of genetic variants on the basis of other 
variables, I compared the C statistics along with their confidence intervals derived 
from the model with and without genetic predictors. Moreover, I conducted a U-
statistic based test to determine whether the predicted probabilities from one model 
were more concordant with the observed estimates than the other model (Harrell Jr, 
2015). This test quantifies the proportion of subject pairs where there is less difference 
between predicted and observed estimates in one model than the other. I performed 
the U-statistic based test using the ‘rcorrp.cens’ function in the ‘Hmisc’ R package 
(URL4-16).  A p-value <0.05, which means there is 95% of chance that one model is 
more concordant than the other, was considered as statistically significant 
improvement.    
The other important property to evaluate the model performance is calibration—the 
overall agreement between predicted and observed probability. In the context of 
survival analysis where both the predicted and observed survival probabilities vary by 
time, the calibration of the model is therefore usually evaluated at a fixed time point. 
From a clinical point of view, I employed the 5-year survival as the observation time 
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to compare the agreement of predicted and actual survival outcomes.  I first grouped 
the individuals using the quartiles of the linear predictor of the prediction model under 
study. For each group, the observed Kaplan-Meier survival estimates were derived 
and contrasted with the mean predicted survival estimates. The calibration plot was 
constructed by plotting the predicted probabilities against the observed estimates for 
each risk group of patients. This plot allowed a visual assessment of the departure 
from the ideal calibration line with a slope of 1 and intercept of 0.  
In addition to evaluating the model calibration graphically, I also performed a Hosmer–
Lemeshow (HL) test to assist determining whether the model was well-calibrated 
(Hosmer Jr et al, 2013). The HL test statistic (H) is given by the following equation:  










where G refers to the number of groups categorised by the linear predictor, O1 and 
O0 denote the number of observed events and non-events, and E1 and E0 represent 
the expected number assuming that the proportion of observed and predicted events 
are the same across all the risk groups (G).  It has been shown that the test statistic 
asymptotically follows a chi square distribution from which the p-value is generated.  
I employed the ‘hoslem.test’ function in the ‘ResourceSelection’ R package (URL4-
17) to conduct the HL test and examine the model calibration at the 5th year after 
diagnosis. A p-value<0.05 was deemed as significant departure from calibration.   
 
 
Adjusting for over-optimism 
Adjusting the model performance 
Model performance metrics, such as the C statistic, are commonly too optimistic if 
they were estimated from the dataset used to develop the model. This often leads to 
poorer prediction accuracy when applying the model to new patients.  Hence, 
methods have been proposed to adjust this over-optimism; this procedure is also 
commonly known as internal validation of the developed model. In this case, since I 
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developed the genetic predictor in the UK Biobank cohort, over-optimism was 
expected in the C statistic derived from the same cohort. With regard to the SOCCS 
cohort, the first step of validating the genetic predictor was immune to over-fitting as 
the model was fixed, and the SOCCS cohort was used as an external source. 
However, over-optimism arose in the second step when the genetic predictor was 
combined with other variables and the model was re-fitted. Therefore, internal 
validation was also performed for the new model established in the SOCCS study.  
I adopted a bootstrapping approach in this thesis to correct for potential over-optimism 
of the C statistic. In contrast to cross-validation which divides the sample into equally 
sized groups, bootstrapping is a re-sampling technique that draws samples from the 
dataset under study and therefore it allows replacement.  I generated 200 bootstrap 
samples and repeatedly calculated 200 C statistics following the procedure described 
above. Then the corrected C statistic along with its confidence interval was derived 
from the bootstrap sample distribution. Bootstrapping was conducted using the 
‘validate’ function in the ‘rms’ R package (ULR 4.15).   
 
Adjusting the model presentation 
As stated in the previous sections, I re-fitted the Cox model by combining the genetic 
predictor and other variables, which again introduced over-optimism into the model. 
Although the C statistic was adjusted to evaluate the model performance, the 
coefficients estimated from the newly-fitted model still remained inflated and therefore 
needed to be corrected before the model being presented. This was done by 
calculating and applying a metric called ‘shrinkage factor’ (Harrell Jr, 2015; 
Steyerberg, 2019). In particular, I first took a bootstrap sample, fitted the same Cox 
model, and obtained a new set of coefficients.  Then the new coefficients were utilised 
to create a new linear predictor for each individual in the cohort.  I re-fitted the Cox 
model using the new linear predictor as the covariate and extracted the coefficient of 
the predictor. This process was repeated in 200 bootstrap samples and the average 
of these coefficients was retrieved as the shrinkage factor (SF). I then applied this 
factor to shrink the original coefficients. Based on the expression of Cox regression 
model introduced previously, the ultimate model predicting the probability of surviving 
time t was presented as:  
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S(t) = 𝑆0(t)exp ((𝑆𝐹×(𝛽1𝑋1+𝛽2𝑋2+⋯+𝛽𝑛𝑋𝑛)) 
S0 refers to the baseline survival probability which can be derived from the baseline 
hazard estimated from the Cox regression. Betas are the regression coefficients from 
the original fitted model. Further details regarding the model shrinkage can be found 
in references of (Harrell Jr, 2015; Steyerberg, 2019).   
 
4.3.3 Genome-wide association study  
 
Study design  
As described in Chapter 2, the final part of the thesis is a GWAS investigating the 
whole genome to identify potential novel variants associated with CRC survival. 
Overall, we employed a two-step approach for this section. Firstly, the SOCCS cohort 
was used as the discovery dataset to perform the main GWA analysis. Secondly, any 
genetic variants identified at GWAS significance (p<5x10-8) were further validated by 
a meta-analysis combining datasets of summary statistics from the UK Biobank cohort, 
the QUASAR2 trial, and the pooled dataset of the VICTOR and SCOT trial. With 
respect to covariates, age at diagnosis, sex and AJCC stage were adjusted for the 
SOCCS cohort and the three clinical trial datasets. For the UK Biobank cohort, only 
age at diagnosis and sex were adjusted as AJCC stage was unavailable. For the 
outcome of CRC-specific survival, the validation analysis was only conducted in the 
UK Biobank cohort due to data availability.  In addition, the summary statistics derived 
from the GWAS in the SOCCS were utilised for gene and gene-set based enrichment 
analysis to explore putative genes and biological pathways associated with CRC 
survival. I also performed GWA analysis separately within stage II/III and stage IV 
CRC patients in the SOCCS study. Figure 4-8 presents the overall study design for 
this section.  
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ith individual in the cohort (either 0 or 1) and the expected number of events for the 
same individual at time t (Therneau et al, 1990). Mathematically it is expressed as:   
𝑀?̂? = 𝛿𝑖 − Λ̂0(𝜏𝑖)𝑒Υ̂1𝑍1+⋯+Υ̂𝑘𝑍𝑘  
where Λ0 refers to the baseline cumulative hazard at time point τi, and δi denotes the 
observation event (0 or 1). Z1 to Zk are covariates excluding the genetic variant of 
interest. In this study, Martingale residuals were calculated by fitting a standard Cox 
regression model with age at diagnosis, sex and AJCC as covariates using the ‘coxph’ 
function. It has been demonstrated that the Martingale residual is linearly related to 
the potential effect of the remaining variable, that is, the genetic variant under analysis 
(Therneau et al, 1990). In concordance with previous studies (Joshi et al, 2017; 
Therneau et al, 1990), the calculated Martingale residuals were then scaled up by 
1/(the proportion of events) to generate a 1:1 correspondence with the regression 
coefficients of genetic variants to be analysed.  Finally, we regressed the scaled 
residuals on the genetic variant (coded under the additive model) by fitting a 
univariable linear regression model as follows: 
𝑃 = 𝛽𝑋 + 𝑒 
Where β is the estimated genetic effect—approximated log-transformed hazard ratio 
of each variant. A Ward test was performed to obtain the two-sided p-value to examine 
if the β was significantly different from the null. I repeated the linear regression model 
for each of the eight million variants throughout the genome using the SNPtest (v2.50) 
software (URL4-18). Although it has been widely-accepted that the Martingale 
residual approach is a reasonable approximation to the standard Cox model with 
considerably reduced computational load, simulation studies found that there is a 2%-
4% loss of statistical power for the residual approach (Reynisson, 2018). Therefore, I 
re-fitted the standard Cox regression models for genetic variants identified from the 
Martingale residual based approach at a relatively lenient threshold p<5x10-7, and 
variants at GWAS significance (p<5x10-8) from the re-fitted Cox models were 
considered as significant GWAS signals and were passed on for replication.   
Considering that metastatic CRCs (stage IV) may have different genetic components 
in contrast with locally advanced CRCs (stage II and III), stratified GWA analyses 
were conducted following the same procedure above in stage II/III and stage IV CRC 
patients separately.   
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To visualise potential signals of genetic effects across the genome, I created 
Manhattan plots on a genomic scale by stacking the log-base-10 of the p-values for 
associations of all genetic variants grouped by chromosomes in genomic order. 
Genetic variants with strong associations, for example with p< 5x10-8, tend to rise up 
high in the plot. Manhattan plots were generated using the ‘Manhattan’ function in the 
‘qqman’ R package (URL4-19). In addition to Manhattan plots, I also constructed 
quantile-quantile (QQ) plots to visualise the genetic effect of all tested variants. The 
quantiles of log-base-10 of observed p-values obtained from the GWAS was plotted 
against the quantiles of log-base-10 of p-values sampled from a theoretical uniform 
distribution ranging from 0 to 1. A straight line with a slope of 1 is expected if overall 
there is no genetic effect on the outcome or if the study is underpowered. Due to the 
LD among variants, a real genetic effect manifests as an upward tail in a QQ plot. I 
created QQ plots using the ‘qqPlot’ function in the ‘GWASTools’ R package (URL4-
20).   
Unadjusted confounding can lead to systematic inflation in GWAS results—that is, a 
global excess of higher observed p-values than the theoretical distribution. This is 
often caused by unaccounted population structure and can be visualised by a 
systematic upward deviation from the diagonal of the QQ plot. In addition to the graph, 
I also quantified the extent of possible inflation by calculating the inflation factor 
denoted by lambda (λ). According to the method proposed by Aulchenko et al. 
(Aulchenko et al, 2007), I calculated the genome-wide inflation factor by regressing 
the observed p-values on the theoretical distribution using the ‘estlambda’ function in 
the ‘GenABEL’ R package (URL4-21). A lambda value>1.1 was considered as 
presence of inflation (Yang et al, 2011).         
I adopted the same method as in previous candidate genetic association studies to 
estimate the statistical power of this GWAS (Owzar et al, 2012). An α level at GWAS 
significance (5x10-8) was employed along with the same set of other metrics including 
the sample size, proportion of events, effect sizes and minor allele frequencies.   
Replication analysis  
Associations of genetic variants with CRC survival that reached GWAS significance 
(p<5x10-8) were validated by meta-analysis combining three datasets. Standard Cox 
regression models adjusted for age at diagnosis, sex and AJCC stage were 
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conducted in the QUASAR2, VICTOR and SCOT trials to investigate associations 
between variants discovered in the SOCCS and overall survival of CRC patients.  
Both overall and CRC-specific survival were included as outcomes in the UK Biobank 
cohort without adjusting for AJCC stage due to unavailable data. I then extracted the 
summary statistics from the regression models fitted in these datasets including the 
regression coefficients along with their standard errors of the genetic variants. Given 
the concordant ethnicity across all included study cohorts, I implemented a fixed-
effect model meta-analysis, which has been widely used in GWAS meta-analyses, to 
obtain pooled estimates of genetic effects of these variants.  In contrast with the 
random-effects model used in the meta-analysis in Chapter 3, the fixed-effect model 
assumes a constant effect of the factor under study across all included datasets.  I 
employed an inverse-variance weighted (IVW) estimator to combine effect estimates 
extracted from each validation study. To be specific, let Xi be the ith effect estimate, 
namely the regression coefficient of the ith study. The IVW approach defines the weight 





Where Vi is the variance of Xi. Weighted by Wi, the IVW estimator of the pooled effect 











Xi is normally distributed with a sufficiently large sample size, so is the XFE. Therefore, 
a Z score can be generated to infer the significance of XFE.  In addition, I used the I2 
statistic to evaluate potential heterogeneity of effect sizes from each included study 
(Higgins et al, 2003). A two-sided p-value<0.05 was considered as a statistically 
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significant association that was successfully replicated in the three independent 
datasets. I carried out the meta-analyses and created forest plots displaying the 
individual and pooled effect estimates using the ‘metagen’ function in the ‘meta’ R 
package (URL4-22).  
 
Gene and Gene-set based enrichment analysis   
By performing a GWAS, I interrogated individual effects of approximately eight million 
genetic variants on CRC survival outcomes. However, survival of CRC patients is a 
complex trait resulting from polygenic effects of variations in multiple genomic regions. 
Each genetic variant may contribute only a very small fraction of the effect which can 
be undetectable by a GWAS with limited statistical power. Therefore, gene and gene-
set based pathway analysis has been proposed to group millions of genetic variants 
based on their known biological function, and then to test the joint effect of these 
variants as a group on the outcome of interest (de Leeuw et al, 2015). This type of 
analysis can not only indicate functional implications by identifying significant signals 
enriched in genes or sets of genes involved in key biological pathways, but also 
provide higher statistical power due to the reduced number of statistical tests.  
Here I employed the Multi-marker Analysis of GenoMic Annotation (MAGMA) 
approach to conduct gene and gene-set based pathway analyses (de Leeuw et al, 
2015) using the summary statistics of the main GWAS including all SOCCS patients. 
The MAGMA analysis was implemented using the online portal of Functional Mapping 
and Annotation of Genome-Wide Association Studies (FUMA, URL4-23) (Watanabe 
et al, 2017). For the gene based test, genetic variants included in the preceding 
GWAS were first annotated and mapped to a total of 35,808 genes curated in the 
Ensembl genome database (build 85) (URL4-9). Then the genetic effects on CRC 
survival outcomes of variants within the same gene were aggregated. To be specific, 
the MAGMA approach proposed a SNP-wise model leveraging the summary statistics 
of the GWAS results. In particular, the summary statistics including the effect 
estimates, standard errors and p-values for all genetic variants mapped in a specific 
gene were used to re-construct their test statistics (MAGMA uses Chi-square statistic). 
Then the mean statistic of these variants in the gene was estimated to infer the 
statistical significance of the gene-wise effect. It is worth noting that the linkage 
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disequilibrium needs to be adjusted in order to model the distribution of the variants’ 
test statistics. In this study, the 1000 Genomes Project phase 3 was adopted as the 
reference panel to create an LD matrix and account for the LD structure among the 
variants. Similar to the GWAS, I created Manhattan plots to show the gene based 
signals.              
Results of gene based tests were utilised in subsequent gene-set based pathway 
analysis. Mapped genes were aggregated and assigned to ~ 4,728 gene-sets 
involved in different biological pathways curated in The Molecular Signatures 
Database (MSigDB v5.3)(Liberzon et al, 2015; Watanabe et al, 2017).  Leeuw et al. 
proposed a competitive model to analyse the gene-set based effect. This test 
examines whether associations of genes encompassed in the set with CRC survival 
outcomes are generally stronger than genes outside the set by harnessing p-values 
from the gene based tests above (de Leeuw et al, 2015). To be specific, the method 
first creates a statistic Z from the gene based p-values by:  
 Z = Φ−1(1 − 𝑝) 
Where it takes the inverse cumulative standard normal distribution of 1-p. Then a 
linear regression model is fitted as:   
Z = 𝛽0𝑠𝐿 + 𝑆𝑠𝛽𝑠 + 𝜖 
Where β0L is the intercept, and Ss denotes whether the gene is included in the set s 
(Ss=1 or 0). A one-sided test is then conducted to determine if βs is significantly larger 
than 0. In order to adjust for gene-gene correlations, the competitive model derives a 
gene-gene correlation matrix from correlations of genetic variants in each pairs of 
genes (de Leeuw et al, 2015).  With respect to evaluating statistical significance, the 
FUMA implements a Bonferroni correction to adjust the α level to 0.05/n where n 
denotes the number genes and gene sets.    
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4.4 Summary  
 
This chapter describes the study cohorts and presents details of the study design and 
statistical methods implemented in the thesis.  The SOCCS cohort was used as the 
main discovery dataset for the genetic association studies and the GWAS, whilst the 
UK Biobank cohort along with three clinical trial datasets were employed to replicate 
possible discoveries. The Cox regression model was used to estimate effect of each 
genetic variant on overall and CRC-specific survival outcomes of CRC patients. For 
the predictive modelling, I used the UK Biobank cohort to develop the genetic 
predictor and tested its predictive performance as well as added predictive value of 
the genetic predictor on the bases of other non-genetic factors using the SOCCS 
cohort. The model performance was evaluated by examining the discriminative ability 
and the model calibration. The results of each part of analyses are presented in 
Chapter 5.     
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Chapter 5 Results 
 
5.1 Introduction  
 
This chapter presents the results of the analysis in response to the objectives listed 
in Chapter 2. The first section summarises the basic characteristics of the included 
variables and survival outcomes of patients from the SOCCS and UK Biobank cohorts. 
Descriptive analysis of the associations between these variables and survival 
outcomes is also presented. In the second section, the main results of the validation 
study on previously reported genetic variants associated with CRC survival are 
described. Next in the third section, I present the prediction models combining these 
previously reported variants and other variables. Results of model performance in 
predicting CRC survival are also presented. The fourth section features the results 
from candidate association studies testing two groups of genetic variants—variants 
associated with CRC risk and variants reportedly linked with survival outcomes of 
other types of cancers. Finally, the fifth section presents the results of the genome-
wide association study using the SOCCS cohort and replication analysis based on a 
meta-analysis of the summary statistics from the UK Biobank and the clinical trial 
datasets.  
 
5.2 Descriptive analysis of the study cohorts 
 
This section presents basic characteristics of the participants included in the analysis. 
Detailed information regarding the definition and obtainment of study variables can be 
found in Chapter 4. To be specific, the results of patient selection are presented firstly. 
Then characteristics of covariates including missing data are reported. Genetic 
association analyses in this thesis were conducted on the basis of complete case 
analysis; therefore, no missing data were present in covariates used in these analyses 
including age at diagnosis, sex and AJCC stage. Missing values were only identified 
in other variables (tumour grade and site). Finally, descriptive analysis of survival 
outcomes of the study cohorts and associations between the covariates and survival 
outcomes are presented in this section.  
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5.2.1 Patient selection  
 
Study of Colorectal Cancer in Scotland 
As mentioned previously, the survival time of each CRC patient was calculated from 
the date of definitive treatment to the date of death (or alive until January 1st 2018). 
Therefore, I was unable to construct the survival time if the date of definitive treatment 
was missing; these patients were excluded from the analysis (N=46). I also excluded 
527 patients with missing covariates including age at diagnosis, sex and AJCC stage. 
In addition, ten patients with stage 0 designation were also excluded because they 
could be a mixture of patients with polyps or with pathologic complete response (no 
residual tumour identified) to neoadjuvant therapy. I further excluded 94 cases 
diagnosed with appendix and endocrine tumour. Presented in Figure 5-1 is the 
diagram of patient selection for the SOCCS study.  A total of 5,675 CRC patients were 
eligible for the final analysis.  
 




Figure 5-1 Diagram of patient selection for the Study of Colorectal Cancer in Scotland. 
Adapted from the previous publication (He et al, 2019b) with permission. The original source 
is an open access article under the terms of the Creative Commons Attribution License. 




UK Biobank  
Given that disease characteristics such as AJCC stage were still unavailable in the 
UK Biobank cohort, no disease-based quality control, for example exclusion of stage 
0 patients, was conducted. Therefore, I included all CRC cases with genotype data 
that passed genotyping quality control from the case-control study (Project 7411).  
Twelve patients with missing information on age at diagnosis were excluded. Figure 
5-2 shows the diagram of patient selection for the UK Biobank study dataset.  Finally, 
a total of 4,887 CRC patients were included.  
Individuals excluded during 
genotyping quality control: 
High missing rate (N=147) 
Non-European ethnicity (N=77) 
Relatedness or duplicates (N=2,525)  
Sex discrepancy (N=55) 
Extreme heterozygosity (N=50)  
Controls with cancer history (N=931) 
Sample issue (N=54) 
Cases excluded:  
Appendix, endocrine tumour 
or unavailable diagnostic 
status (N=94)  
Missing age at diagnosis, 
date of definitive treatment or 
AJCC stage (N=517) 
Stage 0 cases (N=10) 
  
Individuals genotyped in the 
SOCCS study:  
CRC cases: N=6,821 
controls*: N=14,692  
CRC cases not matched 
in the phenotype 
database (N=346) 
CRC cases included for 
analysis:  
N=5,675 





Figure 5-2 Patient selection procedure from the UK Biobank study 
*controls were only used for QC, not included in analysis of this thesis   
 
5.2.2 Covariates   
 
As described in Chapter 4, the SOCCS cohort included a total of 5,675 patients 
diagnosed with CRC and the UK Biobank cohort included 4,887 patients (incident and 
prevalent CRC cases). Based on the recommendations from the Canadian Cancer 
Society on prognostic factors of CRC (introduced in Chapter 1), the AJCC stage and 
the tumour grade were available in the SOCCS cohort and therefore they were 
extracted along with other basic characteristics including age at CRC diagnosis, sex 
and tumour site (colon or rectum). Given that enhanced cancer data had not been 
released by the UK Biobank, only age at diagnosis and sex were included as 
covariates for the study cohort in this thesis. Descriptive statistics along with the 
Individuals excluded during genotyping quality 
control: 
High missing rate (N=698) 
Non-European ethnicity (N=44) 
Self-defined non-white ethnicity (N=966) 
Relatedness or duplicates (N=211)  
Sex discrepancy (N=56) 
Extreme heterozygosity (N=21)  
Controls with cancer history (N=4,615) 
Individuals genotyped in the UK Biobank study (Project 7441):  
CRC cases: N=6,360 
controls*: N=25,440  
CRC cases included for analysis:  
N=4,887 
Chapter 5 Results 
117 
 
number of missing values of these variables are summarised in Table 5-1. Categorical 
or binary variables are presented as exact numbers and percentages; continuous 
variables are presented as median and interquartile range (IQR). 
Table 5-1 Basic characteristics and descriptive statistics of eligible non-genetic variables from 
the SOCCS (n=5,675) and UK Biobank study (n=4,887) 
Variables* SOCCS Missing UK Biobank  Missing 
Age at diagnosis 
(years) 64.5(54.6-71.6) 0 62.2(55.8-67.2) 0 
Sex  0  0 
Male  3,235(57%)  2,063(42%)  
Female 2,440(43%)  2,824(58%)  
AJCC stage  0  NA 
I 1,005(17.7%)  NA  
II 1,891(33.3%)    
III 1,995(35.2%)    
IV 784(13.8%)    
Tumour grade  839(14.8%)  NA 
1 (well) 185(3.3%)  NA  
2 (moderate) 3,954(69.7%)    
3 (poor/undifferentiated) 697(12.3%)    
Tumour site  66(1.2%)  NA 
Colon  3,392(59.8%)  NA  
Rectum 2,201(38.8)    
Colon and rectum 16(0.3%)     
*Continuous variables are presented with median and interquartile range.   
AJCC, the American Joint Committee on Cancer; NA, not available. 
 
5.2.3 Survival outcomes   
 
Kaplan-Meier estimates—probabilities of CRC patients in SOCCS and UK Biobank 
cohorts surviving over 1, 3, 5 and 10 years—were calculated and listed in Table 5-2. 
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The survival rates of the UK Biobank cohort (N=4,887) were mostly higher than rates 
of the SOCCS cohort (N=5,675) at each observation time. Results of log-rank test 
also suggested a statistically significant difference in terms of the survival estimates 
between the two study cohorts (p<0.001 for both overall and CRC-specific survival).  
 
Table 5-2 Kaplan-Meier estimates for overall and CRC-specific survival of patients in the 
SOCCS and UK Biobank cohort 
  Kaplan-Meier estimates (95%CI) 
Time (years) SOCCS UK Biobank 
Overall survival   
1 0.958(0.953-0.963) 0.957(0.951-0.962) 
3 0.824(0.814-0.834) 0.886(0.877-0.895) 
5 0.738(0.726-0.751) 0.838(0.828-0.849) 




1 0.963(0.958-0.968) 0.964(0.958-0.969) 
3 0.845(0.835-0.855) 0.908(0.900-0.916) 
5 0.775(0.763-0.787) 0.872(0.863-0.882) 
10 0.705(0.691-0.719) 0.828(0.817-0.840) 
 CI, confidence interval; CRC, colorectal cancer 
 
Notably, the UK Biobank cohort consisted of 2,474 incident and 2,080 prevalent CRC 
cases. It is widely accepted that prevalent cases suffer from potential selection bias—
patients with less severe disease are more likely to be selected into the study, leading 
to the appearance of higher observed survival rates than expected. Therefore, I 
plotted survival curves of Kaplan-Meier estimates of the incident and prevalent CRC 
cases in the UK Biobank separately along with survival estimates of patients in the 
SOCCS cohort to visualise this potential difference caused by the inclusion of 
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of prevalent CRC cases and incident cases in the UK Biobank hinted to selection bias 
present amongst the prevalent CRC cases. In order to eliminate this bias, subsequent 
survival analysis of the UK Biobank was only conducted using incident CRC cases.  
After excluding prevalent cases, the median follow-up time of the UK Biobank cohort 
was 5.3 years (quartiles: 3.5-7.5). There had been 765 deaths (30.9%) of any causes 
until the censoring time; among them, 587 patients (76.7% of all deaths) died from 
CRC-related causes. With regard to the SOCCS study, the median follow-up time of 
the SOCCS cohort was 5.1 years (IQR: 2.4-11.4). During the follow-up time, an 
aggregate of 1,918(33.8%) patients died, and 1,358 (70.8% of all deaths) of them died 
from CRC-related causes. 
 
5.2.4 Associations between covariates and CRC survival  
 
Associations between these aforementioned variables and survival outcomes of CRC 
in both cohorts were examined by fitting univariable Cox models. Table 5-3 presents 
detailed effect estimates and p-values for each association analysis. No stringent 
correction for multiple testing was applied to evaluate statistical significance at this 
point. In particular, male CRC patients showed significantly favoured overall and 
CRC-specific survival outcomes, and this association was consistent across the two 
study cohorts. With respect to age at diagnosis, significant association between 
increased age and poorer survival was only observed for overall survival of the 
SOCCS cohort. However, younger age at diagnosis was significantly associated with 
inferior CRC-specific survival for both cohorts.  
Table 5-3 Summary of associations between covariates and survival outcomes of CRC using 
univariable Cox regression 
 SOCCS(n=5,675)  UK Biobank 
(n=2,474) 
 
Variables HR(95%CI) p  HR(95%CI) p  
Overall survival      
Age at diagnosis 1.015(1.011-1.019) 5.33E-12 0.995(0.984-1.006) 0.342 
Sex (Male vs 
Female) 
0.864(0.788-0.946) 0.002 0.733(0.632-0.850) 4.0E-5 
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 SOCCS(n=5,675)  UK Biobank 
(n=2,474) 
 
AJCC stage  2.194(2.075-2.320) 3.3E-168 NA  
Tumour grade 1.334(1.186-1.502) 1.74E-6 NA  
Tumour site(rectum 
vs. colon) 
1.009(0.920-1.106) 0.850 NA  
     
CRC-specific 
survival  
    
Age at diagnosis  0.992(0.988-0.997) 0.002 0.984(0.972-0.996) 0.009 
Sex (Male vs 
Female) 
0.894(0.802-0.997) 0.043 0.807(0.682-0.953) 0.012 
AJCC stage  3.240(3.018-3.477) 1.60E-232 NA  




1.026(0.920-1.144) 0.647 NA  
HR, hazard ratio; CI, confidence interval; BMI, body mass index; CRP, C-reaction protein; 
AJCC, the American Joint Committee on Cancer; NA, not available.  
 
As for the pathological variables (tumour stage and grade), analysis was only 
conducted in the SOCCS cohort due to data availability. In concordance with previous 
evidence, more advanced tumour stage and grade were both strongly associated with 
inferior survival outcomes of CRC patients (p<0.001) in the SOCCS dataset. Kaplan-
Meier survival curves stratified by AJCC stage and tumour grade are plotted in Figure 
5-5 and Figure 5-6 respectively. As shown in Figure 5-5, the 5-year overall survival 
rates for stage I to IV CRC patients in the SOCCS study were 93%, 84%, 72% and 
27%. The 5-year CRC-specific survival rates were 97%, 89%, 75% and 28% for stage 
I to IV patients respectively. In respect to tumour grade, patients diagnosed with grade 
1 to 3 tumours had 5-year overall survival rates of 81%, 76% and 67%. The 5-year 
CRC-specific survival rates were 88% for grade 1, 80% for grade 2 and 70% for grade 
3 patients.




Figure 5-5 Stage-stratified Kaplan-Meier estimates of CRC patients in the SOCCS study. 
(A for overall survival and B for CRC-specific survival). 
 




Figure 5-6 Grade-stratified Kaplan-Meier estimates of CRC patients in the SOCCS study. 
(A for overall survival and B for CRC-specific survival). 
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5.3 Candidate association studies  
 
5.3.1 Validation of genetic variants previously linked with CRC 
survival  
 
Eligible variants  
The initial search in the GWAS catalogue yielded three GWASs reporting significant 
associations (p<10-5) between 51 autosomal genetic variants and CRC survival 
outcomes (Pander et al, 2015; Phipps et al, 2016; Xu et al, 2015). Eight variants were 
excluded due to linkage disequilibrium with other identified variants (r2>0.2). 
Eventually, a total of 43 variants were included in the analysis, and their basic 
characteristics are listed in Table 5-4. Among the included 43 variants, two variants—
rs209489 and rs885036—were reported to be associated with CRC survival at GWAS 
significance level (p<5x10-8) (Pander et al, 2015) (Phipps et al, 2016). These two 
variants were identified in a subgroup of metastatic CRC patients. The variant 
rs209489 was associated with disease-free survival whereas rs885036 was 
associated with progression-free survival. With respect to different survival outcomes 
of CRC patients, 24 out of the 43 variants were reported to be associated with 
disease-free survival; 15 variants with overall survival; and the remaining three 
variants with progression-free survival of CRC patients. Xu et al. conducted stratified 
GWAS analysis by tumour site (Xu et al, 2015), 10 variants were identified specifically 
in colon cancer patients, and 17 variants were associated with survival outcomes of 
rectal cancer patients (Table 5-4). Additional details of the effect estimates for each 
listed variant can be found in the GWAS catalogue. 
 
Table 5-4 Summary details of the included genetic variants previously associated with CRC 
survival 
Variant locus MA MAF Gene Reported outcomes Reference 
rs10921219 1q31.2 A 0.46 AL390957.1 Colon cancer(OS) Xu,2015 
rs6720296 2p21 C 0.48 LINC01121 Colorectal cancer (MSI-L/S) (DFS) Xu,2015 
rs885036 2q11.2 A 0.45 MGAT4A Colorectal cancer(metastatic)(PFS) Pander,2015 
rs17048372 2q14.1 T 0.15 DPP10 Colon cancer(OS) Xu,2015 
rs4377367 2q21.1 C 0.19 ARHGEF4 Colorectal cancer(metastatic)(PFS) Pander,2015 
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Variant locus MA MAF Gene Reported outcomes Reference 
rs16867335 2q31.3 T 0.2 AC009478.1 Rectal cancer(OS) Xu,2015 
rs6854845 4q13.3 T 0.12 Intergenic Rectal cancer(OS) Xu,2015 
rs17026425 4q31.23 A 0.08 IQCM Rectal cancer(OS) Xu,2015 
rs13180087 5p12 C 0.18 HCN1 Colon cancer(OS) Xu,2015 
rs10040610 5p15.31 C 0.21 Intergenic Colorectal cancer (MSI-L/S) (OS) Xu,2015 
rs157411 5q13.1 G 0.33 Intergenic Rectal cancer(OS) Xu,2015 
rs1493383 5q33.2 T 0.1 GRIA1 Colorectal cancer (MSI-L/S) (OS) Xu,2015 
rs17057166 5q33.3 T 0.09 LINC01847 Rectal cancer(DFS) Xu,2015 
rs12187751 5q34 G 0.09 AC113414.1 Colorectal cancer (MSI-L/S) (OS) Xu,2015 
rs4868304 5q35.2 T 0.14 LINC01484 Rectal cancer(DFS) Xu,2015 
rs209489 6p12.1 C 0.08 ELOVL5 Colorectal cancer (metastastic) (DFS) Phipps,2016 
rs2073016 6p21.1 C 0.18 APOBEC2 Colorectal cancer(metastatic)(PFS) Pander,2015 
rs1573948 6p25.1 C 0.1 Intergenic Rectal cancer(OS) Xu,2015 
rs4959799 6p25.2 C 0.14 SLC22A23 Rectal cancer(DFS) Xu,2015 
rs17087282 6q25.3 A 0.11 Intergenic Colorectal cancer (MSI-L/S) (OS) Xu,2015 
rs10275272 7p21.1 T 0.28 TWIST1 Rectal cancer(DFS) Xu,2015 
rs2936519 8p23.1 A 0.27 Intergenic Colorectal cancer(metastatic)(PFS) Pander,2015 
rs7004484 8q24.22 C 0.3 EFR3A Rectal cancer(OS) Xu,2015 
rs1998584 9p23 T 0.41 Intergenic Colorectal cancer (MSI-L/S) (OS) Xu,2015 
rs11138220 9q21.31 G 0.13 Intergenic Rectal cancer(DFS) Xu,2015 
rs1407508 9q22.33 C 0.02 AL136084.1 Colorectal cancer (MSI-L/S) (DFS) Xu,2015 
rs1555895 10p15.3 A 0.5 Intergenic Rectal cancer(OS) Xu,2015 
rs1570271 10q25.3 A 0.14 Intergenic Rectal cancer(DFS) Xu,2015 
rs9419702 10q26.3 C 0.26 Intergenic Rectal cancer(DFS) Xu,2015 
rs12224794 11p12 A 0.42 LRRC4C Colorectal cancer(OS) Phipps,2016 
rs3781663 11q13.3 G 0.31 ANO1 Rectal cancer(DFS) Xu,2015 
rs912294 13q12.3 A 0.47 Intergenic Colorectal cancer (MSI-L/S) (DFS) Xu,2015 
rs17280262 14q32.2 T 0.04 Intergenic Colon cancer(DFS) Xu,2015 
rs1075232 15q13.3 A 0.1 AC104759.1 Colorectal cancer (non-metastatic)(OS) Phipps,2016 
rs8035094 15q13.3 C 0.1 Intergenic Colon cancer(DFS) Xu,2015 
rs10152207 15q14 A 0.09 Intergenic Rectal cancer(OS) Xu,2015 
rs338389 15q23 G 0.49 Intergenic Rectal cancer(OS) Xu,2015 
rs3794924 18q12.1 A 0.1 DSG3 Colon cancer(OS) Xu,2015 
rs1372474 18q21.2 G 0.07 LINC01919 Colorectal cancer(metastatic)(OS) Phipps,2016 
rs6105057 20p12.1 G 0.28 ISM1 Colon cancer(OS) Xu,2015 
rs658495 20p13 G 0.04 C20orf27 Colon cancer(DFS) Xu,2015 
rs4812219 20q13.33 T 0.14 Intergenic Colon cancer(OS) Xu,2015 
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Variant locus MA MAF Gene Reported outcomes Reference 
rs139156 22q13.31 A 0.26 PARVG Colon cancer(OS) Xu,2015 
CRC, colorectal cancer; CC, colon cancer; RC, rectal cancer; mCRC, metastatic colorectal 
cancer; OS, overall survival; DFS, disease-free survival; PFS, progression-free survival. MSI-
L/S, microsatellite instability-low/stable 
 
Statistical power  
Given that there were 43 independent candidate variants to be investigated, a 
Bonferroni corrected α level of 0.001 was employed to estimate the statistical power 
for this study. As shown in Table 5-4, the minor allele frequency (MAF) of included 
genetic variants ranged from 0.02 to 0.50; therefore, a range of MAFs starting from 
0.01 to 0.50 was used for power estimation. In combination with the sample size 
(n=5,675) and the number of events in the SOCCS cohort—34% for overall survival 
and 24% for CRC-specific survival, statistical power was estimated based on a range 
of potential genetic effect sizes (hazard ratio) from 1.05 to 1.60 under the additive 
genetic model. Using the formula provided by Owzar et al. (Owzar et al, 2012), this 
study had a power of 85% to detect a hazard ratio of 1.25 on overall survival for 72% 
(31/43) of included variants (MAF> 0.15), and the power for CRC-specific survival 
was 66%. Power curves at different levels of hazard ratios and MAFs are plotted in 
Figure 5-7. As shown, this study had limited power (<0.5) to detect an effect as large 
as 1.6 for the variant with the lowest MAF of 0.01. 




Figure 5-7 Power curves for the SOCCS validation study of genetic variants previously 
linked with CRC survival 
 
Main results  
 
I fitted Cox regression models adjusting for age at diagnosis, sex and AJCC stage to 
investigate associations between each of the 43 variants and survival outcomes of 
CRC. After correcting for multiple testing using the FDR approach, no genetic variants 
were statistically significantly associated with overall survival (FDR corrected p-
value<0.05). With regard to results not corrected for multiple testing, four variants 
(rs11138220, rs17026425, rs6854845, rs17057166) were associated with overall 
survival at p<0.05. In particular, three variants (rs17026425, rs6854845, rs17057166) 
showed the same direction of effects as the previous GWAS—the minor alleles of 
these three variants conferred higher overall death hazard. However, an opposite 
effect for the variant rs11138220 was found when compared to the original GWAS (Xu 
et al, 2015). Our results suggested a favourable overall survival for the minor allele 
(G) (HR=0.88, 95%CI=0.79-0.98, uncorrected p=0.016), whereas Xu et al. reported 
that the G allele was associated with worse disease-free survival for rectal cancer 
patients (HR=2.76, 95%CI=1.77-4.31, p=8.0x10-6). The effect estimates (HR) along 
with both uncorrected and FDR-corrected p-values of these 43 variants on overall 
survival are presented in Table 5-5.  
 
Chapter 5 Results 
129 
 
Table 5-5 Summary of associations between 43 variants previously linked with CRC survival 
and overall survival of CRC patients in the SOCCS study (N=5,675).  
Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs11138220 G 0.13  Intergenic 0.88(0.79-0.98) 0.016  0.462  
rs17026425 A 0.08  IQCM 1.16(1.01-1.33) 0.039  0.462  
rs6854845 T 0.12  Intergenic 1.14(1.01-1.29) 0.040  0.462  
rs17057166 T 0.09  LINC01847 1.14(1.00-1.29) 0.042  0.462  
rs17087282 A 0.11  Intergenic 1.14(1.00-1.29) 0.054  0.467  
rs17280262 T 0.04  Intergenic 0.86(0.74-1.01) 0.064  0.467  
rs6720296 C 0.48  LINC01121 1.05(0.99-1.12) 0.122  0.689  
rs912294 A 0.47  Intergenic 0.95(0.89-1.01) 0.127  0.689  
rs1570271 A 0.14  Intergenic 1.08(0.97-1.21) 0.172  0.689  
rs139156 A 0.26  PARVG 0.92(0.82-1.04) 0.176  0.689  
rs16867335 T 0.20  AC009478.1 0.95(0.87-1.03) 0.183  0.689  
rs2073016 C 0.18  APOBEC2 1.05(0.97-1.14) 0.189  0.689  
rs1372474 G 0.07  LINC01919 1.08(0.96-1.21) 0.212  0.689  
rs3794924 A 0.10  DSG3 0.94(0.85-1.04) 0.219  0.689  
rs13180087 C 0.18  HCN1 1.06(0.96-1.16) 0.271  0.751  
rs1407508 C 0.02  AL136084.1 0.93(0.82-1.07) 0.313  0.751  
rs10040610 C 0.21  Intergenic 1.05(0.95-1.16) 0.347  0.751  
rs3781663 G 0.31  ANO1 1.03(0.96-1.11) 0.365  0.751  
rs4377367 C 0.19  ARHGEF4 0.96(0.89-1.05) 0.373  0.751  
rs2936519 A 0.27  Intergenic 0.95(0.86-1.06) 0.381  0.751  
rs12224794 A 0.42  LRRC4C 0.97(0.91-1.04) 0.387  0.751  
rs4959799 C 0.14  SLC22A23 0.94(0.82-1.08) 0.395  0.751  
rs17048372 T 0.15  DPP10 0.97(0.89-1.05) 0.422  0.751  
rs10152207 A 0.09  Intergenic 1.04(0.94-1.14) 0.428  0.751  
rs1573948 C 0.10  Intergenic 1.04(0.94-1.15) 0.441  0.751  
rs885036 A 0.45  MGAT4A 0.98(0.91-1.04) 0.444  0.751  
rs4812219 T 0.14  Intergenic 1.04(0.92-1.17) 0.554  0.899  
rs1075232 A 0.10  AC104759.1 1.04(0.90-1.20) 0.572  0.899  
rs6105057 G 0.28  ISM1 0.98(0.91-1.06) 0.602  0.913  
rs10921219 A 0.46  AL390957.1 0.98(0.92-1.05) 0.637  0.925  
rs338389 G 0.49  Intergenic 0.99(0.93-1.05) 0.682  0.925  
rs1493383 T 0.10  GRIA1 0.98(0.90-1.07) 0.689  0.925  
rs658495 G 0.04  C20orf27 1.03(0.87-1.22) 0.714  0.925  
rs1555895 A 0.50  Intergenic 1.01(0.95-1.08) 0.715  0.925  
rs9419702 C 0.26  Intergenic 1.01(0.94-1.09) 0.759  0.945  
rs209489 C 0.08  ELOVL5 0.98(0.87-1.11) 0.773  0.945  
rs12187751 G 0.09  AC113414.1 1.01(0.90-1.14) 0.826  0.956  
rs4868304 T 0.14  LINC01484 1.01(0.92-1.10) 0.866  0.968  
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Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs10275272 T 0.28  TWIST1 1.01(0.91-1.12) 0.880  0.968  
rs7004484 C 0.30  EFR3A 1.00(0.93-1.09) 0.942  0.979  
rs157411 G 0.33  Intergenic 1.00(0.93-1.07) 0.944  0.979  
rs1998584 T 0.41  Intergenic 1.00(0.94-1.07) 0.960  0.979  
rs8035094 C 0.10  Intergenic 1.00(0.88-1.13) 0.979  0.979  
MA, minor allele; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval; Pfdr, 
p-values corrected using the false positive rate approach. 
 
With respect to results of CRC-specific survival, again no statistically significant 
associations between any of the 43 variants and CRC-specific survival were identified 
in the SOCCS cohort after correcting for multiple testing using the FDR approach. The 
only variant with a p-value<0.05 prior to FDR-correction was rs11138220. Similar to 
its effect on overall survival, a potential favourable effect on CRC-specific survival was 
identified to be linked with the minor allele G (HR=0.85, 95%CI=0.75-0.97, 
uncorrected p=0.016), which was discordant with the original finding. Detailed effect 
estimates and p-values can be found in Table 5-6:  
 
Table 5-6 Summary of associations between 43 variants previously linked with CRC survival 
and CRC-specific survival of CRC patients in the SOCCS study (N=5,675).  
Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs11138220 G 0.13  Intergenic 0.85(0.75-0.97) 0.016  0.700  
rs17280262 T 0.04  Intergenic 0.84(0.70-1.01) 0.069  0.767  
rs1372474 G 0.07  LINC01919 1.13(0.99-1.29) 0.078  0.767  
rs139156 A 0.26  PARVG 0.89(0.77-1.02) 0.087  0.767  
rs2073016 C 0.18  APOBEC2 1.09(0.99-1.19) 0.087  0.767  
rs16867335 T 0.20  AC009478.1 0.92(0.84-1.02) 0.112  0.771  
rs6720296 C 0.48  LINC01121 1.05(0.98-1.14) 0.187  0.771  
rs3781663 G 0.31  ANO1 1.05(0.96-1.14) 0.276  0.771  
rs12187751 G 0.09  AC113414.1 1.08(0.94-1.23) 0.289  0.771  
rs17087282 A 0.11  Intergenic 1.09(0.93-1.27) 0.290  0.771  
rs912294 A 0.47  Intergenic 0.96(0.89-1.04) 0.299  0.771  
rs6854845 T 0.12  Intergenic 1.08(0.93-1.26) 0.303  0.771  
rs12224794 A 0.42  LRRC4C 0.96(0.89-1.04) 0.308  0.771  
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Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs1570271 A 0.14  Intergenic 1.06(0.93-1.21) 0.347  0.771  
rs10040610 C 0.21  Intergenic 1.06(0.94-1.19) 0.349  0.771  
rs6105057 G 0.28  ISM1 0.96(0.87-1.05) 0.379  0.771  
rs885036 A 0.45  MGAT4A 0.97(0.90-1.04) 0.384  0.771  
rs1407508 C 0.02  AL136084.1 0.93(0.79-1.09) 0.389  0.771  
rs10275272 T 0.28  TWIST1 1.05(0.93-1.19) 0.393  0.771  
rs1573948 C 0.10  Intergenic 1.05(0.94-1.18) 0.394  0.771  
rs17057166 T 0.09  LINC01847 1.07(0.92-1.24) 0.395  0.771  
rs17048372 T 0.15  DPP10 0.96(0.88-1.06) 0.469  0.771  
rs209489 C 0.08  ELOVL5 0.95(0.83-1.09) 0.491  0.771  
rs2936519 A 0.27  Intergenic 0.96(0.84-1.09) 0.494  0.771  
rs10152207 A 0.09  Intergenic 1.04(0.93-1.16) 0.494  0.771  
rs157411 G 0.33  Intergenic 0.97(0.90-1.05) 0.494  0.771  
rs338389 G 0.49  Intergenic 0.97(0.90-1.05) 0.495  0.771  
rs13180087 C 0.18  HCN1 1.04(0.93-1.17) 0.502  0.771  
rs4377367 C 0.19  ARHGEF4 0.97(0.88-1.07) 0.508  0.771  
rs4959799 C 0.14  SLC22A23 0.95(0.81-1.12) 0.540  0.772  
rs10921219 A 0.46  AL390957.1 0.98(0.90-1.06) 0.544  0.772  
rs8035094 C 0.10  Intergenic 0.97(0.84-1.11) 0.634  0.849  
rs1493383 T 0.10  GRIA1 0.98(0.88-1.08) 0.640  0.849  
rs4812219 T 0.14  Intergenic 1.03(0.90-1.18) 0.656  0.849  
rs1555895 A 0.50  Intergenic 1.01(0.94-1.09) 0.776  0.947  
rs3794924 A 0.10  DSG3 0.99(0.87-1.11) 0.808  0.947  
rs658495 G 0.04  C20orf27 0.98(0.81-1.18) 0.808  0.947  
rs9419702 C 0.26  Intergenic 0.99(0.91-1.08) 0.818  0.947  
rs7004484 C 0.30  EFR3A 0.99(0.90-1.09) 0.897  0.964  
rs1075232 A 0.10  AC104759.1 0.99(0.83-1.17) 0.898  0.964  
rs1998584 T 0.41  Intergenic 1.00(0.92-1.07) 0.898  0.964  
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Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs17026425 A 0.08  IQCM 1.00(0.83-1.19) 0.956  0.984  
rs4868304 T 0.14  LINC01484 1.00(0.90-1.11) 0.984  0.984  
MA, minor allele; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval; Pfdr, 
p-values corrected using the false positive rate approach. 
 
Then I extracted the reported effect estimates from the original studies and compared 
them with our results using the SOCCS cohort; the comparison of the four variants 
that were associated with CRC survival (uncorrected p<0.05) in our study is 
summarised in Table 5-7. Compared with the original reports, our results tended to 
show smaller effect sizes although different survival outcomes were used. According 
to the results of power estimation (Figure 5-7), this study would have a power of 100% 
to detect associations of these variants with survival outcomes in the SOCCS cohort 
assuming the same effect sizes with previous findings. 
 
Table 5-7 Comparison of estimates in original reports and the SOCCS of variants associated 
with CRC survival (p<0.05 in the SOCCS) (N=5,675)  
   Effect estimate   
Variant Gene Reported 
outcomes 
Reported HRs HRs in SOCCS 
rs17026425 IQCM OS(RC) 5.06(2.67-9.60) 1.16(1.01-1.33) 
rs17057166 LINC01847 DFS(RC) 5.56(2.91-10.64) 1.14(1.00-1.29) 
rs6854845 Intergenic DFS(RC) 4.12(2.34-7.26) 1.14(1.01-1.29) 
rs11138220 Intergenic DFS(RC) 2.76(1.77-4.31) 0.88(0.79-0.98) 
    0.85(0.75-0.97)* 
*CRC-specific survival in the SOCCS. Other estimates are for overall survival.  
HR, hazard ratio, DFS, disease-free survival; RC, rectal cancer   
 
In addition to testing individual effects of included variants, I also created a polygenic 
risk score (PRS) by counting the total number of risk alleles of the 43 variants for each 
patient in the SOCCS study. The risk allele of each variant that was detrimental for 
CRC survival was ascertained from the original GWASs. Colorectal cancer patients 
in the SOCCS study carried an average of 17.1 risk alleles (standard deviation=3.3). 
The distribution of the number of risk alleles carried by individuals from the SOCCS 
is plotted in Figure 5-8. As shown, the PRS of variants previously linked with CRC 
survival were approximately normally distributed. A Cox regression model with the 
same group of covariates was performed, and the result indicated no significant effect 
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on either overall (HR=1.00, 95% CI=0.99-1.02, p=0.775) or CRC-specific survival 
(HR=1.00, 95% CI=0.98-1.01, p=0.91) of the PRS.  
 
 
Figure 5-8 Distribution of polygenic risk score of variants associated with CRC survival in 
the SOCCS study 
 
Stratified analysis  
  
I also conducted genetic association analyses stratified by sex, stage (II/III and IV) 
and tumour site (colon and rectum) under the additive genetic model. Overall, none 
of these 43 genetic variants showed significant association with either overall or CRC-
specific survival after correction for multiple testing within any strata. Nonetheless, a 
number of variants were identified to be associated with survival outcomes of CRC at 
nominal significance (uncorrected p<0.05).  
 
To be specific, in male CRC patients (N=3,225), two variants were associated with 
overall survival (rs6854845: HR=1.26, 95%CI=1.08-1.48, uncorrected p=0.004, 
Pfdr=0.086; rs3794924: HR=0.87, 95%CI=0.76-0.99, uncorrected p=0.038, 
Pfdr=0.497), whereas another variant rs1573948 was observed to be associated with 
CRC-specific survival in male CRC patients (HR=1.16, 95%CI=1.00-1.33, 
uncorrected p=0.043, Pfdr=0.710). With respect to female patients (N=2,440) in the 
SOCCS study, five variants were identified to be associated with CRC survival at 
p<0.05, and among them, I found associations of the variant rs17280262 with both 
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overall and CRC-specific survival. Effect estimates of these aforementioned variants 
(p<0.05) are summarised in Table 5-8. A full list of 43 variants along with the 
summarised effects are presented in Appendix Table S6. 
 
Table 5-8 Summary of associations (p<0.05) between variants previously linked with CRC 
survival and outcomes of CRC patients in the SOCCS study stratified by sex  
 Variant MA MAF HR(95%CI) P(uncorrected) Pfdr 
Female (N=3,225)      
OS rs17280262 T 0.04 0.69(0.53-0.89) 0.005 0.237 
 rs1998584 T 0.41 0.90(0.81-1.00) 0.044 0.559 
 rs1407508 C 0.02 0.80(0.64-1.00) 0.048 0.559 
       
CSS rs17280262 T 0.04 0.65(0.47-0.89) 0.008 0.309 
 rs11138220 G 0.13 0.76(0.61-0.95) 0.014 0.309 
 rs3781663 A 0.31 1.14(1.00-1.30) 0.048 0.584 
Male (N=2,440)      
OS rs6854845 T 0.12 1.26(1.08-1.48) 0.004 0.086 
 rs3794924 A 0.10 0.87(0.76-0.99) 0.038 0.497 
       
CSS rs1573948 C 0.10 1.16(1.00-1.33) 0.043 0.710 
MA, minor allele; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval; Pfdr, 
p-values adjusted using the false positive rate approach. OS, overall survival, CSS, CRC-
specific survival 
 
With respect to analyses stratified by stage, a total of 3,886 stage II/III and 784 stage 
IV CRC patients were included. For stage II/III patients, the A allele of the variant 
rs17087282 was associated with inferior overall survival (HR=1.18, 95% CI=1.01-1.39, 
uncorrected p=0.038, Pfdr=0.645). As for CRC-specific survival, a copy of G allele of 
the variant rs1372474 was associated with 19% higher hazards of death of any 
causes (HR=1.19, 95% CI=1.01-1.42, uncorrected p=0.041, Pfdr=0.938). However, 
for stage IV patients, I did not identify any associations with either overall or CRC-
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specific survival with p-values less than 0.05. The full list of results is presented in 
Appendix Table 7.  
In relation to tumour site, a total of 3,392 patients with colon cancer and 2,201 patients 
with rectal cancer were included in analysis. For colon cancer patients, I found five 
variants associated with survival outcomes with uncorrected p<0.05 (presented in 
Table 5-9); among them, the variants rs11138220 and rs3794924 were detected in 
associations with both overall and CRC-specific survival. Regarding rectal cancer 
patients, six variants were associated with overall survival whereas no variants were 
related to CRC-specific survival at p<0.05 (Table 5-9). Detailed information of all 
results can be found in Appendix Table 8.   
 
Table 5-9 Summary of associations (p<0.05) between variants previously linked with CRC 
survival and outcomes of CRC patients in the SOCCS study stratified by tumour site. 
 Variant MA MAF HR(95%CI) P(uncorrected) Pfdr 
Colon (N=3,392)      
OS rs3794924 A 0.10 0.82(0.71-0.94) 0.006 0.266 
 rs17087282 A 0.11 1.24(1.05-1.46) 0.012 0.266 
 rs11138220 G 0.13 0.85(0.74-0.97) 0.018 0.266 
 rs16867335 T 0.20 0.90(0.80-1.00) 0.050 0.547 
       
CSS rs1372474 G 0.07 1.22(1.02-1.45) 0.029 0.531 
 rs3794924 A 0.10 0.84(0.71-1.00) 0.046 0.531 
 rs11138220 G 0.13 0.84(0.71-1.00) 0.046 0.531 
Rectum (N=2,201)      
OS rs12224794 A 0.42 0.88(0.79-0.97) 0.010 0.339 
 rs6854845 T 0.12 1.24(1.02-1.50) 0.027 0.339 
 rs13180087 C 0.18 1.18(1.02-1.37) 0.029 0.339 
 rs139156 C 0.26 0.82(0.69-0.98) 0.031 0.339 
 rs17026425 A 0.08 1.25(1.01-1.56) 0.044 0.339 
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 Variant MA MAF HR(95%CI) P(uncorrected) Pfdr 
 rs1570271 G 0.14 1.19(1.00-1.41) 0.046 0.339 
MA, minor allele; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval; Pfdr, 
p-values adjusted using the false positive rate approach. OS, overall survival, CSS, CRC-
specific survival 
 
Sensitivity analysis  
In order to test potential genetic effects of recessive pattern, I examined the 
associations of these 43 variants with CRC survival by comparing individuals carrying 
two copies of risk alleles versus those with zero or one risk allele. In total, four genetic 
variants (rs16867335, rs17057166, rs17280262, rs6854845) were identified to be 
associated with both overall and CRC-specific survival with p<0.05. Three out of these 
four variants (rs17057166, rs17280262, rs6854845) remained significantly associated 
both survival outcomes after correction for multiple testing using the FDR approach. I 
summarise the effect estimates of these four variants in Table 5-10. Additional details 
regarding the results of other 39 variants can be found in Appendix Table 9. 
Table 5-10 Summary of associations (p<0.05) between variants previously linked with CRC 
survival and outcomes of CRC patients in the SOCCS study under recessive model (N=5,675)   
 Variant MG MGF HR(95%CI) P(uncorrected) Pfdr 
OS rs17280262 TT 0.01 0.55(0.42-0.70) 1.98E-6 8.71E-5 
 rs17057166 TT 0.01 0.60(0.47-0.75) 1.58E-5 3.48E-4 
 rs6854845 TT 0.02 0.63(0.50-0.79) 8.42E-5 0.001 
 rs16867335 TT 0.05 0.66(0.49-0.89) 0.007 0.072 
       
CSS rs17280262 TT 0.01 0.54(0.41-0.71) 8.48E-6 3.73E-4 
 rs17057166 TT 0.01 0.57(0.43-0.74) 2.19E-5 4.55E-4 
 rs6854845 TT 0.02 0.57(0.44-0.74) 3.50E-5 4.55E-4 
 rs16867335 TT 0.05 0.58(0.40-0.83) 0.003 0.038 
MG, minor genotype; MGF, minor genotype frequency; HR, hazard ratio; CI, confidence 
interval; Pfdr, p-values adjusted using the false positive rate approach. OS, overall survival, 
CSS, CRC-specific survival.  
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For the three significant associations that survived the FDR correction, I further 
validated the associations between these variants and CRC survival in the UK 
Biobank cohort (N=2,474) under the recessive model. Overall, I failed to observe any 
significant effects (p<0.05) of these four variants on either overall or CRC-specific 
survival (presented in Table 5-11). Notably, for the variant rs17057166, I was unable 
to estimate its effect on CRC-specific survival in the UK Biobank cohort due to the 
absence of CRC-related deaths observed in CRC patients carrying the effect 
genotype. Although no variants were successfully replicated with statistical 
significance, after harmonising the reference genotype for each variant, concordant 
direction of effects were observed for all of the four variants (Table 5-11). 
 
Table 5-11 Summarised associations in the UK Biobank cohort between variants identified 
from the SOCCS study under recessive model (N=2,474)  
 Variant MG MGF HR(95%CI) P 
OS  rs16867335 TT 0.05 0.85(0.56-1.27) 0.420 
 rs17057166 TT 0.01 0.79(0.20-3.17) 0.739 
 rs17280262 TT 0.01 0.93(0.23-3.75) 0.924 
 rs6854845 TT 0.02 0.92(0.43-1.93) 0.816 
      
CSS      
 rs16867335 TT 0.05 0.69(0.41-1.16) 0.160 
 rs6854845 TT 0.02 0.68(0.25-1.82) 0.442 
 rs17280262 TT 0.01 0.58(0.08-4.12) 0.584 
 rs17057166 TT 0.01 NA NA 
MG, minor genotype; MGF, minor genotype frequency; HR, hazard ratio; CI, confidence 
interval; Pfdr, p-values adjusted using the false positive rate approach. OS, overall survival, 
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5.3.2 Predictive modelling of CRC-survival variants 
 
Genetic predictor development in the UK Biobank dataset  
Full model with 43 genetic variants  
I included the same set of 43 variants used in the preceding validation study and fitted 
a multi-variable Cox regression model on overall and CRC-specific survival using 
incident CRC cases (N=2,474) in the UK Biobank cohort. The estimated coefficients 
are presented in Table 5-12. We observed 18 (42%) variants with effect alleles that 
were associated with favourable overall survival (regression coefficient<0) and 
another group of 18 variants associated with favourable CRC-specific survival (Table 
5-12). These variants were therefore modelled with opposite direction of effects 
compared to the original published GWASs, given that the effect allele for each 
candidate variant had been harmonised. I then created a genetic linear predictor (GP) 
by summing up the number of effect alleles multiplied by their corresponding 
regression coefficients. Notably, the genetic predictor was developed in a similar 
approach compared to the polygenic risk score except that effect alleles were 
weighted by coefficients derived from the fitted Cox model to form the genetic 
predictor.    
 
Table 5-12 Regression coefficients for the 43 genetic variants reportedly associated with CRC 
survival in the UK Biobank (N=5,675)  
Variant MA MAF Gene Regression coefficients  
    OS CSS 
rs10040610 C 0.21  Intergenic 0.0587 0.0819 
rs10152207 A 0.09  Intergenic -0.0997 -0.1187 
rs10275272 T 0.28  TWIST1 0.0118 0.1203 
rs1075232 A 0.10  AC104759.1 0.1076 0.1044 
rs10921219 A 0.46  AL390957.1 -0.0199 -0.0742 
rs11138220 G 0.13  Intergenic 0.0027 0.0050 
rs12187751 G 0.09  AC113414.1 -0.0221 0.1233 
rs12224794 A 0.42  LRRC4C -0.0121 0.0104 
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Variant MA MAF Gene Regression coefficients  
rs13180087 C 0.18  HCN1 -0.1610 -0.0768 
rs1372474 G 0.07  LINC01919 0.1244 0.1367 
rs139156 A 0.26  PARVG -0.1112 -0.0804 
rs1407508 C 0.02  AL136084.1 -0.2627 -0.2622 
rs1493383 T 0.10  GRIA1 0.0052 0.0868 
rs1555895 A 0.50  Intergenic 0.0281 0.0117 
rs1570271 A 0.14  Intergenic 0.0411 0.0586 
rs1573948 C 0.10  Intergenic 0.0724 0.0950 
rs157411 G 0.33  Intergenic -0.0044 0.0068 
rs16867335 T 0.20  AC009478.1 0.0276 -0.0538 
rs17026425 A 0.08  IQCM 0.0783 0.0365 
rs17048372 T 0.15  DPP10 -0.0251 -0.0082 
rs17057166 T 0.09  LINC01847 -0.0296 -0.1161 
rs17087282 A 0.11  Intergenic 0.0318 -0.0254 
rs17280262 T 0.04  Intergenic 0.1019 0.0410 
rs1998584 T 0.41  Intergenic 0.0024 0.0147 
rs2073016 C 0.18  APOBEC2 -0.0033 -0.0398 
rs209489 C 0.08  ELOVL5 0.1335 0.1211 
rs2936519 A 0.27  Intergenic 0.0735 0.0835 
rs338389 G 0.49  Intergenic -0.0056 -0.0095 
rs3781663 G 0.31  ANO1 0.0869 0.1069 
rs3794924 A 0.10  DSG3 0.1082 0.0927 
rs4377367 C 0.19  ARHGEF4 0.0968 0.0976 
rs4812219 T 0.14  Intergenic 0.0596 0.1114 
rs4868304 T 0.14  LINC01484 0.1214 0.1178 
rs4959799 C 0.14  SLC22A23 0.0845 0.0669 
rs6105057 G 0.28  ISM1 0.0004 -0.0070 
rs658495 G 0.04  C20orf27 -0.0934 -0.1347 
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Variant MA MAF Gene Regression coefficients  
rs6720296 C 0.48  LINC01121 -0.0770 -0.1284 
rs6854845 T 0.12  Intergenic -0.1194 -0.1932 
rs7004484 C 0.30  EFR3A 0.0495 0.0667 
rs8035094 C 0.10  Intergenic 0.0142 0.0342 
rs885036 A 0.45  MGAT4A -0.0022 -0.0516 
rs912294 A 0.47  Intergenic -0.0490 -0.0127 
rs9419702 C 0.26  Intergenic -0.1049 -0.1049 
MA, minor allele; MAF, minor allele frequency; OS, overall survival, CSS, CRC-specific 
survival 
 
Feature selection  
A LASSO regression model was fitted so as to select variants with potential predictive 
value from these 43 candidates. After applying a 10-fold cross-validation, the tuning 
factor lambda was identified at 0.0461 for overall survival and 0.0249 for CRC-specific 
survival corresponding to the most parsimonious model with the cross-validation 
prediction error within one standard error (SE) of the minimum. However, no variants 
were selected into the ultimate model. Similarly, I identified no variants remaining in 
the final model after performing backward selection (p<0.15). Given the absence of 
any variants that survived feature selection, only the full model with all variants was 
further evaluated. 
 
Predictive performance of the genetic predictor after internal validation  
The Harrell’s concordance index (C statistic) was used to evaluate the discriminative 
performance of the genetic predictor developed from the UK Biobank cohort. Both the 
observed and predicted survival estimates were obtained in order to derive the C 
statistic. The observed survival estimates were extracted directly from the Kaplan-
Meier estimates, whilst the predicted survival rates were derived from the LP of the 
43 genetic variants and the baseline hazard function estimated from the fitted Cox 
model. Based on the observed and predicted survival estimates in the UK Biobank 
cohort, the genetic predictor yielded an apparent C statistic (without internal validation) 
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of 0.558 (95%CI=0.502-0.595) for overall survival and 0.570 (95%CI= 0.502-0.613) 
for CRC-specific survival. 
As introduced in Chapter 4, over-optimism could be generated if the performance is 
estimated directly from the same dataset in which the predictor is developed. 
Therefore, I conducted internal validation by re-evaluating and summarising the C 
statistics in 200 bootstrap samples. The results showed that the C statistic was 
reduced to 0.510 (95% CI=0.498-0.521) for overall survival and 0.518 (95% CI=0.498-
0.530) for CRC-specific survival after bootstrapping. The fact that the confidence 
intervals of C statistic after bootstrapping included the null value (0.5) indicated a 
statistically non-significant discriminative ability for the full model of 43 variants after 
internal validation. The decreased C statistics for both outcomes supported the 
presence of over-fitting for the genetic predictor. As described in section 4.3.2, over-
fitting could be quantified by the shrinkage factor (SF) and the model could be 
adjusted by applying the SF. From the bootstrap samples, I obtained a shrinkage 
factor (SF) of 0.4729 for overall survival and 0.4868 for CRC-specific survival. Then 
the regression coefficients listed in Table 5-12 were multiplied with the SF to generate 
two new sets of coefficients to calculate the shrunken LP and corresponding predicted 
survival estimates for each individual. The observed survival rates and the updated 
predicted survival rates are presented in Table 5-13. I then performed the Hosmer-
Lemeshow test to assess the accordance of the observed and predicted estimates 
derived from the adjusted model. The results of the test showed significant departure 
of the predicted rates from the observed estimates (p<0.001). Additionally, to visualise 
the relationship between the observed and predicted estimates, calibration curves are 
plotted in Figure 5-9. As depicted, the adjusted model after internal validation showed 
inaccurate model calibration for both overall and CRC-specific survival.  
 
Table 5-13 Comparison between observed and predicted 5-year survival estimates stratified 
by the quartiles of the shrunken 43-variant genetic predictor in the UK Biobank (N=2,474) 
 5-year Survival estimates 
Quartiles (GP)    
Overall survival Observed Predicted  HL-p 
Q1 0.835 0.748 1.8E-8 
Q2 0.810 0.723  
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 5-year Survival estimates 
Q3 0.799 0.706  
Q4 0.719 0.681  
CRC-specific 
survival 
   
Q1 0.833 0.828 3.2E-6 
Q2 0.813 0.807  
Q3 0.809 0.791  
Q4 0.709 0.768  








Figure 5-9 Calibration plots of the adjusted model of 43-variant genetic predictor predicting 
5-year overall (A) and CRC-specific survival (B). 
 
I regressed the observed survival estimates on the predictive value in a linear 
regression model to obtain the coefficient along with the intercept that were used to 
recalibrate the predictive survival rates (overall survival: β=1.9010, intercept=-0.6172; 
CRC-specific survival: β=2.1757, intercept=-0.9459). Based on the shrunken model, 
a 5-year baseline survival rate of 0.7156 for overall survival and 0.7997 for CRC-
specific survival was derived. Combining the baseline survival and the shrunken 
regression coefficients, the predicted 5-year survival rates are expressed as follows:  
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Predicted 5-year overall survival:  
1.9010 × (0.7156exp(0.4729×𝐺𝑃)) − 0.6172 
Predicted 5-year CRC-specific survival:  
2.1757 × (0.7997exp(0.4868×𝐺𝑃)) − 0.9459 
 
Following the formula above, the genetic predictor was then externally validated in 
the SOCCS dataset.   
 
 
Predictive modelling in the SOCCS study 
External validation of the genetic predictor  
I first investigated the association between the genetic predictor created for each 
patient in the SOCCS and survival outcomes in a univariable Cox model. However, 
no significant association was found for either overall (HR=0.93, 95%CI=0.76-1.13, 
p=0.457) or CRC-specific survival (HR=1.05, 95%CI=0.86-1.28, p=0.622). The 
stratified overall and CRC-specific survival curves by quartiles of the genetic predictor 
are plotted in Figure 5-10. As shown by the figure, the genetic predictor was unable 
to efficiently differentiate CRC patients in the SOCCS of varied observed survival 
outcomes. With respect to the discriminative performance, a positive yet insignificant 
C statistic was observed when applying the genetic predictor to predict overall survival 
(C=0.512, 95%CI=0.480-0.544) of CRC patients in the SOCCS study. However, for 
CRC-specific survival, a negative point estimate of C statistic (0.499) was obtained 
with the 95% confidence interval also including the null (95%CI=0.464-0.534).  




Figure 5-10 Kaplan-Meier estimates of overall (A) and CRC-specific (B) survival stratified 
by the 43-variant genetic predictor in SOCCS  
 
To evaluate the model calibration, I extracted the predicted and observed 5-year 
survival rates for each quartile of the genetic predictor. These estimates are listed in 
Table 5-14. Although the predicted survival rates decreased in sequence, the 
corresponding observed rates almost remained unchanged, indicating poor prediction 
accuracy of the genetic predictor. This could also be seen from the calibration plots 
of overall and CRC-specific survival (Figure 5-11).  
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Table 5-14 Comparison between observed and predicted 5-year survival estimates stratified 
by the quartiles of the 43-variant genetic predictor in the SOCCS (N=5,675)  
 5-year survival 
estimates 
 
Quartiles (GP)    
Overall survival Observed Predicted  HL-p 
Q1 0.747 0.809 4.1E-13 
Q2 0.721 0.764  
Q3 0.736 0.733  
Q4 0.748 0.682  
CRC-specific 
survival 
   
Q1 0.771 0.871 1.9E-13 
Q2 0.751 0.829  
Q3 0.778 0.795  
Q4 0.770 0.744  








Figure 5-11 Calibration plots of the 43-variant genetic predictor predicting 5-year overall (A) 
and CRC-specific survival (B) in the SOCCS 
 
Combining the genetic predictor with other variables  
I further assessed the potential added predictive value of the 43-variant genetic 
predictor on the basis of a baseline model including other non-genetic predictors. 
Given that tumour site was not significantly associated with either overall or CRC-
specific survival (Table 5-3), two Cox regression models were fitted—the baseline 
model (Model 1) included non-genetic predictors of age at diagnosis, sex, AJCC stage 
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and tumour grade, and the Model 2 added the genetic predictor to the baseline model. 
The regression coefficients of these two models are summarised in Table 5-15. In the 
multivariable model, age and AJCC stage were significantly associated with overall 
survival (p<0.05), whereas AJCC stage and tumour grade were associated with CRC-
specific survival. 
 
Table 5-15 Summarised coefficients of Cox regression models with or without the genetic 
predictor in SOCCS (N=4,836) 
 Model 1*  Model 2**  
Variables HR(95%CI) P HR(95%CI) P 
Overall survival    
Age  1.023(1.018-1.028) 5.9E-20 1.023(1.018-1.028) 1.1E-19 
Sex (Male) 1.174(1.059-1.302) 0.002 1.176(1.060-1.304) 0.002 
Stage 2.113(1.891-2.253) 3.5E-119 2.111(1.980-2.251) 2.0E-115 
Grade 1.064(0.941-1.204) 0.322 1.067(0.944-1.207) 0.300 
GP NA  0.849(0.684-1.054) 0.138 
     
CRC-specific survival    
Age 1.003(0.997-1.008) 0.345 1.003(0.997-1.008) 0.347 
Sex (Male) 1.102(0.972-1.249) 0.128 1.102(0.973-1.249) 0.128 
Stage 3.100(2.855-3.366) 4.7E-163 3.100(2.855-3.366) 1.3E-159 
Grade 1.231(1.065-1.423) 0.005 1.231(1.065-1.424) 0.005 
GP NA  0.992(0.793-1.240) 0.941 
*Model 1 includes non-genetic predictors of age at diagnosis, sex, AJCC stage and tumour 
grade   
**Model 2 includes the genetic predictor and predictors in Model 1   
HR, hazard ratio; CI, confidence interval; GP, genetic predictor; NA, not available  
 
The potential added discriminative performance of the genetic predictor was 
evaluated by comparing the C statistics of the two models after internal validation 
using the same bootstrapping procedure in UK Biobank. I first calculated the apparent 
C statistic using the same SOCCS cohort from which the two models had been 
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derived. For the outcome of overall survival, the baseline model with age, sex, AJCC 
stage and tumour grade showed a significant C statistic of 0.703(95%CI=0.675-0.734) 
after bootstrapping. The addition of the genetic predictor led to an almost equivalent 
point estimate of C statistic (0.704) along with a confidence interval (95%CI=0.677-
0.731). The U-statistic based test found no significant increase of model concordance 
with the addition of the genetic predictor (p=0.46). Pertaining to the other outcome of 
CRC-specific survival, the baseline model yielded a C statistic of 0.761 
(95%CI=0.732-0.790) after internal validation. A slightly reduced point estimate of C 
statistic was identified in the model 2 after adding the genetic predictor (C=0.760, 
95%CI=0.729-0.789). Similarly, the U-statistic based test did not detect a significant 
change in the discriminative ability with the addition of the genetic predictor (p=0.50). 
I then applied the same procedure and re-estimated the shrinkage factors in 200 
bootstrap samples to quantify the potential over-optimism. For the baseline model 1, 
a shrinkage factor was identified showing only slight optimism for both overall 
(SF=0.994) and CRC-specific survival (SF=0.998). Similarly, shrinkage factors of the 
model 2 with the genetic predictor were also close to 1 (overall survival: SF=0.996, 
CRC-specific survival: SF=0.991). The shrinkage factors were applied to adjust and 
re-fit the models. Both the observed and predicted 5-year survival estimates were 
calculated to evaluate the model calibration. Results of the Hosmer-Lemeshow test 
found no significant deviation of predicted 5-year overall (Model 1: p=0.110; Model 2: 
p=0.251) and CRC-specific survival (Model 1: p=0.132, Model 2: p=0.290) from the 
observed estimates for the two models. The calibration plots of the baseline Model 1 
and Model 2 for both the 5-year overall and CRC-specific survival in the SOCCS are 
presented in Figure 5-12 and Figure 5-13 respectively. As shown, prediction models 
in SOCCS of non-genetic prognostic factors with or without the genetic predictor were 
generally well-calibrated except for patients with moderate 5-year survival rates (50%-
70%) where the predicted survival rates tended to be lower than the observed survival 
rates. 
 




Figure 5-12 Calibration plots of the prediction model of non-genetic factors (age, sex, AJCC 








Figure 5-13 Calibration plots of the prediction model combining the genetic and non-genetic 
factors (age, sex, AJCC stage and tumour grade) predicting 5-year overall (A) and CRC-
specific survival (B) in the SOCCS cohort. 
 
Predictive modelling in locally advanced (stage II/III) CRC  
Although I failed to detect significant increase of model performance by adding the 
genetic predictor into the model, the genetic predictor was still retained to develop 
prediction models in stage II/III (N=3,886) CRC patients in the SOCCS cohort.  
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Firstly, I fitted a Cox regression model including the genetic predictor, age at diagnosis, 
sex, AJCC stage (II or III) and tumour grade as covariates. The effect estimates of 
covariates are summarised in Table 5-16. I observed that age, sex and stage were 
significantly associated with overall survival (p<0.05), whilst sex, stage and tumour 
grade were significant prognostic factors for CRC-specific survival (p<0.05) in the 
multivariable model.  
Table 5-16 Summarised coefficients of Cox regression models for stage II/III CRC patients in 
SOCCS (N=3,886) 
Variables HR(95%CI) P HR(95%CI) P 
Overall survival  CRC-specific survival 
Age  1.028(1.022-1.035) 3.83E-19 1.005(0.998-1.012) 0.177 
Sex  
(Male vs Female) 
1.248(1.098-1.419) 7.27E-4 1.189(1.014-1.394) 0.034 
Stage  
(III vs II) 
1.625(1.429-1.847) 1.18E-13 2.320(1.960-2.747) 1.52E-22 
Grade 1.148(0.989-1.334) 0.070 1.355(1.132-1.622) 9.49E-4 
GP 0.895(0.683-1.173) 0.422 1.045(0.788-1.387) 0.760 
HR, hazard ratio; CI, confidence interval; GP, genetic predictor; NA, not available  
A linear predictor combining these factors weighted by their regression coefficients 
was created for each individual, and the Kaplan-Meier estimates of each quartile of 
the linear predictor are plotted in Figure 5-14 to display the survival outcomes of stage 
II/III patients stratified by the multivariable model. The summarised C statistic derived 
from the model after bootstrapping was 0.604(95%CI=0.563-0.643) for overall 
survival and 0.636(95%CI=0.592-0.680) for CRC-specific survival. 
 




Figure 5-14 Kaplan-Meier estimates of stage II/III patients in the SOCCS stratified by the 
linear predictor (A: overall survival; B: CRC-specific survival) 
 
The shrinkage factor was 0.969 for overall survival and 0.978 for CRC-specific 
survival respectively. Then the regression coefficients listed in Table 5-16 were 
multiplied with the shrinkage factor to adjust the model and obtained updated 
coefficients to predict 5-year survival probabilities. The predicted 5-year survival rates 
estimated from the developed model and observed 5-year survival estimates 
extracted from the Kaplan-Meier curves grouped by quartiles of the linear predictor 
are presented in the Table 5-17. The result of Hosmer-Lemeshow test did not suggest 
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significant departure of the predicted 5-year survival rates from the observed 
estimates for both overall and CRC-specific survival (Table 5-17). Calibration plots 
(Figure 5-15) also showed that these two adjusted models were generally well-
calibrated, except that the model might be less sensitive in predicting CRC-specific 
survival for patients of relatively good survival outcome with an observed survival rate 
of approximately 90% (Figure 5-15B).   
Table 5-17 Comparison between observed and predicted 5-year survival estimates in stage 
II/III patients of the SOCCS study stratified by the quartiles of the linear predictor (N=3,886) 
 5-year survival estimates  
Quartiles (LP)    
Overall survival  Observed Predicted  HL-p 
Q1 0.845 0.854 0.280 
Q2 0.807 0.792  
Q3 0.760 0.737  
Q4 0.663 0.640  
CRC-specific survival    
Q1 0.904 0.890 0.188 
Q2 0.886 0.859  
Q3 0.748 0.759  
Q4 0.713 0.701  
Q, quartile; CRC, colorectal cancer; HL-p, p-value of the Hosmer-Lemeshow test; LP, linear 
predictor of genetic and non-genetic factors 
 




Figure 5-15 Calibration plots of the prediction models predicting 5-year overall (A) and 
CRC-specific survival (B) of stage II/III patients in the SOCCS cohort. 
 
Similar to the previous procedure, I regressed the observed 5-year survival estimates 
on the predicted values in a univariable linear regression model and obtain the 
coefficient along with the intercept to further re-calibrate the model (overall survival: 
β=0.8593, intercept=0.1192; CRC-specific survival: β=0.9014, intercept=0.1344). The 
5-year baseline survival was also retrieved from the adjusted model (0.7680 for overall 
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survival and 0.8165 for CRC-specific survival). The re-calibrated 5-year survival 
probability for a given stage II/III CRC patient is then expressed as:   
Predicted 5-year overall survival:  
0.8593 × (0.7680exp(0.969×(0.028×𝐴𝑔𝑒+0.2215×𝑆𝑒𝑥(1 𝑓𝑜𝑟 𝑀𝑎𝑙𝑒)+0.4845×𝐴𝐽𝐶𝐶 𝑠𝑡𝑎𝑔𝑒+0.1382×𝑡𝑢𝑚𝑜𝑢𝑟 𝑔𝑟𝑎𝑑𝑒−0.1107×𝐺𝑃)))
+ 0.1192 
Predicted 5-year CRC-specific survival:   
 




In clinical practice, there has been interest in identifying high/low risk stage II/III CRC 
patients for tailored treatment strategy. Therefore, in addition to predicting the 
absolute survival probability, I further explored potential performance of these factors 
to characterise patients of different risk profiles within the stage II and stage III strata 
separately. Cox regression models were fitted in stage II and stage III patients with 
age, sex, tumour grade and the genetic predictor as covariates. Then I assigned the 
patients into high- and low-risk groups by the median of the linear predictor derived 
from the fitted model. The linear predictors along with the cut-off median values 
obtained from the models are summarised in the Table 5-18 below. I then plotted the 
Kaplan-Meier survival curves for stage II and III patients with high and low risk of 
deaths in Figure 5-16. As shown in the plots, the risk score combining age, sex, 
tumour grade and the genetic predictor might be less sensitive in stratifying stage III 
CRC patients. However, once externally validated, it might be useful to assist in 
identifying low risk stage II patients with potential favoured overall survival (not for 
CRC-specific survival) as candidates who might be exempt from intensive treatment 
strategies.   
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Table 5-18 Summarised score rules of characterising stage II/III patients with high/low risk 
profiles  
 Risk profiling score Cut-off median of the 
score  









   









GP, genetic predictor, CRC, colorectal cancer 
 
 




Figure 5-16 Kaplan-Meier estimates of low and high-risk stage II/III patients stratified by the 
linear predictor (A: overall survival; B: CRC-specific survival) 
 
 
5.3.3 Variants associated with CRC risk  
 
Eligible variants 
As stated in section 4.3.1, genetic variants associated with CRC risk were extracted 
directly from the two latest meta-analysis of GWASs (to date) that also include all 
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previously known CRC-risk variants (Huyghe et al, 2019; Law et al, 2019). Initially, a 
total of 141 autosomal genetic variants associated with CRC risk at p<5x10-8 were 
extracted from these two meta-analyses. No additional independent variants were 
retrieved after searching the GWAS catalogue. After excluding variants in linkage 
disequilibrium with other variants, a total of 128 genetic variants were eligible for this 
candidate genetic association study at last. These 128 variants were originally 
discovered and reported in 24 GWASs (Al-Tassan et al, 2015; Dunlop et al, 2012; 
Huyghe et al, 2019; Jia et al, 2013; Jiang et al, 2015; Law et al, 2019; Peters et al, 
2013; Real et al, 2014; Schmit et al, 2018; Schmit et al, 2014; Study et al, 2008; 
Tanikawa et al, 2018; Tenesa et al, 2008; Tomlinson et al, 2007; Tomlinson et al, 
2011; Tomlinson et al, 2008; Wang et al, 2014; Wang et al, 2016; Whiffin et al, 2014; 
Zeng et al, 2016; Zhang et al, 2014). Included genetic variants were located in 
chromosomes 1 to 20 (details presented in Table 5-19).  
Table 5-19 Summary details of the included genetic variants previously associated with CRC 
risk  
Variant Locus MA MAF Gene Reference 
rs12143541 1p32.3 G 0.07 TTC22 Law, 2019 
rs61776719 1p34.3 C 0.38 FHL3 Law, 2019 
rs72647484 1p36.12 T 0.03 Intergenic Law, 2019 
rs10911251 1q25.3 A 0.37 LAMC1 Law, 2019 
rs6658977 1q41 T 0.21 LINC02257 Law, 2019 
rs11692435 2q11.2 G 0.02 ACTR1B Law, 2019 
rs448513 2q24.2 C 0.50 TANC1 Huyghe, 2019 
rs11903757 2q32.3 C 0.12 Intergenic Law, 2019 
rs11893063 2q33.1 A 0.30 AC019330.1 Law, 2019 
rs7593422 2q33.1 T 0.35 SATB2 Law, 2019 
rs13020391 2q35 C 0.30 PNKD Law, 2019 
rs2279290 3p14.1 G 0.11 LRIG1 Law, 2019 
rs9831861 3p21.1 G 0.43 AC096887.1 Law, 2019 
rs35360328 3p22.1 A 0.08 Intergenic Law, 2019 
rs12635946 3q13.2 C 0.29 Intergenic Law, 2019 
rs72942485 3q13.2 G 0.05 BOC Huyghe, 2019 
rs10049390 3q22.2 A 0.43 SLCO2A1 Huyghe, 2019 
rs10936599 3q26.2 C 0.27 MYNN Law, 2019 
rs1370821 4q22.2 T 0.26 Intergenic Law, 2019 
rs1391441 4q24 A 0.34 TET2 Huyghe, 2019 
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Variant Locus MA MAF Gene Reference 
rs17035289 4q24 T 0.25 Intergenic Law, 2019 
rs3987 4q26 G 0.39 LINC02264 Law, 2019 
rs75686861 4q31.21 A 0.03 HHIP Law, 2019 
rs186722897 4q32.2 T 0.10 Intergenic Law, 2019 
rs35509282 4q32.2 A 0.23 Intergenic Law, 2019 
rs1445011 5p13.1 C 0.13 Intergenic Law, 2019 
rs7708610 5p13.1 A 0.32 Intergenic Huyghe, 2019 
rs2735940 5p15.33 A 0.47 TERT Law, 2019 
rs77776598 5p15.33 C 0.03 SLC6A18 Law, 2019 
rs12522693 5q23.3 G 0.11 Intergenic Law, 2019 
rs639933 5q31.1 C 0.31 C5orf66 Law, 2019 
rs647161 5q31.1 A 0.46 C5orf66 Law, 2019 
rs62404966 6p12.1 C 0.13 BMP5 Law, 2019 
rs4711689 6p21.1 A 0.23 TFEB Law, 2019 
rs6933790 6p21.1 T 0.20 TFEB Law, 2019 
rs1321310 6p21.2 C 0.28 Intergenic Law, 2019 
rs16878812 6p21.31 A 0.13 FKBP5 Law, 2019 
rs2516420 6p21.32 C 0.06 HCP5 Huyghe, 2019 
rs9271770 6p21.32 A 0.29 HLA-DQA1 Law, 2019 
rs3131043 6p21.33 G 0.49 HCG20 Law, 2019 
rs2070699 6p24.1 T 0.36 EDN1 Law, 2019 
rs6928864 6q21 C 0.29 Intergenic Law, 2019 
rs10951878 7p12.3 C 0.45 AC004870.4 Law, 2019 
rs3801081 7p12.3 G 0.25 TNS3 Law, 2019 
rs12672022 7p13 T 0.13 TBRG4 Huyghe, 2019 
rs16892766 8q23.3 C 0.08 Intergenic Law, 2019 
rs4313119 8q24.21 G 0.28 Intergenic Huyghe, 2019 
rs6983267 8q24.21 G 0.39 CASC8 Law, 2019 
rs1412834 9p21.3 T 0.31 CDKN2B-AS1 Law, 2019 
rs34405347 9q22.33 T 0.17 Intergenic Huyghe, 2019 
rs10980628 9q31.3 C 0.16 LPAR1 Huyghe, 2019 
rs10795668 10p14 G 0.23 RNA5SP299 Law, 2019 
rs10994860 10q11.23 C 0.16 A1CF Law, 2019 
rs704017 10q22.3 G 0.45 ZMIZ1-AS1 Law, 2019 
rs1035209 10q24.2 T 0.12 Intergenic Law, 2019 
rs4919687 10q24.32 G 0.19 CYP17A1 Law, 2019 
rs11196171 10q25.2 G 0.5 TCF7L2 Law, 2019 
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Variant Locus MA MAF Gene Reference 
rs12241008 10q25.2 C 0.19 VTI1A Law, 2019 
rs4450168 11p15.4 C 0.08 SBF2 Law, 2019 
rs174537 11q12.2 G 0.3 MYRF Law, 2019 
rs3824999 11q13.4 G 0.33 POLD3 Law, 2019 
rs4944940 11q13.4 G 0.03 CHRDL2 Law, 2019 
rs2186607 11q22.1 T 0.37 TRPC6 Huyghe, 2019 
rs3087967 11q23.1 T 0.27 C11orf53 Law, 2019 
rs2238126 12p13.2 G 0.23 ETV6 Law, 2019 
rs10849432 12p13.31 T 0.17 Intergenic Law, 2019 
rs10849438 12p13.31 G 0.17 Intergenic Law, 2019 
rs11064437 12p13.31 C 0.16 TPI1/RPL13P5 Law, 2019 
rs10774214 12p13.32 T 0.45 CCND2-AS1 Law, 2019 
rs3217810 12p13.32 T 0.05 CCND2 Law, 2019 
rs3217874 12p13.32 T 0.42 CCND2 Huyghe, 2019 
rs11610543 12q12 G 0.48 Intergenic Huyghe, 2019 
rs11169552 12q13.13 C 0.25 ATF1 Law, 2019 
rs4759277 12q13.3 A 0.37 LRP1 Huyghe, 2019 
rs7398375 12q13.3 C 0.32 LRP1 Law, 2019 
rs3184504 12q24.12 C 0.15 SH2B3 Law, 2019 
rs72013726 12q24.21 C 0.48 Intergenic Law, 2019 
rs73208120 12q24.22 G 0.05 NOS1 Law, 2019 
rs10161980 13q13.2 C 0.35 AL139383.1 Law, 2019 
rs9537521 13q13.2 G 0.18 AL139383.1 Law, 2019 
rs12427600 13q13.3 C 0.20 SMAD9 Law, 2019 
rs45597035 13q22.1 A 0.20 KLF5 Law, 2019 
rs78341008 13q22.1 C 0.02 Intergenic Huyghe, 2019 
rs1330889 13q22.3 C 0.13 LINC00446 Law, 2019 
rs7993934 13q34 T 0.42 COL4A2 Law, 2019 
rs1570405 14q22.2 G 0.50 Intergenic Law, 2019 
rs35107139 14q22.2 C 0.48 BMP4 Law, 2019 
rs17094983 14q23.1 G 0.10 LINC01500 Huyghe, 2019 
rs11632715 15q13.3 A 0.45 Intergenic Law, 2019 
rs16959063 15q13.3 A 0.01 FMN1 Law, 2019 
rs16969681 15q13.3 T 0.20 SCG5 Law, 2019 
rs17816465 15q13.3 A 0.12 FMN1 Law, 2019 
rs73376930 15q13.3 G 0.32 GREM1 Law, 2019 
Chapter 5 Results 
 
162 
Variant Locus MA MAF Gene Reference 
rs4776316 15q22.31 A 0.22 SMAD6 Law, 2019 
rs56324967 15q22.33 C 0.39 SMAD3 Huyghe, 2019 
rs10152518 15q23 G 0.37 Intergenic Law, 2019 
rs7495132 15q26.1 T 0.15 CRTC3 Law, 2019 
rs9929218 16q22.1 G 0.26 CDH1 Law, 2019 
rs61336918 16q23.2 A 0.39 Intergenic Law, 2019 
rs2696839 16q24.1 G 0.34 Intergenic Law, 2019 
rs847208 16q24.1 A 0.33 LINC01081 Law, 2019 
rs899244 16q24.1 T 0.21 AC009154.1 Law, 2019 
rs1078643 17p12 A 0.45 TMEM238L Law, 2019 
rs12603526 17p13.3 C 0.05 NXN Law, 2019 
rs73975588 17p13.3 A 0.07 NXN Law, 2019 
rs17836917 17q12 G 0.05 ASIC2 Law, 2019 
rs983318 17q24.3 A 0.12 LINC00511 Huyghe, 2019 
rs75954926 17q25.3 G 0.47 AC144831.1 Huyghe, 2019 
rs4939827 18q21.1 T 0.35 SMAD7 Law, 2019 
rs285245 19p13.11 T 0.12 AC020911.2 Law, 2019 
rs10411210 19q13.11 C 0.26 RHPN2 Law, 2019 
rs1800469 19q13.2 G 0.37 TMEM91 Law, 2019 
rs12979278 19q13.33 T 0.24 MAMSTR Law, 2019 
rs73068325 19q13.43 T 0.16 MZF1-AS1 Huyghe, 2019 
rs2423279 20p12.3 C 0.36 AL031679.1 Law, 2019 
rs28488 20p12.3 T 0.29 BMP2 Huyghe, 2019 
rs6085661 20p12.3 T 0.30 Intergenic Law, 2019 
rs961253 20p12.3 A 0.29 Intergenic Law, 2019 
rs994308 20p12.3 C 0.50 Intergenic Huyghe, 2019 
rs2295444 20q11.22 C 0.39 PIGU Law, 2019 
rs2179593 20q13.12 A 0.32 TOX2 Law, 2019 
rs6065668 20q13.12 C 0.28 Intergenic Law, 2019 
rs1810502 20q13.13 C 0.46 Intergenic Law, 2019 
rs4811050 20q13.13 A 0.19 Intergenic Law, 2019 
rs6066825 20q13.13 A 0.49 PREX1 Law, 2019 
rs6091213 20q13.13 C 0.35 Intergenic Law, 2019 
rs1741640 20q13.33 C 0.33 LAMA5 Law, 2019 
rs3787089 20q13.33 C 0.38 RTEL1 Law, 2019 
MA, minor allele; MAF, minor allele frequency 
 




This study included 128 CRC-risk variants. An approximated Bonferroni corrected α 
level of 5x10-4 was adopted for this study. Similar to the power estimation for the 
validation study described in section 5.3.1, I used the same group of parameters 
including a sample size of 5,675 for the SOCCS cohort, the proportion of events (34% 
for deaths of any causes and 24% for CRC-related deaths) and a range of MAFs (from 
0.01 to 0.50) to estimate the power for this study. This had a power of 81% and 60% 
for overall and CRC-specific survival in the SOCCS cohort in order to detect an effect 
of 1.25 for 80% (108/128) of the CRC-risk variants. The power curves for this study 
are plotted in Figure 5-17. As suggested by the curves, this study was underpowered 
(<50%) to identify a small to moderate effect for any rare variants (MAF<0.01).  
 
Figure 5-17 Power curves for the two candidate genetic association studies of genetic 





Chapter 5 Results 
 
164 
Main analysis  
Similar to the procedure mentioned in section 5.3.1, I estimated effect estimates of 
the 128 genetic variants on CRC survival by fitting Cox regression models adjusting 
for age at diagnosis, sex and AJCC stage in the SOCCS cohort. Overall, after 
correcting for multiple testing, none of the 128 variants were significantly associated 
with either overall or CRC-specific survival (Pfdr<0.05). The effect estimates of the 
128 variants on overall survival are summarised in Table 5-20. Fifteen genetic 
variants were found to be associated with overall survival at p<0.05 prior to FDR 
correction; among them, I identified eight variants of which the CRC-risk increasing 
alleles showed detrimental effects on overall survival (rs12143541, rs3087967, 
rs3217810, rs3217874, rs34405347, rs4759277, rs6065668, rs9929218).  
 
Table 5-20 Summary of associations between 128 CRC-risk variants and overall survival of 
CRC patients in the SOCCS study (N=5,675).  
Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs6065668 T 0.28  Intergenic 0.90(0.83-0.96) 0.003  0.250  
rs12143541 G 0.07  TTC22 1.13(1.04-1.24) 0.006  0.250  
rs34405347 G 0.17  Intergenic 0.84(0.74-0.95) 0.007  0.250  
rs9537521 A 0.18  AL139383.1 1.10(1.02-1.17) 0.008  0.250  
rs10994860 T 0.16  A1CF 1.11(1.02-1.20) 0.016  0.250  
rs3217810 T 0.05  CCND2 1.13(1.02-1.25) 0.016  0.250  
rs11196171 G 0.50  TCF7L2 0.91(0.83-0.98) 0.017  0.250  
rs3087967 C 0.27  C11orf53 0.92(0.86-0.99) 0.017  0.250  
rs10161980 G 0.35  AL139383.1 1.08(1.01-1.15) 0.019  0.250  
rs174537 T 0.30  MYRF 1.08(1.01-1.16) 0.019  0.250  
rs16959063 A 0.01  FMN1 0.72(0.53-0.97) 0.034  0.378  
rs9929218 A 0.26  CDH1 0.93(0.86-0.99) 0.035  0.378  
rs847208 A 0.33  LINC01081 0.93(0.88-1.00) 0.042  0.417  
rs3217874 T 0.42  CCND2 1.07(1.00-1.14) 0.049  0.437  
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rs4759277 A 0.37  LRP1 1.07(1.00-1.14) 0.050  0.437  
rs10951878 T 0.45  AC004870.4 0.94(0.88-1.00) 0.054  0.438  
rs3184504 C 0.15  SH2B3 0.94(0.88-1.00) 0.058  0.438  
rs73208120 G 0.05  NOS1 1.10(1.00-1.22) 0.061  0.438  
rs9831861 G 0.43  AC096887.1 1.06(1.00-1.14) 0.065  0.442  
rs4919687 A 0.19  CYP17A1 1.06(0.99-1.14) 0.076  0.491  
rs7398375 G 0.32  LRP1 0.93(0.86-1.01) 0.079  0.491  
rs4776316 G 0.22  SMAD6 0.94(0.87-1.01) 0.110  0.637  
rs7593422 T 0.35  SATB2 0.95(0.89-1.01) 0.113  0.637  
rs35107139 C 0.48  BMP4 1.05(0.98-1.13) 0.133  0.641  
rs73376930 G 0.32  GREM1 1.06(0.98-1.14) 0.136  0.641  
rs1570405 A 0.50  Intergenic 1.05(0.98-1.13) 0.137  0.641  
rs2279290 G 0.11  LRIG1 0.94(0.87-1.02) 0.143  0.641  
rs2696839 C 0.34  Intergenic 0.95(0.90-1.02) 0.143  0.641  
rs6066825 G 0.49  PREX1 1.05(0.98-1.12) 0.149  0.646  
rs2238126 G 0.23  ETV6 0.94(0.86-1.03) 0.167  0.702  
rs1800469 G 0.37  TMEM91 1.05(0.98-1.13) 0.184  0.749  
rs6983267 T 0.39  CASC8 1.04(0.98-1.11) 0.196  0.749  
rs1391441 A 0.34  TET2 0.96(0.89-1.02) 0.200  0.749  
rs11064437 T 0.16  TPI1/RPL13P5 0.48(0.15-1.51) 0.208  0.749  
rs3824999 G 0.33  POLD3 0.96(0.90-1.02) 0.210  0.749  
rs3131043 G 0.49  HCG20 1.04(0.98-1.11) 0.220  0.749  
rs13020391 T 0.30  PNKD 1.04(0.97-1.11) 0.226  0.749  
rs17836917 A 0.05  ASIC2 1.16(0.91-1.47) 0.226  0.749  
rs10936599 T 0.27  MYNN 1.05(0.97-1.13) 0.230  0.749  
rs983318 A 0.12  LINC00511 1.05(0.97-1.13) 0.238  0.754  
Chapter 5 Results 
 
166 
Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs647161 A 0.46  C5orf66 1.04(0.97-1.11) 0.251  0.772  
rs35509282 A 0.23  Intergenic 0.94(0.86-1.04) 0.256  0.772  
rs10152518 A 0.37  Intergenic 0.96(0.88-1.03) 0.261  0.772  
rs12603526 C 0.05  NXN 1.13(0.91-1.40) 0.282  0.786  
rs61776719 A 0.38  FHL3 1.04(0.97-1.10) 0.283  0.786  
rs3801081 G 0.25  TNS3 0.96(0.90-1.03) 0.284  0.786  
rs2186607 A 0.37  TRPC6 0.97(0.91-1.03) 0.300  0.800  
rs961253 A 0.29  Intergenic 0.97(0.91-1.03) 0.315  0.800  
rs6085661 T 0.30  Intergenic 0.97(0.91-1.03) 0.319  0.800  
rs10849438 G 0.17  Intergenic 0.95(0.87-1.05) 0.324  0.800  
rs78341008 C 0.02  Intergenic 0.94(0.83-1.06) 0.332  0.800  
rs4313119 T 0.28  Intergenic 1.04(0.96-1.12) 0.336  0.800  
rs1741640 C 0.33  LAMA5 1.04(0.96-1.12) 0.349  0.800  
rs62404966 T 0.13  BMP5 0.97(0.90-1.04) 0.352  0.800  
rs285245 T 0.12  AC020911.2 0.95(0.86-1.06) 0.360  0.800  
rs12427600 C 0.20  SMAD9 1.03(0.96-1.11) 0.361  0.800  
rs639933 A 0.31  C5orf66 0.97(0.91-1.04) 0.365  0.800  
rs72647484 C 0.03  Intergenic 0.95(0.85-1.06) 0.372  0.800  
rs10849432 T 0.17  Intergenic 0.95(0.86-1.06) 0.381  0.800  
rs2516420 T 0.06  HCP5 0.95(0.83-1.07) 0.387  0.800  
rs4944940 A 0.03  CHRDL2 0.93(0.78-1.10) 0.388  0.800  
rs16892766 C 0.08  Intergenic 0.96(0.86-1.06) 0.397  0.806  
rs11893063 A 0.30  AC019330.1 0.97(0.92-1.04) 0.417  0.828  
rs1321310 C 0.28  Intergenic 0.97(0.90-1.04) 0.420  0.828  
rs10411210 T 0.26  RHPN2 1.05(0.93-1.18) 0.435  0.834  
rs45597035 G 0.20  KLF5 1.03(0.96-1.10) 0.436  0.834  
Chapter 5 Results 
167 
 
Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs17816465 A 0.12  FMN1 1.03(0.95-1.12) 0.456  0.847  
rs56324967 C 0.39  SMAD3 0.97(0.91-1.05) 0.459  0.847  
rs1412834 C 0.31  CDKN2B-AS1 0.98(0.92-1.04) 0.463  0.847  
rs10774214 C 0.45  CCND2-AS1 0.98(0.91-1.04) 0.470  0.849  
rs10980628 C 0.16  LPAR1 1.03(0.95-1.11) 0.480  0.850  
rs73975588 C 0.07  NXN 0.97(0.88-1.07) 0.492  0.850  
rs4811050 A 0.19  Intergenic 1.03(0.95-1.12) 0.501  0.850  
rs11903757 C 0.12  Intergenic 0.97(0.89-1.06) 0.502  0.850  
rs1078643 A 0.45  TMEM238L 1.03(0.95-1.11) 0.503  0.850  
rs11610543 G 0.48  Intergenic 1.02(0.96-1.09) 0.515  0.858  
rs2735940 G 0.47  TERT 1.02(0.96-1.09) 0.534  0.860  
rs16878812 G 0.13  FKBP5 0.97(0.88-1.07) 0.539  0.860  
rs186722897 T 0.10  Intergenic 0.96(0.83-1.10) 0.544  0.860  
rs6933790 C 0.20  TFEB 1.03(0.94-1.13) 0.546  0.860  
rs75686861 A 0.03  HHIP 1.03(0.93-1.14) 0.549  0.860  
rs17035289 C 0.25  Intergenic 1.03(0.94-1.12) 0.557  0.862  
rs12241008 C 0.19  VTI1A 0.97(0.88-1.08) 0.579  0.886  
rs7495132 T 0.15  CRTC3 1.03(0.93-1.13) 0.602  0.887  
rs4711689 A 0.23  TFEB 0.98(0.92-1.05) 0.605  0.887  
rs12635946 T 0.29  Intergenic 1.02(0.95-1.09) 0.608  0.887  
rs1035209 T 0.12  Intergenic 0.98(0.91-1.06) 0.639  0.887  
rs6928864 A 0.29  Intergenic 0.97(0.86-1.10) 0.650  0.887  
rs2295444 T 0.39  PIGU 1.01(0.95-1.08) 0.652  0.887  
rs6091213 C 0.35  Intergenic 0.98(0.91-1.06) 0.657  0.887  
rs73068325 T 0.16  MZF1-AS1 1.02(0.94-1.11) 0.665  0.887  
rs994308 T 0.50  Intergenic 1.01(0.95-1.08) 0.666  0.887  
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rs7708610 A 0.32  Intergenic 0.99(0.92-1.05) 0.673  0.887  
rs11632715 A 0.45  Intergenic 0.99(0.93-1.05) 0.677  0.887  
rs72013726 C 0.48  Intergenic 0.99(0.92-1.05) 0.677  0.887  
rs77776598 C 0.03  SLC6A18 0.97(0.85-1.11) 0.678  0.887  
rs12522693 A 0.11  Intergenic 0.98(0.89-1.08) 0.679  0.887  
rs12979278 T 0.24  MAMSTR 1.01(0.95-1.09) 0.684  0.887  
rs10795668 A 0.23  RNA5SP299 1.01(0.95-1.08) 0.689  0.887  
rs704017 G 0.45  ZMIZ1-AS1 0.99(0.92-1.06) 0.714  0.911  
rs1445011 C 0.13  Intergenic 0.99(0.92-1.06) 0.726  0.917  
rs75954926 G 0.47  AC144831.1 0.99(0.92-1.07) 0.745  0.922  
rs16969681 T 0.20  SCG5 0.98(0.88-1.10) 0.761  0.922  
rs61336918 T 0.39  Intergenic 1.01(0.94-1.08) 0.765  0.922  
rs2423279 C 0.36  AL031679.1 0.99(0.92-1.07) 0.771  0.922  
rs72942485 A 0.05  BOC 0.96(0.73-1.27) 0.773  0.922  
rs1370821 T 0.26  Intergenic 1.01(0.95-1.08) 0.775  0.922  
rs448513 C 0.50  TANC1 0.99(0.93-1.06) 0.781  0.922  
rs2179593 A 0.32  TOX2 0.99(0.92-1.06) 0.795  0.929  
rs3787089 T 0.38  RTEL1 1.01(0.94-1.08) 0.818  0.929  
rs2070699 T 0.36  EDN1 0.99(0.93-1.06) 0.822  0.929  
rs1330889 C 0.13  LINC00446 1.01(0.92-1.11) 0.824  0.929  
rs12672022 C 0.13  TBRG4 1.01(0.93-1.10) 0.826  0.929  
rs4450168 C 0.08  SBF2 0.99(0.91-1.08) 0.829  0.929  
rs9271770 A 0.29  HLA-DQA1 0.99(0.91-1.08) 0.859  0.954  
rs6658977 T 0.21  LINC02257 0.99(0.93-1.06) 0.875  0.960  
rs10049390 A 0.43  SLCO2A1 1.01(0.93-1.09) 0.888  0.960  
rs11692435 A 0.02  ACTR1B 0.99(0.88-1.12) 0.888  0.960  
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rs899244 T 0.21  AC009154.1 0.99(0.92-1.07) 0.896  0.960  
rs28488 T 0.29  BMP2 1.00(0.93-1.07) 0.913  0.960  
rs1810502 T 0.46  Intergenic 1.00(0.94-1.07) 0.914  0.960  
rs7993934 T 0.42  COL4A2 1.00(0.93-1.07) 0.917  0.960  
rs10911251 C 0.37  LAMC1 1.00(0.94-1.07) 0.928  0.960  
rs17094983 A 0.10  LINC01500 1.00(0.91-1.11) 0.935  0.960  
rs4939827 C 0.35  SMAD7 1.00(0.94-1.06) 0.938  0.960  
rs11169552 T 0.25  ATF1 1.00(0.93-1.07) 0.958  0.973  
rs35360328 A 0.08  Intergenic 1.00(0.91-1.09) 0.966  0.973  
rs3987 G 0.39  LINC02264 1.00(0.94-1.07) 0.989  0.989  
MA, minor allele; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval; Pfdr, 
p-values corrected using the false positive rate approach. 
 
In relation to CRC-specific survival, details of effect estimates of other variants on 
CRC-specific survival can be found in Table 5-20. Ten variants were identified with 
an uncorrected p<0.05 (Table 5-20). Among these 10 variants, the CRC-risk 
increasing alleles of seven variants were observed to be associated with inferior CRC-
specific survival (rs12143541, rs2696839, rs3217810, rs34405347, rs4759277, 
rs6065668, rs7495132). 
 
Table 5-20 Summary of associations between 128 CRC-risk variants and CRC-specific 
survival of CRC patients in the SOCCS study (N=5,675).  
Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs6065668 T 0.28  Intergenic 0.89(0.82-0.97) 0.011  0.880  
rs10994860 T 0.16  A1CF 1.13(1.02-1.24) 0.018  0.836  
rs12143541 G 0.07  TTC22 1.13(1.02-1.25) 0.023  0.832  
rs847208 A 0.33  LINC01081 0.92(0.85-0.99) 0.027  0.836  
rs4759277 A 0.37  LRP1 1.09(1.01-1.18) 0.028  0.836  
rs7495132 T 0.15  CRTC3 1.13(1.01-1.26) 0.032  0.836  
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rs35509282 A 0.23  Intergenic 0.88(0.78-0.99) 0.033  0.926  
rs34405347 G 0.17  Intergenic 0.85(0.73-0.99) 0.042  0.836  
rs3217810 T 0.05  CCND2 1.13(1.00-1.27) 0.044  0.880  
rs2696839 C 0.34  Intergenic 0.93(0.86-1.00) 0.048  0.832  
rs2238126 G 0.23  ETV6 0.90(0.82-1.00) 0.053  0.836  
rs7398375 G 0.32  LRP1 0.91(0.83-1.00) 0.056  0.836  
rs3087967 C 0.27  C11orf53 0.93(0.86-1.00) 0.062  0.676  
rs10951878 T 0.45  AC004870.4 0.93(0.87-1.01) 0.073  0.836  
rs72647484 C 0.03  Intergenic 0.89(0.78-1.01) 0.079  0.603  
rs4811050 A 0.19  Intergenic 1.09(0.99-1.20) 0.085  0.836  
rs12427600 C 0.20  SMAD9 1.07(0.98-1.17) 0.123  0.912  
rs4776316 G 0.22  SMAD6 0.93(0.85-1.02) 0.124  0.832  
rs35107139 C 0.48  BMP4 1.07(0.98-1.16) 0.131  0.836  
rs73376930 G 0.32  GREM1 1.07(0.98-1.17) 0.137  0.962  
rs3217874 T 0.42  CCND2 1.06(0.98-1.14) 0.139  0.836  
rs9537521 A 0.18  AL139383.1 1.06(0.98-1.15) 0.153  0.836  
rs10161980 G 0.35  AL139383.1 1.06(0.98-1.14) 0.160  0.836  
rs11196171 G 0.50  TCF7L2 0.93(0.85-1.03) 0.161  0.603  
rs6066825 G 0.49  PREX1 1.06(0.98-1.15) 0.176  0.836  
rs7593422 T 0.35  SATB2 0.95(0.88-1.02) 0.181  0.823  
rs12979278 T 0.24  MAMSTR 1.06(0.97-1.15) 0.182  0.955  
rs2279290 G 0.11  LRIG1 0.94(0.85-1.03) 0.200  0.836  
rs2186607 A 0.37  TRPC6 0.95(0.89-1.03) 0.214  0.836  
rs6658977 T 0.21  LINC02257 1.05(0.97-1.14) 0.215  0.933  
rs1800469 G 0.37  TMEM91 1.06(0.97-1.15) 0.217  0.832  
rs174537 T 0.30  MYRF 1.05(0.97-1.14) 0.218  0.832  
Chapter 5 Results 
171 
 
Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs17836917 A 0.05  ASIC2 1.19(0.90-1.59) 0.222  0.836  
rs3131043 G 0.49  HCG20 1.05(0.97-1.13) 0.231  0.955  
rs647161 A 0.46  C5orf66 1.05(0.97-1.14) 0.237  0.836  
rs13020391 T 0.30  PNKD 1.05(0.97-1.14) 0.243  0.967  
rs45597035 G 0.20  KLF5 1.05(0.97-1.14) 0.256  0.836  
rs75686861 A 0.03  HHIP 1.07(0.95-1.21) 0.267  0.997  
rs3824999 G 0.33  POLD3 0.96(0.89-1.03) 0.269  0.832  
rs1570405 A 0.50  Intergenic 1.05(0.96-1.14) 0.272  0.836  
rs16959063 A 0.01  FMN1 0.83(0.59-1.16) 0.273  0.836  
rs3987 G 0.39  LINC02264 1.04(0.97-1.13) 0.280  0.832  
rs10849438 G 0.17  Intergenic 0.94(0.84-1.05) 0.282  0.836  
rs9929218 A 0.26  CDH1 0.96(0.88-1.04) 0.294  0.836  
rs10152518 A 0.37  Intergenic 0.95(0.87-1.05) 0.320  0.836  
rs11903757 C 0.12  Intergenic 0.95(0.86-1.05) 0.322  0.836  
rs899244 T 0.21  AC009154.1 0.95(0.87-1.05) 0.322  0.832  
rs72942485 A 0.05  BOC 1.17(0.85-1.61) 0.331  0.836  
rs73208120 G 0.05  NOS1 1.06(0.94-1.20) 0.336  0.832  
rs2516420 T 0.06  HCP5 0.93(0.80-1.08) 0.343  0.832  
rs1412834 C 0.31  CDKN2B-AS1 0.97(0.89-1.04) 0.354  0.955  
rs3801081 G 0.25  TNS3 0.96(0.89-1.04) 0.355  0.836  
rs1035209 T 0.12  Intergenic 0.96(0.87-1.05) 0.359  0.961  
rs1741640 C 0.33  LAMA5 1.04(0.95-1.15) 0.377  0.836  
rs17094983 A 0.10  LINC01500 1.05(0.93-1.19) 0.409  0.832  
rs6983267 T 0.39  CASC8 1.03(0.96-1.11) 0.409  0.603  
rs10936599 T 0.27  MYNN 1.04(0.95-1.13) 0.411  0.832  
rs35360328 A 0.08  Intergenic 1.05(0.94-1.16) 0.415  0.836  
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rs994308 T 0.50  Intergenic 1.03(0.96-1.11) 0.416  0.875  
rs12635946 T 0.29  Intergenic 1.03(0.95-1.12) 0.419  0.836  
rs186722897 T 0.10  Intergenic 0.93(0.79-1.10) 0.420  0.603  
rs16878812 G 0.13  FKBP5 0.95(0.85-1.07) 0.433  0.955  
rs10795668 A 0.23  RNA5SP299 0.97(0.89-1.05) 0.446  0.836  
rs73068325 T 0.16  MZF1-AS1 1.04(0.94-1.14) 0.446  0.836  
rs9831861 G 0.43  AC096887.1 1.03(0.95-1.11) 0.453  0.616  
rs6085661 T 0.30  Intergenic 0.97(0.90-1.05) 0.456  0.832  
rs961253 A 0.29  Intergenic 0.97(0.90-1.05) 0.475  0.836  
rs11692435 A 0.02  ACTR1B 0.95(0.82-1.10) 0.476  0.603  
rs17816465 A 0.12  FMN1 1.03(0.94-1.14) 0.483  0.823  
rs4450168 C 0.08  SBF2 0.96(0.87-1.07) 0.489  0.603  
rs285245 T 0.12  AC020911.2 0.96(0.85-1.08) 0.498  0.823  
rs6933790 C 0.20  TFEB 1.04(0.93-1.16) 0.504  0.836  
rs7993934 T 0.42  COL4A2 0.97(0.90-1.05) 0.504  0.603  
rs10774214 C 0.45  CCND2-AS1 0.97(0.90-1.06) 0.505  0.836  
rs12603526 C 0.05  NXN 0.91(0.68-1.21) 0.505  0.836  
rs28488 T 0.29  BMP2 0.97(0.90-1.06) 0.522  0.832  
rs12241008 C 0.19  VTI1A 0.96(0.85-1.09) 0.533  0.832  
rs11064437 T 0.16  TPI1/RPL13P5 0.70(0.22-2.19) 0.535  0.997  
rs4939827 C 0.35  SMAD7 1.02(0.95-1.11) 0.536  0.836  
rs11893063 A 0.30  AC019330.1 0.98(0.91-1.05) 0.542  0.961  
rs2179593 A 0.32  TOX2 0.97(0.90-1.06) 0.553  0.832  
rs11610543 G 0.48  Intergenic 1.02(0.95-1.10) 0.557  0.997  
rs4919687 A 0.19  CYP17A1 1.02(0.94-1.11) 0.561  0.603  
rs17035289 C 0.25  Intergenic 0.97(0.87-1.08) 0.570  0.823  
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rs10980628 C 0.16  LPAR1 1.03(0.94-1.12) 0.577  0.692  
rs1370821 T 0.26  Intergenic 0.98(0.91-1.06) 0.582  0.836  
rs4944940 A 0.03  CHRDL2 0.94(0.77-1.16) 0.583  0.836  
rs77776598 C 0.03  SLC6A18 0.96(0.82-1.12) 0.596  0.836  
rs61336918 T 0.39  Intergenic 1.02(0.94-1.11) 0.604  0.836  
rs639933 A 0.31  C5orf66 0.98(0.91-1.06) 0.612  0.603  
rs3787089 T 0.38  RTEL1 1.02(0.94-1.11) 0.615  0.832  
rs10411210 T 0.26  RHPN2 1.04(0.90-1.20) 0.617  0.836  
rs6091213 C 0.35  Intergenic 0.98(0.90-1.07) 0.621  0.836  
rs1321310 C 0.28  Intergenic 0.98(0.90-1.07) 0.639  0.836  
rs16892766 C 0.08  Intergenic 1.03(0.91-1.16) 0.643  0.955  
rs3184504 C 0.15  SH2B3 0.98(0.91-1.06) 0.644  0.871  
rs56324967 C 0.39  SMAD3 0.98(0.90-1.07) 0.649  0.836  
rs16969681 T 0.20  SCG5 1.03(0.91-1.17) 0.650  0.832  
rs6928864 A 0.29  Intergenic 0.97(0.83-1.12) 0.655  0.832  
rs10911251 C 0.37  LAMC1 1.02(0.94-1.10) 0.656  0.836  
rs2295444 T 0.39  PIGU 1.02(0.94-1.10) 0.663  0.836  
rs983318 A 0.12  LINC00511 1.02(0.93-1.11) 0.675  0.836  
rs62404966 T 0.13  BMP5 0.98(0.90-1.07) 0.704  0.935  
rs7708610 A 0.32  Intergenic 0.99(0.91-1.07) 0.710  0.880  
rs2423279 C 0.36  AL031679.1 0.98(0.90-1.08) 0.720  0.683  
rs10849432 T 0.17  Intergenic 1.02(0.90-1.16) 0.736  0.836  
rs10049390 A 0.43  SLCO2A1 1.02(0.93-1.11) 0.741  0.836  
rs72013726 C 0.48  Intergenic 1.01(0.94-1.09) 0.745  0.836  
rs75954926 G 0.47  AC144831.1 0.99(0.90-1.08) 0.769  0.823  
rs11169552 T 0.25  ATF1 1.01(0.93-1.10) 0.786  0.961  
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Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs1078643 A 0.45  TMEM238L 0.99(0.90-1.08) 0.805  0.603  
rs12672022 C 0.13  TBRG4 1.01(0.91-1.12) 0.818  0.603  
rs704017 G 0.45  ZMIZ1-AS1 0.99(0.92-1.07) 0.827  0.832  
rs78341008 C 0.02  Intergenic 0.99(0.85-1.14) 0.836  0.832  
rs12522693 A 0.11  Intergenic 0.99(0.89-1.10) 0.864  0.900  
rs2735940 G 0.47  TERT 1.01(0.93-1.09) 0.868  0.871  
rs61776719 A 0.38  FHL3 1.01(0.93-1.09) 0.881  0.836  
rs1330889 C 0.13  LINC00446 0.99(0.88-1.11) 0.883  0.937  
rs1810502 T 0.46  Intergenic 0.99(0.92-1.07) 0.888  0.836  
rs448513 C 0.50  TANC1 1.00(0.92-1.08) 0.907  0.603  
rs73975588 C 0.07  NXN 1.01(0.90-1.13) 0.912  0.836  
rs2070699 T 0.36  EDN1 1.00(0.92-1.08) 0.917  0.997  
rs11632715 A 0.45  Intergenic 1.00(0.93-1.08) 0.925  0.832  
rs1391441 A 0.34  TET2 1.00(0.92-1.09) 0.937  0.836  
rs1445011 C 0.13  Intergenic 1.00(0.92-1.09) 0.981  0.836  
rs4313119 T 0.28  Intergenic 1.00(0.91-1.10) 0.986  0.844  
rs4711689 A 0.23  TFEB 1.00(0.93-1.08) 0.991  0.836  
rs9271770 A 0.29  HLA-DQA1 1.00(0.91-1.10) 0.997  0.836  
MA, minor allele; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval; Pfdr, 
p-values corrected using the false positive rate approach. 
 
 
I also created a polygenic risk score (PRS) for each individual in the SOCCS cohort 
by adding up the number of CRC-risk increasing alleles of the 128 genetic variants. 
Here an assumption was made that each CRC-risk increasing allele carried the same 
detrimental prognostic effect on CRC survival. On average, each CRC patient in the 
cohort carries 34.9 (standard deviation=6.7) CRC-risk increasing alleles. As shown in 
Figure 5-18, the distribution of the PRS of CRC-risk variants is approximately normal. 
I then fitted a Cox regression model with age, sex and AJCC as covariates to 
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investigate the association between the CRC-risk PRS and survival outcomes. The 
results suggested neither overall (HR=1.00, 95%CI=0.95-1.04, p=0.864) nor CRC-
specific survival (HR=1.03, 95%CI=0.97-1.08, p=0.340) was significantly associated 
with the CRC-risk PRS. 
 
 




I investigated additive genetic effects of the 128 CRC-risk variants stratified by sex, 
AJCC stage and tumour site. Multiple testing was corrected separately using the FDR 
approach within each stratum. Stratified by sex, no significant associations were 
observed between any of the 128 variants and survival outcomes of CRC after FDR 
correction, although a number of suggestive associations with uncorrected p<0.05 
were found. To be specific, I detected eight associations between genetic variants 
and overall survival in male patients and six variants were associated with CRC-
specific survival (uncorrected p<0.05). In female patients, nine genetic CRC-risk 
variants were associated with overall survival and 12 variants associated with CRC-
specific survival. I summarised the effect estimates along with the uncorrected and 
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 Variant MA MAF HR(95%CI) P(uncorrected) Pfdr 
 rs3217810 T 0.05 1.21(1.04-1.40) 0.016 0.459 
 rs3131043 G 0.49 1.13(1.02-1.26) 0.018 0.459 
 rs6065668 T 0.28 0.88(0.78-0.98) 0.024 0.519 
 rs3217874 T 0.42 1.12(1.01-1.24) 0.036 0.569 
 rs9929218 A 0.26 0.89(0.79-0.99) 0.038 0.569 
 rs28488 T 0.29 0.89(0.80-1.00) 0.047 0.569 
CSS       
 rs3131043 G 0.49 1.18(1.04-1.33) 0.008 0.397 
 rs6065668 T 0.28 0.84(0.73-0.96) 0.011 0.397 
 rs13020391 T 0.3 1.17(1.04-1.33) 0.012 0.397 
 rs3087967 C 0.27 0.86(0.76-0.97) 0.018 0.397 
 rs847208 A 0.33 0.86(0.77-0.98) 0.018 0.397 
 rs10161980 G 0.35 1.16(1.02-1.31) 0.019 0.397 
 rs28488 T 0.29 0.86(0.76-0.98) 0.021 0.397 
 rs9537521 A 0.18 1.16(1.02-1.31) 0.026 0.423 
 rs10980628 C 0.16 1.16(1.01-1.33) 0.037 0.519 
 rs72647484 C 0.03 0.80(0.64-0.99) 0.041 0.519 
 rs35107139 C 0.48 1.14(1.00-1.30) 0.044 0.519 
 rs4759277 A 0.37 1.13(1.00-1.28) 0.048 0.520 
MA, minor allele; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval; Pfdr, 
p-values adjusted using the false positive rate approach. OS, overall survival, CSS, CRC-
specific survival 
 
As for stage-stratified analysis, no statistically significant associations survived FDR 
correction. Nevertheless, I observed 12 CRC-risk variants associated with overall 
survival with uncorrected p-values<0.05, and seven variants for CRC-specific survival 
for stage II/III. With respect to stage IV patients, seven CRC-risk variants were related 
to overall survival and six variants were observed to be associated with CRC-specific 
survival. Summarised results of associations with uncorrected p<0.05 in stage II/III 
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and stage IV patients are presented in Table 5-22. A full list of results of the 128 CRC 
variants can be found in Appendix Table 11. 
 
 
Table 5-22 Summary of associations (p<0.05) between CRC-risk variants and survival of CRC 
patients in the SOCCS study stratified by stage 
 Variant MA MAF HR(95%CI) P(uncorrected) Pfdr 
Stage II/III (N=3,886)      
OS       
 rs9537521 A 0.18 1.13(1.04-1.23) 0.005 0.236 
 rs10161980 G 0.35 1.13(1.03-1.22) 0.006 0.236 
 rs6065668 T 0.28 0.88(0.80-0.96) 0.006 0.236 
 rs847208 A 0.33 0.89(0.82-0.97) 0.008 0.236 
 rs1800469 G 0.37 1.13(1.03-1.24) 0.009 0.236 
 rs3087967 C 0.27 0.90(0.83-0.98) 0.021 0.452 
 rs983318 A 0.12 1.11(1.01-1.22) 0.036 0.516 
 rs1570405 A 0.50 1.09(1.00-1.19) 0.040 0.516 
 rs10951878 T 0.45 0.92(0.85-1.00) 0.047 0.516 
 rs3131043 G 0.49 1.09(1.00-1.19) 0.047 0.516 
 rs11196171 G 0.50 0.90(0.81-1.00) 0.048 0.516 
 rs17816465 A 0.12 1.11(1.00-1.22) 0.048 0.516 
CSS       
 rs3087967 C 0.27 0.86(0.78-0.96) 0.005 0.520 
 rs847208 A 0.33 0.87(0.79-0.97) 0.010 0.520 
 rs6065668 T 0.28 0.86(0.77-0.97) 0.013 0.520 
 rs1800469 G 0.37 1.15(1.02-1.29) 0.019 0.520 
 rs1570405 A 0.50 1.14(1.02-1.27) 0.020 0.520 





Table 5-23 Summary of associations (p<0.05) between CRC-risk variants and survival of 
colon cancer patients (N=3,392) in the SOCCS study  
 Variant MA MAF HR(95%CI) P(uncorrected) Pfdr 
OS       
 rs10994860 T 0.16 1.16(1.05-1.29) 0.005 0.120 
 rs2696839 C 0.34 0.89(0.82-0.96) 0.005 0.120 
 rs34405347 G 0.17 0.77(0.65-0.92) 0.005 0.120 
 rs6065668 T 0.28 0.87(0.79-0.96) 0.005 0.120 
 rs11196171 G 0.5 0.86(0.77-0.96) 0.006 0.120 
 rs174537 T 0.3 1.13(1.04-1.24) 0.006 0.120 
 rs3087967 C 0.27 0.88(0.81-0.97) 0.006 0.120 
 rs3217874 T 0.42 1.12(1.03-1.22) 0.008 0.125 
 rs16959063 A 0.01 0.55(0.35-0.87) 0.010 0.125 
 rs3801081 G 0.25 0.89(0.81-0.97) 0.011 0.125 
 rs847208 A 0.33 0.89(0.82-0.97) 0.011 0.125 
 rs3217810 T 0.05 1.18(1.04-1.35) 0.012 0.125 
 rs35107139 C 0.48 1.12(1.02-1.23) 0.015 0.153 
 rs9929218 A 0.26 0.90(0.82-0.99) 0.024 0.222 
 rs12143541 G 0.07 1.14(1.02-1.28) 0.027 0.231 
 rs9537521 A 0.18 1.10(1.01-1.21) 0.031 0.252 
 rs4759277 A 0.37 1.10(1.01-1.19) 0.034 0.259 
 rs4919687 A 0.19 1.10(1.00-1.21) 0.040 0.288 
 rs3184504 C 0.15 0.92(0.84-1.00) 0.045 0.306 
 rs11610543 G 0.48 1.09(1.00-1.18) 0.048 0.31 
CSS       
 rs10849438 G 0.17  0.82(0.70-0.97) 0.018  0.301  
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 Variant MA MAF HR(95%CI) P(uncorrected) Pfdr 
 rs10994860 T 0.16  1.20(1.06-1.37) 0.004  0.225  
 rs11196171 G 0.50  0.88(0.77-1.00) 0.048  0.371  
 rs11893063 A 0.30  0.90(0.81-0.99) 0.030  0.348  
 rs12143541 G 0.07  1.15(1.00-1.31) 0.045  0.371  
 rs16959063 A 0.01  0.54(0.32-0.93) 0.025  0.328  
 rs2696839 C 0.34  0.87(0.79-0.96) 0.006  0.225  
 rs3087967 C 0.27  0.86(0.78-0.96) 0.006  0.225  
 rs3217810 T 0.05  1.20(1.03-1.41) 0.020  0.301  
 rs3217874 T 0.42  1.11(1.01-1.23) 0.034  0.348  
 rs35509282 A 0.23  0.84(0.72-0.99) 0.038  0.348  
 rs3801081 G 0.25  0.88(0.79-0.97) 0.015  0.301  
 rs4759277 A 0.37  1.15(1.04-1.27) 0.007  0.225  
 rs6065668 T 0.28  0.88(0.78-0.98) 0.021  0.301  
 rs6066825 G 0.49  1.12(1.01-1.24) 0.036  0.348  
 rs7495132 T 0.15  1.16(1.00-1.33) 0.048  0.371  
 rs847208 A 0.33  0.88(0.79-0.97) 0.011  0.285  
MA, minor allele; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval; Pfdr, 
p-values adjusted using the false positive rate approach. OS, overall survival, CSS, CRC-
specific survival 
 
Pertaining to analysis in rectal cancer patients (N=2,201), none of the 128 variants 
remained statistically significant after FDR correction. Five variants were identified 
with uncorrected p-values<0.05. In particular, the G allele of two variants (rs2238126 
and rs2279290) exhibited potential protective effects on overall survival (rs2238126: 
HR=0.85, 95%CI=0.74-0.98, uncorrected p=0.026, Pfdr=0.868; rs2279290: HR=0.84, 
95%CI=0.74-0.96, uncorrected p=0.008, Pfdr=0.834) as well as CRC-specific survival 
(rs2238126: HR=0.82, 95%CI=0.69-0.97, uncorrected p=0.020, Pfdr=0.994; 
rs2279290: HR=0.81, 95%CI=0.69-0.95, uncorrected p=0.009, Pfdr=0.994). In 
addition, the T allele of variant rs7593422 was associated with better overall survival 
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of rectal cancer patients (HR=0.88, 95%CI=0.80-0.97, uncorrected p=0.013, 
Pfdr=0.834), and I also observed an association between variant rs7993934 (T allele) 
and improved CRC-specific survival (HR=0.87, 95%CI=0.77-0.99, uncorrected 
p=0.031, Pfdr=0.994). An additional variant (rs16969681, effect allele: T) was found 
to be associated with inferior CRC-specific survival (HR=1.22, 95%CI=1.02-1.47, 
uncorrected p=0.034, Pfdr=0.994). The full list of results of site-stratified analysis is 
presented in Appendix Table 12. 
 
Sensitivity analysis 
I examined associations between CRC-risk variants and survival outcomes under a 
recessive model as a sensitivity analysis. Three associations were statistically 
significant after FDR correction. In particular, the GG genotype of the variant 
rs10161980 was significantly associated with inferior overall survival (Table 5-24). A 
similar detrimental effect was observed for the AA genotype of the variant rs9537521 
on overall survival. It is worth mentioning that the GG and AA genotypes of these two 
variants were previously linked with reduced CRC risk. With respect to CRC-specific 
survival, patients carrying the TT genotype of rs7495132 had significantly worse 
survival compared with ones with TC or CC genotypes. The TT genotype of this 
variant was associated with increased CRC risk in the previous GWAS. Other variants 
associated with CRC survival outcomes under recessive pattern at nominal 
significance (p<0.05) are summarised in Table 5-24. The full set of results of all the 
128 variants under a recessive model is presented in Appendix Table 13. 
 
Table 5-24 Summary of associations (p<0.05) between CRC-risk variants and survival 
outcomes of CRC patients in the SOCCS study under a recessive model (N=5,675) 
 Variant MG MGF HR(95%CI) P(uncorrected) Pfdr 
OS       
 rs9537521 AA 0.03  1.25(1.11-1.41) 2.50E-04 0.022 
 rs10161980 GG 0.12  1.24(1.10-1.39) 3.40E-04 0.022 
 rs174537 TT 0.09  1.23(1.07-1.41) 0.003 0.091 
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the GG genotype of rs10161980 and CRC-specific survival in the UK Biobank 
(HR=1.26, 95%CI=1.01-1.56, p=0.040). As for the other variant rs7495132, I 
replicated the observed association between the TT genotype and CRC-specific 
survival in the UK Biobank (HR=1.69, 95%CI=1.03-2.79, p=0.038), although no 
significant effect was detected of this variant on overall survival (HR=1.39, 
95%CI=0.86-2.25, p=0.179). I was unable to map the variant rs9537521 or a proxy in 
the UK Biobank cohort as this variant had not been arrayed by the UK Biobank and 
not included in the 1000 Genome Reference Panel. 
 




I obtained 18 studies with a total of 113 autosomal genetic variants associated at p< 
5x10-5 with other solid tumour survival from the initial search in the GWAS catalogue 
(Azad et al, 2016; Ghesquieres et al, 2015; Guo et al, 2015; Khan et al, 2018; Khan 
et al, 2015; Koster et al, 2018; Moore et al, 2017; Rafiq et al, 2014; Sato et al, 2011; 
Shu et al, 2012; Song et al, 2015; Szulkin et al, 2015; Tang et al, 2017; Tang et al, 
2015; Wu et al, 2013; Wu et al, 2010; Yoon et al, 2014; Ziv et al, 2015). Among them, 
31 variants with larger p-values were excluded as they were in linkage disequilibrium 
with other included variants (r2<0.2). Finally, a total of 82 genetic variants were 
included for this study. These variants were reportedly associated with survival 
outcomes of eleven types of cancer—breast cancer (number of variants n=13), 
prostate cancer (n=2), non-small cell lung cancer (n=7), small cell lung cancer (n=1), 
ovarian cancer (n=10), diffuse large B-cell lymphoma (n=2), oesophageal squamous 
cell cancer (n=1), head and neck cancer (n=1), multiple myeloma (n=1), pancreatic 
cancer (n=35) and osteosarcoma (n=9). The RSIDs of the variants for each cancer 
type are summarised in Table 5-25. Among these included variants, seven variants 
(rs2059614, rs72773978, rs148760487, rs2314686, rs7701292, rs763780, 
rs1050631) were identified to be associated with cancer survival at the level of GWAS 
significance (p<5x10-8). With regard to the reported survival outcomes, four variants 
were linked to disease-free survival of cancers; 66 variants were identified to be 
associated with overall survival and six variants were reported using cancer-specific 
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survival as the primary outcome (Table 5-25). Notably, the time-to-recurrence was 
adopted as the primary outcome for one variant associated with non-small cell lung 
cancer survival. Ghesquieres et al. defined a new outcome of event-free survival—
primary events included disease progression, relapse, re-treatment, or death from any 
cause—in their GWAS investigating survival outcomes of diffuse large B-cell 
lymphoma (Ghesquieres et al, 2015).  
Table 5-25 Summary details of the included genetic variants previously associated survival 
outcomes of other cancers 




Gene Reported outcomes Reference 
rs10736390 1p32.3 A 0.46 MROH7 Pancreatic cancer(OS) Tang,2017 
rs1391315 1p34.2 G 0.1 SMAP2 Pancreatic cancer(OS) Tang,2017 
rs16861827 1p36.13 T 0.14 IGSF21 Pancreatic cancer(OS) Tang,2017 
rs1567532 2p12 T 0.14 CTNNA2 Pancreatic cancer(OS) Tang,2017 
rs11398812
0 
2p13.3 A 0.01 PAIP2B Pancreatic cancer(OS) Tang,2017 
rs12620038 2p21 G 0.45 EPCAM-
DT 
Pancreatic cancer(OS) Tang,2017 
rs11499785
5 
2p23.1 A 0.03 Intergenic Prostate cancer(CSS) Szulkin,2015 
rs14876048
7 
2q24.3 G 0.01 Intergenic Breast cancer(CSS) Guo Q,2015 
rs1656402 2q37.1 T 0.33 EIF4E2 Non-small cell lung cancer(OS) Sato,2011 
rs76010824 3p14.1 A 0.06 SUCLG2 Prostate cancer(CSS) Szulkin,2015 
rs4955138 3p22.3 G 0.31 Intergenic Osteosarcoma(OS) Koster,2018 
rs361052 3p25.2 A 0.27 IQSEC1 Pancreatic cancer(OS) Tang,2017 
rs770996 3p26.2 T 0.35 AC034195.
1 
Pancreatic cancer(OS) Tang,2017 
rs4568126 3q13.32 A 0.33 B4GALT4 Pancreatic cancer(OS) Tang,2017 
rs295315 3q23 G 0.37 Intergenic Serous epithelial ovarian cancer(OS) Moore,2017 
rs6797464 3q26.2 A 0.12 MECOM Osteosarcoma(OS) Koster,2018 
rs17248137 4q13.3 G 0.05 Intergenic Osteosarcoma(OS) Koster,2018 
rs11733008 4q22.1 T 0.36 Intergenic Non-small cell lung cancer(OS) Tang,2015 
rs10023113 4q26 G 0.17 CAMK2D Non-small cell lung cancer(OS) Tang,2015 
rs17305086 4q34.3 T 0.11 TENM3-
AS1 
Non-small cell lung cancer(OS) Tang,2015 
rs1454694 4q34.3 C 0.17 Intergenic Non-small cell lung 
cancer(recurrence) 
Yoon,2014 
rs421379 5q14.3 T 0.28 Intergenic Breast cancer(OS) Rafiq,2014 
rs7701292 5q21.3 C 0.08 Intergenic Breast cancer (ER+) (DFS) Khan,2018 
rs7712513 5q23.2 G 0.26 Intergenic Diffuse large B-cell lymphoma(EFS) Ghesquieres,20
15 
rs4285214 5q23.2 T 0.39 ZNF608 Pancreatic cancer(OS) Tang,2017 
rs763780 6p12.2 C 0.09 IL17F Pancreatic cancer(OS) Tang,2017 
rs12209785 6p21.1 G 0.15 RUNX2 Pancreatic cancer(OS) Tang,2017 
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Gene Reported outcomes Reference 
rs4618572 6p25.3 T 0.1 Intergenic Serous epithelial ovarian cancer(OS) Moore,2017 
rs7765004 6q21 C 0.32 Intergenic Diffuse large B-cell lymphoma(EFS) Ghesquieres,20
15 
rs7777171 7p21.2 C 0.47 AGMO Osteosarcoma(OS) Koster,2018 
rs2299187 7q21.11 T 0.07 CACNA2D
1 
Head and neck cancer(OS) Azad,2016 
rs2314686 8p21.2 A 0.13 SLC25A37 Breast cancer (ER+) (DFS) Khan,2018 
rs4382459 8q13.2 T 0.08 PREX2 Pancreatic cancer(OS) Tang,2017 
rs202280 8q21.13 G 0.04 Intergenic Serous epithelial ovarian cancer(OS) Moore,2017 
rs6986444 8q24.12 T 0.33 SNTB1 Osteosarcoma(OS) Koster,2018 
rs55933544 9p24.1 T 0.2 GLDC Osteosarcoma(OS) Koster,2018 
rs823920 9q31.1 G 0.12 Intergenic Pancreatic cancer(OS) Tang,2017 
rs10817611 9q32 C 0.23 WHRN Pancreatic cancer(OS) Tang,2017 
rs10983614 9q33.1 C 0.28 ASTN2 Pancreatic cancer(OS) Tang,2017 
rs1414153 9q33.1 C 0.23 Dec-01 Pancreatic cancer(OS) Tang,2017 
rs1564271 10p12.1 A 0.23 PDSS1 Serous epithelial ovarian cancer(OS) Moore,2017 
rs12358475 10p14 A 0.11 Intergenic Breast cancer(OS) Rafiq,2014 
rs10825036 10q21.1 G 0.19 Intergenic Breast cancer(DFS) Song,2015 
rs17465450 10q22.3 C 0.03 LRMDA Osteosarcoma(OS) Koster,2018 
rs17693104 10q23.1 T 0.35 SH2D4B Serous epithelial ovarian cancer(OS) Moore,2017 
rs1408536 10q26.3 A 0.12 Intergenic Pancreatic cancer(OS) Tang,2017 
rs10767646 11p14.1 T 0.33 BDNF-AS Pancreatic cancer(OS) Tang,2017 
rs10835188 11p14.1 G 0.36 LIN7C Pancreatic cancer(OS) Tang,2017 
rs4150579 11p15.1 A 0.33 GTF2H1 Pancreatic cancer(OS) Tang,2017 
rs10500780 11p15.3 A 0.14 BTBD10 Serous epithelial ovarian 
cancer(PFS) 
Moore,2017 
rs12362504 11p15.4 C 0.38 SBF2 Pancreatic cancer(OS) Tang,2017 
rs10899426 11q14.1 C 0.02 Intergenic Serous epithelial ovarian 
cancer(PFS) 
Moore,2017 
rs1944782 11q21 G 0.21 Intergenic Pancreatic cancer(OS) Tang,2017 
rs716274 11q22.3 G 0.44 Intergenic Small cell lung cancer(OS) Wu,2010 
rs2059614 11q24.2 G 0.04 PKNOX2 Breast cancer(CSS) Guo Q,2015 
rs2900174 12p13.2 G 0.16 PRB2 Pancreatic cancer(OS) Tang,2017 
rs11062040 12p13.3
3 
C 0.46 DCP1B Pancreatic cancer(OS) Tang,2017 








A 0.43 Intergenic Pancreatic cancer(OS) Tang,2017 
rs9593831 13q31.1 T 0.22 Intergenic Pancreatic cancer(OS) Tang,2017 
rs9517906 13q32.3 A 0.42 CLYBL Pancreatic cancer(OS) Tang,2017 
rs7149859 14q24.1 T 0.35 PIGH Breast cancer(CSS) Guo Q,2015 
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Gene Reported outcomes Reference 
rs3784099 14q24.1 A 0.4 RAD51B Breast cancer(OS) Shu,2012 
rs17124276 14q31.3 T 0.33 KCNK10 Pancreatic cancer(OS) Tang,2017 
rs11621975 14q32.3
1 
G 0.08 LINC02320 Serous epithelial ovarian cancer(OS) Moore,2017 
rs166870 15q25.1 T 0.24 Intergenic Breast cancer(DFS) Song,2015 
rs12101726 15q26.2 C 0.24 LINC01579 Pancreatic cancer(OS) Tang,2017 
rs72773978 16p13.1
1 
T 0.11 FOPNL Multiple myeloma(OS) Ziv,2015 
rs4780973 16p13.2 T 0.3 Intergenic Pancreatic cancer(OS) Tang,2017 
rs11639759 16p13.3 T 0.16 RBFOX1 Pancreatic cancer(OS) Tang,2017 
rs9934948 16q22.3 T 0.38 ZFHX3 Breast cancer(OS) Shu,2012 
rs1728400 16q24.1 A 0.33 Intergenic Breast cancer(OS) Rafiq,2014 
rs3795244 17q11.2 T 0.05 ZNF207 Pancreatic cancer(OS) Tang,2017 
rs981621 18p11.2
1 
G 0.45 LDLRAD4 Pancreatic cancer(OS) Tang,2017 





C 0.27 ZNF613 Breast cancer(ER+)(OS) Khan,2015 





Serous epithelial ovarian cancer(OS) Moore,2017 
rs1209950 21q22.2 T 0.18 ETS2 Non-small cell lung cancer(OS) Sato,2011 
rs9981861 21q22.2 C 0.33 DSCAM Non-small cell lung cancer(OS) Sato,2011 
rs9332377 22q11.2
1 
T 0.17 COMT Osteosarcoma(OS) Koster,2018 
OS, overall survival; EFS, event-free survival; PFS, progression-free survival; CSS, cancer-
specific survival; DFS, disease-free survival.  
 
Statistical power 
In this analysis I included 82 variants associated with survival outcomes of other 
cancers. An approximated Bonferroni corrected α level of 5x10-4 was also adopted for 
this study. Similar to the power estimation described in section 5.3.3, this study had a 
power of 81% and 60% for overall and CRC-specific survival in the SOCCS cohort in 
order to detect an effect of 1.25 for 79% (65/82) of the variants previously related to 
survival outcomes of other cancers. As the same set of parameters was used, the 
power curves for this study can also be read from Figure 5-17. 
 
 




Main analysis  
With respect to the 82 genetic variants previously linked with survival outcomes of 
other cancers, I obtained the hazard ratios along with their confidence intervals by 
fitting Cox regression models adjusted for age, sex and AJCC stage. After FDR 
correction, none of these 82 variants were significantly associated with overall or 
CRC-specific survival of patients in the SOCCS cohort. The detailed effect estimates 
of the 82 included variants can be found in Table 5-26. In terms of uncorrected p-
values, I observed three genetic variants (rs1728400, rs17693104 and rs202280) 
associated with overall survival at p<0.05. As for CRC-specific survival, another set 
of three variants (rs17693104, rs6797464 and rs823920) were identified with p<0.05. 
Full lists with detailed results of the associations between the 82 variants and CRC 
survival in SOCCS are presented in the Table 5-27. Among these six variants, the G 
allele of the variant rs6797464 was reportedly associated with favourable overall 
survival of osteosarcoma (Koster et al, 2018); our study found concordant direction of 
effect of the G allele related to better CRC-specific survival of CRC patients. The G 
allele of rs823920 was originally identified to be associated with inferior overall 
survival of pancreatic cancer (Tang et al, 2017). Our result also found the detrimental 
effect of the G allele of this variant on CRC-specific survival. I was unable to compare 
the direction of effects of the remaining four variants with previous findings because 
the effect allele information was unavailable in the original GWASs (Moore et al, 2017; 
Rafiq et al, 2014). Among the 82 candidate variants, a total of 51(62%) variants were 
originally reported without providing information about the effect alleles. Therefore, I 
was unable to construct a PRS for each individual and did not investigate the 
combined effect of these 82 variants as a group on CRC survival outcomes. 
Table 5-26 Summary of associations between 82 genetic variants previously with survival of 
other cancers and overall survival of CRC patients in the SOCCS study (N=5,675) 
Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs202280 G 0.04 Intergenic 1.14(1.02-1.26) 0.018  0.722  
rs17693104 T 0.35 SH2D4B 0.93(0.87-0.99) 0.021  0.722  
rs1728400 A 0.33 Intergenic 0.93(0.87-0.99) 0.026  0.722  
rs2059614 G 0.04 PKNOX2 1.13(0.99-1.28) 0.060  0.793  
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Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs10023113 G 0.17 CAMK2D 1.09(1.00-1.20) 0.062  0.793  
rs17465450 C 0.03 LRMDA 0.88(0.77-1.01) 0.064  0.793  
rs17124276 T 0.33 KCNK10 1.07(1.00-1.16) 0.066  0.793  
rs1408536 A 0.12 Intergenic 1.16(0.98-1.37) 0.089  0.867  
rs1567532 T 0.14 CTNNA2 1.06(0.99-1.14) 0.119  0.867  
rs114997855 A 0.03 Intergenic 1.20(0.94-1.52) 0.137  0.867  
rs7149859 T 0.35 PIGH 0.95(0.89-1.02) 0.161  0.867  
rs6797464 A 0.12 MECOM 0.91(0.80-1.04) 0.163  0.867  
rs166870 T 0.24 Intergenic 1.05(0.98-1.13) 0.169  0.867  
rs2900174 G 0.16 PRB2 1.14(0.94-1.38) 0.172  0.867  
rs12620038 G 0.45 EPCAM-DT 1.05(0.98-1.12) 0.174  0.867  
rs295315 G 0.37 Intergenic 1.05(0.97-1.14) 0.191  0.867  
rs1050631 A 0.26 SLC39A6 1.04(0.98-1.12) 0.207  0.867  
rs9517906 A 0.42 CLYBL 0.96(0.90-1.02) 0.213  0.867  
rs2314686 A 0.13 SLC25A37 0.91(0.78-1.06) 0.226  0.867  
rs4382459 T 0.08 PREX2 0.94(0.84-1.04) 0.231  0.867  
rs9332377 T 0.17 COMT 1.05(0.97-1.15) 0.244  0.867  
rs7765004 C 0.32 Intergenic 1.04(0.97-1.11) 0.251  0.867  
rs823920 G 0.12 Intergenic 1.05(0.96-1.15) 0.256  0.867  
rs12209785 G 0.15 RUNX2 0.96(0.89-1.03) 0.275  0.867  
rs1944782 G 0.21 Intergenic 0.96(0.90-1.03) 0.277  0.867  
rs3795244 T 0.05 ZNF207 0.93(0.81-1.07) 0.306  0.867  
rs1656402 T 0.33 EIF4E2 0.96(0.89-1.04) 0.307  0.867  
rs17305086 T 0.11 TENM3-AS1 0.96(0.89-1.04) 0.326  0.867  
rs76010824 A 0.06 SUCLG2 1.06(0.94-1.19) 0.334  0.867  
rs72773978 T 0.11 FOPNL 1.06(0.94-1.20) 0.356  0.867  
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Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs11733008 T 0.36 Intergenic 1.03(0.97-1.10) 0.357  0.867  
rs113988120 A 0.01 PAIP2B 0.90(0.71-1.14) 0.371  0.867  
rs1352757 A 0.43 Intergenic 1.03(0.97-1.10) 0.375  0.867  
rs1414153 C 0.23 1-Dec 1.04(0.96-1.12) 0.385  0.867  
rs7712513 G 0.26 Intergenic 0.97(0.91-1.04) 0.388  0.867  
rs4568126 A 0.33 B4GALT4 1.03(0.96-1.10) 0.390  0.867  
rs11639759 T 0.16 RBFOX1 0.95(0.84-1.07) 0.405  0.867  
rs10835188 G 0.36 LIN7C 1.03(0.96-1.11) 0.419  0.867  
rs7701292 C 0.08 Intergenic 1.04(0.95-1.13) 0.430  0.867  
rs1564271 A 0.23 PDSS1 1.03(0.96-1.10) 0.434  0.867  
rs148760487 G 0.01 Intergenic 0.90(0.68-1.18) 0.435  0.867  
rs2050203 T 0.16 GAPDHP53 0.97(0.88-1.06) 0.456  0.867  
rs16861827 T 0.14 IGSF21 0.96(0.87-1.06) 0.473  0.867  
rs10767646 T 0.33 BDNF-AS 1.03(0.95-1.11) 0.476  0.867  
rs10500780 A 0.14 BTBD10 1.03(0.94-1.13) 0.497  0.867  
rs4618572 T 0.1 Intergenic 0.97(0.89-1.06) 0.509  0.867  
rs770996 T 0.35 AC034195.1 1.02(0.96-1.09) 0.511  0.867  
rs2299187 T 0.07 CACNA2D1 1.11(0.81-1.53) 0.518  0.867  
rs17248137 G 0.05 Intergenic 1.04(0.92-1.18) 0.523  0.867  
rs1209950 T 0.18 ETS2 0.98(0.92-1.04) 0.526  0.867  
rs716274 G 0.44 Intergenic 0.98(0.92-1.04) 0.526  0.867  
rs9593831 T 0.22 Intergenic 0.97(0.88-1.07) 0.546  0.871  
rs3784099 A 0.4 RAD51B 1.02(0.95-1.10) 0.556  0.871  
rs4150579 A 0.33 GTF2H1 1.02(0.95-1.10) 0.567  0.871  
rs6662005 A 0.22 ERO1B 0.97(0.86-1.09) 0.590  0.871  
rs10817611 C 0.23 WHRN 0.98(0.90-1.07) 0.645  0.871  
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Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs1391315 G 0.1 SMAP2 1.03(0.90-1.18) 0.646  0.871  
rs17548007 T 0.04 Intergenic 1.03(0.92-1.14) 0.646  0.871  
rs55933544 T 0.2 GLDC 0.98(0.91-1.06) 0.650  0.871  
rs7777171 C 0.47 AGMO 0.98(0.92-1.06) 0.654  0.871  
rs421379 T 0.28 Intergenic 0.97(0.84-1.12) 0.664  0.871  
rs4955138 G 0.31 Intergenic 0.98(0.90-1.07) 0.666  0.871  
rs361052 A 0.27 IQSEC1 1.02(0.94-1.10) 0.671  0.871  
rs4285214 T 0.39 ZNF608 0.99(0.93-1.05) 0.674  0.871  
rs1454694 C 0.17 Intergenic 1.02(0.94-1.09) 0.692  0.871  
rs12362504 C 0.38 SBF2 0.99(0.92-1.06) 0.696  0.871  
rs8113308 C 0.27 ZNF613 0.98(0.89-1.08) 0.699  0.871  
rs981621 G 0.45 LDLRAD4 0.99(0.92-1.06) 0.705  0.871  
rs763780 C 0.09 IL17F 0.98(0.84-1.13) 0.748  0.894  
rs9934948 T 0.38 ZFHX3 1.01(0.93-1.11) 0.756  0.894  
rs4780973 T 0.3 Intergenic 1.01(0.94-1.08) 0.804  0.925  
rs6986444 T 0.33 SNTB1 1.01(0.91-1.13) 0.836  0.949  
rs12101726 C 0.24 LINC01579 1.01(0.87-1.17) 0.886  0.982  
rs11062040 C 0.46 DCP1B 1.00(0.93-1.06) 0.900  0.982  
rs9981861 C 0.33 DSCAM 1.00(0.94-1.07) 0.900  0.982  
rs11621975 G 0.08 LINC02320 0.99(0.89-1.11) 0.921  0.992  
rs10983614 C 0.28 ASTN2 1.00(0.94-1.06) 0.946  0.997  
rs10825036 G 0.19 Intergenic 1.00(0.93-1.07) 0.965  0.997  
rs12146774 T 0.18 AC084880.2 1.00(0.91-1.10) 0.973  0.997  
rs10899426 C 0.02 Intergenic 1.00(0.85-1.17) 0.976  0.997  
rs12358475 A 0.11 Intergenic 1.00(0.93-1.07) 0.992  0.997  
rs10736390 A 0.46 MROH7 1.00(0.93-1.07) 0.997  0.997  
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MA, minor allele; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval; Pfdr, 
p-values corrected using the false positive rate approach. 
Table 5-27 Summary of associations between 82 genetic variants previously with survival of 
other cancers and CRC-specific survival of CRC patients in the SOCCS study (N=5,675) 
Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs6797464 A 0.12 MECOM 0.85(0.73-0.98) 0.030 0.594 
rs17693104 T 0.35 SH2D4B 0.92(0.85-0.99) 0.031 0.594 
rs823920 G 0.12 Intergenic 1.11(1.00-1.23) 0.042 0.594 
rs202280 G 0.04 Intergenic 1.13(1.00-1.29) 0.051 0.594 
rs17465450 C 0.03 LRMDA 0.85(0.72-1.00) 0.053 0.594 
rs1728400 A 0.33 Intergenic 0.93(0.86-1.00) 0.060 0.594 
rs17124276 T 0.33 KCNK10 1.09(1.00-1.19) 0.060 0.594 
rs10023113 G 0.17 CAMK2D 1.11(0.99-1.23) 0.063 0.594 
rs1408536 A 0.12 Intergenic 1.22(0.99-1.50) 0.064 0.594 
rs1050631 A 0.26 SLC39A6 1.07(0.99-1.16) 0.096 0.631 
rs76010824 A 0.06 SUCLG2 1.11(0.98-1.27) 0.110 0.631 
rs7712513 G 0.26 Intergenic 0.94(0.86-1.01) 0.110 0.631 
rs2299187 T 0.07 CACNA2D1 1.32(0.93-1.87) 0.117 0.631 
rs10736390 A 0.46 MROH7 1.07(0.98-1.15) 0.118 0.631 
rs7765004 C 0.32 Intergenic 1.06(0.98-1.15) 0.131 0.631 
rs12209785 G 0.15 RUNX2 0.94(0.86-1.02) 0.136 0.631 
rs1567532 T 0.14 CTNNA2 1.07(0.98-1.17) 0.142 0.631 
rs1656402 T 0.33 EIF4E2 0.94(0.86-1.02) 0.157 0.631 
rs2314686 A 0.13 SLC25A37 0.87(0.72-1.06) 0.160 0.631 
rs2900174 G 0.16 PRB2 1.17(0.94-1.47) 0.162 0.631 
rs12620038 G 0.45 EPCAM-DT 1.06(0.98-1.15) 0.165 0.631 
rs1352757 A 0.43 Intergenic 1.05(0.98-1.13) 0.191 0.697 
rs1414153 C 0.23 01-Dec 1.06(0.97-1.17) 0.202 0.704 
rs9517906 A 0.42 CLYBL 0.95(0.88-1.03) 0.210 0.704 
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Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs4780973 T 0.3 Intergenic 1.05(0.97-1.14) 0.238 0.720 
rs114997855 A 0.03 Intergenic 1.19(0.89-1.58) 0.239 0.720 
rs763780 C 0.09 IL17F 0.90(0.75-1.07) 0.240 0.720 
rs4568126 A 0.33 B4GALT4 1.05(0.97-1.13) 0.256 0.740 
rs17248137 G 0.05 Intergenic 1.08(0.94-1.25) 0.284 0.794 
rs4618572 T 0.1 Intergenic 0.95(0.85-1.06) 0.337 0.884 
rs716274 G 0.44 Intergenic 0.96(0.90-1.04) 0.349 0.884 
rs9332377 T 0.17 COMT 1.05(0.95-1.17) 0.360 0.884 
rs1944782 G 0.21 Intergenic 0.96(0.89-1.04) 0.371 0.884 
rs72773978 T 0.11 FOPNL 0.93(0.79-1.09) 0.375 0.884 
rs1209950 T 0.18 ETS2 0.97(0.90-1.04) 0.390 0.884 
rs7149859 T 0.35 PIGH 0.97(0.89-1.04) 0.392 0.884 
rs11733008 T 0.36 Intergenic 1.03(0.96-1.12) 0.412 0.884 
rs4150579 A 0.33 GTF2H1 1.04(0.95-1.13) 0.419 0.884 
rs1454694 C 0.17 Intergenic 1.04(0.95-1.13) 0.440 0.884 
rs9593831 T 0.22 Intergenic 0.96(0.86-1.07) 0.453 0.884 
rs2050203 T 0.16 GAPDHP53 0.96(0.86-1.07) 0.473 0.884 
rs12362504 C 0.38 SBF2 0.97(0.89-1.06) 0.491 0.884 
rs981621 G 0.45 LDLRAD4 0.97(0.89-1.06) 0.496 0.884 
rs2059614 G 0.04 PKNOX2 1.06(0.90-1.23) 0.501 0.884 
rs1564271 A 0.23 PDSS1 1.03(0.95-1.12) 0.513 0.884 
rs295315 G 0.37 Intergenic 1.03(0.94-1.13) 0.514 0.884 
rs10817611 C 0.23 WHRN 1.03(0.93-1.14) 0.516 0.884 
rs4285214 T 0.39 ZNF608 0.98(0.91-1.05) 0.549 0.922 
rs9981861 C 0.33 DSCAM 0.98(0.91-1.06) 0.579 0.954 
rs3795244 T 0.05 ZNF207 0.96(0.81-1.13) 0.597 0.964 
rs55933544 T 0.2 GLDC 0.98(0.89-1.07) 0.627 0.980 
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Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs12146774 T 0.18 AC084880.2 1.03(0.92-1.15) 0.639 0.980 
rs1391315 G 0.1 SMAP2 1.04(0.89-1.21) 0.653 0.980 
rs16861827 T 0.14 IGSF21 0.98(0.87-1.10) 0.673 0.980 
rs10500780 A 0.14 BTBD10 1.02(0.92-1.14) 0.675 0.980 
rs4955138 G 0.31 Intergenic 1.02(0.92-1.13) 0.677 0.980 
rs11639759 T 0.16 RBFOX1 1.03(0.89-1.19) 0.696 0.982 
rs8113308 C 0.27 ZNF613 1.02(0.91-1.14) 0.724 0.982 
rs148760487 G 0.01 Intergenic 0.95(0.69-1.30) 0.756 0.982 
rs7701292 C 0.08 Intergenic 1.02(0.92-1.13) 0.764 0.982 
rs17548007 T 0.04 Intergenic 1.02(0.90-1.16) 0.784 0.982 
rs12358475 A 0.11 Intergenic 1.01(0.93-1.10) 0.792 0.982 
rs4382459 T 0.08 PREX2 0.98(0.87-1.11) 0.807 0.982 
rs10899426 C 0.02 Intergenic 1.02(0.85-1.23) 0.815 0.982 
rs166870 T 0.24 Intergenic 1.01(0.93-1.10) 0.822 0.982 
rs9934948 T 0.38 ZFHX3 0.99(0.89-1.10) 0.837 0.982 
rs770996 T 0.35 AC034195.1 0.99(0.92-1.07) 0.866 0.982 
rs10983614 C 0.28 ASTN2 1.01(0.93-1.09) 0.868 0.982 
rs361052 A 0.27 IQSEC1 1.01(0.91-1.11) 0.873 0.982 
rs11062040 C 0.46 DCP1B 0.99(0.92-1.07) 0.876 0.982 
rs11621975 G 0.08 LINC02320 1.01(0.89-1.14) 0.877 0.982 
rs421379 T 0.28 Intergenic 0.99(0.83-1.17) 0.882 0.982 
rs17305086 T 0.11 TENM3-AS1 0.99(0.90-1.09) 0.899 0.982 
rs10767646 T 0.33 BDNF-AS 1.00(0.92-1.10) 0.917 0.982 
rs113988120 A 0.01 PAIP2B 0.99(0.75-1.30) 0.925 0.982 
rs3784099 A 0.4 RAD51B 1.00(0.91-1.09) 0.933 0.982 
rs10835188 G 0.36 LIN7C 1.00(0.91-1.09) 0.942 0.982 
rs6986444 T 0.33 SNTB1 1.00(0.88-1.13) 0.945 0.982 
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Variant MA MAF Gene HR(95%CI) P(uncorrected) Pfdr 
rs7777171 C 0.47 AGMO 1.00(0.92-1.08) 0.956 0.982 
rs12101726 C 0.24 LINC01579 1.00(0.85-1.19) 0.959 0.982 
rs6662005 A 0.22 ERO1B 1.00(0.87-1.15) 0.987 0.997 
rs10825036 G 0.19 Intergenic 1.00(0.92-1.09) 0.997 0.997 
 MA, minor allele; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval; Pfdr, 
p-values corrected using the false positive rate approach. 
 
Stratified analysis 
I conducted survival analysis stratified by sex, stage and tumour site investigating the 
effects on CRC survival of the 82 genetic variants previously linked with survival 
outcomes of other cancers. Overall, no statistically significant associations that 
survived correction for multiple testing were identified in any strata of patients. With 
respect to sex-stratified analysis, five variants were found to be associated with overall 
survival in male CRC patients (N=3,235); eight variants were related to CRC-specific 
survival in the presence of nominal statistical significance (p<0.05) (Table 5-28). 
Amongst female CRC patients in SOCCS, we found two variants (rs10500780 and 
rs12362504) associated with both overall and CRC-specific survival. Genetic variant 
rs202280 was associated with overall survival of female patients, whereas the variant 
rs10736390 was correlated with CRC-specific survival (Table 5-28). Detailed results 
of all the 82 variants are presented in Appendix Table 14. 
 
Table 5-28 Summary of associations (p<0.05) stratified by sex between CRC survival in the 
SOCCS cohort and genetic variants associated with survival outcomes of other cancers  
 Variant MA MAF HR(95%CI) P(uncorrected) Pfdr 
Male (N=3,235) 
OS       
 rs2059614 G 0.04 1.25(1.06-1.48) 0.008 0.522 
 rs10023113 G 0.17 1.15(1.03-1.30) 0.017 0.522 
 rs12209785 G 0.15 0.89(0.81-0.98) 0.019 0.522 
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 Variant MA MAF HR(95%CI) P(uncorrected) Pfdr 
 rs1408536 A 0.12 1.24(1.00-1.54) 0.048 0.755 
 rs1728400 A 0.33 0.92(0.85-1.00) 0.049 0.755 
CSS       
 rs823920 G 0.12 1.17(1.03-1.33) 0.016 0.480 
 rs12209785 G 0.15 0.88(0.79-0.98) 0.022 0.480 
 rs7712513 G 0.26 0.89(0.80-0.99) 0.026 0.480 
 rs10023113 G 0.17 1.17(1.02-1.35) 0.028 0.480 
 rs17693104 T 0.35 0.90(0.82-0.99) 0.034 0.480 
 rs72773978 T 0.11 0.79(0.63-0.99) 0.043 0.480 
 rs1050631 A 0.26 1.11(1.00-1.23) 0.048 0.480 
 rs1408536 A 0.12 1.30(1.00-1.69) 0.050 0.480 
Female 
(N=2,440) 
      
OS       
 rs202280 G 0.04 1.28(1.09-1.51) 0.003 0.234 
 rs12362504 C 0.38 0.87(0.77-0.98) 0.018 0.665 
 rs10500780 A 0.14 1.15(1.01-1.32) 0.042 0.665 
CSS       
 rs10736390 A 0.46 1.20(1.06-1.36) 0.004 0.317 
 rs12362504 C 0.38 0.84(0.73-0.97) 0.016 0.506 
 rs10500780 A 0.14 1.21(1.03-1.42) 0.018 0.506 
MA, minor allele; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval; Pfdr, 
p-values adjusted using the false positive rate approach. OS, overall survival, CSS, CRC-
specific survival 
 
I identified a total of 22 associations at nominal significance (p<0.05) between 15 
unique genetic variants and survival outcomes of CRC in stage II/III or stage IV CRC 
patients in SOCCS, although none of them retained statistical significance after FDR 
correction. The summarised effect estimates of these 22 associations are presented 
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in Table 5-29 and all non-significant results (p>0.05) are summarised in Appendix 
Table 15. 
Table 5-29 Summary of associations (p<0.05) stratified by stage between CRC survival in the 
SOCCS cohort and genetic variants associated with survival outcomes of other cancers  
 Variant MA MAF HR(95%CI) P(uncorrected) Pfdr 
Stage II/III (N=3,886)      
OS       
 rs1728400 A 0.33 0.90(0.83-0.98) 0.014 0.543 
 rs9517906 A 0.42 0.90(0.83-0.98) 0.014 0.543 
 rs1408536 A 0.12 1.28(1.03-1.60) 0.026 0.543 
 rs4382459 T 0.08 0.85(0.73-0.98) 0.027 0.543 
 rs10835188 G 0.36 1.11(1.00-1.22) 0.041 0.543 
 rs2900174 G 0.16 1.27(1.01-1.60) 0.043 0.543 
 rs17305086 T 0.11 0.90(0.80-1.00) 0.045 0.543 
CSS       
 rs1408536 A 0.12 1.59(1.17-2.15) 0.003 0.160 
 rs9517906 A 0.42 0.86(0.77-0.95) 0.004 0.160 
 rs1728400 A 0.33 0.88(0.80-0.98) 0.016 0.461 
 rs2900174 G 0.16 1.33(1.01-1.77) 0.045 0.679 
 rs361052 A 0.27 1.14(1.00-1.31) 0.047 0.679 
Stage IV (N=784)      
OS       
 rs1050631 A 0.26 1.17(1.04-1.32) 0.010 0.468 
 rs17693104 T 0.35 0.86(0.76-0.97) 0.012 0.468 
 rs1414153 C 0.23 1.20(1.03-1.40) 0.022 0.468 
 rs1454694 C 0.17 1.18(1.02-1.36) 0.022 0.468 
 rs1567532 T 0.14 1.16(1.01-1.33) 0.038 0.579 
CSS       
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 Variant MA MAF HR(95%CI) P(uncorrected) Pfdr 
 rs1050631 A 0.26 1.18(1.04-1.33) 0.008 0.633 
 rs17693104 T 0.35 0.86(0.77-0.98) 0.019 0.633 
 rs1454694 C 0.17 1.18(1.02-1.36) 0.031 0.633 
 rs202280 G 0.04 1.24(1.02-1.52) 0.035 0.633 
 rs4150579 A 0.33 1.16(1.00-1.33) 0.042 0.633 
MA, minor allele; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval; Pfdr, 
p-values adjusted using the false positive rate approach. OS, overall survival, CSS, CRC-
specific survival 
 
Regarding tumour site, I detected no significant associations after FDR correction in 
either colon or rectal cancer patients. Seven associations at nominal significance 
(p<0.05) including six unique genetic variants were found in colon cancer patients 
(details in Table 5-30). For rectal cancer patients, however, I did not identify any 
variants associated with overall survival with uncorrected p<0.05. Three variants were 
correlated with CRC-specific survival of rectal cancer patients in SOCCS in the 
presence of nominal significance (p<0.05). I summarise the detailed results of the 82 
variants in relation to survival outcomes stratified by tumour site in Appendix Table 
16.   
 
Table 5-30 Summary of associations (p<0.05) stratified by tumour site between CRC survival 
in the SOCCS cohort and genetic variants associated with survival outcomes of other cancers 
 Variant MA MAF HR(95%CI) P(uncorrected) Pfdr 
Colon (N=3,392)      
OS       
 rs2059614 G 0.04 1.24(1.05-1.46) 0.009 0.669 
 rs17124276 T 0.33 1.13(1.02-1.24) 0.019 0.669 
 rs17693104 T 0.35 0.91(0.84-0.99) 0.026 0.669 
 rs1567532 T 0.14 1.11(1.01-1.22) 0.032 0.669 
CSS       
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 Variant MA MAF HR(95%CI) P(uncorrected) Pfdr 
 rs823920 G 0.12 1.18(1.04-1.35) 0.010 0.775 
 rs17124276 T 0.33 1.15(1.02-1.29) 0.022 0.775 
 rs8113308 C 0.27 1.15(1.00-1.32) 0.050 0.775 
Rectal (N=2,201)      
CSS       
 rs6797464 A 0.12 0.76(0.60-0.96) 0.024 0.996 
 rs10023113 G 0.17 1.21(1.02-1.43) 0.033 0.996 
 rs17465450 C 0.03 0.76(0.58-1.00) 0.047 0.996 
MA, minor allele; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval; Pfdr, 




I analysed associations between the 82 genetic variants previously linked with 
survival outcomes of other cancers and CRC survival under a recessive model in the 
SOCCS study. Colorectal cancer patients carrying the TT genotype of the variant 
rs2299187 had significantly favourable overall (HR=0.54, 95%CI=0.42-0.70, 
uncorrected p=2.6x10-6, Pfdr=1.8x10-4) and CRC-specific survival (HR=0.52, 
95%CI=0.39-0.69, uncorrected=6.1x10-6, Pfdr=2.6x10-4) compared with ones with AA 
or AT genotypes. This effect showed concordant direction with the original report 
where the TT genotype was linked with improved overall survival of head and neck 
cancer (Azad et al, 2016). I also observed three variants associated with CRC survival 
at nominal significance (p<0.05) although they did not survive FDR correction (Table 
5-31). Additional details on the results of other remaining candidate variants can be 
found in Appendix Table 17. 
Table 5-31 Summary of associations (p<0.05) between survival outcomes of CRC patients in 
the SOCCS study and genetic variants previously linked with survival outcomes of other 
cancers under a recessive model (N=5,675)  
 Variant MG MGF HR(95%CI) P(uncorrected) Pfdr 
OS       
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 Variant MG MGF HR(95%CI) P(uncorrected) Pfdr 
 rs2299187 TT 0.01 0.54(0.42-0.70) 2.6E-06 1.8E-04 
 rs72773978 TT 0.02 0.29(0.09-0.89) 0.03 0.84 
CSS       
 rs2299187 TT 0.01 0.52(0.39-0.69) 6.1E-06 2.6E-04 
 rs17124276 TT 0.02 1.32(1.05-1.65) 0.015 0.424 
 rs6797464 GG 0.02 0.84(0.72-0.99) 0.036 0.555 
 rs10736390 GG 0.21 1.16(1.00-1.35) 0.048 0.555 
MG, minor genotype; MGF, minor genotype frequency; HR, hazard ratio; CI, confidence 
interval; Pfdr, p-values adjusted using the false positive rate approach. OS, overall survival, 
CSS, CRC-specific survival. 
 
I failed to replicate the association between the variant rs2299187 and CRC survival 
in the UK Biobank due to the fact that this variant had a low minor allele frequency (T 
allele: 0.02) and there were no homozygous individuals (TT) present in the UK 
Biobank cohort.  
 
5.4 Genome-wide association analysis  
 
5.4.1 Statistical power   
 
Following similar procedures as in previous sections, I estimated the statistical power 
of the GWA study. The α level of GWAS significance (5x10-8) was used in combination 
with other metrics including the sample size (N=5,675), the minor allele frequency 
(0.01 to 0.50), proportions of events (34% for overall survival and 24% for CRC-
specific survival) and various effect sizes (HR from 1.2 to 2.0). According to the 
method proposed by Owzar et al.(Owzar et al, 2012), the GWA study had a power of 
75% to detect an effect of 1.30 (HR) on overall survival for a genetic variant with a 
minor allele frequency of 0.15. For CRC-specific survival, however, a statistical power 
of 76% was expected to observe an effect of 1.30 for a variant with a minor allele 
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frequency of 0.25. I plotted power curves for variants of varied minor allele frequencies 
in relation to a range of effect sizes in Figure 5-19. As suggested by the power curves, 
the GWA study had limited statistical power (<30%) to identify small or moderate 
survival effects (HR<1.3) for genetic variants with low minor allele frequencies (<0.05) 
especially on CRC-specific survival. Notably, there could be slight overestimation of 
the statistical power (2-4%) as here the power was estimated assuming a Cox 
regression approach whereas the main GWAS analysis was conducted using a 
Martingale residual-based approach (details in page 104).  
 
Figure 5-19 Power curves for the genome-wide association study in the SOCCS cohort 
 
5.4.2 Main results   
 
As described in Chapter 4, I included a total of 8,328,632 autosomal genetic variants 
and investigated their associations with survival outcomes in 5,675 CRC patients of 
the SOCCS cohort using the Martingale residual-based approach. Similar to previous 
candidate association studies, I adjusted for covariates including age at CRC 
diagnosis, sex and AJCC stage to estimate the effect of a certain variant on overall 
and CRC-specific survival. 
For overall survival, I identified 415,724 (4.99%) at p<0.05. Associations between 
these variants (p<0.05) and the survival outcome (measured by the Martingale 
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residual) are presented in the Manhattan plot (Figure 5-20). As shown in the plot, no 
genetic variants were identified to be associated with overall survival with GWAS 
significance (p<5x10-8). The strongest signal was for rs143664541 in chromosome 6 
(Martingale residual coefficient =0.769, SE=0.154, p=5.89x10-7). 
 
 
Figure 5-20 Manhattan plot of GWAS results on overall survival of all CRC patients in the 
SOCCS cohort (blue line: p=10-5, red line=5x10-8) 
 
I also plotted all the eight million observed p-values from the GWA analysis against a 
theoretical null distribution in a QQ plot (Figure 5-21). The QQ plot indicated no 
systematic inflation of statistical significance in the GWAS results on overall survival, 
which was underpinned by an inflation factor (lambda) of 0.9991 (<1.1). 




Figure 5-21 QQ plot of GWAS results on overall survival of all CRC patients in the SOCCS 
cohort 
 
By implementing a less stringent p-value threshold (p<5x10-6), I found a total of 38 
correlated genetic variants associated with overall survival. Pairs of genetic variants 
in linkage disequilibrium (LD) were investigated by calculating the r2 and for pairs with 
r2>0.2, I kept the variant with the smaller p-values in the association with survival 
outcomes in SOCCS. After controlling for LD, I obtained 10 independent genetic 
variants with p-values less than 5x10-6; basic characteristics along with regression 
coefficients of these variants are summarised in Table 5-32.  
Table 5-32 Genetic variants identified from the genome-wide association analysis associated 
with overall survival of CRC patients in the SOCCS cohort (p<5x10-6) using the Martingale-
residual based approach (N=5,675)  
Variant Chr MA MAF Beta SE P 
rs143664541 6 A 0.014 0.769 0.154 5.89E-07 
rs6869766 5 A 0.139 0.248 0.050 7.00E-07 
rs185673294 4 G 0.126 -0.256 0.053 1.23E-06 
rs75809467 9 T 0.034 0.490 0.101 1.32E-06 
rs4484717 8 C 0.429 -0.164 0.034 1.34E-06 
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Variant Chr MA MAF Beta SE P 
rs138959556 16 T 0.037 -0.461 0.096 1.74E-06 
rs4441183 14 A 0.128 0.239 0.050 1.95E-06 
rs34858830 14 A 0.332 0.166 0.036 3.68E-06 
rs141093197 13 T 0.485 0.158 0.034 4.09E-06 
rs60676294 3 G 0.139 0.237 0.052 4.46E-06 
Chr, chromosome; MA, minor allele; MAF, minor allele frequency; Beta, regression coefficients; 
SE, standard error. 
 
I then re-fitted Cox regression models to obtain exact effect estimates and p-values 
of these 10 genetic variants. The summarised results of Cox regression models are 
presented in Table 5-33. Notably, I identified one variant rs143664541 in 
chromosome 6 that reached GWAS statistical significance (HR=1.92, 95%CI=1.52-
2.42, p=4.24x10-8). Given the low minor allele frequency (0.014), I plotted Kaplan-
Meier estimates of this variant in Figure 5-22 under a dominant genetic model 
(GA+AA vs GG). 
 
Table 5-33 Summary of effect estimates from Cox models of GWAS-identified variants 
associated with overall survival in the SOCCS cohort (p<5x10-6)  
Variant Chr MA MAF HR(95%CI) P 
rs143664541 6 A 0.014 1.92(1.52-2.42) 4.24E-08 
rs75809467 9 T 0.034 1.58(1.33-1.87) 1.55E-07 
rs4441183 14 A 0.128 1.26(1.15-1.38) 5.26E-07 
rs6869766 5 A 0.139 1.30(1.17-1.44) 6.02E-07 
rs4484717 8 C 0.429 0.85(0.80-0.91) 7.81E-07 
rs185673294 4 G 0.126 0.77(0.69-0.86) 1.43E-06 
rs60676294 3 G 0.139 1.25(1.14-1.37) 1.82E-06 
rs141093197 13 T 0.485 1.17(1.10-1.25) 2.34E-06 
rs34858830 14 A 0.332 1.18(1.10-1.26) 3.26E-06 
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Variant Chr MA MAF HR(95%CI) P 
rs138959556 16 T 0.037 0.61(0.50-0.76) 4.85E-06 
Chr, chromosome; MA, minor allele; MAF, minor allele frequency; HR, hazard ratio; CI, 
confidence interval.  
 
 
Figure 5-22 Kaplan-Meier estimates of overall survival in the SOCCS stratified by the 
genetic variant rs143664541 
 
With respect to the GWAS on CRC-specific survival, in total, I found 414,706 (4.98%) 
genetic variants associated with CRC-specific survival in the SOCCS cohort. The 
Manhattan plot displaying all the 414,706 signals throughout the genome is presented 
in Figure 5-23. As indicated by the plot, the strongest signal was detected at the same 
variant rs143664541 in chromosome 6 (Martingale residual coefficient=1.04, 
SE=0.182, p=9.10x10-9).  




Figure 5-23 Manhattan plot of GWAS results on CRC-specific survival of all CRC patients 
in the SOCCS cohort (blue line: p=10-5, red line: 5x10-8) 
 
 
Similar to the results of overall survival, the QQ plot of CRC-specific survival 
(presented in Figure 5-24) aggregating p-values from all the eight million variants 
showed no systematic inflation of statistical significance. I also observed an inflation 
factor (lambda) of 1.004 (<1.1) verifying the absence of systematic inflation. 




Figure 5-24 QQ plot of GWAS results on CRC-specific survival of all CRC patients in the 
SOCCS cohort 
 
I then extracted a total of 52 genetic variants associated with CRC-specific survival 
with p<5x10-6. After addressing LD among these variants, 19 independent variants 
were retained (presented in Table 5-34). In addition to rs143664541, I identified 
another variant rs75809467 in chromosome 9 in association with CRC-specific 
survival at p<5x10-7 (Martingale residual coefficient=0.621, standard error=0.119, 
p=2.11x10-7) 
Table 5-34 Genetic variants identified from the genome-wide association analysis associated 
with CRC-specific survival of CRC patients in the SOCCS cohort (p<5x10-6) using the 
Martingale-residual based approach 
Variant  Chr MA MAF Beta SE P 
rs143664541 6 A 0.014 1.045 0.182 9.10E-09 
rs75809467 9 T 0.034 0.621 0.119 2.11E-07 
rs75796335 7 C 0.111 0.317 0.065 1.23E-06 
rs12648214 4 C 0.157 -0.263 0.055 1.44E-06 
rs117363837 7 G 0.213 0.234 0.049 1.86E-06 
rs76941929 11 A 0.022 0.645 0.138 2.86E-06 
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rs72767774 1 A 0.053 0.423 0.09 2.92E-06 
rs17105163 10 A 0.029 0.55 0.118 2.93E-06 
rs79014181 22 A 0.06 0.41 0.088 3.01E-06 
rs1207145 2 G 0.017 -0.731 0.157 3.15E-06 
rs6799780 3 G 0.107 0.266 0.057 3.48E-06 
rs12113115 7 T 0.139 0.265 0.057 3.49E-06 
rs4441183 14 A 0.128 0.274 0.059 3.89E-06 
rs7724103 5 G 0.034 0.516 0.112 4.32E-06 
rs17808098 14 A 0.474 -0.181 0.039 4.36E-06 
rs185274835 8 C 0.011 0.914 0.199 4.37E-06 
rs111411038 8 G 0.019 0.684 0.149 4.74E-06 
rs72803621 10 G 0.044 0.454 0.099 4.78E-06 
rs147529871 6 T 0.02 -0.682 0.149 4.92E-06 
Chr, chromosome; MA, minor allele; MAF, minor allele frequency; Beta, regression coefficients; 
SE, standard error.   
 
The effect estimates on CRC-specific survival of these 19 variants were re-estimated 
in Cox regression models (Table 5-35). I observed two variants (rs143664541 and 
rs75809467) that reached GWAS significance in association with CRC-specific 
survival. In particular, the A allele of the variant rs143664541 conferred significantly 
higher hazard of CRC-related death (HR=1.92, 95%CI=1.52-2.42, p=4.24x10-8). The 
other variant rs75809467, with the T allele as the risk allele, was significantly 
associated with inferior CRC-specific survival (HR=1.81, 95%CI=1.48-2.20, 
p=7.07x10-9). Survival curves of these two variants are plotted in Figure 5-25 and 
Figure 5-26 with the variants coded under a dominant genetic model.  
Table 5-35 Summary of effect estimates from Cox models of GWAS-identified variants 
associated with CRC-specific survival in the SOCCS cohort (p<5x10-6) 
Variant  Chr EA MAF HR(95%CI) P 
rs143664541 6 A 0.014 2.17(1.69-2.78) 1.14E-09 
rs75809467 9 T 0.034 1.80(1.48-2.20) 7.07E-09 
rs76941929 11 A 0.022 1.84(1.47-2.30) 8.37E-08 
rs185274835 8 C 0.011 2.18(1.63-2.90) 1.17E-07 
rs75796335 7 C 0.111 1.36(1.21-1.53) 2.45E-07 
rs17105163 10 A 0.029 1.64(1.36-1.98) 2.86E-07 
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Variant  Chr EA MAF HR(95%CI) P 
rs7724103 5 G 0.034 1.61(1.34-1.94) 5.59E-07 
rs117363837 7 G 0.213 1.26(1.15-1.38) 6.70E-07 
rs72803621 10 G 0.044 1.53(1.29-1.81) 8.65E-07 
rs79014181 22 A 0.06 1.45(1.25-1.68) 9.53E-07 
rs72767774 1 A 0.053 1.45(1.25-1.69) 1.01E-06 
rs12113115 7 T 0.139 1.29(1.16-1.43) 1.28E-06 
rs6799780 3 G 0.107 1.28(1.16-1.42) 1.30E-06 
rs111411038 8 G 0.019 1.76(1.40-2.22) 1.32E-06 
rs4441183 14 A 0.128 1.29(1.16-1.43) 1.89E-06 
rs12648214 4 C 0.157 0.77(0.69-0.86) 2.22E-06 
rs17808098 14 A 0.474 0.84(0.78-0.90) 2.98E-06 
rs1207145 2 G 0.017 0.37(0.24-0.58) 1.63E-05 
rs147529871 6 T 0.02 0.44(0.30-0.64) 2.19E-05 




Figure 5-25 Kaplan-Meier estimates of CRC-specific survival in the SOCCS stratified by 
the genetic variant rs143664541 
 




Figure 5-26 Kaplan-Meier estimates of CRC-specific survival in the SOCCS stratified by 
the genetic variant rs75809467 
 
To sum up, I identified two genetic variants (rs143664541 and rs75809467) 
associated with survival outcomes at GWAS significance (p<5x10-8) of CRC patients 
in the SOCCS study. I created locus-zoom plots to provide visualisation of the 
genomic region near these two variants. Both of these two variants locate in non-
coding regions of the genome. Figure 5-27 (rs143664541) and Figure 5-28 
(rs75809467) annotate flanking genes as well as the LD structure surrounding the two 
variants. As shown by the Figure 5-27, the variant rs143664541 locates in an 
intergenic region near the FRK gene in chromosome 6, whereas rs75809467 locates 
between the GDA and the C9orf57 gene in chromosome  9 (Figure 5-28). The plots 
also suggest lack of variants in strong linkage disequilibrium (r2>0.8) with these two 
variants. 
 




Figure 5-27 Locus-zoom plot for variant rs143664541 
 
 
Figure 5-28 Locus-zoom plot for variant rs75809467 
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5.4.3 Replication of discoveries    
 
The discoveries of two genetic variants (rs143664541 and rs75809467) were 
validated in the UK Biobank cohort and datasets from three published clinical trials 
including the VICTOR, the SCOT and the QUASAR2 trial. As described in preceding 
sections, the UK Biobank study cohort include 2,474 incident CRC patients. With 
respect to the trial datasets, in collaboration with Dr. Claire Palles (Institute of Cancer 
and Genomic Sciences, the University of Birmingham), we were able to collect 4,768 
stage II/III patients from a pooled dataset of the VICTOR, SCOT and QUASAR2 trials 
for rs143664541. Eventually, the association of rs143664541 with overall survival was 
validated in an aggregate sample of 7,242 CRC patients. I obtained the final effect 
estimates by combining hazard ratios along with their standard errors from these 
datasets in a fixed-effect meta-analysis. Overall, I did not observe a significant 
association (HR=1.32, 95%CI=0.90-1.93, p=0.152). The forest plot of the meta-
analysis is presented in Figure 5-29. It is worth noting that although no significant 
association was detected, the direction of effects observed in the three replication 
datasets was concordant with the direction from the SOCCS study—The A allele was 
related to worse survival outcomes. No significant heterogeneity was detected among 
these three datasets (I2=0%, Phet=0.61).  
 
Figure 5-29 Forest plot of meta-analysis of replication datasets on the variant rs143664541 
 
The outcome of CRC-specific survival was available only in the UK Biobank study. 
Similarly, I identified a point estimate of effect with concordant direction yet 
insignificant association between the variant rs143664541 and CRC-specific survival 
(HR=1.32, 95%CI=0.73-2.40, p=0.361).  
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Pertaining to the other variant rs75809467, we managed to include a total of 4,771 
stage II/III CRC patients from the three trials along with the 2,474 patients from the 
UK Biobank to conduct the replication analysis. Meta-analysis found no significant 
effect of this variant on overall survival (HR=0.90, 95%CI=0.72-1.14, p=0.394). The 
point estimates of effect of this variant observed from replication datasets were 
inconsistent with estimates from the SOCCS. I present the forest plot of the fixed-
effect meta-analysis in Figure 5-30. This variant was not significantly associated with 
CRC-specific survival in the UK Biobank cohort either (HR=0.91, 95% CI=0.66-1.25, 




Figure 5-30 Forest plot of meta-analysis of replication datasets on the variant rs75809467 
 
5.4.4 Gene and Gene-set based enrichment analysis   
 
All included genetic variants were mapped to 18,420 protein coding genes by the 
FUMA platform (Watanabe et al, 2017). The mapped genes were further grouped into 
15,480 gene-sets curated in the MSigDB database (Liberzon et al, 2015). According 
to the number of genes and gene-sets tested in this part of analysis, a Bonferroni 
corrected α level was applied to evaluate the statistical significance of the results 
(gene based analysis: α=2.71x10-6; gene-set based analysis: α=3.23x10-6). 
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Overall survival   
Gene based analysis  
For the outcome of overall survival, I did not observe any significant signals among 
the mapped 18,420 genes (p<2.71x10-6). The Manhattan plot aggregating all these 
test results is presented in Figure 5-31.  
 
 
Figure 5-31 Manhattan plot of genome-wide gene based analysis on overall survival of 
CRC patients in the SOCCS cohort (red line: p=2.71x10-6) 
 
Similar to the preceding variant-based GWA analysis, I plotted all the p-values 
obtained from all the gene based tests against the theoretical null distribution to 
examine systematic excess of statistical significance. The QQ plot is shown in Figure 
5-32. Based on these p-values, I observed a genome-wide inflation factor of 1.017, 
indicating the absence of systematic inflation of the observed results (λ<1.1).  
 




Figure 5-32 QQ plot of genome-wide gene based analysis on overall survival of CRC 
patients in the SOCCS cohort 
 
Although no significant signals were detected after correcting for multiple testing, I 
observed one gene (ECHDC1) with the strongest signal associated with overall 
survival (p=1.58x10-5). This gene locates in the chromosome 6 and encodes the 
protein Ethylmalonyl-CoA decarboxylase 1. A total of 122 genetic variants in this gene 
were included in the gene based analysis (the detailed list of variants can be found at 
URL4-23).   
 
Gene-set based analysis  
In relation to the gene-set based analysis, after Bonferroni correction, I identified 
significant enrichment of gene signals in one set of genes involved in the biosynthetic 
process of galactolipid (MSigDB ID: go_galactolipid_biosynthetic_process) 
associated with overall survival of CRC patients (p=2.09x10-6). This set included six 
genes whose basic characteristics as well as test statistics obtained from the gene 
based analysis are presented in 
Table 5-36. 




Table 5-36 Genes involved in the biosynthetic process of galactolipid  
Gene Gene ID Chr No. 
variants 
P* 
GAL3ST1 ENSG00000128242 22 55 0.002 
B3GALT1 ENSG00000172318 2 89 0.031 
FA2H ENSG00000103089 16 206 0.058 
B4GALT3 ENSG00000158850 1 8 0.101 
B3GALT2 ENSG00000162630 1 14 0.149 
UGT8 ENSG00000174607 4 137 0.289 
*P-values of gene based tests for each gene  
Chr, chromosome  
 
CRC-specific survival  
Gene based analysis  
The Manhattan plot of genome-wide gene based analysis on CRC-specific survival 
presented in Figure 5-33. As shown by the plot, I detected one statistically significant 
association after Bonferroni correction between the CCDC135 gene and CRC-specific 
survival of patients in SOCCS. This gene locates in the chromosome 16 and encodes 
the Coiled-coil domain-containing protein 135. A total of 76 genetic variants in this 
gene were included to test the potential overall effect.   
 




Figure 5-33 Manhattan plot of genome-wide gene based analysis on CRC-specific survival 
of CRC patients in the SOCCS cohort 
 
Regarding the distribution of statistical significance, the QQ plot (Figure 5.34) 
provided moderate evidence of the presence of enriched signals. I obtained an 
inflation factor of 1.042 for the results of gene based analysis on CRC-specific survival.     
 
Figure 5-34 QQ plot of genome-wide gene-set based analysis on overall survival of CRC 
patients in the SOCCS cohort 
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When implementing a relatively lenient significance threshold, six genes were 
associated with CRC-specific survival with p<5x10-5. Their basic characteristics along 
with the test statistic are presented in Table 5-37.  
 
Table 5-37 Summary of genes associated with CRC-specific survival identified from the 
genome-wide gene based analysis (p<5x10-5)  
Gene Gene ID Chr No. variants P 
CCDC135 ENSG00000159625 16 76 9.92E-07 
BBS9 ENSG00000122507 7 1387 8.28E-06 
HSPH1 ENSG00000120694 13 22 1.19E-05 
ADAMTS5 ENSG00000154736 21 143 2.49E-05 
SIGLECL1 ENSG00000179213 19 64 2.64E-05 
UVRAG ENSG00000198382 11 516 4.62E-05 
Chr, chromosome  
 
Gene-set based analysis  
With respect to gene-set based analysis on CRC-specific survival, I identified a 
statistically significant enrichment of signals in the set of genes associated with up-
regulating the differentiation of adipocyte (MSigDB ID: 
urs_adipocyte_differentiation_up) (p=2.52x10-7). This gene set includes 65 mapped 
genes and additional information about these genes can be found in Table 5-38.   
 
Table 5-38 Genes involved in the up-regulating the differentiation of adipocyte 
Gene Gene ID CHR No. 
variants 
P* 
PLEK ENSG00000115956 2 177 0.012 
LYPLA1 ENSG00000120992 8 103 0.019 
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Gene Gene ID CHR No. 
variants 
P* 
MASP1 ENSG00000127241 3 220 0.020 
COL7A1 ENSG00000114270 3 22 0.022 
LIPC ENSG00000166035 15 472 0.022 
DGAT1 ENSG00000185000 8 12 0.025 
PCDH7 ENSG00000169851 4 1095 0.067 
ECM2 ENSG00000106823 9 101 0.069 
ADIPOQ ENSG00000181092 3 48 0.079 
PLIN2 ENSG00000147872 9 115 0.082 
CHST1 ENSG00000175264 11 43 0.087 
ALDH1A2 ENSG00000128918 15 1832 0.110 
LRP8 ENSG00000157193 1 181 0.113 
FXYD1 ENSG00000266964 19 4 0.118 
SLC24A2 ENSG00000155886 9 760 0.130 
IGFBP2 ENSG00000115457 2 23 0.152 
C1orf61 ENSG00000125462 1 24 0.153 
TNFAIP2 ENSG00000185215 14 27 0.188 
GPD1 ENSG00000167588 12 5 0.189 
VTN ENSG00000109072 17 24 0.201 
DPT ENSG00000143196 1 147 0.203 
PFKFB3 ENSG00000170525 10 312 0.231 
AGT ENSG00000135744 1 51 0.236 
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Gene Gene ID CHR No. 
variants 
P* 
SKAP1 ENSG00000141293 17 697 0.238 
PTPN21 ENSG00000070778 14 196 0.249 
CAP2 ENSG00000112186 6 400 0.272 
ATP2B2 ENSG00000157087 3 1349 0.278 
ALDH6A1 ENSG00000119711 14 92 0.284 
PTPRS ENSG00000105426 19 645 0.294 
LBP ENSG00000129988 20 110 0.302 
FABP4 ENSG00000170323 8 18 0.327 
MTUS1 ENSG00000129422 8 836 0.377 
STAT5B ENSG00000173757 17 70 0.379 
PPARG ENSG00000132170 3 362 0.415 
MMP7 ENSG00000137673 11 28 0.440 
ATP8A2 ENSG00000132932 13 1925 0.497 
ABCE1 ENSG00000164163 4 19 0.506 
CIR1 ENSG00000138433 2 94 0.507 
FABP5 ENSG00000164687 8 1 0.515 
KCNH2 ENSG00000055118 7 74 0.524 
CTSG ENSG00000100448 14 7 0.524 
DPF2 ENSG00000133884 11 23 0.541 
AMT ENSG00000145020 3 7 0.541 
C8orf59 ENSG00000176731 8 10 0.559 
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Gene Gene ID CHR No. 
variants 
P* 
APOB ENSG00000084674 2 61 0.577 
ACOX3 ENSG00000087008 4 307 0.607 
ADORA2B ENSG00000170425 17 49 0.613 
HSD11B2 ENSG00000176387 16 10 0.613 
E2F1 ENSG00000101412 20 13 0.621 
FABP7 ENSG00000164434 6 11 0.623 
GLUL ENSG00000135821 1 26 0.639 
MTMR12 ENSG00000150712 5 242 0.661 
PLCD1 ENSG00000187091 3 73 0.669 
MAP4K3 ENSG00000011566 2 427 0.670 
INSR ENSG00000171105 19 631 0.746 
PTPRZ1 ENSG00000106278 7 443 0.769 
ACSL1 ENSG00000151726 4 211 0.771 
TFCP2 ENSG00000135457 12 219 0.795 
CRYAB ENSG00000109846 11 12 0.809 
SMARCB1 ENSG00000099956 22 262 0.817 
USP8 ENSG00000138592 15 259 0.838 
LPL ENSG00000175445 8 277 0.840 
RXRA ENSG00000186350 9 364 0.868 
DGKG ENSG00000058866 3 497 0.884 
APLNR ENSG00000134817 11 9 0.958 
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*P-values of gene based tests for each gene  
Chr, chromosome  
 
5.4.5 Stage-stratified GWAS 
 
GWAS in stage II/III patients   
Based on the same procedure described in aforementioned GWASs, I also performed 
GWAS in patients diagnosed with locally advanced (stage II/III) CRC. A total of 3,886 
CRC patients in the SOCCS study with 8,328,632 autosomal genetic variants were 
included in this analysis. Among all included variants, I detected 402,488 (4.83%) 
variants associated with overall survival and 407,825 (4.90%) variants associated with 
CRC-specific survival respectively using the Martingale-residual based approach. The 
Manhattan plots displaying all variants with p<0.05 from the two GWASs on overall 
and CRC specific survival are presented in Figure 5-35.  
 




Figure 5-35 Manhattan plot of GWAS results on survival outcomes of stage II/III CRC 
patients in the SOCCS cohort (A for overall survival and B for CRC-specific survival; blue 
line: p=10-5, red line: 5x10-8) 
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As depicted by the Manhattan plots, I identified one genetic locus in chromosome 5 
that showed aggregated signals of correlated variants associated with overall and 
CRC-specific survival in stage II/III CRC patients. The top hit in this locus reached 
GWAS significance in the association with CRC-specific survival (rs323694: 
Martingale residual coefficient=0.287, SD=0.052, p=3.25x10-8) 
With respect to the distribution of all genetic variants, I created QQ plots for the two 
outcomes and present them in Figure 5-36. 




Figure 5-36 QQ plot of GWAS results on survival outcomes of stage II/III CRC patients in 
the SOCCS cohort (A for overall survival and B for CRC-specific survival) 
 
The QQ plots indicate good concordance between the observed and theoretical 
distribution of p-values, and the inflation factors also suggest no systematic inflation 
of the GWAS results (overall survival: λ=0.988; CRC-specific survival: λ= 0.992).  
I extracted genetic variants in association with overall or CRC-specific survival 
outcomes at p<5x10-6. Initially, the GWAS on overall survival identified 24 variants 

Chapter 5 Results 
227 
 
 rs10735490 1 A 0.18 -0.31 0.067 4.37E-06 
 rs7253608 19 T 0.306 0.274 0.06 4.78E-06 
Chr, chromosome; MA, minor allele; MAF, minor allele frequency; Beta, regression coefficients; 
Se, standard error; Indel, insertion-deletion variant; OS, overall survival; CRC-specific survival   
 
Then, I re-estimated the effects of these above genetic variants on overall and CRC-
specific survival in the context of Cox regression models. Notably, the variant 
rs323694 in chromosome 5 retained GWAS significance with an effect on CRC-
specific survival (HR=1.33, 95% CI=1.20-1.47, p=2.92x10-8). Detailed results of other 
variants are presented in Table 5-40.  
 
Table 5-40 Summary of effect estimates from Cox models of GWAS-identified variants 
associated with survival outcomes of stage II/III patients in the SOCCS cohort (p<5x10-6)  
 Variant Chr MA MAF HR(95%CI) P 
OS       
 rs144559033 20 T 0.011 2.20(1.62-3.00) 6.16E-07 
 rs568921 5 C 0.446 1.22(1.13-1.33) 1.06E-06 
 rs62184746 2 G 0.491 0.81(0.74-0.88) 3.03E-06 
 rs117392919 17 A 0.026 1.72(1.37-2.17) 3.80E-06 
 rs233176 16 T 0.308 1.23(1.12-1.34) 5.17E-06 
 rs6806922 3 C 0.162 0.76(0.67-0.86) 7.28E-06 
 rs7191260 16 G 0.077 0.67(0.56-0.80) 7.49E-06 
 rs6962371 7 C 0.046 0.57(0.44-0.73) 1.40E-05 
 rs4444042 11 G 0.043 0.81(0.67-0.98) 3.07E-02 
       
CSS       
 rs323694 5 G 0.424 1.33(1.20-1.47) 2.92E-08 
 rs143664541 6 A 0.014 2.42(1.75-3.34) 9.90E-08 
 rs72832931 17 C 0.022 2.09(1.57-2.78) 3.48E-07 
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 Variant Chr MA MAF HR(95%CI) P 
 rs79014181 22 A 0.059 1.59(1.32-1.91) 1.20E-06 
 rs75796335 7 C 0.113 1.44(1.24-1.67) 1.88E-06 
 rs10735490 1 A 0.18 0.75(0.67-0.85) 3.90E-06 
 rs7253608 19 T 0.306 1.30(1.16-1.46) 4.16E-06 
 rs55698139 8 G 0.402 0.78(0.70-0.87) 4.37E-06 
 rs6445392 3 C 0.4 0.78(0.70-0.87) 4.53E-06 
 rs66494751 7 G 0.258 1.29(1.16-1.44) 4.57E-06 
 rs201806734 11 T(Indel) 0.04 1.33(1.05-1.67) 1.57E-02 
Chr, chromosome; MA, minor allele; MAF, minor allele frequency; HR, hazard ratio; CI, 
confidence interval; OS, overall survival; CSS, CRC-specific survival 
 
The GWAS-identified variant rs323694 is an intergenic variant located between the 
IRX2 and the LOC100506858 gene. I created a locus-zoom plot to show the LD 
structure and annotated genes near the variant in Figure 5-37. There are a number 
of flanking variants in moderate to strong LD (r2>0.6) with the top variant. 
 
Figure 5-37 Locus-zoom plot for variant rs323694 
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Given that the minor allele (G) of the variant rs323694 is relatively common 
(MAF=0.42 in SOCCS), I plotted the Kaplan-Meier survival estimates of carriers of 
three genotypes separately (Figure 5-38). The survival curves in the figure indicate a 
possible recessive genetic effect of this variant on CRC-specific survival. I 
investigated the association between this variant and CRC-specific survival under a 




Figure 5-38 Kaplan-Meier estimates of CRC-specific survival in stage II/III CRC patients in 
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GWAS in stage IV patients  
I investigated effects of eight million autosomal genetic variants on survival outcomes 
of 784 stage IV patients. Using the Martingale residual-based approach, a total of 
410,207(4.92%) and 413,833 (4.97%) genetic variants were associated with overall 
and CRC-specific survival of stage IV CRC patients (p<0.05) respectively. I presented 
these associations based on their statistical significance in Manhattan plots (Figure 
5-39. No significant signals with p<5x10-8 were identified in these two GWASs.  




Figure 5-39 Manhattan plot of GWAS results on survival outcomes of stage IV CRC patients 
in the SOCCS cohort (A for overall survival and B for CRC-specific survival; blue line: p=10-
5, red line: 5x10-8) 
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Regarding the overall distribution of all associations of the eight million genetic 
variants, I estimated the inflation factors of the two GWASs on overall and CRC-
specific survival of stage IV patients. A lambda value of 0.998 was observed for the 
GWAS on overall survival and 0.997 for CRC-specific survival. The QQ plots, 
presented in Figure 5-40, also suggested the absence of systematic inflation of 
statistical significance. 
 
Figure 5-40 QQ plot of GWAS results on survival outcomes of stage IV CRC patients in the 
SOCCS cohort (A for overall survival and B for CRC-specific survival) 
 
I also screened for associations between genetic variants and survival outcomes with 
p<5x10-6. In total, the GWASs identified variants for overall survival and for CRC-
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specific survival. After controlling for LD, 13 independent variants (r2<0.2) remained 
in association with overall survival and 11 variants were associated with CRC-specific 
survival. The original regression coefficients along with standard errors of these 
variants are summarised in Table 5-41. 
 
Table 5-41 Genetic variants identified from the genome-wide association analysis associated 
with survival outcomes of stage IV CRC patients in the SOCCS cohort (p<5x10-6) using the 
Martingale-residual based approach  
 Variant Chr MA MAF Beta SE P 
OS        
 rs76804061 7 C 0.019 -1.168 0.217 1.01E-07 
 rs13061928 3 G 0.177 -0.39 0.077 5.79E-07 
 rs78621268 5 C 0.111 0.494 0.098 6.45E-07 
 rs117432600 13 A 0.011 -1.547 0.311 7.76E-07 
 rs142605534 6 G 0.306 -0.312 0.064 1.57E-06 
 rs111935424 18 C 0.014 -1.306 0.271 1.66E-06 
 rs190425907 12 T 0.009 -1.664 0.347 1.97E-06 
 rs4856722 3 C 0.014 -1.324 0.278 2.18E-06 
 rs145764000 15 A 0.021 -0.986 0.208 2.44E-06 
 rs79151344 2 G 0.072 -0.556 0.118 2.84E-06 
 rs186078581 1 C 0.014 -1.233 0.262 2.93E-06 
 rs144281883 14 A 0.104 -0.486 0.103 3.05E-06 
 rs140179875 11 C 0.016 -1.26 0.273 4.70E-06 
CSS        
 rs183168900 7 C 0.020 -1.128 0.227 7.81E-07 
 rs35582295 22 G 0.029 -0.996 0.201 8.99E-07 
 rs13061928 3 G 0.177 -0.386 0.079 1.32E-06 
 rs192825132 13 A 0.011 -1.562 0.322 1.48E-06 
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 Variant Chr MA MAF Beta SE P 
 rs142605534 6 G 0.306 -0.317 0.066 1.77E-06 
 rs117505118 8 A 0.010 -1.569 0.332 2.70E-06 
 rs144281883 14 A 0.104 -0.499 0.106 2.78E-06 
 rs12928306 16 A 0.176 -0.373 0.079 3.15E-06 
 rs75731204 12 T 0.364 -0.312 0.067 3.63E-06 
 rs13045825 20 G 0.020 -1.07 0.23 3.94E-06 
 rs74588306 4 G 0.036 -0.766 0.165 4.12E-06 
Chr, chromosome; MA, minor allele; MAF, minor allele frequency; Beta, regression coefficients; 
Se, standard error; Indel, insertion-deletion variant; OS, overall survival; CRC-specific survival    
 
I then re-estimated the hazard ratios of these genetic variants in Cox regression 
models. However, none of the variants reached GWAS significance; the detailed 
results of effect estimates obtained from Cox models are presented in the following 
Table 5-42. 
Table 5-42 Summary of effect estimates from Cox models of GWAS-identified variants 
associated with survival outcomes of stage IV patients in the SOCCS cohort (p<5x10-6)  
  Variant  Chr MA MAF HR(95%CI) P 
OS             
  rs78621268 5 C 0.111 1.59(1.34-1.89) 1.31E-07 
  rs142605534 6 G 0.306 0.72(0.63-0.83) 2.24E-06 
  rs13061928 3 G 0.177 0.67(0.57-0.79) 3.09E-06 
  rs144281883 14 A 0.104 0.62(0.50-0.78) 2.88E-05 
  rs79151344 2 G 0.072 0.59(0.45-0.76) 5.05E-05 
  rs76804061 7 C 0.019 0.31(0.17-0.57) 1.41E-04 
  rs186078581 1 C 0.014 0.22(0.10-0.51) 4.55E-04 
  rs111935424 18 C 0.014 0.24(0.11-0.54) 4.68E-04 
  rs117432600 13 A 0.011 0.20(0.08-0.50) 5.82E-04 
  rs4856722 3 C 0.014 0.29(0.14-0.58) 5.83E-04 
  rs145764000 15 A 0.021 0.41(0.24-0.68) 5.96E-04 
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  rs190425907 12 T 0.009 0.21(0.08-0.57) 2.15E-03 
  rs140179875 11 C 0.016 0.73(0.43-1.26) 2.57E-01 
CSS             
  rs142605534 6 G 0.306 0.72(0.62-0.82) 2.65E-06 
  rs75731204 12 T 0.364 0.72(0.63-0.83) 3.95E-06 
  rs13061928 3 G 0.177 0.67(0.57-0.80) 6.21E-06 
  rs12928306 16 A 0.176 0.68(0.57-0.81) 1.09E-05 
  rs144281883 14 A 0.104 0.61(0.48-0.77) 2.62E-05 
  rs35582295 22 G 0.029 0.32(0.19-0.56) 4.57E-05 
  rs74588306 4 G 0.036 0.46(0.31-0.69) 1.63E-04 
  rs183168900 7 C 0.02 0.34(0.19-0.60) 2.68E-04 
  rs13045825 20 G 0.02 0.34(0.19-0.62) 3.54E-04 
  rs192825132 13 A 0.011 0.12(0.04-0.44) 1.15E-03 
  rs117505118 8 A 0.01 0.16(0.05-0.50) 1.56E-03 
Chr, chromosome; MA, minor allele; MAF, minor allele frequency; HR, hazard ratio; CI, 
confidence interval; OS, overall survival; CSS, CRC-specific survival 
 
  





In this chapter, I presented my results grouped in four analytic sections. Firstly, in the 
descriptive analysis, survival outcomes of prevalent cases in the UK Biobank were 
found to be significantly better than incident cases, therefore the prevalent cases were 
excluded from subsequent analysis due to potential selection bias. The first part of 
the thesis is a replication study of 43 genetic variants reportedly associated with CRC 
survival. None of these previously identified associations were successfully replicated 
after adjusting for multiple testing in the SOCCS cohort. In the second part, a genetic 
predictor combining these 43 known genetic variants was developed in the UK 
Biobank, and it showed weak predictive value on 5-year survival outcomes of patients 
in the UK Biobank. The external validation found no meaningful predictive 
performance of the developed genetic predictor in the SOCCS cohort. In addition, the 
genetic predictor did not appear to add extra predictive value to other non-genetic 
variables in SOCCS. In the third part, 128 genetic variants associated with CRC risk 
and 82 variants previously linked with survival outcomes of other cancers were tested 
in terms of their potential effects on CRC survival. None of these variants showed 
significant effect on either overall or CRC-specific survival of CRC patients in the 
SOCCS under an additive genetic model. A possible recessive genetic effect on 
survival outcomes was identified for two CRC-risk variants (rs10161980 and 
rs7495132) in both the SOCCS and UK Biobank cohorts. In the last part of the thesis 
which features a genome-wide association study on CRC survival, the variant 
rs143664541 was identified to be significantly associated with both overall and CRC-
specific survival; another variant rs75809467 showed a significant effect on CRC-
specific survival in the SOCCS cohort. However, neither of them remained significant 
in the replication analysis based on meta-analyses combining the UK Biobank cohort 
and three clinical trial datasets. By conducting gene and gene-set based analysis 
using the SOCCS cohort, I observed potential enrichment of genetic signals in the 
CCDC135 gene for overall survival, and in two gene sets involved in biosynthetic 
process of galactolipid (overall survival) and up-regulating the differentiation of 
adipocyte (CRC-specific survival) respectively.  
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Chapter 6 Discussion  
 
6.1 Introduction  
 
This chapter is divided into two parts: discussion of the methodological perspectives 
and interpretation of the main findings. Firstly, strengths and limitations of the study 
design, data sources and statistical analysis will be discussed. In the second part, 
main results derived from Chapters 3 and 5 will be summarised, and the interpretation 
of these results will be discussed in relation to the strength of evidence and potential 
biological implications. Genetic variants, genes and gene sets identified from this 
thesis that may be associated with survival outcomes of CRC will be discussed 
separately. Finally, conclusions and recommendations for future research will be 
summarised.  
 
6.2 Methodological perspectives  
 
6.2.1 Study design   
 
Systematic literature review and meta-analysis  
The main strengths and limitations of the published systematic literature review have 
been presented in the discussion section of Chapter 3 (page 66). In this section, main 
points in relation to the study design of the systematic review will be summarised and 
aspects that have not been extensively discussed in the published paper will also be 
described. 
 
Study selection  
I searched for published literature using the MEDLINE and Embase databases. The 
literature search was restricted to articles in English and, therefore, prediction models 
published in other languages were not reviewed. With respect to the inclusion and 
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exclusion criteria, only multivariable prediction models with no less than two predictors 
were included. This resulted in the exclusion of studies investigating the predictive 
value of a single factor. In order to distinguish prediction models from simple 
association studies, only published papers that reported quantitative measures of 
model performance were deemed as eligible in this review. Moreover, I also excluded 
studies in which specific prediction rules were not reported or the prediction tools such 
as an online calculator were unavailable because a prediction model could not be 
independently validated and updated unless the prediction rules were explicitly 
presented.   
 
Critical appraisal  
In this review I used the CHARMS checklist to appraise the methodological quality of 
included prediction models (Moons et al, 2014). This checklist evaluates each model 
for six domains: participants, predictors, outcome, events per variable (EPV), cohort 
attrition and data analysis (see details in Appendix Table 1). This checklist is not 
specifically designed for studies on time-to-event outcomes and, therefore, survival 
related biases such as ‘health volunteer’ bias (further explained in the section 
‘Selection bias’, page 236) cannot be assessed using this checklist. Given that critical 
appraisal of prediction models is based on personal judgment and can be inevitably 
subjective, a second reviewer, Dr Xue Li from the Usher Institute, conducted a parallel 
evaluation in a random sample of 25% of included models. Three models (9%) were 
identified with discrepant assignments of risk of bias, but agreement was reached 
after discussion. Based on the CHARMS checklist the same research team proposed 
an updated tool named ‘PROBAST’ to appraise prediction models (Moons et al, 2019). 
The new tool integrates two previous domains (EPV and cohort attrition) into the data 
analysis domain and thus only four domains are used to assess each model. More 
importantly, the new tool suggests assigning an overall risk of bias to each model. In 
particular, only models with low risk of bias for all domains can be assigned with low 
risk, which will not change the main finding of the systematic review where only two 
models reported by Rees at al. were classified as overall low risk of bias(Rees et al, 
2008b). 
 




I performed a random-effects meta-analysis to combine metrics evaluating model 
performance considering potential heterogeneity across multiple studies under varied 
clinical settings. A strength of this review is that the meta-analysis was conducted 
using only external validation studies and the initial model development study was 
excluded to avoid overestimation on the model performance. In this study, I was only 
able to conduct meta-analysis for reported C statistics based on data availability. 
Currently, there have been multiple methods to estimate the C statistic for time-to-
event data (Blanche et al, 2013). For example, it can be calculated as the area under 
the receiver operating characteristic curve (ROC) at a specific observation point. In 
addition, it can be derived from the definition—the proportion of randomly selected 
pairs of individuals in which an individual with longer observed survival time shows 
higher predicted survival probability. Other methods such as time-dependent ROC 
can also be applied to calculate the C statistic (Blanche et al, 2013). However, detailed 
methods used to derive the C statistics were mostly not reported among included 
prediction models. Hence, I was unable to harmonise the reported C statistics and the 
pooled estimates could be inaccurate. Another limitation for the meta-analyses of 
prediction models is that quantitative methods to detect potential risk of bias have not 
been well developed. In a previously published umbrella review, we appraised the 
meta-analysis by applying a range of metrics including heterogeneity, small study 
effects, excess significance, prediction interval and credibility ceilings (He et al, 
2018a). However, currently, only the prediction interval, which indicates possible 
range for the performance of a future validation study, has been recommended when 
conducting meta-analysis of prediction models (Debray et al, 2017). In the systematic 
review of this thesis, I calculated the 95% prediction intervals of C statistics when 
more than three validation studies were available. None of the models were identified 
with prediction intervals excluding the null (0.50), indicating the presence of 
substantial amount of uncertainty regarding the discriminative performance of future 
validation studies. Whether other metrics can be used to evaluate evidence strength 
of prediction models, still remain unclear. Future efforts should explore possible 
integration of multiple quantitative methods to appraise meta-analyses of prediction 
models. 
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Data sources for genetic association studies   
Study cohorts 
In this thesis, multiple CRC patient cohorts were employed. Of them, the SOCCS 
study is used as the main discovery cohort of genetic association studies. SOCCS is 
a prospectively collected population-based cohort that recruits patients from Scotland 
after their CRC diagnosis and then follows them up. The fact that they are already 
diagnosed with CRC may influence levels of specific biomarkers and the way they 
respond to questions. However, this should not affect the genotypic, demographic 
(age and sex) and pathological (AJCC stage, tumour site and tumour grade) variables 
included in the analysis. The other study cohort used in this thesis is comprised of 
incident CRC cases from the UK Biobank, which is also a prospectively collected 
population-based cohort in UK. As opposed to SOCCS, participants developed CRC 
after they entered the study. Prospective cohorts are considered as a preferable study 
design compared to retrospective cohorts, which are prone to more potential sources 
of biases, especially in the setting of investigating prognostic effects.  
 
Selection bias 
Notably, the prevalent CRC cases from the UK Biobank were excluded from analysis. 
As shown in Figure 5.1 and 5.2, prevalent CRC cases showed significantly better 
survival outcomes compared to incident cases from the UK Biobank as well as the 
SOCCS study. This is known as ‘left truncation’ or ‘survival bias’ in survival analysis. 
Left truncation happens when participants conditioning upon them not having 
experienced the event of interest are included. In this case, prevalent CRC cases from 
the UK Biobank were only included given they were alive at recruitment. This causes 
exclusion of prevalent cases who had inferior survival outcomes (died before 
recruitment) and therefore can introduce bias especially when comparing the results 
to general population. The SOCCS study is not severely affected by survival bias 
because all CRC patients were enrolled upon diagnosis, and similar survival 
estimates were found for SOCCS patients compared with incident cases in UK 
Biobank (Figure 5.1 and 5.2). There have been statistical models developed to 
accommodate left-truncated data. For example, the PROC PHREG module (URL6-1) 
can provide adjusted survival estimates accounting for the truncation time—in this 
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case, the time from CRC diagnosis to enrolment of the prevalent cases. However, the 
methodology of dealing with left truncation in predictive modelling and large-scale 
analysis such as GWAS has not been well developed. Therefore, prevalent UK 
Biobank cases were excluded prior to analysis so as to derive unbiased estimates. 
After excluding prevalent cases in UK Biobank, a 5-year overall survival rate of 75% 
and 74% was observed for the UK Biobank and SOCCS study respectively. These 
survival rates are higher than the 5-year survival rates provided by Scottish Cancer 
Registry (61%) (URL1-2), CRUK (60%) (URL1-3) and NCI (65%) (NCI, 2018) under 
the same follow-up scheme (from CRC diagnosis to death). By investigating the 
stage-specific 5-year survival estimates, I observed comparable survival rates for 
stage I (93%) and stage II (83%) patients in SOCCS compared with estimates 
provided by CRUK (95%-100% for stage I and 80%-90% for stage II patients). 
However, higher 5-year overall survival rates were found for stage III (72%) and stage 
IV (27%) patients in SOCCS than the registry data from CRUK (65% for stage III and 
5%-10% for stage IV patients). It should be noted that survival rates provided by 
cancer registry are relative rates which take into account the expected death rates of 
the general population with similar age but without the disease. This makes the 
relative survival rates slightly higher than the actual overall survival, which does not 
change the fact that survival rates estimated from the SOCCS and UK Biobank 
cohorts are higher than registry data, especially for patients with stage III and IV CRC. 
These observed discrepancies may be explained by the ‘healthy volunteer’ selection 
bias—individuals with worse health status are less likely to participate in such cohort 
studies (Fry et al, 2017). This bias can also be reflected by the observed percentage 
of stage IV patients in SOCCS (13.8%) which is evidently lower than the population 
percentage (20%) provided by CRUK (URL1-3). 
In addition to the SOCCS and UK Biobank cohorts, three published clinical trials were 
used in this thesis as part of the validation analysis. As described in section 4.2.3, the 
three trials included stage II and III CRC patients with varied chemotherapy strategies. 
Although, a total of 4,768 patients were provided by these trials, these datasets may 
not be fully representative of the CRC patient population. Firstly, these trials targeted 
stage II/III CRC patients, which only represent a subpopulation of all CRC patients 
compared to the SOCCS and UK Biobank cohorts. Secondly, included CRC patients 
were highly selected based on predefined inclusion criteria, rendering these datasets 
prone to selection bias. For instance, all the trials included CRC patients with 
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performance status scores of 0 or 1 (Iveson et al, 2018; Kerr et al, 2016; Midgley et 
al, 2010), meaning that sick patients who needed extra assistance (scores of 2, 3 and 
4) were excluded. Thus, these datasets could be severely influenced by the ‘healthy 
volunteer’ bias. Another issue is that patients allocated to the treatment arm received 
exploratory treatment strategies, which could also lead to varied survival rates 
compared to the patients with standard treatment. Therefore, findings derived from 
these three datasets merit further validation in future large population-based cohorts. 
Although the observed survival rates of the study cohorts included in the thesis may 
not be fully representative of the CRC patient population, the relative effect estimates 
(HRs) of genetic and non-genetic factors should still be generalizable (Fry et al, 2017). 
However, in terms of prediction models reported in the thesis, one should be vigilant 
given the presence of the aforementioned selection bias. As introduced in Chapter 5 
(page 141), baseline survival rates and relative effect estimates for candidate 
predictors are both required to obtain the predictive survival probability for a given 
individual. Although the relative effect estimates reported in Chapter 5 can be directly 
applied to make predictions, the baseline survival rates could be biased due to the 
study cohorts being unrepresentative. Therefore, one should update the baseline 
survival rates according to the target population before applying these prediction 
models. 
 
Main variables  
Genetic variables---Standard genotyping arrays along with rigorous quality control 
and imputation processes were used for both cohorts (details presented in page 70 
and 79, Chapter 4). The genotype data of these two cohorts have been included in 
multiple published GWASs (Dunlop et al, 2012; Law et al, 2019). In this thesis, 
germline genetic variations were tagged by single nucleotide polymorphisms (SNPs) 
detected by SNP arrays. The main strengths of SNP arrays include their high 
resolution to assay millions of SNPs throughout the genome in one experiment and 
lower cost compared to other high throughput technologies such as sequencing. 
However, there are also limitations for SNPs arrays. For example, these arrays are 
unable to efficiently recognise chromosomal anomalies such as balanced 
translocations (with no missing or extra chromosomal materials) and inversions which 
are also possible germline genetic markers for disease outcomes (Mao et al, 2007). 
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Analytical tools have been developed to identify some chromosomal changes such 
as aneuploidies (abnormal chromosome copy number) (Ting et al, 2006). However, 
genetic data prepared for GWASs were used in this thesis; therefore, other germline 
genetic markers such as chromosomal changes were not employed. Future 
exploration may consider investigating germline markers other than SNPs in relation 
to their prognostic effects on CRC survival. Genotype imputation was performed for 
all the study cohorts used in this thesis in order to expand the coverage and improve 
statistical power of GWASs. In particular, the SHAPEIT-IMPUTE2 method (technical 
details are presented in page 73, Chapter 4) was adopted to impute the un-genotyped 
loci. Roshyara et al. compared performance of different imputation methods in a 
cohort of 2,500 individuals (Roshyara et al, 2016). Their results showed that the 
SHAPEIT-IMPUTE2 method might overestimate the certainty of genotype 
distributions, but this effect diminished as the sample size increased (Roshyara et al, 
2016). Given the relatively large sample size for both the SOCCS (~20K) and UK 
Biobank (~500K) cohorts used for imputation, this effect should not be problematic for 
the imputed genotype data of this thesis. As genotypes are estimated based on the 
LD structure rather than measured genotypes, imputation error is therefore inevitable. 
Imputation error leads to increased uncertainty and causes loss of statistical power 
for an imputed SNP compared to the same SNP if genotyped (Huang et al, 2009). 
However, previous evidence found that imputation error rates are generally low (2%-
6%) for widely used methods including the SHAPEIT-IMPUTE2 approach (Pei et al, 
2008). 
Non-genetic variables---The SOCCS cohort included age at diagnosis, sex, AJCC 
stage, tumour grade and tumour site, whereas only age at diagnosis and sex were 
available in the UK Biobank cohort. Demographic variables such as age and sex can 
be generally considered to be accurately measured. Tumour site and grade for 
patients from SOCCS were extracted from pathology reports and therefore, 
measurement error should also be rare. 
   
As the strongest predictor of survival outcomes, the AJCC stage was assigned 
according to pathology reports for patients who underwent surgical resection, 
whereas patients without surgery were staged based on imaging prior to treatment. 
As described in page 114 Chapter 5, ten stage 0 rectal cancer patients were identified 
and excluded from analysis as they might have received neoadjuvant radiotherapy 
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(applied before surgery) which could shrink the tumour and result in a downgraded 
stage in the pathology report. However, the remaining rectal cancer patients (N=2,201) 
in SOCCS were not manually checked to identify candidates with shrunken tumour 
after neoadjuvant radiotherapy. This led to inclusion of rectal cancer patients with 
possible underestimated stage, which could potentially bias the analysis. In addition, 
the AJCC stage is in fact a combination of three different measures (T, N and M). 
There has been evidence showing that modelling the TNM measures separately may 
improve prediction performance compared to the numeric AJCC stage (Li et al, 2014). 
Given that the focus of this thesis is to examine the potential added predictive value 
by germline genetic variants, the numeric AJCC stage was, therefore, directly used to 
predict CRC survival. 
  
There have been other factors associated with CRC survival. For example, the 
Canadian Cancer Society recommends lympho-vascular invasion, histological type of 
CRC, CEA, MSI, bowel obstruction or perforation and somatic mutations including 
KRAS and BRAF mutations as prognostic indicators for CRC (URL1-9). These factors 
are not collected in SOCCS and have not been released in UK Biobank. Future efforts 
are expected to aggregate patient cohorts with more of these prognostic factors 
recorded to improve prediction of CRC survival. Another important factor that can 
significantly influence survival outcomes is the treatment that patients received. 
Adding details of the treatment into the model can not only improve predictive 
performance, but also can assist accurately estimating effects of genetic variants. 
There are ongoing efforts in our group in linking the SOCCS data to external 
databases maintained by oncologists to obtain treatment data for patients in SOCCS. 
Treatment effects will be properly modelled in future investigations.  
 
Genetic association studies 
Variant selection for candidate association studies  
The first step of the thesis was a systematic literature review aiming to summarise all 
published prediction models used to predict CRC survival and to identify potential 
germline genetic markers employed as predictors. No germline genetic variants were 
used in the identified published prediction models. Given that only prediction models 
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with quantitative assessment of model performance were included in the review, 
genetic variants investigated in genetic association studies were not reviewed in this 
step. In the second step, I validated previously reported variants that were associated 
with CRC survival outcomes using the SOCCS cohort. Variants were retrieved from 
the GWAS catalogue. By searching the GWAS catalogue, the eligible variants were 
restricted to ones identified by published GWASs. Therefore, genetic variants 
reported by candidate association studies were not considered. These variants were 
often selected based on established or putative biological mechanisms hence they 
may truly influence CRC prognosis. However, candidate association studies are 
hypothesis-driven and previously published studies could be subjected to multiple 
sources of biases (Ioannidis et al, 2001). For example, it has been reported that 
published candidate genetic association studies showed prominent excess of 
statistical significance which could possibly be attributed to publication bias (Kavvoura 
et al, 2008). Moreover, approximately 90% of previous candidate association studies 
did not control for multiple testing in a random sample of studies from 2001 to 2003, 
indicating pervasive false positive findings (Yesupriya et al, 2008). A field synopsis 
can systematically summarise and critically appraise published candidate association 
studies. A latest field synopsis on CRC risk, conducted by our group, identified 18 
variants with high credibility, 72% of which were validated by subsequent GWASs 
(Montazeri et al, 2019). Hence, a field synopsis on survival outcomes is needed as 
more candidate association studies are published before further validation analysis 
can be planned. As for the variants retrieved from the GWAS catalogue, a relatively 
lenient threshold (p<10-5) was used to screen for variants, which potentially raised the 
probability of type I error. In order to control for LD among eligible variants, an r2<0.2 
was used to exclude variants in LD. This could potentially cause exclusion of variants 
with larger effects on CRC survival in SOCCS. The aforementioned caveats about 
variant selection also apply to the other two candidate association studies in this 
thesis based on two hypotheses. The first hypothesis is that genetic variants known 
to be associated with CRC risk have subsequent effect on CRC progression and 
therefore serve as a potential prognostic indicator. The second hypothesis is that 
there exists a shared genetic basis of tumour progression across multiple cancer 
types, and variants associated with survival outcomes of other cancers also influence 
CRC survival. The rationale of these two hypotheses is described in Chapter 2. Due 
to a small number of variants being tested at a time, hypothesis-driven association 
studies are advantageous over GWAS in terms of statistical power when a relatively 
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small sample size is available. In addition to the variants selected in this thesis, there 
are other candidate variants possibly associated with CRC survival. For example, 
genetic variants may impact survival outcomes of CRC through modifying patients’ 
response to therapeutic agents such as 5-fluorouracil which has been widely used in 
chemotherapy for CRC patients. Previously published GWASs have identified a 
number of genetic variants to be associated with response to 5-fluorouracil (Chung et 
al, 2013; Low et al, 2013). These variants could be tested in a separate hypothesis-
driven association study to further examine their impact on survival outcomes of CRC.  
GWAS 
Under no prior hypothesis, GWAS has been widely considered as a more 
comprehensive and unbiased approach compared with candidate association studies 
(Eberle et al, 2007). It facilitates identification of novel genetic risk loci that have not 
been linked to the outcome of interest, revealing possible new biological mechanisms 
involved in the disease. One of the main strengths of GWAS is the high reproducibility 
of its findings. Marigorta et al. reported that an estimate of 40% to 94% of GWAS-
identified variants have been successfully replicated by later GWAS meta-analyses 
(Marigorta et al, 2018). In addition, GWAS can also shed light on the overall genetic 
architecture of a given trait by displaying the distribution of statistical significance of 
genetic signals throughout the genome. Despite clear advantages of GWAS, there 
are also limitations for this study design. For example, GWAS is conducted in a limited 
number of populations—some ethic groups are therefore not represented. Although 
germline genetic variations are generally not influenced by environmental factors, 
population stratification can confound the observed genetic associations through 
varying genetic allele frequencies (Hellwege et al, 2017). However, results of the PCA 
analysis indicated that population stratification was unlikely to have major impact on 
studies in this thesis (see Chapter 4, page 71). In addition, GWASs are penalised by 
multiple testing with millions of genetic variants being examined. A GWAS based on 
limited sample size can result in elevated rates of type II error (false negative findings), 
especially for variants of low MAF with small effects on the outcome. As shown in 
Chapter 5 (page 198), the GWAS based on 5,675 CRC cases in SOCCS is 
underpowered to detect small to moderate genetic effects (HR<1.4) for variants with 
MAF<0.05. This limitation can be overcome by future collaborative efforts aggregating 
multiple CRC cohorts to achieve improved statistical power. Another strategy is to 
reduce the number of tests; this includes approaches adopted in this thesis such as 
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aforementioned candidate association analyses and gene or gene-set based analysis. 
An additional limitation for GWASs based on SNP arrays is that effects of rare genetic 
variants cannot be effectively detected (Tam et al, 2019). Although a huge number of 
un-genotyped variants are recovered through imputation, such rare variants are hard 
to be accurately imputed. Ongoing efforts of whole genome or whole exome 
sequencing are expected to unravel possible rare variants that influence CRC survival. 
Validation analysis 
In this thesis, a two-stage study design was employed for both candidate association 
studies and the GWAS. To be specific, the SOCCS study was used as the primary 
discovery dataset, whereas the UK Biobank cohort was used for replication of findings 
from candidate association studies and meta-analysis of UK Biobank and three 
clinical trials were used to validate GWAS-identified variants. Replication in an 
independent dataset is crucial in genetic association studies in terms of avoiding false 
positive findings. In addition to statistical significance by chance, possible non-random 
biases in the discovery set can also be detected by independent replication. For 
example, if the SNP array consistently generates incorrect genotypes for a specific 
variant, this cannot be corrected by accumulating more samples. However, an 
independent dataset genotyped by a different array can effectively detect these errors. 
Biased measurement may also occur at the outcome level. In this case, follow-up of 
CRC patients for each cohort was conducted by different teams, and therefore 
spurious findings driven by possible biased survival outcomes are unlikely to be 
validated in an independent cohort. Although combining all available cohorts into a 
discovery set would markedly increase the sample size, the two-stage approach was 
adopted in this thesis given that diverse clinical settings and different structure of 




Overall survival and CRC-specific survival were employed as study outcomes in this 
thesis. The definitions along with the strengths and limitations of different endpoint 
such as overall survival and disease-free survival are introduced in Chapter 1 (page 
29). Currently, overall survival is still widely accepted as the gold standard endpoint 
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in prognostic studies of oncology (Sargent et al, 2005). It is worth mentioning that the 
survival time for patients in SOCCS was defined as the time span from the date of 
definitive treatment (surgery or chemo/radiotherapy) to the date of death. Whilst the 
UK Biobank cohort used the date of diagnosis obtained from the Cancer Registry as 
the starting point as the date of definitive treatment was unavailable, and the endpoint 
(date of death) was retrieved from National Death Registry. Cancer Registry in UK 
defines the date of cancer diagnosis following the algorithm provided by the European 
Network of Cancer Registries (see details in the previous publication (Tyczynski et al, 
2003)). The date of CRC diagnosis contains a mixture of following event dates in a 
declining order of priority: date of first histological confirmation, date documented in 
pathology report and date of first admission to hospital due to CRC. Given the fact 
that the date of CRC diagnosis should be no later than the start of treatment, the 
survival rate estimates would have been lower if the date of definitive treatment was 
used as the starting point. As discussed in the previous section (page 244), this should 
not bias the relative effect estimates (HR) if the time interval between diagnosis and 
treatment is independent from the genetic variant (Fry et al, 2017). However, future 
efforts are still expected, if possible, to re-calibrate the prediction model derived from 
the UK Biobank after harmonising the starting point of follow-up. As with the SOCCS 
study, the other three trials used in this thesis defined the follow-up time as from the 
date of randomisation (or the date treatment started) to the date of death. Date of 
definitive treatment is widely used in clinical settings as the starting point to evaluate 
the effect of certain treatment. The length of the delay is highly variable depending on 
the status of the disease and different medical systems over the world. Using the date 
of definitive treatment instead of diagnosis as the starting point will result in lower 
absolute survival estimates. There has been evidence showing that this effect of 
treatment delay on survival outcomes could be attenuated as the observation time 
period increases, especially when the follow-up time is longer than 3 years from the 
date of diagnosis (Roder et al, 2019). Hence, treatment delay should be less 
problematic given the relatively long median follow-up time (≥3 years) for all the study 
cohorts used in the thesis.  
It should be noted that assigning the specific cause of death can be subjective, 
although a parallel independent evaluation was performed by a colorectal surgeon 
and a low percentage of discrepancies was found between the two reviewers (1%). 
For example, a patient who died from myocardial infarction would be considered as a 
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non-CRC related death based on our criteria (page 76, Chapter 4). However, the 
myocardial infarction could possibly be induced by chemotherapy, which could not be 
reflected in the death certificate. Different criteria of assigning cause of death can lead 
to varied observed survival estimates for CRC-specific survival. The primary cause of 
death for participants from UK Biobank was assigned by the UK Biobank and was 
retrieved directly for analysis. 
 
Summary of strengths & limitations for study design  
Strengths:  
Systematic literature review: 
*A comprehensive systematic literature and meta-analysis was conducted to identify 
potential genetic variants that had been used in published prediction models, and to 
quantitively evaluate performance of published models.  
*Meta-analyses of C statistics reported in published prediction models were only 
conducted using external validation studies, which avoided inflated estimation of 
model performance.  
Genetic association studies:  
*The main study cohorts including the SOCCS and UK Biobank cohorts are 
population-based and prospectively collected.  
*Rigorous quality control was conducted for genotyping and imputation of the 
genotype data for the SOCCS and UK Biobank cohorts. 
*Both hypothesis-driven (candidate association studies) and hypothesis-free (GWAS) 
approaches were adopted to identify genetic variants associated with CRC survival. 
*A two-stage study design was adopted which consists of a discovery set and 
independent validation sets for genetic variants identified by the candidate association 
studies and the GWAS.   
 




Systematic literature review: 
*The systematic literature review only included published prediction models, which 
reported quantitative measures of model performance. Therefore, predictors used by 
studies that did not report model performance might have been missed.    
*Meta-analyses on metrics other than C statistics were not conducted due to data 
availability reported by published models. 
Genetic association studies:  
*Exclusion of prevalent CRC cases from the UK Biobank cohorts caused loss of 
statistical power.  
*All the datasets including the SOCCS, UK Biobank and three published clinical trials 
were subjected to ‘healthy volunteer’ bias. 
*The AJCC tumour stage for part of rectal cancer patients from SOCCS was possibly 
underestimated due to neoadjuvant therapy.  
*Clinical and pathological variables were unavailable in the UK Biobank cohorts. 
*Key prognostic factors such as somatic mutations and treatment were not collected 
for the SOCCS and UK Biobank cohorts.  
*Analysis was based on imputed GWAS data assayed by SNP chips, thus germline 
variations such as chromosomal anomalies were not investigated. 
*A comprehensive field synopsis to identify genetic variants reported by published 
candidate genetic association studies was not conducted. 
* Candidate genetic variants other than the three groups of variants included in the 
thesis were not investigated. 
* For validation analysis, only the UK Biobank cohort was used to validate variants 
identified from candidate association studies, whereas for GWAS, CRC-specific 
survival was not investigated due to data availability.  
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*Definitions of survival outcomes including the starting and end points were not 
harmonised, which led to varied observed survival estimates. However, relative 
effects (HRs) derived from this thesis should be generalizable.  
* Due to limited sample size of included cohorts, analysis in this thesis is 
underpowered to detect small prognostic effects on survival outcomes, especially for 
variants with low minor allele frequency.  
*Assignment of cause of death can be subjective, which could impact observed 
estimates of CRC-specific survival. 
*For predictive modelling, due to limited data availability, prediction models including 
clinic-pathological variables were not externally validated.  
 
6.2.2 Statistical analysis  
 
Survival analysis 
All analyses were performed using the Cox regression model which is the most widely 
used model to analyse time-to-event outcomes. The key assumption for this model is 
that the effect of a certain factor remains constant with time, namely the proportional 
hazard assumption. Although the Cox model has been widely adopted in various 
studies including clinical trials, prediction models and large-scale omics analysis such 
as GWAS, the proportional hazard assumption has seldom been examined in 
published literature(Guyot et al, 2011). Thus far, there have been different methods 
proposed to check this assumption, among which graphic examination is the most 
straightforward method. If the assumption holds, survival curves stratified by different 
values of a certain factor should be generally parallel to one another over the 
observation time window. Kaplan-Meier curves listed in Chapter 5 present generally 
parallel curves for non-genetic factors including the AJCC stage (Figure 5-5), tumour 
grade (Figure 5-6) and genetic variants identified from the GWAS of this thesis 
(Figure 5-25 Kaplan-Meier estimates of CRC-specific survival in the SOCCS stratified 
by the genetic variant rs143664541, Figure 5-26 for rs75809467 and Figure 5-38 for 
rs323694), indicating no visible departure from the proportional hazard assumption. 
Besides graphical examination, statistical tests have also been proposed to detect 
Chapter 6 Discussion 
 
252 
potential violated proportional hazards assumption. One of the most commonly used 
tests is based on the Schoenfeld residual, which is defined as the difference between 
the covariate value for a certain individual and the weighted average of the covariate 
for all individuals under risk. The test examines the correlation between the scaled 
Schoenfeld residual and observation time (Schoenfeld, 1980). It is unrealistic to 
examine millions of genetic variants included in the GWAS, thus I performed the test 
using the SOCCS cohort for genetic variants identified in this thesis (rs143664541, 
rs75809467, rs323694 and rs7495132), and identified no evidence of significant 
violation to the proportional hazards assumption for these four variants (p>0.05). 
However, this test has been questioned due to possible spurious findings based on 
arbitrarily scaled time variable (Park & Hendry, 2015), and the results of the test 
should be interpreted with caution. 
  
In order to improve the computational efficiency for the GWAS, I used a Martingale 
residual-based approach to estimate effects of eight million genetic variants on CRC 
survival. Technical details of this approach are described in Chapter 4 (page 104). 
Transformed from the standard Cox model this method, therefore, also relies on the 
same proportional hazard assumption. The main strength of this method is that the 
Cox model only needs to be fitted once including all the non-genetic covariates and 
the Martingale residuals generated from the fitted Cox model can be used as a new 
‘phenotype’ and be tested using linear regression models which lead to remarkably 
increased computational efficiency. Reynisson et al. conducted simulation studies to 
compare different methods for GWAS using time-to-event data and found that the 
Martingale residual-based method showed slightly lower statistical power compared 
to standard Cox regression (Reynisson, 2018). However, they also identified a lower 
false discovery rate (type I error rate) for this method than standard Cox regression 
(Reynisson, 2018). Therefore, the Martingale residual-based approach adopted in the 
GWAS of this thesis is expected to provide more conservative results. In order to 
identify possible false negative findings from the Martingale residual-based approach, 
I also re-estimated the effects of variants with p<5x10-6 using standard Cox regression.    
Notably, there are other models available that do not necessarily rely on the 
proportional hazards assumption, such as the parametric Weibull model (Carroll, 
2003). As opposed to the semiparametric Cox model, parametric methods pre-specify 
the survival function and are dependent on a distributional assumption, which is hard 
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to test. Some argue that hazard ratios estimated from the Cox model may still be 
useful if the proportional hazard assumption is violated (Boyd et al, 2012), although 
loss of statistical power could be expected (Syed et al, 2016). The hazard ratios under 
this circumstance could to some extend be interpreted as ‘time-averaged’ effects. 
Future investigations may be considered to model the genetic effect using other 
methods such as the Weibull model.   
With respect to the multivariable Cox model used to estimate genetic effects, I 
included age at diagnosis, sex and AJCC stage as covariates using the SOCCS 
cohort, and for UK Biobank, only age and sex were added in the model as stage was 
unavailable. Inclusion or exclusion of specific covariates has long been a dilemma. 
Mefford et al. summarised different situations of covariates and provided 
recommendations (Mefford & Witte, 2012). Common demographic factors such as 
age and sex can be deemed to be independent from autosomal genetic determinants 
and they are preferable to be included if they are associated with the outcome under 
study as increased statistical power is expected after adding them into the model 
(Mefford & Witte, 2012). This also applies for time-to-event outcomes according to 
previous simulation studies (Karrison & Kocherginsky, 2018). The situation for 
inclusion of the AJCC stage as a covariate is less easily perceived. As mentioned 
previously, AJCC stage is one of the strongest predictors of survival outcomes of CRC. 
Therefore, including AJCC stage in the model would increase statistical power to 
detect genetic effect provided that the stage is independent from the genetic variant. 
However, the relationships between genetic variants and stage at diagnosis remain 
largely unknown. It is possible that a genetic variant that determines tumour 
invasiveness results in more advanced stage of CRC at diagnosis, and then more 
advanced stage leads to worse survival outcome. In this case, the stage works as an 
effect mediator between the genetic variant and the outcome. Inclusion of an effect 
mediator could cause over-adjustment and lead to possibly diluted estimates of the 
genetic effects (Schisterman et al, 2009). I checked the genetic variants identified 
from this thesis (rs143664541, rs75809467, rs323694 and rs7495132) and found that 
none of them was significantly correlated with AJCC stage (p<0.05) in SOCCS. Thus, 
the effect estimates of these variants are relatively unlikely to have been affected by 
over-adjustment.  
Patients who died from non-CRC related causes were considered as censored when 
analysing CRC-specific survival in this thesis. In fact, cases who died from non-CRC 
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related causes are different from those who were alive until the end of observation 
since the occurrence of non-CRC related death precluded the patient from CRC-
related death. This is also known as ‘competing risks’. Previous research has 
demonstrated that the Kaplan-Meier method tend to provide higher estimated event 
rates than the true cause-specific event rates in the presence of competing risks 
(Andersen et al, 2012; Feakins et al, 2018). Statistical methods, such as the Fine-
Gray model (Fine & Gray, 1999) and the Lunn-McNeil model (Lunn & McNeil, 1995), 
have been proposed to address the competing risks by modelling the competing 
events separately. However, adding these models will drastically increase 
computational burden, and statistical tools that integrate these models in the setting 
of large-scale omics analysis as well as predictive modelling have not been well 
developed. Thus, competing risks were not modelled in the analysis. Previous 
evidence showed that the presence of competing risks can influence the observed 
survival rates, but it tends not to bias the relative effect estimates (HRs) derived from 
the Cox model (Feakins et al, 2018). In addition, the Cox model is also advantageous 
in terms of interpretation of the cause-specific hazard ratios which directly reflect how 
the variable of interest, such as genetic variants, are linked to survival rates, whilst 
interpretation of relative effect estimates derived from competing risk models is not 
straightforward (Andersen et al, 2012).  
 
Statistical power and multiple testing 
The statistical power for the genetic association studies was calculated based on the 
method provided by Owzar et al. (Owzar et al, 2012). Parameters which need to be 
specified to estimate power using this approach include: α level, sample size, 
proportion of events, assumed genetic model and effect size. The main strength of 
this method is that it does not rely on the contiguous alternative assumption which 
applies to most existing power estimation methods (Hsieh & Lavori, 2000). Under this 
assumption, the effect size should converge to zero at a constant rate. Owzar et al. 
argued that methods developed under this assumption may only be accurate when 
the expected effect size is reasonably small, and, therefore, these methods may not 
be suitable for designing GWAS (Owzar et al, 2012). Given the limited sample size of 
the SOCCS and UK Biobank cohorts, relatively large genetic effects could be detected 
after correcting for multiple testing. Thus, the method proposed by Owzar et al. was 
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employed to estimate the power in this thesis. However, some caveats still need to 
be noted for the power estimation. Firstly, this method was developed based on the 
Cox model; hence the limitations of the Cox model which have been discussed also 
apply to the power estimation. Secondly, inclusion of covariates could alter the 
statistical power, but the covariate structure is not accounted for by this method. 
Thirdly, as described in Chapter 4, I conducted the GWAS using a Martingale residual 
based approach which has been shown to have slightly lower statistical power than 
the standard Cox model (Reynisson, 2018). Fourthly, the statistical power was 
estimated under the additive genetic model, which was used as the main analysis of 
this thesis, and hence the estimated power should not be applied to the sensitivity 
analysis under the recessive genetic model. In summary, the estimated statistical 
power should be only considered as an approximation rather than an accurate value. 
In order to derive the statistical power after controlling for multiple testing, the α level 
was corrected by applying the Bonferroni correction. This is a rather stringent 
approach, which aims to control the familywise type I error—that is the probability of 
at least one test being false positive. As a trade-off, it leads to elevated type II error 
(false negative rate). Therefore, I also adopted another less stringent approach, 
namely the FDR correction, to evaluate the statistical significance of the results from 
the validation study of variants previously linked with CRC survival and the other two 
hypothesis-driven association studies. In fact, variants that remained significant after 
FDR correction also survived the Bonferroni correction. It is worth mentioning that in 
these genetic association studies, I only included independent variants by controlling 
the r2. Under this circumstance, the FDR approach could be advantageous because 
it is less likely to exclude true associations compared to the Bonferroni correction, 
although both approaches produced the same results in this thesis. However, in the 
setting of GWAS where there exists intrinsic LD throughout the genome, the FDR 
approach could suffer from loss of statistical power by not accounting for the LD 
structure (Kaler & Purcell, 2019). Previous efforts have been made to estimate the 
burden of multiple testing for GWAS in the presence of LD, and the results 
demonstrated a million independent tests in Europeans (Pe'er et al, 2008). Since then 
a Bonferroni corrected threshold (p< 5x10-8) has become the standard of evaluating 
statistical significance in GWAS. This threshold was therefore used in this thesis to 
report discoveries. Recently, more flexible methods of determining the significance 
threshold have been proposed using variant-based heritability for different traits of 
Chapter 6 Discussion 
 
256 
interest with an attempt to further reduce false negative rates (Kaler & Purcell, 2019). 
However, these methods have not been widely used and should be further validated. 
Predictive modelling 
The Cox regression model was used to obtain effect estimates for each included 
predictor. Strengths and limitations of the Cox model have been discussed in previous 
sections. Recently, other methods have gradually been applied in published literature 
to develop prognostic prediction models. For example, some studies showed that the 
Weibull model might outperform the Cox model in some aspects such as goodness-
of-fit (Baghestani et al, 2015). Given that the main focus of this section of the thesis 
is to test the potential added predictive value of genetic variants, the performance of 
models developed using other methods such as the Weibull model was not evaluated. 
Once genetic variants that can robustly predict CRC survival are identified, efforts 
should set out to explore methods such as the parametric Weibull model or more 
advanced approaches like neural networks to develop models with better 
performance.  
As for model performance, Harrell’s C statistic was employed as the main metric to 
evaluate the discriminative performance of developed models. One advantage of the 
C statistic is that it has a natural interpretation—the proportion of randomly selected 
pairs with correct predictions, and the statistic is well defined for continuous, binary 
and censored outcomes. Currently it has become one of the most widely used 
measure of model performance. However, the interpretation of C statistic becomes 
less straightforward when comparing the performance of different models. The 
incremental value of C statistic is not additive and has no direct interpretation 
(McKeigue, 2019; Pencina et al, 2012). Moreover, it has been shown that the 
incremental value of C statistic is highly dependent on the performance of the baseline 
model (McKeigue, 2019). Although a U statistic-based test can be employedto assist 
inference on the incremental predictive value by examining if one model is more 
concordant than the other, it is still hard to interpret and quantify the magnitude of the 
potential gain of prediction performance after adding a new predictor. Novel metrics 
such as the expected information for discrimination have been proposed recently as 
potential alternatives of the C statistic (McKeigue, 2019). However, how these metrics 
can be applied in censored data remains unclear. Nonetheless, there might be limited 
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implications in terms of the interpretation of the results of this thesis, as the C statistic 
remained approximately unchanged after including the genetic variants. 
With respect to model calibration, the Hosmer-Lemeshow test along with visual 
examination of the calibration plot were used. One general caveat for these two 
methods is that they evaluate the model calibration at a specific time point and survival 
outcomes are dichotomised. I chose the 5th year since diagnosis as the cut-off time to 
evaluate model calibration, as the 5-year survival outcomes are generally used in 
clinical practice to assess prognosis of cancer patients. However, it should be noted 
that model calibration may vary at different observation times. The Hosmer-Lemshow 
test examines the hypothesis that the predicted and observed number of events are 
the same across all risk groups (details in Chapter 4 page 100). Although widely 
adopted in published literature, this test has been criticised as categorisation of risk 
groups is largely arbitrary and the test tends to generate unstable results (Bertolini et 
al, 2000). Moreover, this test is also sensitive to sample size. Kramer et al. conducted 
a simulation study and found that as the sample size reached 50,000, the Hosmer-
Lemshow test would almost certainly provide significant findings (p<0.05) for 
simulated models with only slight departure from perfect fit (Kramer & Zimmerman, 
2007). In this case, a significant finding from the Hosmer-Lemshow test does not 
necessarily mean the model is poorly calibrated. Therefore, other measures are 
needed to assist evaluating the model calibration. I used calibration plots as a visual 
presentation of the overall agreement of the observed and predicted survival rates. 
Recently, other metrics such as the calibration slope and the observed/expected ratio 
have been proposed (Crowson et al, 2016). These metrics should be investigated 
exhaustively once a compelling genetic predictor has been identified to be integrated 
into future models. 
 
Missing data  
Missing data are prevalent in medical research. Common reasons for this problem 
include, but are not limited to: participants did not report relevant information; 
investigators failed to collect it; or the information was simply unavailable. Regression 
analysis built in most statistical platforms is performed only in observations with 
complete information, also known as complete case analysis (CCA). Missing data 
mainly take three different patterns—missing completely at random (MCAR), missing 
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at random (MAR), and missing not at random (MNAR) (Robins & Wang, 2000). The 
MCAR means that the probability of a missing value is independent from any other 
patients’ characteristic and is only determined by chance. Under this circumstance, 
unbiased results will be obtained from CCA as the completed observations can be 
seen as a random sample from the original population. Missing at random (MAR) is 
based on the assumption that missing values are solely dependent on observed 
information, which makes it possible to re-construct the incomplete records with 
certain amount of uncertainty using methods such as multiple imputation. As for the 
third form, the MNAR means that missing data are dependent on unobserved 
information. Currently, there has been no general approaches to address MNAR.   
In this thesis, missing data are present primarily in the SOCCS study. With respect to 
genotype data of SOCCS, approximately 10% of the participants were excluded 
during quality control. Nonetheless, distribution of principle components of genotyped 
individuals is tightly clustered with the UK population (Figure 4-1). Therefore, it is less 
likely that exclusion of these individuals systematically biased the genotype 
distribution of the cohort. As for non-genetic variables, the proportion of missing 
values for these variables are: age at diagnosis (1%), date of definitive treatment 
(0.7%), AJCC stage (6.5%), tumour grade (14.8%) and tumour site (1.2%). Given that 
only a small number of variables were included, it could be unsafe to assume the 
missing patterns of these variables are solely dependent on observed information, 
and it is highly possible that other uncollected variables can impact on the 
missingness (MNAR). Under such circumstances, methods such as multiple 
imputation that only leverage observed information to impute missing values can, by 
contrast, introduce bias (Hughes et al, 2019). It should be noted that analysis in the 
thesis was conducted following the CCA which could also generate biased estimates 
if the missing data were MAR or MNAR (Altman & Bland, 2007).  Future efforts are 
needed to collect more variables for each study cohort and extensively investigate 
possible mechanism behind the missing pattern, and address this issue before 
subsequent analysis. Another challenge lies in the prohibitive computational burden 
especially in the setting of large-scale omics analysis such as GWAS with millions of 
tests being conducted and predictive modelling where hundreds of equally-sized 
bootstrap samples are generated. There is a pressing need to develop analytical tools 
with high computational efficiency to combine methods such as multiple imputation 
where multiple imputed samples were generated with analyses like GWAS and 
bootstrapping. 




Summary of strengths & limitations for statistical analysis 
Strengths: 
* Effect estimates derived from Cox regression models had clear interpretation. 
* Covariates included in the multivariable analysis (age at diagnosis, sex and AJCC 
stage) increased statistical power.   
*A Martingale residual-based approach, transformed from the Cox model, was used 
in the GWAS to estimate effects of genetic variants on CRC survival. This approach 
provides more conservative results with lower type I error rates and can improve 
computational efficiency.  
*The method used to estimate statistical power does not rely on the contiguous 
alternative assumption, and it can potentially provide more accurate estimates for 
expected large effects.  
Limitations: 
*The proportional hazards assumption might not be valid for some genetic variants. 
Future efforts may consider estimating effects of genetic variants using other methods, 
such as the Weibull model, and comparing the findings with estimates from the Cox 
model. Potential time-varying genetic effects should be further explored if this 
assumption is violated.  
*Potential competing risk effects for non-CRC related death were not modelled, 
leading to possible overestimated CRC-specific survival rates using the Kaplan-Meier 
approach.   
*Results of power estimation should not be considered as accurate values given that 
the structure of included covariates was not considered.  
*For predictive modelling, only the C statistics, the Hosmer-Lemeshow test and 
calibration plots were adopted to evaluate model performance. These metrics have 
their own limitations. The C statistics has no clear interpretation when assessing the 
incremental value after adding a new predictor. Spurious findings could be generated 
Chapter 6 Discussion 
 
260 
from the Hosmer-Lemeshow test due to arbitrary categorisation of risk groups, 
especially when the sample size is large. The calibration plot cannot provide 
quantitative assessment of model calibration. Thus, more novel metrics should be 
employed to extensively evaluate prediction models developed in this thesis. 
    
*Possible mechanisms of missing data were not investigated due to limited data. 




6.3 Interpretation of main findings  
 
6.3.1 Systematic literature review 
 
Main findings 
The systematic literature review included a total of 83 primary model development 
studies and 52 external validation studies that investigated the predictive value of 
candidate prognostic factors of CRC. The main predictors used in these published 
prediction models included age at diagnosis, sex, AJCC stage, TNM stage, tumour 
grade and biomarkers such as CEA. Somatic genetic alterations, for example BRAF 
mutation and microRNA markers, were only investigated in 3 published prediction 
models (Goossens-Beumer et al, 2015b; Manceau et al, 2014; Zhang et al, 2013). No 
prediction models used germline genetic markers in predicting CRC survival. This 
finding could be due to the limited evidence supporting associations between specific 
germline genetic variants and survival outcomes of CRC, which points to the main 
focus of this thesis.  
As for the predictive performance of published models identified in this review, I found 
that most models showed low to modest discriminative performance (evaluated by C 
statistics). In addition, the majority of included models were subject to potential risk of 
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bias. The main sources of risk of bias stemmed from loss to follow-up of the study 
cohort and methodological flaws in data analysis, for example the lack of internal 
validation when reporting the model performance. I identified eight models 
(Basingstoke preoperative score, Fong score, Iwatsuki score, Memorial Sloan 
Katherine Cancer Center nomogram, Nordinger score, Peritoneal Surface Disease 
Severity Score, Kanemistu nomogram and Valentini nomogram) that had been 
validated in at least two external datasets and conducted meta-analyses to evaluate 
the pooled external performance of these models. Meta-analyses found significant 
discriminative ability (the 95% CI of the C statistic excluding the null) for five out of 
eight models (Basingstoke score, Fong score, Nordinger score, Peritoneal Surface 
Disease Severity Score and Valentini nomogram) in predicting six survival outcomes 
of CRC patients (details in Chapter 2). Among these five models, the Fong score was 
externally validated four times. It used seven predictors (positive resection margin, 
extrahepatic lesion, metastases-free period, number of metastases, the largest size 
of metastasis, CEA and lesion of regional lymph nodes for primary tumour), and the 
meta-analysis found significant discriminative ability for the score to predict 
recurrence-free and overall survival of CRC patients with liver metastasis after 
curative resection. All the five models used clinic-pathological predictors that were not 
available in the SOCCS or the UK Biobank cohorts; therefore, I was unable to further 
validate these models. 
 
6.3.2 Candidate association studies   
 
 
Validation and predictive modelling of published genetic variants associated 
with CRC survival  
 
Main findings  
A total of 43 genetic variants previously reported to be associated with CRC survival 
were identified by searching the GWAS catalogue and their associations with overall 
and CRC-specific survival were validated in the SOCCS study. However, no 
significant associations between any individual variant or the polygenic risk score that 
combined all 43 variants and survival outcomes of CRC were observed after 
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correcting for multiple testing. Although small effects cannot be confidently excluded 
due to limited sample size, these findings indicated no major effects of these 
previously identified variants on prognosis of CRC patients.  
The results of this section suggested poor reproducibility of previous GWASs. This 
could be due to different characteristics of the study cohort. For example, the previous 
GWAS by Pander et al. focused on only stage IV patients who had received certain 
treatment strategies (Pander et al, 2015). Different study outcomes could also 
potentially explain these inconsistent findings. Although different outcomes such as 
DFS and RFS show generally good concordance with OS (Sargent et al, 2005), 
statistical power varies across these outcomes due to different number of events. It is 
worth mentioning that 41 of the 43 (95%) variants (except for rs209489 and rs885036) 
did not reach GWAS significance (p<5x10-8) in the original report. Moreover, 39 out 
of the 43 variants (91%) were identified by GWASs with relatively small sample sizes 
(N<1,000), pointing to possible false positive findings or overestimation of the genetic 
effects in the published GWASs. With respect to associations not corrected for 
multiple testing, three genetic variants (rs17026425, rs6854845 and rs17057166) 
were identified to be associated with overall survival of CRC patients from the SOCCS 
study at p<0.05 and showed the same direction of effects compared to the original 
GWAS reports. These variants are discussed in the sections below. 
 
Rs17026425  
Xu et al. reported a significant association between the A allele of the variant 
rs17026425 and inferior overall survival of rectal cancer patients in a Canadian cohort 
(Xu et al, 2015). In addition to a similar effect on overall survival of all CRC patients 
from SOCCS, I also observed a suggestive association (uncorrected p<0.05) between 
this variant and overall survival of rectal cancer patients based on the results of a 
stratified analysis. Interestingly, neither the analysis in this thesis nor in the original 
GWAS by Xu et al. found a significant association of this variant among colon cancer 
patients, indicating that this effect may be more prominent in rectal cancer. This 
variant is an intron variant in the IQ motif containing M (IQCM) gene located in 
chromosome 6. According to the Human Protein Atlas (URL6-2), this gene is highly 
expressed only in testis tissue. Intriguingly, our results found a significant association 
between this variant and overall survival of male CRC patients from the SOCCS study. 
It is worth noting that this variant is located in the binding region of the JUN/JUND 
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transcription factors which are highly expressed in human CRC tissue (Wang et al, 
2000). The results of this section therefore merit further investigation in the potential 
biological function of this locus. 
 
Rs6854845  
This is an intergenic variant located in the super-enhancer—a cluster of cis-regulatory 
elements with high density of transcriptional factors—closest to the BTC gene which 
encodes the Betacellulin protein. This protein is a member of the Epidermal Growth 
Factors (EGF) and serves as a ligand for the EGF receptor. Nagaoka et al. found that 
the BTC gene is highly expressed in human CRC tissue (Nagaoka et al, 2016). 
Additionally, this gene showed significantly higher level of expression in wild-type 
KRAS CRC cases compared to KRAS mutated cases (Nagaoka et al, 2016), 
indicating potential different roles of the BTC gene in carcinogenesis and progression 
of the two types of CRC. However, currently there has been a paucity of evidence 
supporting a direct association between the variant rs6854845 and expression of the 
BTC gene. Cong et al. conducted an in vitro investigation by generating G>T mutation 
(T as mutated allele) for rs6854845 in colon cells using the Crispr/Cas9 technique 
(Cong et al, 2019). They observed that colon cells with this mutation showed 
significantly altered chromosomal structure of the super-enhancer compared with 
those without the mutation. In addition, significantly higher expression of several key 
genes near this variant, including the CXCL2, 3, 5, 6, 8, EREG and EPGN genes, was 
found in colon cells with the mutated rs6854845 than in cells of wild-type (Cong et al, 
2019). However, no significant difference was found for the expression of the BTC 
gene (Cong et al, 2019). Among these genes with altered expression, previous 
evidence found potential associations between highly expressed CXCL 2 and 3 genes 
in CRC tumour tissue and improved overall survival of patients (Lv & Li, 2019). As for 
the EREG gene, Qu et al. reported that highly expressed EREG gene mediated 
through promoter demethylation can activate the Epidermal Growth Factor Receptor 
(EGFR) pathway in CRC carcinogenesis (Qu et al, 2016). Thus far, there has been 
limited evidence showing the roles of CXCL 5, 6, 8 genes and the EPGN gene in CRC 
carcinogenesis or progression. Our findings along with the original GWAS by Xu et al. 
justify further investigation in the biological role of rs6854845 in CRC development 
and progression. 





This variant was originally related to disease-free survival of rectal cancer patients in 
the GWAS by Xu et al (Xu et al, 2015). In this thesis, I observed suggestive 
association between this variant and overall survival for all CRC patients from the 
SOCCS study. However, no association was detected in the stratified analysis among 
rectal cancer patients. Although a possible recessive effect was found for this variant 
in SOCCS, I failed to validate it using the UK Biobank cohort. This variant is an intron 
variant located in the LINC01847 gene. Thus far, there has been a dearth of evidence 
regarding the biological function of this variant or the gene.  
 
Combined effect and predictive value  
In addition to investigating individual effect of each variant, I also explored the 
combined predictive value of the 43 variants. Multivariable regression found that 
approximately half (42%) of the variants showed opposite direction of effects 
compared to the original GWASs, which is close to what is expected by chance 
(p=0.34 of a Chi2 test). Moreover, none of the 43 variants remained in the model after 
applying feature selection using both the LASSO and backward selection methods. 
This underpins the absence of meaningful predictive value for any of the included 
variants. The predictive performance of the 43 variants was evaluated using both the 
UK Biobank cohort from which the prediction model was derived and the SOCCS 
study as an external validation dataset. In the UK Biobank cohort, although positive 
point estimates of C statistics (>0.5) were observed, the 95% confidence intervals 
included the null (0.5) after internal validation using bootstrapping. This means that a 
model with significantly positive discriminative ability cannot be trained and derived 
using the 43 genetic variants to predict survival outcomes of CRC. External validation 
was then conducted using the fitted 43-variant model in the SOCCS study. The model 
showed no predictive value in SOCCS given that the observed survival estimates 
remained approximately unchanged as the predicted survival estimates increased. 
Moreover, a negative point estimate of C statistic (0.499) was observed when using 
the model to predict CRC-specific survival in SOCCS. In addition, the 43 variants 
showed no added predictive value on the basis of other known prognostic factors 
including age at diagnosis, AJCC stage and tumour grade. 
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In summary, analysis of this section found that genetic variants identified by previous 
GWASs to be associated with CRC survival are unable to efficiently predict survival 
outcomes of CRC patients in two external patient cohorts. This agrees with findings 
from the previous replication analyses that none of the 43 genetic variants remained 
significantly associated with CRC survival in SOCCS. It also points to the findings 
from the systematic literature review that no genetic variants have been employed by 
published prediction models. Given possible false positive or over-estimated genetic 
effects identified from previous small-scale GWASs, future larger GWASs and meta-
analyses combining previous GWASs are needed to identify genetic variants that are 
robustly associated with CRC survival and can potentially be applied to improve 
predicting survival outcomes of CRC.   
 
CRC-risk variants  
Main findings  
In this section, I investigated potential subsequent effects of 128 common CRC-risk 
variants identified from previous meta-analyses of GWAS studies (Huyghe et al, 2019; 
Law et al, 2019), on survival outcomes using the SOCCS study. Under an additive 
genetic model, none of the CRC-risk variants showed a significant association with 
survival outcomes after correcting for multiple testing. The polygenic risk score 
representing the overall genetic susceptibility to CRC was not associated with survival 
outcomes either. No signals were detected in stratified analyses after correcting for 
multiple testing. These findings indicate that currently known CRC-risk variants as a 
group have limited influence on subsequent survival outcomes after diagnosis. The 
heritable components of the observed variation of survival outcomes may have 
distinct genetic architecture that warrants separate GWASs to identify survival-related 
genetic loci. However, individual small effects of each CRC-risk variant cannot be 
excluded due to the limited sample size. As mentioned in Chapter 4 (page 88), the 
additive genetic model has limited statistical power to detect potential recessive 
genetic effects (Pereira et al, 2009). Sensitivity analysis using a recessive genetic 
model was conducted for the 128 genetic variants. Two variants (rs7495132 and 
rs10161980) remained significantly associated with CRC survival in SOCCS after 
correcting for multiple testing and their recessive effects were also observed in UK 
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Biobank. Given that these two variants failed to reach statistical significance in the 
additive analysis, they are more likely to follow a recessive mode of inheritance. 
 
Rs7495132  
I found that patients from the SOCCS study with the TT genotype of rs7495132 had 
significantly worse CRC-specific survival. However, no significant recessive effect 
was found for this variant on overall survival in either SOCCS or UK Biobank. The T 
allele of this variant was identified as a CRC-risk increasing allele in the original 
GWAS meta-analysis. Located in chromosome 15, rs7495132 is an intron variant of 
the CRTC3 gene which encodes the protein CREB regulated transcription co-
activator 3 (CRTC3). Previous evidence shows that the CRTC3 protein can regulate 
energy balance and is associated with weight gain in a mouse model (Song et al, 
2010). According to the results of Genotype-Tissue Expression (GTEx) project 
(URL6-3), the T allele of rs7495132 is associated with lower expression of the CRTC3 
gene in human musculoskeletal tissue and subcutaneous adipose tissue. However, 
no significant association is present in colonic tissue based on the GTEx results. Thus 
far, the impact of adiposity on prognosis of CRC patients is still controversial (Silva et 
al, 2019). Some studies reported that the adiposity is a potential protective factor for 
CRC survival (Asghari-Jafarabadi et al, 2009), whereas other studies support a 
detrimental prognostic effect of adiposity (Haydon et al, 2006). Various factors such 
as different treatment strategies, varied definition of adiposity and methodological 
biases could be behind these inconsistent findings. There is a pressing need for future 
research to further reveal the biological function of rs7495132 in the adiposity-
mediated pathway involved in CRC progression. 
Rs10161980  
In addition to rs7495132, I identified another variant, rs10161980, associated with 
overall survival in SOCCS and CRC-specific survival in UK Biobank. This variant, 
located in chromosome 13, is an intron variant of the AL139383.1 gene. There has 
been a paucity of evidence revealing associations between this variant and 
expression of any genes. The biological function of the AL139383.1 gene also 
remains to be understood. 
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Comparison to previous studies  
There have been two studies with similar study design that investigated prognostic 
effect of smaller numbers of CRC-risk variants (Abuli et al, 2013; Smith et al, 2015). 
Smith et al. included 2,083 CRC patients as a discovery dataset and 5,552 patients 
as a validation dataset (Smith et al, 2015). They identified only one variant rs9929218 
in chromosome 16 that was significantly associated with CRC survival in both cohorts. 
This variant is an intron variant that lies in the CDH1 gene which encodes the protein 
E-cadherin. E-cadherin is a widely known tumour suppressor that plays an essential 
role in cell-cell adhesion. Evidence has shown that loss of function of E-cadherin can 
cause tumour progression and metastasis (Takeichi, 1991). Rs9929218 is in strong 
LD with rs16260 that affects CDH1 expression (Li et al, 2000). Therefore, rs9929218 
may influence CRC progression by mediating the CDH1 expression. In this thesis, 
however, a nominally significant (p<0.05) yet opposite effect of this variant was 
observed on overall survival of patients in SOCCS under the additive genetic model. 
Smith et al. reported that patients with AA genotype had significantly inferior overall 
survival, but in this thesis, I observed a potential protective effect of the A allele on 
overall survival of patients from SOCCS. No significant recessive genetic effect was 
found on either overall or CRC-specific survival in my analysis. A few possible 
explanations could be behind these inconsistent findings. Firstly, Smith et al. used a 
discovery cohort of stage IV CRC patients. Colorectal cancer with stronger metastatic 
potential may have different genetic determinants compared to CRCs diagnosed at 
early stages. Notably, in stratified analysis of 784 stage IV CRC patients from SOCCS, 
I failed to observe a significant association between this variant and CRC survival 
either. Secondly, Smith et al. found that rs9929218 was significantly correlated with 
treatment response of chemotherapy and therefore they adjusted for treatment 
strategy in their survival analysis. However, this thesis is limited by treatment data 
being unavailable and therefore this effect could not be further explored using our 
study cohorts. Investigation of this variant using well-documented large cohorts 
should still be considered. With respect to the other study by Abuli et al. (Abuli et al, 
2013), a total of 16 CRC-risk variants were investigated in 1,235 CRC patients. 
However, no significant associations were found after correcting for multiple testing. 
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Variants previously linked with survival outcomes of other cancers 
Main findings  
The second hypothesis is that genetic variants associated with survival outcomes of 
other cancers may also affect prognosis of CRC. I included 82 variants reported by 
previous GWASs and tested their associations with overall and CRC-specific survival 
of patients from the SOCCS study. Overall, none of the variants remained statistically 
significant after correcting for multiple testing, although four variants (rs1728400, 
rs17693104, rs6797464 and rs823920) were found to be associated with CRC 
survival at nominal significance (uncorrected p<0.05). These findings indicated that 
major effects of these genetic variants on CRC survival are unlikely. Different cancer 
types may have distinct genetic determinants in terms of survival outcomes after 
diagnosis.  
Rs17693104  
This is an intron variant of the SHD4B gene in chromosome 10, was initially reported 
to be associated with overall survival of serous epithelial ovarian cancer. In this thesis, 
I found a concordant effect of the T allele on inferior overall and CRC-specific survival 
of CRC patients in SOCCS. Notably, earlier evidence has suggested that this variant 
was associated with sensitivity of Capecitabin--an agent that has been regularly 
administrated to CRC patients (O'Donnell et al, 2012). Therefore, our results indicate 
that rs17693104 could potentially influence CRC survival by modifying treatment 
response of patients who have been taking Capecitabin. The possible metabolic 
pathways and mechanisms should be further explored in the future. According to the 
results of GTEx, the T allele of rs17693104 is associated with higher expression of 
the RP11-137H2.4 gene in multiple types of human tissue. This gene encodes the 
long non-coding RNA (LncRNA) RP11-137H2.4. Ouimet et al. conducted in vitro 
investigations to characterise biological function of the RP11-137H2.4 using human 
acute lymphoblastic leukaemia (ALL) cell lines (Ouimet et al, 2017). They found that 
silencing RP11-137H2.4 led to significantly increased cell apoptosis (Ouimet et al, 
2017). Thus far, there has been limited evidence concerning the function of RP11-
137H2.4 in CRC carcinogenesis or progression. These findings provided perspectives 
for future research to explore the possible role of rs17693104 in CRC progression by 
regulating the level of LncRNA RP11-137H2.4.  




Koster et al. identified an intron variant rs6797464 in the MECOM gene, which minor 
allele (A) was associated with worse overall survival of osteosarcoma (Koster et al, 
2018). A concordant effect of the A allele of rs6797464 was found on CRC-specific 
survival in SOCCS, although this effect did not survive correction for multiple testing. 
The MECOM gene encodes the MDS1 (Myelodysplastic Syndrome 1) and EVI1 
(Ecotropic Viral Integration Site 1) complex locus protein which is widely accepted as 
an oncoprotein. It was initially linked with the pathogenesis of leukaemia. Evidence 
has shown that this protein is involved in aberrant cell development in the bone 
marrow (Morishita et al, 1988; White et al, 2013). Recently, higher expression of the 
MDS1 and EVI1 complex locus protein has been identified in colon cancer 
(Shackelford et al, 2006). Studies also found that this oncoprotein could increase the 
resistance of tumour cells to treatment agents such as taxol (Liu et al, 2006). Makondi 
et al. conducted gene enrichment analysis, and identified the highly expressed 
MECOM gene as a potential biomarker of irinotecan resistance (Makondi et al, 2017). 
They also found that the expression of MECOM gene was associated with disease-
free survival of CRC patients (Makondi et al, 2017). However, there has been a dearth 
of evidence supporting the direct link between the germline variant rs6797464 and 
the MECOM gene expression, which merits further exploration.  
Rs1728400 and rs823920  
With respect to the other two variants with suggestive associations with CRC survival, 
rs1728400 was initially identified to be linked with overall survival of breast cancer 
patients (Rafiq et al, 2014). In this thesis, I found a protective effect of the minor allele 
A on overall survival of CRC patients in SOCCS. However, the effect allele was not 
reported in the original GWAS by Rafiq et al. This variant, located in chromosome 16, 
is an intergenic variant near the LINC00917 and the AC092327.1 genes, whose 
biological function has not been well characterised. Rs823920 was initially reported 
to be associated with overall survival of pancreatic cancer patients (Tang et al, 2017). 
I observed a concordant detrimental effect of the minor allele G on CRC-specific 
survival. This variant is an intergenic variant close to the ARL2BPP7 and the 
MTND3P4 gene. There has been a lack of evidence concerning the biological function 
of this variant too. Given the fact that these suggestive associations did not survive 
FDR correction and could be chance findings, further replication is needed. 
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6.3.3 Genome-wide association study 
 
Main findings  
In this section, a total of 8,328,632 autosomal genetic variants were investigated to 
identify potential novel genetic determinants on survival outcomes of CRC. As shown 
in the QQ plots, the overall genetic effect of the whole genome on CRC survival 
appears to be small. This may be attributed to possible low heritability of the survival 
outcome as a trait that is influenced by a large number of environmental factors. Low 
statistical power could also be behind the observed lack of genetic signals. Given the 
large number of imputed variants and the relatively small sample size (N=5,675), the 
variant-based heritability was not estimated as recommended by previous studies 
(Yang et al, 2015). Hence, there is compelling rationale for future efforts to combining 
multiple GWAS datasets on CRC survival by meta-analysis to reach sufficient 
statistical power. 
In the analysis combining CRC patients of all stages, I identified one variant 
rs143664541 in chromosome 6 associated with overall survival of CRC patients in 
SOCCS at the threshold of GWAS significance (p<5x10-8). Although effects of 
concordant direction were found in external validation datasets including the UK 
Biobank and other three published clinical trials, no significant association was 
observed in a meta-analysis. As for CRC-specific survival, two variants (rs143664541 
and rs75809467) were identified at GWAS significance. Rs75809467 was not 
associated with overall survival in external datasets. Due to limited data availability, 
external validation was only conducted for overall survival. I also performed stratified 
GWASs in locally advanced (stage II/III) and metastatic (stage IV) CRC patients 
separately. For stage II/III patients, I observed a variant rs323694 in chromosome 5 
that was significantly associated with CRC-specific survival (p<5x10-8). No significant 
signals were detected in the analysis within stage IV patients. In terms of the gene 
based analysis, I observed significant enrichment of signals in the CCDC135 gene 
associated with CRC-specific survival after correcting for multiple testing. Genes 
involved in the biosynthetic process of galactolipids and up-regulating the 
differentiation of adipocytes were found to harbour enriched genetic signals 
associated with CRC survival. 
Rs143664541  
This is an intergenic variant located near the FRK gene. According to the National 
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Center for Biotechnology Information (NCBI) gene database (URL6-4), the FRK gene 
encodes the Fyn-related kinase which may suppress cell growth by intervening in the 
G1 and S phase of the cell cycle (URL6-4). Currently, there is no evidence that shows 
that rs143664541 can influence the FRK gene expression. The exact biological 
implication of this variant remains unclear. According to the results from the 
PhenoScanner (Staley et al, 2016) (URL6-5) where genotype-phenotype associations 
from the UK Biobank full cohort are indexed, the minor allele (A) of this variant is 
significantly correlated with higher risk of death from oesophagogastric diseases 
(p=9.4x10-6). By searching the FRK gene using the PhenoScanncer, I identified 360 
associations (p<5x10-8) between genetic variants within the gene and different traits 
among which 80 (22%) traits were deaths due to different causes. However, I failed 
to observe significant enrichment of genetic signals in this gene on CRC survival 
outcomes using the gene based analysis. Future research is expected to uncover 
biological function of this gene. In respect to the variant rs143664541, although 
statistically significant associations were found between the variant and overall and 
CRC-specific survival in SOCCS, these associations failed to replicate in external 
datasets. However, a concordant direction of effects was found across multiple 
external datasets. These findings indicate possible over-estimation of the genetic 
effect of this variant in SOCCS. It is worth mentioning that this variant is imputed in 
SOCCS instead of directly genotyped. Moreover, this variant has a low minor allele 
frequency in SOCCS (1.4%) and even lower in general European population (0.3% in 
the 1000 Genome Project). Although an info score greater than 0.80 across all the 
datasets for this variant suggests acceptable imputation accuracy, imputation error 
could still bias the observed genetic effect. As shown in the locus zoom plot (Figure 
5.25), there is poor LD structure near this variant which restrains selection of any 
proxies of this variant. Future efforts are needed to re-estimate the effect of this variant 
on CRC survival based on genotyped or sequence data.  
Rs75809467  
As to the other variant I identified from combined analysis of all CRC patients, 
rs75809467 is located in the non-coding transcript exon of the BTF3P4 gene which is 
a pseudogene with unclear biological function. This variant was significantly 
associated with CRC-specific survival in SOCCS. Although validation analysis on the 
same outcome was not performed due to data availability, an opposite direction of 
effect was observed from the UK Biobank and the three clinical trials overall survival 
(see Figure 5.25). Given the general concordance of direction of effects for these two 
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outcomes, it is likely that the genetic effect of the minor allele (T) on CRC-specific 
survival in SOCCS is not real. Future well-designed studies with large sample sizes 
are still expected to investigate this variant.   
Rs323694  
With respect to stratified GWAS in stage II/III CRC patients, the variant rs323694 was 
identified to be significantly associated with CRC-specific survival (p<5x10-8). Given 
that the stage data have not been released in UK Biobank and cause of death for 
each patient was unavailable in the three clinical trials, I was unable to conduct 
validation analysis for this variant. There is a pressing need for the observed effect of 
this variant to be validated in independent cohorts of stage II/III CRC patients before 
it can be used to assist predicting survival outcomes. Rs323694 is an intergenic 
variant near the IRX2 and LOC100506858 gene. Currently, the biological implication 
of this variant has been poorly understood. It is worth noting that no significant 
association was found between this variant and CRC survival among stage IV patients. 
I conducted stratified GWASs in stage II/III and stage IV patients separately based on 
the assumption that the genetic background could be different for CRC patients with 
varied metastatic potential. A recent analysis based on exome-sequencing data of 
metastatic CRC patients showed that most CRCs metastasise before the primary 
tumour is clinically detectable (Hu et al, 2019). This finding provides further evidence 
that CRCs with high metastatic potential could be a distinct disease subtype 
compared with ones with lower metastatic potential. Therefore, GWASs stratified by 
stage should be considered in future investigations.      
Gene based analysis  
By conducting gene based analysis, I identified significant enrichment of genetic 
signals in the CCDC135 gene associated with CRC-specific survival. This gene is 
located in chromosome 16 and encodes the Coiled-coil domain-containing protein 
135 (CCDC135). According to the gene database provided by NCBI (URL6-4), the 
CCDC135 protein can regulate germ cells differentiation during spermatogenesis. 
Thus far there has been no evidence showing any roles of CCDC135 in CRC 
carcinogenesis and progression. Based on the data from the Human Protein Atlas 
(URL6-6), the CCDC135 gene is highly expressed only in testis. The Human Protein 
Atlas also incorporates the data from The Cancer Genome Atlas (TCGA), and 
analysis using different cancer tissues found that the CCDC135 expression is 
enriched in endometrial cancer. Survival analysis suggested that higher expression 
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of CCDC135 in endometrial cancer tissue was associated with significantly favourable 
survival outcome. As for CRC, the CCDC135 gene was highly expressed in 143/454 
tumour samples, but higher expression of this gene had no significant effect on overall 
survival of CRC patients from the TCGA project (URL6-6). Future research is needed 
to investigate whether the CCDC135 gene can serve as a prognostic indicator for 
CRC patients.  
Gene-set based analysis  
With regard to the results of gene-set based analysis, significant enrichment of genetic 
signals was found in two sets of genes. The first set of genes are involved in the 
biosynthetic process of galactolipids. Galactolipids are a subtype of glycolipid with 
galactose as the sugar group. Hou et al. revealed that galactolipids can suppress 
inflammatory mediators and serve as a potential anti-cancer agent for melanoma 
using a mouse model (Hou et al, 2007). Another study conducted by Yang et al. also 
leveraged mice with implanted melanoma (Hou et al, 2007), and they found that plant 
galactolipid can suppress lung metastasis of melanoma by decreasing tumour 
necrosis factor (TNF) α mediated pulmonary vascular permeability (Hou et al, 2007). 
Currently there has been limited research evidence supporting possible anti-cancer 
roles of galactolipids in CRC. The second gene-set identified, is involved in up-
regulating the differentiation of adipocytes. There has been an abundance of evidence 
supporting the role of adipocytes in carcinogenesis and metastasis of multiple human 
malignancies. Firstly, studies have shown that dysfunctional adipocytes can directly 
down-regulate the inflammatory-immune-angiogenic response system and hence 
promote cancer cell proliferation and metastasis (Nieman et al, 2013). Secondly, 
adipocytes can secrete factors such as TNF α and interleukin-6 that participate in key 
pathways in CRC carcinogenesis and progression (Hodge et al, 2005; Pikarsky et al, 
2004). Thirdly, adipocytes can regulate the tumour microenvironment of CRC and 
subsequently contribute to CRC invasion (Tabuso et al, 2017). Although the molecular 
mechanisms of adipocytes affecting CRC progression have been underpinned by 
cumulated evidence, epidemiological studies have yielded inconsistent results 
regarding the prognostic effect of adiposity on CRC survival, as described in the 
previous section discussing CRC-risk variants. Future research is still needed to 
clearly explain the role of adiposity in CRC progression. It should be noted that 
findings of enriched genetic signals in genes and gene-sets in this thesis have not 
been verified in external datasets. Therefore, validation studies are needed to confirm 
these results before further characterisation of detailed molecular mechanisms. 
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6.4 Conclusions and recommendations  
 
This thesis sets out to explore impact of germline genetic variations on survival 
outcomes of CRC patients using multiple patient cohorts including SOCCS, UK 
Biobank and three published clinical trials. Overall, the inheritable genetic 
components, represented by germline genetic variants throughout the genome, may 
contribute to only a relatively small part of variance in survival outcomes of CRC 
patients. However, several genetic variants were identified to be possibly associated 
with CRC survival and merit future investigation. Outlined below are main conclusions 
and recommendations derived from each part of the thesis. 
  
6.4.1 Systematic literature review 
 
In the first part of the thesis, I systematically reviewed published prediction models on 
survival outcomes of CRC including 83 model development studies and 52 external 
validation studies. None of the reviewed models included germline genetic variants 
as predictors. Somatic mutations such as the KRAS and BRAF mutations were used 
by a few models. Most published prediction models have not been validated in 
external datasets and are subject to potential sources of bias which mainly include 
cohort attrition and methodological flaws. There have been eight models (Basingstoke 
preoperative score, Fong score, Iwatsuki score, Memorial Sloan Katherine Cancer 
Center nomogram, Nordinger score, Peritoneal Surface Disease Severity Score, 
Kanemistu nomogram and Valentini nomogram) that had been validated in multiple 
external datasets. Meta-analyses of the model performance metrics (C statistics) 
showed low to modest discriminative performance. 
In order to further improve prediction, future investigations should explore the added 
predictive value of germline genetic variants that are associated with CRC survival 
such as genetic variants identified from this thesis and other studies once the reported 
associations have been confirmed by independent studies. Other novel predictors 
such as microRNAs should also be integrated. Besides developing new models, 
published prediction models should be validated by more independent efforts. The 
real-world impact and cost-effectiveness of published models are also expected to be 
studied before they can be routinely applied in clinical practice. Careful consideration 
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of factors used to predict survival outcomes of CRC is necessary and this systematic 
review can guide the selection of prognostic predictors in the future. 
 
6.4.2  Candidate association studies   
 
Validation of genetic variants previously reported to be associated with CRC 
survival  
In this section, I investigated 43 genetic variants identified by previous GWASs that 
were associated with survival outcomes of CRC. Overall, no genetic variants were 
found to be significantly associated with either overall or CRC-specific survival after 
correction for multiple testing. As for the combined effect of the 43 variants, I did not 
observed significant association between a polygenic risk score and CRC survival of 
patients from the SOCCS cohort. In addition, the 43 variants combined showed no 
predictive value either used alone or together with other known non-genetic factors. 
Our results suggested poor reproducibility of previously identified variants. Previous 
findings of genetic effects may be false positive. Given the sample size of the SOCCS 
cohort, I concluded that previously identified variants associated with CRC have no 
major effect on survival outcomes of CRC patients, although small effects for each 
individual variant cannot be confidently excluded.  
Although none of the 43 variants survived multiple testing, three genetic variants 
(rs17026425, rs6854845 and rs17057166) were identified with concordant direction 
of effects compared to the original GWASs at a nominal significance level (p<0.05). 
Validation studies of large sample size may be considered in the future. Large GWASs 
with sufficient statistical power are needed to identify genetic variants robustly 
associated with CRC survival. 
I also tested another two groups of genetic variants in this section based on two 
distinct hypotheses. Firstly, I examined associations between 128 CRC-risk variants 
and survival outcomes in SOCCS. Using an additive genetic model, no genetic 
variants were significantly associated with CRC survival after correcting for multiple 
testing. Similarly, the CRC-risk polygenic score was not associated with survival 
outcomes in SOCCS either. However, potential recessive effects were observed for 
two CRC-risk variants (rs7495132 in the CRTC3 gene and rs10161980 in the 
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AL139383.1 gene) using the SOCCS study and significant recessive effects were also 
detected in the UK Biobank. The second hypothesis was to test whether genetic 
variants associated with survival outcomes of other cancers may also affect prognosis 
of CRC. However, no significant signals were found among the 82 included variants 
and survival outcomes of CRC in SOCCS.  
Future studies should focus on further validating the potential recessive effects of the 
two CRC-risk variants, especially in other populations. Given the fact that little is 
known regarding the biological function of these two variants, our results also merit 
characterisation of possible molecular mechanisms and biological pathways in which 
these two variants are involved. As for genetic variants associated survival outcomes 
of other cancers, our findings indicated limited effects of them on CRC survival, and 
therefore pointed to the presence of possible distinct genetic architectures of survival 
outcomes across different cancers which should be investigated by separate GWASs 
in the future.  
 
6.4.3 Genome-wide association study   
 
In this section, more than eight million autosomal genetic variants were scanned to 
identify novel genetic loci associated with survival outcomes of CRC. The overall 
distribution of statistical significance revealed possible low heritability for survival 
outcomes of CRC. However, lack of statistical power could also explain this finding. 
Using the SOCCS cohort as the discovery set, two variants (rs143664541 near the 
FRK gene and rs75809467 in the BTF3P4 gene) were found to be significantly 
associated with survival outcomes of CRC (p<5x10-8). Meta-analysis combining effect 
estimates from the UK Biobank cohort and three clinical trials was used to validate 
these two findings. However, no significant associations were detected for either of 
the two variants (p<0.05), although concordant effect estimates of rs143664541 were 
found across the validation datasets compared to findings in SOCCS. By conducting 
stratified GWAS in locally advanced CRC patients (stage II/III), another variant 
(rs323694 near the IRX2 gene) was observed to be significantly associated with 
survival outcomes of CRC (p<5x10-8). In terms of the results of gene based analysis, 
I observed significant enrichment of genetic signals in the CCDC135 gene, and for 
gene-set based analysis, two sets of genes involved in biosynthetic process of 
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galactolipids and up-regulating the differentiation of adipocytes respectively were 
found to harbour significant enrichment of genetic signals in relation to survival 
outcomes of CRC patients.   
Considering that CRC-specific survival was not investigated in the validation datasets 
and that heterogeneous study designs and variable structures were adopted by these 
datasets, findings from the GWAS using the SOCCS cohort should be further 
validated by large well-documented cohorts in the future. These genetic variants, 
genes and gene sets, once confirmed by future validation, should then be explored in 
terms of their biological implications in CRC progression and metastasis. The results 
of this section also call for collaborative efforts of aggregating large study cohorts and 
performing meta-analysis combining multiple cohorts to obtain sufficient statistical 
power for more discoveries of genetic variants that can potentially affect survival 
outcomes of CRC patients.  
 
6.5 Implications for clinical practice and future policy 
  
Thus far, genetic determinants of long-term survival outcomes of CRC patients remain 
poorly understood. The systematic review in this thesis identified a dearth of prediction 
models that used germline genetic markers as predictors. Published prediction 
models mainly adopted well-established clinic-pathological factors associated with 
CRC survival, mainly including tumour stage and histological features. In the meta-
analysis the eight models that had been validated in at least two external datasets 
were found to have significantly positive discriminative performance. These models 
could potentially assist in selecting CRC patients with expected worse prognosis and 
informing possibly more intensive treatment strategy. However, these identified 
models should be further investigated in terms of their real-word impact and cost-
effectiveness by conducting model impact studies and health-economic modelling. 
Current clinical guidelines have not recommended any of these prediction models to 
be routinely applied, and our systematic review supports no change to current 
recommendations. 
Currently, there have been no germline genetic markers listed as prognostic factors 
for CRC in clinical guidelines or recommendations of official organisations such as 
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the Canadian Cancer Society. This is due to lack of robust evidence supporting 
associations between any genetic variants and CRC survival. In candidate genetic 
association studies of this thesis, I identified two variants (rs7495132 and rs10161980) 
with possible recessive genetic effects on CRC survival, but further validation on these 
associations and exploration in their potential predictive value are needed before any 
recommendations can be made. Genome-wide association analysis also revealed 
suggestive evidence on two variants (rs143664541 and rs323694) which merit further 
validation in other datasets. Findings in this thesis provide possible candidates for 
future investigation in terms of both biological function and clinical utility. However, it 
is still premature to integrate any of these germline genetic variants into management 
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